BMP	O
-	O
6	O
inhibits	O
growth	O
of	O
mature	O
human	O
B	O
cells	O
;	O
induction	O
of	O
Smad	O
phosphorylation	O
and	O
upregulation	B-Positive_regulation
of	O
Id1	O

Background	O

Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
belong	O
to	O
the	O
TGF	O
-	O
beta	O
superfamily	O
and	O
are	O
secreted	O
proteins	O
with	O
pleiotropic	O
roles	O
in	O
many	O
different	O
cell	O
types	O
.	O

A	O
potential	O
role	O
of	O
BMP	O
-	O
6	O
in	O
the	O
immune	O
system	O
has	O
been	O
implied	O
by	O
various	O
studies	O
of	O
malignant	O
and	O
rheumatoid	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
explored	O
the	O
role	O
of	O
BMP	O
-	O
6	O
in	O
normal	O
human	O
peripheral	O
blood	O
B	O
cells	O
.	O

Results	O

The	O
B	O
cells	O
were	O
found	O
to	O
express	O
BMP	O
type	O
I	O
and	O
type	O
II	O
receptors	O
and	O
BMP	O
-	O
6	O
rapidly	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
Smad1/5/8	O
.	O

Furthermore	O
,	O
Smad	O
-	O
phosphorylation	B-Phosphorylation
was	O
followed	B-Positive_regulation
by	O
upregulation	B-Positive_regulation
of	O
Id1	O
mRNA	O
and	O
Id1	O
protein	O
,	O
whereas	O
Id2	O
and	O
Id3	O
expression	B-Gene_expression
was	O
not	O
affected	B-Regulation
.	O

Furthermore	O
,	O
we	O
found	O
that	O
BMP	O
-	O
6	O
had	O
an	O
antiproliferative	O
effect	O
both	O
in	O
naive	O
(	O
CD19+CD27	O
-	O
)	O
and	O
memory	O
B	O
cells	O
(	O
CD19+CD27+	O
)	O
stimulated	O
with	O
anti	O
-	O
IgM	O
alone	O
or	O
the	O
combined	O
action	O
of	O
anti	O
-	O
IgM	O
and	O
CD40L	O
.	O

Additionally	O
,	O
BMP	O
-	O
6	O
induced	O
cell	O
death	O
in	O
activated	O
memory	O
B	O
cells	O
.	O

Importantly	O
,	O
the	O
antiproliferative	O
effect	O
of	O
BMP	O
-	O
6	O
in	O
B	O
-	O
cells	O
was	O
completely	O
neutralized	O
by	O
the	O
natural	O
antagonist	O
,	O
noggin	O
.	O

Furthermore	O
,	O
B	O
cells	O
were	O
demonstrated	O
to	O
upregulate	B-Positive_regulation
BMP	O
-	O
6	O
mRNA	O
upon	O
stimulation	O
with	O
anti	O
-	O
IgM	O
.	O

Conclusion	O

In	O
mature	O
human	O
B	O
cells	O
,	O
BMP	O
-	O
6	O
inhibited	O
cell	O
growth	O
,	O
and	O
rapidly	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
Smad1/5/8	O
followed	B-Positive_regulation
by	O
an	O
upregulation	B-Positive_regulation
of	O
Id1	O
.	O

Background	O

Members	O
of	O
the	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
superfamily	O
play	O
central	O
roles	O
in	O
controlling	O
cellular	O
proliferation	O
,	O
differentiation	O
,	O
migration	O
and	O
apoptosis	O
[	O
1	O
]	O
.	O

These	O
cytokines	O
can	O
be	O
divided	O
into	O
three	O
subgroups	O
:	O
TGF	O
-	O
beta	O
,	O
the	O
activins/inhibins	O
,	O
and	O
the	O
bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
,	O
of	O
which	O
the	O
latter	O
constitute	O
the	O
largest	O
family	O
.	O

BMPs	O
are	O
30	O
-	O
38	O
kDa	O
hetero	O
-	O
or	O
homodimeric	O
proteins	O
originally	O
identified	O
by	O
their	O
ability	O
to	O
induce	O
ectopic	O
cartilage	O
and	O
bone	O
formation	O
[	O
2	O
,	O
3	O
]	O
.	O

Several	O
studies	O
have	O
demonstrated	O
an	O
essential	O
role	O
of	O
these	O
proteins	O
during	O
embryogenesis	O
,	O
and	O
more	O
recently	O
,	O
also	O
in	O
adult	O
tissues	O
[	O
1	O
]	O
.	O

TGF	O
-	O
beta	O
has	O
been	O
intensively	O
studied	O
in	O
normal	O
and	O
malignant	O
haematopoietic	O
cells	O
and	O
is	O
one	O
of	O
the	O
most	O
potent	O
endogenous	O
negative	O
regulators	O
known	O
to	O
date	O
.	O

[	O
4	O
]	O
.	O

In	O
contrast	O
,	O
the	O
effect	O
of	O
BMPs	O
in	O
the	O
immune	O
system	O
has	O
not	O
been	O
widely	O
investigated	O
.	O

In	O
that	O
respect	O
,	O
BMP	O
-	O
2	O
,	O
-	O
4	O
and	O
-	O
7	O
have	O
been	O
found	O
to	O
control	O
differentiation	O
of	O
hematopoietic	O
stem	O
cells	O
[	O
5	O
]	O
and	O
early	O
T	O
cell	O
development	O
[	O
6	O
,	O
7	O
]	O
.	O

BMP	O
-	O
6	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
number	O
of	O
cobblestone-area	O
-	O
forming	O
cells	O
of	O
normal	O
human	O
haematopoietic	O
cells	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
BMP	O
-	O
2	O
,	O
-	O
4	O
,	O
6	O
and	O
-	O
7	O
had	O
an	O
antiproliferative	O
and	O
a	O
proapoptotic	O
effect	O
on	O
multiple	O
myeloma	O
cells	O
[	O
9	O
-	O
11	O
]	O
.	O

In	O
addition	O
,	O
by	O
gene	O
expression	O
profiling	O
,	O
BMP	O
-	O
6	O
significantly	O
increased	B-Positive_regulation
the	O
predictive	O
value	O
for	O
a	O
multi	O
-	O
gene	O
signature	O
test	O
and	O
was	O
associated	O
with	O
a	O
poor	O
outcome	O
in	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
(	O
DLBCL	O
)	O
[	O
12	O
]	O
.	O

BMP	O
-	O
6	O
,	O
like	O
the	O
other	O
BMP	O
members	O
,	O
signals	O
through	O
ligation	B-Binding
and	O
heterodimerzation	B-Binding
of	O
BMP	O
type	O
I	O
[	O
activin-like	O
-	O
kinase	O
(	O
ALK	O
)	O
]	O
and	O
type	O
II	O
serine	O
-	O
threonine	O
kinase	O
receptors	O
,	O
which	O
subsequently	O
propagates	O
the	O
signal	O
downstream	O
by	O
phosphorylating	O
Smad	O
proteins	O
.	O

BMP	O
-	O
6	O
can	O
signal	O
through	O
the	O
ligation	B-Binding
of	O
the	O
type	O
I	O
receptors	O
Act	O
-	O
RIA	O
,	O
BMP	O
-	O
RIA	O
,	O
and	O
BMP	O
-	O
RIB	O
and	O
the	O
type	O
II	O
receptors	O
BMP	O
-	O
RII	O
,	O
Act	O
-	O
RIIA	O
and	O
Act	O
-	O
RIIB	O
,	O
which	O
lead	B-Positive_regulation
to	O
the	O
phosphorylation	B-Phosphorylation
of	O
the	O
receptor	O
Smads	O
(	O
Smad	O
-	O
1	O
,	O
Smad	O
-	O
5	O
,	O
and	O
Smad	O
-	O
8	O
)	O
.	O

The	O
R	O
-	O
Smads	O
then	O
form	B-Binding
complexes	I-Binding
with	O
the	O
co	O
-	O
Smad	O
(	O
Smad4	O
)	O
and	O
are	O
translocated	B-Localization
into	O
the	O
nucleus	O
where	O
they	O
exert	O
gene	O
regulation	O
[	O
1	O
,	O
13	O
]	O
.	O

Given	O
the	O
reported	O
role	O
of	O
BMP	O
-	O
6	O
in	O
B	O
-	O
cell	O
malignancies	O
and	O
haematopoietic	O
progenitor	O
cells	O
,	O
we	O
wanted	O
to	O
explore	O
its	O
potential	O
role	O
in	O
normal	O
human	O
B	O
cells	O
.	O

We	O
studied	O
the	O
effects	O
of	O
BMP	O
-	O
6	O
on	O
proliferation	O
and	O
apoptosis	O
on	O
resting	O
and	O
stimulated	O
B	O
cells	O
.	O

Furthermore	O
,	O
the	O
expression	B-Gene_expression
of	O
BMP	O
receptors	O
and	O
BMP	O
-	O
6	O
induced	B-Positive_regulation
activation	O
of	O
the	O
Smad	O
signalling	O
pathway	O
with	O
subsequent	O
regulation	B-Regulation
of	O
the	O
target	O
genes	O
Id1	O
-	O
Id4	O
,	O
were	O
resolved	O
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
B	O
cells	O
also	O
were	O
capable	O
of	O
producing	B-Gene_expression
BMP	O
-	O
6	O
.	O

BMP	O
-	O
6	O
inhibits	O
anti	O
-	O
IgM	O
induced	O
proliferation	O
of	O
human	O
B	O
cells	O

The	O
effects	O
of	O
BMP	O
-	O
6	O
on	O
normal	O
and	O
neoplastic	O
hematopoietic	O
cells	O
prompted	O
us	O
to	O
investigate	O
the	O
effects	O
of	O
BMP	O
-	O
6	O
on	O
normal	O
human	O
B	O
cells	O
.	O

All	O
experiments	O
in	O
this	O
study	O
were	O
performed	O
under	O
serum	O
-	O
free	O
conditions	O
as	O
FCS	O
has	O
been	O
shown	O
to	O
interfere	O
with	O
BMP	O
-	O
signalling	O
[	O
14	O
]	O
(	O
own	O
observations	O
)	O
.	O

To	O
study	O
the	O
effect	O
of	O
BMP	O
-	O
6	O
on	O
proliferation	O
,	O
B	O
-	O
cells	O
from	O
healthy	O
volunteers	O
were	O
stimulated	O
with	O
anti	O
-	O
IgM	O
and/or	O
CD40L	O
in	O
the	O
presence	O
or	O
absence	O
of	O
BMP	O
-	O
6	O
for	O
three	O
days	O
.	O

We	O
found	O
that	O
BMP	O
-	O
6	O
led	O
to	O
a	O
35	O
%	O
mean	O
reduction	O
of	O
anti-IgM	O
-	O
induced	O
DNA	O
synthesis	O
(	O
n	O
=	O
8	O
;	O
p	O
<	O
/=	O
0.0002	O
,	O
Figure	O
1A	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
B	O
cells	O
treated	O
with	O
anti	O
-	O
IgM	O
and	O
CD40L	O
(	O
26	O
%	O
mean	O
reduction	O
,	O
n	O
=	O
6	O
;	O
p	O
<	O
/=	O
0.023	O
)	O
.	O

The	O
BMP-6	O
-	O
induced	O
inhibition	O
of	O
proliferation	O
was	O
dose	O
-	O
dependent	O
in	O
both	O
peripheral	O
B	O
cells	O
(	O
Figure	O
1B	O
)	O
and	O
the	O
Burkitt	O
lymphoma	O
cell	O
line	O
Ramos	O
(	O
40	O
%	O
reduction	O
of	O
DNA	O
synthesis	O
,	O
Figure	O
1C	O
)	O
.	O

The	O
BMP	O
-	O
6	O
effects	O
could	O
be	O
reversed	O
by	O
addition	O
of	O
the	O
extracellular	O
inhibitor	O
Noggin	O
(	O
Figure	O
1D	O
)	O
.	O

Similarly	O
,	O
a	O
combination	O
of	O
the	O
soluble	O
BMP	O
receptors	O
BMP-RIB	O
-	O
Fc	O
and	O
BMP-RII	O
-	O
Fc	O
also	O
neutralized	O
the	O
effects	O
of	O
BMP	O
-	O
6	O
(	O
data	O
not	O
shown	O
)	O
.	O

Next	O
,	O
we	O
wanted	O
to	O
test	O
whether	O
BMP	O
-	O
6	O
had	O
different	O
effect	O
on	O
naive	O
and	O
memory	O
B	O
cells	O
.	O

Naive	O
(	O
CD19+CD27	O
-	O
)	O
and	O
memory	O
(	O
CD19+CD27+	O
)	O
B	O
cells	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
cell	O
sorting	O
of	O
immunobead	O
-	O
isolated	O
CD19+	O
B	O
cells	O
[	O
15	O
]	O
,	O
and	O
tested	O
for	O
their	O
capacity	O
to	O
proliferate	O
in	O
the	O
presence	O
of	O
BMP	O
-	O
6	O
.	O

However	O
,	O
BMP	O
-	O
6	O
inhibited	O
anti	O
-	O
IgM	O
induced	O
DNA	O
synthesis	O
in	O
the	O
two	O
subpopulations	O
to	O
a	O
similar	O
extent	O
,	O
with	O
a	O
mean	O
reduction	O
of	O
DNA	O
-	O
synthesis	O
of	O
45	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
/=	O
0	O
,	O
004	O
)	O
for	O
naive	O
B	O
cells	O
and	O
48	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
/=	O
0	O
,	O
001	O
)	O
for	O
memory	O
B	O
cells	O
(	O
Figure	O
1E	O
)	O
.	O

BMP	O
-	O
6	O
induces	O
cell	O
death	O
in	O
human	O
memory	O
B	O
cells	O
and	O
Ramos	O
cells	O

Next	O
,	O
we	O
wanted	O
to	O
establish	O
whether	O
BMP	O
-	O
6	O
also	O
could	O
affect	O
the	O
viability	O
of	O
normal	O
B	O
cells	O
.	O

Cell	O
viability	O
was	O
determined	O
by	O
propidium	O
iodide	O
(	O
PI	O
)	O
staining	O
after	O
culture	O
with	O
or	O
without	O
BMP	O
-	O
6	O
for	O
48	O
hours	O
.	O

Interestingly	O
,	O
BMP	O
-	O
6	O
showed	O
a	O
small	O
,	O
but	O
reproducible	O
mean	O
increase	O
of	O
cell	O
death	O
from	O
17	O
to	O
23	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
/=	O
0	O
,	O
003	O
)	O
in	O
anti	O
-	O
IgM	O
stimulated	O
CD27+	O
memory	O
B	O
cells	O
.	O

Furthermore	O
,	O
Ramos	O
cells	O
showed	O
a	O
mean	O
increase	O
in	O
cell	O
death	O
from	O
20	O
to	O
50	O
%	O
(	O
n	O
=	O
3	O
,	O
p	O
<	O
0	O
,	O
001	O
,	O
figure	O
3	O
)	O
after	O
BMP	O
-	O
6	O
treatment	O
.	O

In	O
contrast	O
,	O
cell	O
death	O
of	O
total	O
CD19+	O
cells	O
(	O
n	O
=	O
6	O
;	O
p	O
<	O
/=	O
0	O
,	O
32	O
;	O
data	O
not	O
shown	O
)	O
or	O
CD27-IgG	O
-	O
naive	O
B	O
cells	O
was	O
not	O
significantly	O
affected	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
/=	O
0	O
,	O
65	O
,	O
figure	O
2	O
)	O
.	O

Human	O
B	O
cells	O
express	O
BMP	O
-	O
6	O
receptors	O

Detailed	O
knowledge	O
regarding	O
expression	O
of	O
different	O
BMP	O
receptors	O
in	O
B	O
cells	O
is	O
currently	O
not	O
available	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
BMPs	O
in	O
human	O
B	O
cells	O
,	O
we	O
performed	O
western	O
blot	O
analysis	O
for	O
type	O
I	O
and	O
type	O
II	O
BMP	O
receptors	O
.	O

This	O
analysis	O
revealed	O
that	O
the	O
type	O
I	O
receptors	O
Act	O
-	O
RIA	O
,	O
BMP	O
-	O
RIB	O
and	O
the	O
type	O
II	O
receptors	O
BMP	O
-	O
RII	O
and	O
Act	O
-	O
RIIb	O
are	O
expressed	B-Gene_expression
on	O
resting	O
human	O
B	O
-	O
cells	O
(	O
Figure	O
4	O
)	O
.	O

Ramos	O
cells	O
expressed	B-Gene_expression
the	O
type	O
I	O
receptors	O
Act	O
-	O
RIA	O
,	O
weakly	O
BMP	O
-	O
RIB	O
and	O
the	O
type	O
II	O
receptor	O
BMP	O
-	O
RII	O
,	O
but	O
more	O
weakly	O
than	O
normal	O
B	O
cells	O
(	O
Figure	O
4	O
)	O
.	O

HL60	O
cells	O
were	O
used	O
for	O
comparison	O
and	O
weakly	O
expressed	B-Gene_expression
Act	O
-	O
RIA	O
and	O
BMP	O
-	O
RII	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
normal	O
human	O
B	O
cells	O
and	O
Ramos	O
cells	O
express	O
a	O
set	O
of	O
BMP	O
receptors	O
,	O
previously	O
shown	O
to	O
bind	B-Binding
BMP	O
-	O
6	O
[	O
16	O
]	O
.	O

BMP	O
-	O
6	O
induces	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
Smad1/5/8	O

Upon	O
ligand	O
binding	O
,	O
the	O
type	O
II	O
receptor	O
transphosphorylates	O
and	O
activates	O
the	O
type	O
I	O
receptor	O
.	O

Type	O
I	O
receptors	O
can	O
signal	O
via	O
several	O
pathways	O
.	O

We	O
examined	O
the	O
effect	O
of	O
BMP	O
-	O
6	O
on	O
Smad	O
phosphorylation	O
,	O
as	O
the	O
activation	O
of	O
Smad	O
is	O
considered	O
to	O
be	O
a	O
major	O
signalling	O
pathway	O
for	O
BMPs	O
[	O
17	O
]	O
.	O

B	O
cells	O
were	O
cultured	O
in	O
serum	O
-	O
free	O
media	O
over	O
night	O
and	O
then	O
treated	O
with	O
BMP	O
-	O
6	O
for	O
various	O
time	O
points	O
.	O

Total	O
protein	O
lysates	O
were	O
prepared	O
,	O
and	O
the	O
amounts	O
of	O
the	O
phosphorylated	B-Phosphorylation
forms	O
of	O
Smad1/5/8	O
were	O
determined	O
by	O
western	O
blot	O
analysis	O
.	O

Interestingly	O
,	O
treatment	O
with	O
500	O
ng/ml	O
BMP	O
-	O
6	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
Smad	O
.	O

The	O
BMP	O
-	O
6	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
was	O
high	O
at	O
the	O
earliest	O
time	O
point	O
tested	O
(	O
15	O
minutes	O
)	O
,	O
and	O
remained	O
high	O
for	O
at	O
least	O
48	O
hours	O
(	O
Figure	O
5	O
)	O
.	O

A	O
similar	O
phosphorylation	O
was	O
observed	O
in	O
Ramos	O
cells	O
,	O
but	O
not	O
in	O
HL60	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

Furthermore	O
,	O
we	O
also	O
tested	O
whether	O
other	O
known	O
downstream	O
signalling	O
pathways	O
of	O
BMP	O
-	O
6	O
could	O
be	O
triggered	O
by	O
BMP	O
-	O
6	O
in	O
human	O
B	O
cells	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
any	O
significant	O
changes	B-Regulation
in	O
the	O
level	O
of	O
phospho	B-Phosphorylation
-	O
STAT3	O
or	O
phospho	B-Phosphorylation
-	O
p38	O
upon	O
BMP	O
-	O
6	O
treatment	O
of	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

BMP	O
-	O
6	O
induces	B-Positive_regulation
upregulation	B-Positive_regulation
of	O
Id1	O

Next	O
,	O
we	O
wanted	O
to	O
explore	O
whether	O
the	O
BMP	O
-	O
6	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
Smad	O
1/5/8	O
also	O
could	O
induce	O
transcriptional	O
changes	O
of	O
target	O
genes	O
.	O

In	O
this	O
regard	O
,	O
the	O
inhibitors	O
of	O
DNA	O
binding	O
proteins	O
(	O
Ids	O
)	O
are	O
considered	O
to	O
be	O
some	O
of	O
the	O
major	O
target	O
genes	O
for	O
Smad	O
-	O
signalling	O
[	O
17	O
]	O
.	O

Thus	O
,	O
B	O
cells	O
were	O
pre	O
-	O
incubated	O
over	O
night	O
in	O
X	O
-	O
VIVO	O
15	O
,	O
and	O
then	O
cultured	O
in	O
medium	O
alone	O
or	O
in	O
the	O
presence	O
of	O
BMP	O
-	O
6	O
for	O
various	O
time	O
points	O
before	O
preparation	O
of	O
total	O
RNA	O
.	O

The	O
amount	O
of	O
Id1	O
-	O
Id4	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Interestingly	O
,	O
we	O
observed	O
a	O
specific	O
four	O
-	O
fold	O
upregulation	B-Positive_regulation
of	O
Id1	O
mRNA	O
in	O
BMP-6	O
-	O
treated	O
B	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

The	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
Id1	O
mRNA	O
was	O
characteristic	O
of	O
an	O
early	O
inducible	O
gene	O
,	O
with	O
maximal	O
upregulation	B-Positive_regulation
two	O
hours	O
after	O
the	O
addition	O
of	O
BMP	O
-	O
6	O
and	O
returned	O
to	O
baseline	O
after	O
24	O
hours	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
changes	B-Regulation
were	O
observed	O
for	O
Id2	O
and	O
Id3	O
mRNA	O
,	O
whereas	O
Id4	O
-	O
transcripts	O
were	O
not	O
detectable	B-Positive_regulation
(	O
Figure	O
7	O
,	O
data	O
not	O
shown	O
)	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
BMP-6	O
-	O
induced	B-Positive_regulation
upregulation	B-Positive_regulation
of	O
Id1	O
mRNA	O
also	O
was	O
correlated	B-Positive_regulation
with	O
upregulation	B-Positive_regulation
of	O
Id1	O
protein	O
as	O
well	O
.	O

The	O
increase	B-Positive_regulation
in	O
Id1	O
protein	O
level	O
was	O
detectable	O
after	O
one	O
hour	O
and	O
increased	B-Positive_regulation
until	O
24	O
hours	O
after	O
BMP	O
-	O
6	O
addition	O
,	O
showing	O
a	O
16	O
-	O
fold	O
upregulation	B-Positive_regulation
compared	O
with	O
t0	O
(	O
p	O
<	O
/=	O
0.020	O
,	O
n	O
=	O
4	O
)	O
(	O
Figure	O
8	O
and	O
9	O
)	O
.	O

In	O
line	O
with	O
the	O
mRNA	O
data	O
,	O
no	O
consistent	O
change	B-Regulation
in	O
the	O
amounts	B-Gene_expression
of	O
Id2	O
and	O
Id3	O
protein	O
could	O
be	O
observed	O
(	O
Figure	O
8	O
and	O
9	O
)	O
.	O

We	O
were	O
able	O
to	O
block	B-Negative_regulation
the	O
Id1	O
specific	O
band	O
with	O
a	O
blocking	O
peptide	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
Id1	O
could	O
be	O
a	O
possible	O
target	O
gene	O
for	O
mediating	O
the	O
effects	O
of	O
BMP	O
-	O
6	O
in	O
human	O
B	O
cells	O
,	O
whereas	O
Id2	O
and	O
Id3	O
not	O
seem	O
to	O
be	O
involved	O
.	O

BMP	O
-	O
6	O
production	B-Gene_expression
in	O
B	O
cells	O

The	O
fact	O
that	O
BMP	O
-	O
6	O
has	O
been	O
reported	O
to	O
act	O
as	O
an	O
autocrine	O
stimulator	O
in	O
chondrocytes	O
[	O
18	O
]	O
and	O
ovarium	O
[	O
19	O
]	O
,	O
prompted	O
us	O
to	O
investigate	O
whether	O
normal	O
human	O
B	O
cells	O
could	O
produce	B-Gene_expression
BMP	O
-	O
6	O
upon	O
stimulation	O
.	O

Ramos	O
cells	O
,	O
which	O
have	O
been	O
described	O
to	O
express	B-Transcription
BMP	O
-	O
6	O
mRNA	O
endogenously	O
[	O
20	O
]	O
,	O
and	O
the	O
T	O
cell	O
line	O
Jurkat	O
,	O
served	O
as	O
positive	O
and	O
negative	O
controls	O
,	O
respectively	O
.	O

Endogenous	O
BMP	O
-	O
6	O
mRNA	O
levels	O
in	O
normal	O
B	O
cells	O
were	O
quantified	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
after	O
stimulation	O
with	O
anti	O
-	O
IgM	O
for	O
different	O
time	O
points	O
.	O

Interestingly	O
,	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
BMP	O
-	O
6	O
mRNA	O
was	O
characteristic	O
of	O
an	O
early	O
-	O
to	O
intermediate	O
inducible	O
gene	O
with	O
maximal	O
upregulation	B-Positive_regulation
four	O
hours	O
after	O
the	O
addition	O
of	O
anti	O
-	O
IgM	O
.	O

The	O
level	O
of	O
BMP	O
-	O
6	O
mRNA	O
was	O
back	B-Negative_regulation
to	I-Negative_regulation
baseline	I-Negative_regulation
after	O
24	O
hours	O
upon	O
stimulation	O
(	O
Figure	O
10	O
)	O
.	O

Furthermore	O
,	O
both	O
FCS	O
and	O
human	O
AB	O
-	O
serum	O
induced	B-Positive_regulation
significant	O
upregulation	B-Positive_regulation
of	O
BMP	O
-	O
6	O
mRNA	O
(	O
Figure	O
11	O
)	O
.	O

Interestingly	O
,	O
in	O
a	O
separate	O
study	O
we	O
have	O
found	O
that	O
normal	O
human	O
T	O
cells	O
do	O
not	O
express	B-Transcription
BMP	O
-	O
6	O
mRNA	O
after	O
activation	O
(	O
Sivertsen	O
et	O
al	O
,	O
manuscript	O
in	O
preparation	O
)	O
.	O

Next	O
,	O
we	O
wanted	O
to	O
detect	O
BMP	O
-	O
6	O
protein	O
in	O
normal	O
B	O
-	O
cells	O
and	O
tested	O
various	O
commercially	O
available	O
antibodies	O
.	O

However	O
,	O
in	O
our	O
hands	O
these	O
anti-BMP	O
-	O
6	O
antibodies	O
did	O
only	O
recognize	B-Binding
the	O
recombinant	O
BMP	O
-	O
6	O
protein	O
and	O
not	O
the	O
native	O
protein	O
.	O

Discussion	O

Recent	O
studies	O
have	O
demonstrated	O
an	O
important	O
role	O
for	O
BMP	O
superfamily	O
members	O
in	O
hematopoietic	O
stem	O
cells	O
,	O
early	O
thymocytes	O
[	O
6	O
,	O
7	O
]	O
and	O
B	O
-	O
cell	O
malignancies	O
[	O
8	O
,	O
11	O
,	O
12	O
]	O
,	O
but	O
a	O
role	O
for	O
BMPs	O
in	O
normal	O
human	O
B	O
cells	O
has	O
previously	O
not	O
been	O
reported	O
.	O

The	O
present	O
study	O
demonstrated	O
a	O
significant	O
antiproliferative	O
effect	O
of	O
BMP	O
-	O
6	O
in	O
peripheral	O
blood	O
CD19+	O
B	O
cells	O
.	O

Additionally	O
,	O
BMP	O
-	O
6	O
induced	O
cell	O
death	O
in	O
CD27+	O
memory	O
B	O
cells	O
as	O
well	O
as	O
in	O
a	O
Burkitt	O
lymphoma	O
cell	O
line	O
(	O
Ramos	O
)	O
.	O

Importantly	O
,	O
BMP	O
-	O
6	O
induced	B-Positive_regulation
a	O
rapid	O
and	O
marked	O
increase	B-Positive_regulation
in	O
Smad	O
-	O
1/5/8	O
phosphorylation	B-Phosphorylation
.	O

Furthermore	O
,	O
the	O
BMP	O
-	O
6	O
induced	B-Positive_regulation
Smad	O
phosphorylation	B-Phosphorylation
was	O
followed	B-Positive_regulation
by	O
a	O
selective	O
upregulation	B-Positive_regulation
of	O
Id1	O
mRNA	O
and	O
subsequent	O
Id1	O
protein	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
demonstrated	O
antiproliferative	O
effect	O
of	O
BMP	O
-	O
6	O
in	O
anti	O
-	O
IgM	O
treated	O
B	O
cells	O
was	O
significant	O
and	O
dose	O
-	O
dependent	O
.	O

Importantly	O
,	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
BMP	O
-	O
6	O
could	O
be	O
completely	O
neutralized	O
by	O
the	O
use	O
of	O
a	O
natural	O
inhibitor	O
,	O
Noggin	O
.	O

This	O
is	O
in	O
line	O
with	O
others	O
,	O
showing	O
that	O
Noggin	O
can	O
function	O
as	O
a	O
BMP	O
-	O
6	O
antagonist	B-Negative_regulation
[	O
21	O
,	O
22	O
]	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
soluble	O
BMP-RIB	O
-	O
Fc	O
and	O
BMP-RII	O
-	O
Fc	O
fusion	O
proteins	O
also	O
neutralized	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
BMP	O
-	O
6	O
in	O
human	O
B	O
cells	O
.	O

Interestingly	O
,	O
as	O
for	O
other	O
TGF	O
family	O
members	O
,	O
bifunctional	O
effects	O
have	O
also	O
been	O
demonstrated	O
for	O
BMPs	O
.	O

Whereas	O
several	O
of	O
the	O
BMPs	O
have	O
been	O
shown	O
to	O
promote	O
proliferation	O
in	O
various	O
cell	O
types	O
including	O
condrocytes	O
[	O
23	O
]	O
,	O
liver	O
[	O
24	O
]	O
and	O
granulosa	O
cells	O
[	O
25	O
]	O
,	O
antiproliferative	O
effects	O
and	O
induction	O
of	O
apoptosis	O
has	O
been	O
reported	O
for	O
B	O
and	O
T	O
lineage	O
cells	O
.	O

Similar	O
effects	O
as	O
demonstrated	O
for	O
BMP	O
-	O
6	O
on	O
human	O
B	O
cells	O
in	O
the	O
present	O
study	O
,	O
were	O
demonstrated	O
for	O
BMP	O
-	O
2	O
,	O
4	O
,	O
6	O
and	O
-	O
7	O
in	O
human	O
myeloma	O
cells	O
[	O
9	O
-	O
11	O
]	O
.	O

Other	O
members	O
of	O
the	O
BMP	O
-	O
family	O
have	O
also	O
been	O
reported	O
to	O
induce	O
apoptosis	O
,	O
including	O
in	O
mouse	O
B	O
lineage	O
cells	O
[	O
26	O
]	O
.	O

Additionally	O
,	O
BMP	O
-	O
4	O
inhibits	O
thymocyte	O
proliferation	O
[	O
6	O
]	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
role	O
of	O
BMPs	O
in	O
the	O
regulation	O
of	O
proliferation	O
and	O
apoptosis	O
is	O
highly	O
cell	O
type	O
dependent	O
.	O

To	O
examine	O
how	O
BMP	O
-	O
6	O
exerts	O
its	O
functional	O
effects	O
in	O
B	O
cells	O
,	O
we	O
analysed	O
BMP	O
receptor	O
expression	O
by	O
western	O
blot	O
analysis	O
.	O

Human	O
peripheral	O
B	O
cells	O
were	O
found	O
to	O
express	B-Gene_expression
the	O
BMP	O
type	O
I	O
receptors	O
Act	O
-	O
RIA	O
and	O
BMP	O
-	O
RIB	O
,	O
and	O
the	O
type	O
II	O
-	O
receptors	O
BMP	O
-	O
RII	O
and	O
Act	O
-	O
RIIb	O
,	O
which	O
signal	O
after	O
binding	B-Binding
of	O
several	O
BMPs	O
,	O
including	O
BMP	O
-	O
6	O
[	O
16	O
,	O
13	O
]	O
.	O

To	O
further	O
explore	O
BMP	O
-	O
6	O
induced	O
signalling	O
,	O
activation	O
of	O
several	O
pathways	O
is	O
possible	O
.	O

The	O
major	O
signalling	O
pathway	O
known	O
to	O
date	O
,	O
is	O
activation	O
of	O
R	O
-	O
Smads	O
[	O
13	O
,	O
27	O
]	O
.	O

In	O
that	O
respect	O
,	O
BMPs	O
have	O
been	O
shown	O
to	O
exert	O
antiproliferative	O
effects	O
in	O
B	O
lineage	O
cells	O
via	O
phosphorylation	O
of	O
R	O
-	O
Smad	O
[	O
11	O
,	O
28	O
]	O
.	O

Furthermore	O
,	O
BMP	O
-	O
2	O
has	O
been	O
shown	O
to	O
induce	B-Positive_regulation
activation	B-Positive_regulation
of	O
STAT3	O
in	O
myeloma	O
cells	O
[	O
9	O
]	O
.	O

However	O
,	O
phosphorylation	O
of	O
R	O
-	O
Smad	O
was	O
not	O
investigated	O
in	O
that	O
study	O
.	O

BMP	O
-	O
2	O
has	O
also	O
been	O
shown	O
to	O
induce	O
phosphorylation	O
of	O
p38	O
[	O
29	O
]	O
.	O

Thus	O
,	O
phosphorylation	B-Phosphorylation
of	O
p38	O
,	O
STAT3	O
and	O
Smad1/5/8	O
represent	O
important	O
BMP	O
-	O
signalling	O
pathways	O
that	O
mediated	O
the	O
effects	O
of	O
BMPs	O
and	O
even	O
cross	O
-	O
talk	O
between	O
these	O
pathways	O
has	O
been	O
reported	O
[	O
29	O
,	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
were	O
not	O
able	O
to	O
detect	O
BMP-6	O
-	O
induced	B-Positive_regulation
changes	B-Regulation
in	O
the	O
phosphorylation	B-Phosphorylation
status	O
of	O
STAT3	O
or	O
p38	O
in	O
human	O
peripheral	O
B	O
cells	O
.	O

Instead	O
,	O
a	O
rapid	O
and	O
marked	O
phosphorylation	B-Phosphorylation
of	O
Smad1/5/8	O
was	O
revealed	O
.	O

In	O
a	O
parallel	O
study	O
,	O
we	O
have	O
found	O
that	O
other	O
BMPs	O
also	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
Smad1/5/8	O
in	O
peripheral	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
are	O
currently	O
pursuing	O
microarray	O
studies	O
to	O
identify	O
the	O
signalling	O
pathways	O
and	O
target	O
genes	O
that	O
are	O
differently	O
regulated	O
by	O
the	O
various	O
BMPs	O
in	O
human	O
B	O
cells	O
.	O

Upregulation	B-Positive_regulation
of	O
Id1	O
via	O
Smad1/5/8	O
phosphorylation	B-Phosphorylation
is	O
a	O
known	O
mechanism	B-Regulation
for	O
BMP	O
-	O
6	O
signalling	O
in	O
other	O
cell	O
systems	O
[	O
31	O
,	O
32	O
]	O
and	O
regulation	O
of	O
Id	O
-	O
proteins	O
is	O
thought	O
to	O
be	O
an	O
important	O
mechanism	O
for	O
Smad	O
-	O
signalling	O
[	O
17	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
experiments	O
revealed	O
a	O
specific	O
four	O
-	O
fold	O
upregulation	B-Positive_regulation
for	O
Id1	O
in	O
BMP-6	O
-	O
treated	O
B	O
cells	O
,	O
while	O
the	O
amount	B-Gene_expression
of	O
Id2	O
-	O
Id4	O
remained	B-Positive_regulation
unchanged	I-Positive_regulation
.	O

In	O
agreement	O
with	O
this	O
,	O
western	O
blot	O
analysis	O
demonstrated	O
an	O
upregulation	B-Positive_regulation
of	O
Id1	O
protein	O
,	O
while	O
the	O
amount	B-Gene_expression
of	O
Id2	O
and	O
Id3	O
protein	O
levels	O
remained	B-Positive_regulation
unchanged	I-Positive_regulation
.	O

Previously	O
,	O
Id1	O
has	O
been	O
considered	O
not	O
to	O
be	O
expressed	B-Gene_expression
in	O
later	O
developmental	O
stages	O
than	O
pro	O
-	O
B	O
cells	O
[	O
33	O
,	O
34	O
]	O
,	O
and	O
its	O
constitutive	O
expression	B-Gene_expression
has	O
been	O
reported	O
to	O
impair	O
mouse	O
B	O
cell	O
development	O
[	O
35	O
]	O
.	O

Therefore	O
,	O
our	O
demonstration	O
of	O
the	O
time	O
-	O
dependent	O
upregulation	B-Positive_regulation
of	O
Id1	O
mRNA	O
and	O
protein	O
in	O
mature	O
normal	O
human	O
B	O
cells	O
is	O
of	O
particular	O
interest	O
.	O

In	O
that	O
respect	O
,	O
it	O
is	O
noteworthy	O
that	O
TGF	O
-	O
beta	O
signalling	O
in	O
early	O
and	O
mature	O
B	O
cells	O
induces	B-Positive_regulation
both	O
Id2	O
and	O
Id3	O
expression	B-Gene_expression
[	O
36	O
,	O
37	O
]	O
,	O
but	O
not	O
Id1	O
(	O
data	O
not	O
shown	O
)	O
.	O

Interestingly	O
,	O
these	O
results	O
show	O
that	O
various	O
members	O
of	O
the	O
TGF	O
-	O
beta	O
family	O
regulate	O
Id	O
proteins	O
differently	O
.	O

Id2	O
and	O
Id3	O
are	O
considered	O
to	O
be	O
the	O
Id	O
proteins	O
mainly	O
expressed	B-Gene_expression
in	O
mature	O
B	O
cells	O
[	O
38	O
]	O
.	O

The	O
present	O
study	O
also	O
found	O
Id2	O
and	O
Id3	O
protein	O
in	O
B	O
cells	O
to	O
be	O
more	O
highly	O
expressed	B-Gene_expression
than	O
Id1	O
in	O
resting	O
B	O
cells	O
.	O

However	O
,	O
BMP	O
-	O
6	O
did	O
not	O
induce	B-Positive_regulation
significant	O
changes	B-Regulation
in	O
the	O
protein	O
expression	B-Gene_expression
of	O
Id2	O
and	O
Id3	O
.	O

It	O
is	O
believed	O
that	O
Id	O
proteins	O
block	O
differentiation	O
and	O
promote	O
proliferation	O
in	O
various	O
cell	O
types	O
[	O
39	O
,	O
33	O
]	O
.	O

Id	O
proteins	O
act	O
as	O
dominant	O
-	O
negative	O
inhibitors	B-Negative_regulation
of	O
E	O
-	O
proteins	O
and	O
Pax5	O
function	O
by	O
forming	B-Binding
dimers	I-Binding
with	O
these	O
proteins	O
,	O
making	B-Positive_regulation
them	O
unable	O
to	O
bind	B-Binding
DNA	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
balance	O
among	O
E	O
-	O
proteins	O
,	O
Pax5	O
and	O
Id	O
proteins	O
might	O
have	O
an	O
important	O
role	O
in	O
activated	O
B	O
cells	O
[	O
38	O
]	O
.	O

In	O
that	O
respect	O
,	O
E	O
-	O
proteins	O
have	O
been	O
implicated	O
in	O
both	O
the	O
promotion	O
and	O
inhibition	O
of	O
cell	O
survival	O
and	O
growth	O
at	O
different	O
points	O
in	O
lymphocyte	O
development	O
[	O
40	O
]	O
.	O

The	O
antiproliferative	O
and	O
death	O
inducing	O
effect	O
of	O
BMP	O
-	O
6	O
in	O
B	O
cells	O
with	O
concomitant	O
upregulation	B-Positive_regulation
of	O
Id1	O
protein	O
is	O
therefore	O
in	O
line	O
with	O
the	O
view	O
that	O
Id	O
proteins	O
are	O
required	O
for	O
the	O
induction	O
of	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	O
-	O
lymphocyte	O
progenitors	O
by	O
TGF	O
-	O
beta	O
[	O
40	O
]	O
.	O

Furthermore	O
,	O
Id	O
proteins	O
are	O
known	O
as	O
important	O
parts	O
of	O
signalling	O
pathways	O
involved	O
in	O
development	O
,	O
cell	O
cycle	O
and	O
tumorigenesis	O
[	O
32	O
]	O
.	O

It	O
is	O
well	O
established	O
that	O
various	O
members	O
of	O
the	O
Id	O
family	O
are	O
overexpressed	O
in	O
a	O
range	O
of	O
human	O
tumours	O
and	O
generally	O
,	O
Id1	O
appears	O
to	O
be	O
the	O
family	O
member	O
most	O
widely	O
overexpressed	B-Positive_regulation
in	O
a	O
variety	O
of	O
human	O
malignancies	O
[	O
41	O
]	O
,	O
including	O
multiple	O
myeloma	O
[	O
42	O
,	O
32	O
]	O
.	O

Additionally	O
,	O
our	O
findings	O
that	O
BMP	O
-	O
6	O
activates	O
intracellular	O
signalling	O
pathways	O
in	O
human	O
B	O
cells	O
might	O
be	O
of	O
potential	O
pathophysiological	O
significance	O
in	O
lymphoma	O
and	O
inflammation	O
.	O

High	B-Positive_regulation
BMP	O
-	O
6	O
mRNA	B-Transcription
expression	I-Transcription
in	O
DLBCL	O
has	O
been	O
shown	O
to	O
correlate	O
to	O
unfavourable	O
outcome	O
[	O
12	O
]	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
of	O
interest	O
that	O
targeted	O
expression	B-Gene_expression
of	O
Id1	O
to	O
B	O
-	O
lymphocytes	O
resulted	O
in	O
aberrant	O
B	O
cell	O
development	O
,	O
massive	O
apoptosis	O
,	O
and	O
subsequent	O
development	O
of	O
B	O
cell	O
lymphomas	O
[	O
35	O
]	O
.	O

Moreover	O
,	O
BMP	O
-	O
6	O
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
[	O
43	O
,	O
44	O
]	O
and	O
elevated	B-Positive_regulation
levels	B-Gene_expression
of	O
Id1	O
and	O
Id3	O
have	O
been	O
found	O
in	O
the	O
synovia	O
of	O
RA	O
-	O
patients	O
[	O
45	O
]	O
.	O

Altogether	O
,	O
these	O
results	O
point	O
to	O
an	O
important	O
role	O
for	O
Id	O
proteins	O
in	O
the	O
regulation	O
of	O
normal	O
B	O
cell	O
homeostasis	O
and	O
in	O
diseases	O
,	O
where	O
B	O
cells	O
are	O
involved	O
.	O

It	O
will	O
therefore	O
be	O
important	O
to	O
further	O
elucidate	O
the	O
role	O
of	O
Id	O
-	O
1	O
in	O
human	O
B	O
cells	O
by	O
selective	O
over	B-Positive_regulation
expression	B-Gene_expression
or	O
inhibition	B-Negative_regulation
of	O
Id	O
-	O
1	O
gene	O
expression	B-Gene_expression
.	O

Given	O
the	O
role	O
of	O
BMP	O
-	O
6	O
in	O
mature	O
human	O
B	O
cells	O
demonstrated	O
here	O
,	O
identification	O
of	O
BMP	O
-	O
6	O
producing	B-Gene_expression
cells	O
in	O
vivo	O
with	O
possibility	O
of	O
interaction	O
with	O
naive	O
and	O
memory	O
B	O
cells	O
might	O
contribute	O
to	O
the	O
understanding	O
of	O
mature	O
B	O
cell	O
biology	O
.	O

High	B-Positive_regulation
BMP	O
-	O
6	O
mRNA	B-Transcription
expression	I-Transcription
in	O
DLBCL	O
has	O
been	O
detected	O
by	O
gene	O
expression	O
profiling	O
[	O
12	O
]	O
.	O

Furthermore	O
,	O
production	B-Transcription
of	O
BMP	O
-	O
6	O
transcripts	O
in	O
normal	O
activated	O
B	O
cells	O
was	O
detected	O
in	O
the	O
same	O
study	O
.	O

Of	O
note	O
,	O
an	O
autocrine	B-Regulation
BMP	O
-	O
6	O
loop	O
has	O
been	O
reported	O
by	O
others	O
in	O
chondrocytes	O
and	O
in	O
the	O
ovarium	O
[	O
46	O
,	O
19	O
,	O
18	O
]	O
.	O

Therefore	O
,	O
we	O
wanted	O
to	O
explore	O
the	O
possibility	O
for	O
an	O
autocrine	B-Regulation
BMP	O
-	O
6	O
loop	O
in	O
human	O
B	O
cells	O
.	O

We	O
analysed	O
the	O
expression	B-Transcription
BMP	O
-	O
6	O
mRNA	O
in	O
peripheral	O
blood	O
B	O
cells	O
by	O
real	O
-	O
time	O
PCR	O
,	O
and	O
report	O
here	O
the	O
upregulation	B-Positive_regulation
of	O
endogenous	O
BMP	O
-	O
6	O
transcripts	O
after	O
stimulation	O
with	O
FCS	O
,	O
human	O
AB	O
-	O
serum	O
and	O
,	O
most	O
importantly	O
,	O
anti	O
-	O
IgM	O
.	O

However	O
,	O
our	O
attempts	O
to	O
study	O
BMP	O
-	O
6	O
protein	O
levels	O
were	O
unsuccessful	O
due	O
to	O
problems	O
with	O
unspecific	O
binding	O
of	O
the	O
anti-BMP	O
-	O
6	O
antibodies	O
tested	O
,	O
and	O
lack	O
of	O
specific	O
staining	O
in	O
control	O
cells	O
known	O
to	O
express	B-Transcription
BMP	O
-	O
6	O
mRNA	O
.	O

In	O
contrast	O
,	O
the	O
recombinant	O
protein	O
was	O
readily	O
detected	O
.	O

In	O
that	O
respect	O
,	O
few	O
investigators	O
have	O
detected	B-Gene_expression
BMP	O
-	O
6	O
protein	O
in	O
humans	O
,	O
especially	O
in	O
non	O
-	O
pathogenic	O
tissue	O
.	O

The	O
possibility	O
of	O
BMP	O
-	O
6	O
production	B-Gene_expression
in	O
human	O
B	O
-	O
cells	O
is	O
in	O
line	O
with	O
a	O
recent	O
work	O
that	O
reported	O
the	O
production	B-Gene_expression
of	O
BMP	O
-	O
6	O
in	O
mouse	O
B	O
cells	O
,	O
infiltrating	O
the	O
bone	O
marrow	O
of	O
mice	O
with	O
inflammatory	O
arthritis	O
[	O
43	O
]	O
.	O

In	O
this	O
study	O
,	O
a	O
role	O
for	O
BMPs	O
in	O
the	O
inflammatoric	O
process	O
of	O
arthritis	O
was	O
suggested	O
.	O

The	O
upregulation	B-Positive_regulation
of	O
the	O
BMP-6	O
-	O
transcripts	O
after	O
IgM	O
-	O
crosslinking	O
is	O
of	O
pathophysiologic	O
interest	O
[	O
12	O
]	O
.	O

A	O
loss	O
of	O
TGF-beta	O
-	O
responsiveness	O
has	O
been	O
suggested	O
to	O
be	O
a	O
critical	O
contribution	O
to	O
malignant	O
transformation	O
[	O
47	O
,	O
48	O
]	O
and	O
similar	O
oncogenic	O
mechanisms	O
have	O
been	O
postulated	O
for	O
BMPs	O
.	O

Lines	O
of	O
evidence	O
suggest	O
[	O
49	O
]	O
that	O
at	O
early	O
stages	O
of	O
carcinogenesis	O
,	O
BMP	O
-	O
6	O
is	O
not	O
a	O
tumour	O
promoter	O
,	O
but	O
suppresses	O
benign	O
and	O
malignant	O
tumour	O
outgrowth	O
.	O

These	O
findings	O
are	O
in	O
good	O
agreement	O
with	O
previous	O
findings	O
for	O
other	O
TGF	O
-	O
beta	O
family	O
members	O
,	O
including	O
TGF	O
-	O
beta1	O
and	O
BMP	O
-	O
4	O
[	O
50	O
]	O
,	O
indicating	O
that	O
cellular	O
context	O
of	O
the	O
BMP	O
target	O
cell	O
might	O
define	O
the	O
various	O
observed	O
effects	O
.	O

In	O
contrast	O
to	O
the	O
upregulation	B-Positive_regulation
of	O
BMP	O
-	O
6	O
transcript	O
in	O
B	O
cells	O
,	O
we	O
were	O
not	O
able	O
to	O
detect	B-Transcription
BMP	O
-	O
6	O
transcripts	O
in	O
human	O
peripheral	O
blood	O
CD4+	O
or	O
CD8+	O
T	O
cells	O
(	O
resting	O
or	O
stimulated	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
;	O
data	O
not	O
shown	O
)	O
,	O
consistent	O
with	O
the	O
findings	O
in	O
T	O
cell	O
lines	O
[	O
20	O
]	O
and	O
T	O
cells	O
in	O
mice	O
[	O
43	O
]	O
.	O

Other	O
potential	O
BMP	O
-	O
6	O
sources	O
for	O
mature	O
B	O
cells	O
in	O
vivo	O
might	O
be	O
other	O
cells	O
of	O
the	O
immune	O
system	O
or	O
tissue	O
with	O
contact	O
to	O
the	O
hematopoietic	O
system	O
.	O

One	O
well	O
recognized	O
source	O
for	O
BMP	O
-	O
6	O
production	B-Gene_expression
is	O
the	O
human	O
bone	O
and	O
bone	O
marrow	O
stroma	O
[	O
51	O
,	O
8	O
]	O
.	O

Furthermore	O
,	O
it	O
is	O
noteworthy	O
that	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
highly	B-Positive_regulation
express	B-Transcription
BMP	O
-	O
6	O
mRNA	O
[	O
52	O
]	O
,	O
and	O
vascular	O
endothelium	O
has	O
been	O
reported	O
to	O
produce	B-Gene_expression
BMP	O
-	O
6	O
[	O
53	O
]	O
.	O

These	O
studies	O
might	O
imply	O
a	O
role	O
for	O
BMP	O
-	O
6	O
in	O
transendothelial	O
migration	O
of	O
B	O
cells	O
.	O

BMP	O
-	O
6	O
mRNA	O
has	O
been	O
demonstrated	B-Transcription
in	O
murine	O
macrophage	O
cell	O
lines	O
,	O
but	O
not	O
in	O
humans	O
[	O
54	O
]	O
.	O

In	O
accordance	O
with	O
these	O
findings	O
,	O
other	O
human	O
cell	O
lines	O
of	O
neutrophil	O
and	O
monocytic	O
origin	O
have	O
been	O
described	O
to	O
be	O
negative	B-Transcription
for	O
the	O
BMP	O
-	O
6	O
transcript	O
[	O
20	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
currently	O
no	O
report	O
about	O
BMP	O
-	O
6	O
production	B-Gene_expression
of	O
human	O
dendritic	O
cells	O
.	O

Conclusion	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
BMP	O
-	O
6	O
induces	O
activation	O
of	O
intracellular	O
Smad	O
signalling	O
in	O
mature	O
human	O
B	O
-	O
cells	O
with	O
consecutive	B-Positive_regulation
production	B-Gene_expression
of	O
Id1	O
protein	O
.	O

Furthermore	O
,	O
we	O
report	O
that	O
BMP	O
-	O
6	O
has	O
an	O
antiproliferative	O
effect	O
in	O
B	O
cells	O
stimulated	O
with	O
anti	O
-	O
IgM	O
alone	O
or	O
the	O
combined	O
action	O
of	O
anti	O
-	O
IgM	O
and	O
CD40L	O
.	O

Additionally	O
,	O
BMP	O
-	O
6	O
induces	O
cell	O
death	O
in	O
activated	O
memory	O
B	O
cells	O
and	O
Ramos	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
a	O
rationale	O
to	O
further	O
examine	O
the	O
role	O
of	O
BMP	O
-	O
6	O
signalling	O
in	O
normal	O
B	O
cell	O
biology	O
as	O
well	O
as	O
in	O
pathologic	O
conditions	O
like	O
B	O
cell	O
malignancies	O
and	O
autoimmune	O
disorders	O
.	O

Cell	O
culture	O

If	O
not	O
specified	O
,	O
all	O
cells	O
were	O
cultured	O
in	O
X	O
-	O
VIVO	O
15trade	O
(	O
BioWhittaker	O
,	O
Verviers	O
,	O
Belgium	O
)	O
serum	O
-	O
free	O
medium	O
at	O
37degreesC	O
and	O
5	O
%	O
CO2	O
in	O
air	O
.	O

Peripheral	O
blood	O
was	O
provided	O
by	O
the	O
Blood	O
Bank	O
at	O
Buskerud	O
Regional	O
Hospital	O
with	O
formal	O
agreement	O
by	O
the	O
patients	O
,	O
and	O
approval	O
by	O
the	O
regional	O
ethics	O
committee	O
.	O

Highly	O
purified	O
resting	O
human	O
B	O
-	O
lymphocytes	O
(	O
CD19+	O
cells	O
)	O
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
by	O
rosetting	O
with	O
immunomagnetic	O
beads	O
(	O
Dynabeads	O
M450	O
;	O
Dynal	O
,	O
Oslo	O
,	O
Norway	O
)	O
as	O
described	O
[	O
55	O
]	O
.	O

This	O
procedure	O
yields	O
less	O
than	O
0.5	O
%	O
T	O
cells	O
,	O
0.1	O
%	O
NK	O
cells	O
,	O
and	O
0.5	O
%	O
monocytes	O
as	O
judged	O
by	O
indirect	O
immunofluorescence	O
staining	O
.	O

The	O
following	O
cell	O
lines	O
from	O
human	O
lymphoid	O
malignancies	O
were	O
maintained	O
in	O
RPMI	O
1640	O
(	O
PAA	O
Laboratories	O
GmbH	O
,	O
Pasching	O
,	O
Austria	O
)	O
supplemented	O
with	O
10	O
%	O
foetal	O
bovine	O
serum	O
(	O
FCS	O
)	O
,	O
100	O
units/ml	O
penicillin	O
G	O
,	O
and	O
100	O
units/ml	O
of	O
streptomycin	O
sulphate	O
,	O
but	O
serum	O
-	O
starved	O
for	O
at	O
least	O
four	O
hours	O
and	O
cultured	O
in	O
X	O
-	O
VIVO	O
15trade	O
when	O
included	O
in	O
experiments	O
:	O
EBV	O
-	O
negative	O
BL	O
cell	O
lines	O
Ramos	O
(	O
ECACC	O
85030802	O
)	O
,	O
HL60	O
(	O
JCRB0085	O
)	O
.	O

Growth	O
factors/supplements	O

The	O
following	O
reagents	O
were	O
used	O
at	O
indicated	O
concentrations	O
:	O
recombinant	O
human	O
(	O
rhu	O
)	O
BMP	O
-	O
6	O
(	O
1	O
mug/ml	O
,	O
if	O
not	O
specified	O
otherwise	O
)	O
,	O
rhu	O
BMP-RIB/ALK	O
-	O
6/Fc	O
Chimera	O
(	O
5	O
mug/ml	O
)	O
,	O
rhu	O
BMPR	O
-	O
II/Fc	O
Chimera	O
(	O
5	O
mug/ml	O
)	O
,	O
and	O
recombinant	O
mouse	O
Noggin	O
(	O
5	O
mug/ml	O
)	O
were	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
;	O
Anti	O
-	O
IgM	O
F	O
(	O
ab	O
)	O
2	O
fragments	O
of	O
rabbit	O
polyclonal	O
antibodies	O
to	O
human	O
IgM	O
heavy	O
chain	O
(	O
37.5	O
mug/ml	O
)	O
was	O
obtained	O
from	O
Dako	O
,	O
Copenhagen	O
,	O
Denmark	O
and	O
rhu	O
CD40	O
ligand	O
(	O
CD40L	O
,	O
10	O
ng/ml	O
)	O
was	O
a	O
gift	O
from	O
Immunex	O
Corp	O
.	O

(	O
Seattle	O
,	O
WA	O
)	O
.	O

Antibodies	O
used	O
for	O
flow	O
cytometric	O
analysis	O
and	O
immunoblot	O
analysis	O

Antibodies	O
against	O
the	O
human	O
BMP	O
-	O
receptors	O
Act	O
-	O
RIA	O
,	O
BMP	O
-	O
RIB	O
,	O
BMPR	O
-	O
II	O
,	O
Act	O
-	O
RIIA	O
and	O
Act	O
-	O
RIIb	O
were	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
.	O

Detection	O
of	O
the	O
BMP-6	O
-	O
protein	O
has	O
been	O
tried	O
with	O
the	O
following	O
antibodies	O
:	O
goat	O
polyclonal	O
anti-BMP	O
-	O
6	O
(	O
Santa	O
Cruz	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
,	O
monoclonal	O
mouse	O
anti-BMP	O
-	O
6	O
and	O
polyclonal	O
goat	O
anti-BMP	O
-	O
6	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
,	O
and	O
mouse	O
monoclonal	O
anti-BMP	O
-	O
6	O
(	O
Chemicon	O
International	O
Inc	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Characterisation	O
of	O
BMP	O
-	O
signalling	O
pathways	O
was	O
done	O
by	O
use	O
of	O
anti-phospho	O
-	O
Smad1	O
,	O
-	O
5	O
,	O
-	O
and	O
8	O
polyclonal	O
antibody	O
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Expression	B-Gene_expression
levels	I-Gene_expression
of	O
Id1	O
-	O
3	O
proteins	O
were	O
detected	O
with	O
polyclonal	O
rabbit	O
antibody	O
and	O
detection	O
was	O
blocked	B-Negative_regulation
with	O
blocking	O
peptide	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

As	O
secondary	O
antibodies	O
served	O
anti	O
-	O
mouse	O
,	O
anti	O
-	O
goat	O
or	O
anti	O
-	O
rabbit	O
IgG	O
-	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
from	O
Dakocytomation	O
AS	O
(	O
Copenhagen	O
,	O
Denmark	O
)	O
for	O
immunoblot	O
analysis	O
.	O

Anti-beta	O
-	O
actin	O
was	O
from	O
Santa	O
-	O
Cruz	O
.	O

From	O
Becton	O
Dickinson	O
(	O
San	O
Jose	O
,	O
CA	O
)	O
,	O
we	O
purchased	O
anti-CD19	O
-	O
PE	O
,	O
anti-CD19	O
-	O
FITC	O
.	O

The	O
antibodies	O
used	O
for	O
cell	O
sorting	O
were	O
anti	O
-	O
CD19	O
PC5	O
from	O
Immunotech	O
SA	O
(	O
Marseille	O
,	O
France	O
)	O
and	O
anti	O
-	O
CD27	O
PE	O
from	O
Becton	O
Dickinson	O
,	O
Biosciences	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cell	O
sorting	O

Highly	O
purified	O
CD19+CD27	O
-	O
or	O
CD19+CD27+	O
cells	O
were	O
obtained	O
by	O
staining	O
CD19+	O
cells	O
with	O
anti	O
-	O
CD27	O
PE	O
and	O
CD19	O
PC5	O
mAbs	O
for	O
30	O
minutes	O
at	O
4degreesC	O
,	O
followed	O
by	O
washing	O
with	O
PBS	O
and	O
sorting	O
on	O
FACS	O
DiVa	O
from	O
Becton	O
Dickinson	O
.	O

Western	O
-	O
blot	O
analysis	O

B	O
cells	O
from	O
peripheral	O
blood	O
or	O
cultured	O
cell	O
-	O
lines	O
were	O
lysed	O
in	O
lysis	O
buffer	O
(	O
glycerol	O
10	O
%	O
,	O
beta	O
-	O
mercaptoethanol	O
5	O
%	O
,	O
0.0625	O
M	O
Tris	O
-	O
HCL	O
[	O
pH	O
6.8	O
]	O
,	O
sodium	O
dodecyl	O
sulphate	O
[	O
SDS	O
]	O
2.5	O
%	O
w/vol	O
)	O
.	O

Total	O
protein	O
(	O
30	O
-	O
100	O
mug	O
)	O
from	O
each	O
sample	O
was	O
run	O
on	O
10	O
%	O
or	O
12	O
%	O
SDS/polyacrylamide	O
(	O
SDS/PAGE	O
)	O
gels	O
and	O
blotted	O
onto	O
nitrocellulose	O
filters	O
(	O
Protran	O
;	O
Schleicher	O
&	O
Schuell	O
GmbH	O
,	O
Dassel	O
,	O
Germany	O
)	O
.	O

Blocking	O
,	O
washing	O
and	O
incubation	O
of	O
the	O
filters	O
with	O
primary	O
antibodies	O
were	O
done	O
according	O
to	O
the	O
manufacturer	O
's	O
protocols	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
.	O

After	O
washing	O
with	O
TBS/0.1	O
%	O
Tween	O
-	O
20	O
(	O
TBS	O
-	O
T	O
)	O
,	O
the	O
filters	O
were	O
incubated	O
with	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
coupled	O
to	O
relevant	O
secondary	O
antibodies	O
(	O
see	O
above	O
)	O
for	O
60	O
minutes	O
at	O
RT	O
.	O

Enzyme	O
activity	O
was	O
visualised	O
by	O
the	O
enhanced	O
chemiluminescence	O
system	O
,	O
ECL+PLUS	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
.	O

Densitometric	O
analysis	O
was	O
performed	O
by	O
scanning	O
hyperfilms	O
on	O
a	O
Personal	O
Densitometer	O
SI	O
(	O
Molecular	O
Dynamics	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

Quantification	O
of	O
Id1	O
,	O
Id2	O
and	O
Id3	O
protein	O
was	O
calculated	O
by	O
normalizing	O
the	O
specific	O
protein	O
bands	O
to	O
beta	O
-	O
actin	O
using	O
Image	O
Quant	O
5.5	O
software	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Analysis	O
of	O
BMP	O
-	O
6	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	B-Transcription

Endogenous	O
expression	B-Gene_expression
of	O
the	O
BMP	O
-	O
6	O
gene	O
was	O
examined	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
Absolutely	O
RNAtrade	O
RT	O
-	O
PCR	O
Miniprep	O
Kit	O
(	O
Stratagene	O
Europe	O
,	O
Amsterdam	O
,	O
Netherland	O
)	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

Quantification	O
of	O
the	O
isolated	O
total	O
RNA	O
was	O
achieved	O
by	O
using	O
spectrophotometric	O
OD260	O
measurements	O
.	O

Equal	O
amounts	O
of	O
RNA	O
were	O
then	O
reverse	O
transcribed	O
to	O
cDNA	O
with	O
TaqMan	O
(	O
R	O
)	O
Reverse	O
Transcription	O
Reagents	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
U.S.A	O
)	O
.	O

To	O
measure	O
mRNA	B-Transcription
expression	I-Transcription
of	O
BMP6	O
,	O
Id1	O
-	O
Id4	O
and	O
PGK1	O
PCR	O
were	O
carried	O
out	O
with	O
TaqMan	O
(	O
R	O
)	O
universal	O
master	O
mix	O
.	O

Primers	O
and	O
probes	O
were	O
provided	O
by	O
Assay-on	O
-	O
Demand	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
reactions	O
were	O
carried	O
out	O
in	O
a	O
final	O
volume	O
of	O
25	O
mul	O
(	O
BMP	O
-	O
6	O
)	O
or	O
20	O
mul	O
(	O
ID1	O
)	O
.	O

The	O
cDNA	O
added	O
to	O
each	O
reaction	O
was	O
equivalent	O
to	O
the	O
input	O
of	O
20	O
ng	O
of	O
total	O
RNA	O
.	O

The	O
gene	O
expression	B-Gene_expression
was	O
quantified	O
using	O
the	O
standard	O
curve	O
method	O
(	O
BMP6	O
)	O
,	O
or	O
the	O
comparative	O
CT	O
method	O
(	O
Id1	O
)	O
as	O
described	O
in	O
ABI7700	O
User	O
Bulletin	O
2	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
expression	O
was	O
then	O
normalized	O
to	O
the	O
expression	B-Gene_expression
level	O
of	O
PGK1	O
.	O

PGK1	O
was	O
chosen	O
,	O
because	O
it	O
has	O
been	O
shown	O
to	O
have	B-Gene_expression
low	I-Gene_expression
expression	I-Gene_expression
variability	O
among	O
lymphocyte	O
specimens	O
[	O
56	O
]	O
.	O

Expression	O
levels	O
in	O
B	O
cells	O
were	O
then	O
related	O
to	O
the	O
expression	O
levels	O
in	O
Ramos	O
cells	O
.	O

Cell	O
proliferation	O

For	O
estimation	O
of	O
DNA	O
synthesis	O
,	O
CD19+	O
cells	O
(	O
7.5	O
x	O
104	O
cells/0.2	O
ml	O
)	O
or	O
Ramos	O
cells	O
(	O
1	O
x	O
104	O
cells/0.2	O
ml	O
)	O
were	O
cultured	O
in	O
triplicate	O
in	O
microtiter	O
wells	O
.	O

The	O
cells	O
were	O
pulsed	O
with	O
3.7	O
x	O
104Bq	O
[	O
3H	O
]	O
thymidine	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
for	O
the	O
last	O
16	O
h	O
of	O
a	O
72	O
-	O
h	O
incubation	O
.	O

The	O
cells	O
were	O
harvested	O
using	O
an	O
automated	O
cell	O
harvester	O
(	O
Packard	O
Instrument	O
Company	O
,	O
Meriden	O
,	O
CT	O
,	O
USA	O
)	O
and	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
determined	O
in	O
a	O
scintillation	O
counter	O
(	O
TopCount	O
,	O
Packard	O
Instrument	O
Company	O
Inc.	O
,	O
Meriden	O
,	O
CT	O
)	O
.	O

Determination	O
of	O
cell	O
death	O

Cell	O
death	O
was	O
measured	O
by	O
vital	O
dye	O
exclusion	O
test	O
by	O
staining	O
cells	O
with	O
5	O
mug/ml	O
propidium	O
iodide	O
(	O
[	O
PI	O
]	O
;	O
Calbiochem	O
Corp.	O
;	O
La	O
Jolla	O
,	O
CA	O
;	O
5	O
mg/ml	O
)	O
for	O
one	O
minute	O
on	O
ice	O
.	O

At	O
least	O
1	O
,	O
000	O
cells	O
per	O
sample	O
were	O
run	O
on	O
a	O
BD	O
FACSCalibur	O
flow	O
cytometer	O
.	O

Statistical	O
analysis	O

The	O
statistical	O
significance	O
of	O
differences	O
between	O
groups	O
was	O
determined	O
using	O
the	O
paired	O
two	O
-	O
tailed	O
Wilcoxon	O
nonparametric	O
test	O
,	O
by	O
applying	O
SPSS10.1	O
software	O
(	O
SPSS	O
Inc.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

P	O
values	O
less	O
than	O
0.05	O
were	O
considered	O
significant	O
.	O

Sp1	O
and	O
Sp3	O
regulate	B-Regulation
basal	O
transcription	B-Transcription
of	O
the	O
human	O
APOBEC3G	O
gene	O

APOBEC3G	O
(	O
A3G	O
)	O
,	O
a	O
member	O
of	O
the	O
recently	O
discovered	O
family	O
of	O
human	O
cytidine	O
deaminases	O
,	O
is	O
expressed	B-Gene_expression
in	O
peripheral	O
blood	O
lymphocytes	O
and	O
has	O
been	O
shown	O
to	O
be	O
active	O
against	O
HIV	O
-	O
1	O
and	O
other	O
retroviruses	O
.	O

To	O
gain	O
new	O
insights	O
into	O
the	O
transcriptional	O
regulation	B-Regulation
of	O
this	O
restriction	O
factor	O
,	O
we	O
cloned	O
and	O
characterized	O
the	O
promoter	O
region	O
of	O
A3G	O
.	O

Transcriptional	O
start	O
sites	O
were	O
identified	O
by	O
5'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
.	O

Luciferase	O
reporter	O
assays	O
demonstrated	O
that	O
a	O
1025	O
bp	O
A3G	O
promoter	O
sequence	O
(	O
from	O
-	O
959	O
to	O
+66	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
)	O
displayed	O
constitutive	O
promoter	O
activity	O
.	O

In	O
T	O
cells	O
,	O
the	O
A3G	O
promoter	O
was	O
not	O
inducible	B-Positive_regulation
by	O
mitogenic	O
stimulation	O
,	O
interferon	O
treatment	O
or	O
expression	O
of	O
HIV	O
-	O
1	O
proteins	O
.	O

Using	O
a	O
series	O
of	O
5	O
'	O
deletion	O
promoter	O
constructs	O
in	O
luciferase	O
reporter	O
assays	O
,	O
we	O
identified	O
a	O
180	O
bp	O
region	O
that	O
was	O
sufficient	O
for	O
full	O
promoter	O
activity	O
.	O

Transcriptional	O
activity	O
of	O
this	O
A3G	O
core	O
promoter	O
was	O
dependent	O
on	O
a	O
GC	O
-	O
box	O
(	O
located	O
at	O
position	O
-87/	O
-	O
78	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
)	O
and	O
was	O
abolished	O
after	O
mutation	O
of	O
this	O
DNA	O
element	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
demonstrated	O
that	O
the	O
identified	O
GC	O
-	O
box	O
represented	O
a	O
binding	B-Binding
site	O
for	O
the	O
ubiquitous	O
transcription	O
factors	O
specificity	O
protein	O
(	O
Sp	O
)	O
1	O
and	O
Sp3	O
.	O

INTRODUCTION	O

The	O
recently	O
discovered	O
APOBEC3	O
family	O
of	O
cytidine	O
deaminases	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
antiviral	O
intrinsic	O
immunity	O
(	O
1	O
,	O
2	O
)	O
.	O

In	O
primates	O
,	O
the	O
seven	O
paralogs	O
APOBEC3A	O
,	O
B	O
,	O
C	O
,	O
DE	O
,	O
F	O
,	O
G	O
,	O
H	O
(	O
A3A	O
-	O
H	O
)	O
have	O
been	O
described	O
(	O
3	O
)	O
,	O
and	O
they	O
appear	O
to	O
fulfill	O
individual	O
functions	O
.	O

Human	O
APOBEC3G	O
(	O
A3G	O
)	O
,	O
the	O
most	O
prominent	O
member	O
of	O
the	O
APOBEC3	O
family	O
has	O
been	O
identified	O
as	O
the	O
cellular	O
restriction	O
factor	O
that	O
is	O
responsible	O
for	O
inhibition	O
of	O
virion	O
infectivity	O
factor	O
(	O
Vif	O
)	O
-	O
deleted	B-Negative_regulation
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
in	O
non	O
-	O
permissive	O
cells	O
(	O
4	O
)	O
.	O

A3G	O
is	O
packaged	O
into	O
HIV	O
-	O
1Deltavif	O
particles	O
and	O
causes	O
C-to	O
-	O
U	O
deaminations	O
on	O
the	O
single	O
-	O
stranded	O
viral	O
DNA	O
during	O
reverse	O
transcription	O
(	O
5	O
-	O
8	O
)	O
.	O

This	O
leads	O
to	O
degradation	O
of	O
the	O
uracile	O
-	O
containing	O
DNA	O
by	O
cellular	O
repair	O
mechanisms	O
or	O
to	O
hypermutation	O
of	O
the	O
viral	O
genome	O
(	O
5	O
,	O
6	O
)	O
.	O

As	O
a	O
result	O
,	O
only	O
a	O
marginal	O
fraction	O
of	O
the	O
A3G	O
-	O
containing	O
HIV	O
-	O
1	O
particles	O
is	O
able	O
to	O
complete	O
the	O
replication	O
cycle	O
.	O

In	O
addition	O
to	O
the	O
inhibition	O
of	O
HIV	O
-	O
1	O
,	O
A3G	O
restricts	O
replication	O
of	O
other	O
lentiviruses	O
,	O
gammaretroviruses	O
,	O
deltaretroviruses	O
,	O
spumaviruses	O
,	O
long-terminal	O
-	O
repeat	O
(	O
LTR	O
)	O
-	O
retrotransposons	O
,	O
orthohepadnaviruses	O
and	O
avihepadnaviruses	O
(	O
9	O
-	O
21	O
)	O
.	O

Interestingly	O
,	O
deamination	O
seems	O
not	O
to	O
be	O
the	O
only	O
A3G	O
-	O
mediated	O
antiviral	O
mechanism	O
;	O
in	O
the	O
case	O
of	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
,	O
A3G	O
was	O
shown	O
to	O
restrict	O
virus	O
replication	O
by	O
deamination	O
-	O
independent	O
mechanisms	O
(	O
12	O
,	O
13	O
,	O
19	O
,	O
22	O
-	O
25	O
)	O
.	O

Another	O
member	O
of	O
the	O
APOBEC3	O
family	O
,	O
APOBEC3F	O
(	O
A3F	O
)	O
,	O
appears	O
to	O
have	O
similar	O
activities	O
like	O
A3G	O
(	O
26	O
,	O
27	O
)	O
.	O

A3F	O
is	O
also	O
packaged	O
into	O
HIV	O
-	O
1Deltavif	O
particles	O
and	O
induces	O
similar	O
C-to	O
-	O
U	O
deaminations	O
,	O
although	O
the	O
proteins	O
differ	O
in	O
their	O
target	O
sequences	O
specificity	O
(	O
26	O
,	O
28	O
)	O
.	O

Furthermore	O
,	O
A3F	O
proteins	O
were	O
detected	O
in	O
many	O
tissues	O
that	O
express	B-Gene_expression
A3G	O
and	O
are	O
able	O
to	O
form	B-Binding
heteromultimers	I-Binding
with	O
A3G	O
(	O
26	O
,	O
29	O
,	O
30	O
)	O
.	O

Both	O
proteins	O
localize	B-Localization
to	O
mRNA	O
processing	O
(	O
P	O
)	O
bodies	O
,	O
cytoplasmic	O
compartments	O
involved	O
in	O
the	O
degradation	O
and	O
storage	O
of	O
non	O
-	O
translating	O
mRNAs	O
(	O
30	O
,	O
31	O
)	O
.	O

A3G	O
has	O
been	O
shown	O
to	O
be	O
expressed	B-Gene_expression
in	O
T	O
cells	O
,	O
a	O
relevant	O
cell	O
target	O
for	O
HIV	O
-	O
1	O
in	O
vivo	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
regulation	B-Regulation
(	O
4	O
,	O
29	O
,	O
32	O
)	O
.	O

There	O
is	O
a	O
report	O
describing	O
that	O
mitogenic	O
stimulation	O
of	O
T	O
cells	O
upregulates	B-Positive_regulation
A3G	O
mRNA	B-Gene_expression
levels	I-Gene_expression
,	O
but	O
this	O
was	O
not	O
analyzed	O
on	O
the	O
transcriptional	O
level	O
(	O
33	O
)	O
.	O

Since	O
the	O
A3G	O
promoter	O
has	O
not	O
been	O
systematically	O
analyzed	O
so	O
far	O
,	O
our	O
aim	O
was	O
to	O
clone	O
the	O
A3G	O
promoter	O
and	O
characterize	O
its	O
regulation	B-Regulation
in	O
T	O
cells	O
.	O

In	O
our	O
study	O
,	O
we	O
observed	O
that	O
A3G	O
uses	O
multiple	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
.	O

By	O
generating	O
a	O
series	O
of	O
5	O
'	O
deletions	O
of	O
the	O
A3G	O
promoter	O
,	O
we	O
identified	O
a	O
180	O
bp	O
region	O
that	O
mediated	O
basal	O
transcription	O
.	O

In	O
T	O
cells	O
,	O
transcriptional	O
activity	O
of	O
this	O
core	O
promoter	O
was	O
not	O
inducible	O
by	O
mitogenic	O
stimulation	O
or	O
interferon	O
treatment	O
,	O
but	O
was	O
dependent	O
on	O
a	O
GC	O
-	O
box	O
which	O
was	O
recognized	B-Binding
by	O
Sp	O
(	O
specificity	O
protein	O
)	O
1	O
and	O
Sp3	O
transcription	O
factors	O
.	O

Cell	O
culture	O

The	O
human	O
T	O
cell	O
lines	O
A3.01	O
and	O
PM1	O
(	O
NIBSC	O
,	O
UK	O
)	O
and	O
the	O
human	O
myeloid	O
cell	O
line	O
U937	O
(	O
NIBSC	O
,	O
UK	O
)	O
were	O
grown	O
in	O
complete	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
100	O
U/ml	O
penicillin	O
-	O
streptomycin	O
.	O

The	O
human	O
hepatic	O
cell	O
lines	O
HepG2	O
and	O
Huh7	O
(	O
kindly	O
provided	O
by	O
Dr	O
Thomas	O
Pietschmann	O
,	O
Department	O
of	O
Molecular	O
Virology	O
,	O
University	O
of	O
Heidelberg	O
)	O
as	O
well	O
as	O
HeLa	O
cells	O
were	O
maintained	O
in	O
Dulbecco	O
's	O
high	O
glucose	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
100	O
U/ml	O
penicillin	O
-	O
streptomycin	O
.	O

Cells	O
lines	O
were	O
incubated	O
at	O
37degreesC	O
with	O
100	O
%	O
humidity	O
in	O
5	O
-	O
7	O
%	O
CO2	O
and	O
passaged	O
using	O
standard	O
cell	O
culture	O
techniques	O
.	O

Plasmids	O

For	O
cloning	O
of	O
an	O
APOBEC3G	O
promoter	O
-	O
driven	O
reporter	O
plasmid	O
,	O
genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
T	O
cell	O
line	O
PM1	O
using	O
the	O
DNeasy	O
Kit	O
(	O
Qiagen	O
)	O
.	O

The	O
DNA	O
sequence	O
ranging	O
from	O
positions	O
-	O
959	O
to	O
+66	O
relative	O
to	O
the	O
identified	O
transcription	O
start	O
was	O
amplified	O
via	O
PCR	O
using	O
the	O
primers	O
3Gprom1025	O
(	O
5'-TGTGAACGCGTTGCTGCAGGCCATCTGGATGTATATG	O
-	O
3	O
'	O
)	O
and	O
3Gpromreverse	O
(	O
5'-ACAGCAGATCTAGGGACCTCTGATAAAGACAGG	O
-	O
3	O
'	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
Pwo	O
DNA	O
Polymerase	O
(	O
Roche	O
)	O
using	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
30	O
s	O
,	O
58degreesC	O
for	O
60	O
s	O
,	O
72degreesC	O
for	O
60	O
s	O
;	O
one	O
cycle	O
72degreesC	O
for	O
7	O
min	O
.	O

The	O
amplicon	O
was	O
ligated	O
into	O
the	O
promoterless	O
luciferase	O
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
(	O
Promega	O
)	O
via	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
,	O
which	O
were	O
introduced	O
by	O
the	O
primers	O
.	O

The	O
resulting	O
construct	O
contained	O
1025	O
bp	O
of	O
the	O
A3G	O
promoter	O
and	O
was	O
designated	O
pGL3	O
-	O
APOprom1025	O
.	O

Reporter	O
plasmids	O
containing	O
shorter	O
fragments	O
of	O
the	O
APOBEC3G	O
promoter	O
were	O
constructed	O
using	O
pGL3	O
-	O
APOprom1025	O
as	O
template	O
and	O
the	O
following	O
forward	O
primers	O
:	O
for	O
plasmid	O
pGL3	O
-	O
APOprom502	O
(	O
containing	O
sequence	O
-	O
436/+66	O
)	O
:	O
3Gprom502	O
(	O
5'-TGTGAACGCGTTCCATAACATGGGGACAAGA	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom225	O
(	O
containing	O
sequence	O
-	O
159/+66	O
)	O
:	O
3Gprom225	O
(	O
5'-TGTGAACGCGTCGAGGGCAGGATCCGGGAGT	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom180	O
(	O
containing	O
sequence	O
-	O
114/+66	O
)	O
:	O
3Gprom180	O
(	O
5'-TGTGAACGCGTTCTTGATGGTGGAGAGGAGG	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom150	O
(	O
containing	O
sequence	O
-	O
84/+66	O
)	O
:	O
3Gprom150	O
(	O
5'-TGTGAACGCGTGCGGGACCACCAGGGGAGGGGCTT	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom120	O
(	O
containing	O
sequence	O
-	O
54/+66	O
)	O
:	O
3Gprom120	O
(	O
5'-TGTGAACGCGTTGCTGGCTCAGCCTGGTGTG	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom60	O
(	O
containing	O
sequence	O
+7/+66	O
)	O
:	O
3Gprom60	O
(	O
5'-TGTGAACGCGTCCCTTTGCAATTGCCTTG	O
-	O
3	O
'	O
)	O
;	O
each	O
in	O
combination	O
with	O
the	O
reverse	O
primer	O
3Gpromreverse	O
(	O
described	O
above	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
Pfu	O
Ultra	O
Hotstart	O
(	O
Stratagene	O
)	O
using	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
58degreesC	O
for	O
45	O
s	O
,	O
72degreesC	O
for	O
60	O
s	O
;	O
one	O
cycle	O
72degreesC	O
for	O
7	O
min	O
.	O

As	O
for	O
pGL3	O
-	O
APOprom1025	O
,	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
were	O
introduced	O
via	O
the	O
primers	O
and	O
PCR	O
products	O
were	O
ligated	O
into	O
pGL3	O
-	O
Basic	O
(	O
Promega	O
)	O
via	O
these	O
restriction	O
sites	O
.	O

pGL3	O
-	O
APOprom180mut	O
carries	O
two	O
point	O
mutations	O
(	O
bold	O
)	O
and	O
was	O
generated	O
using	O
the	O
primer	O
3GProm180mut	O
(	O
5'-TGTGAACGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGTTCGGGACCACCAG	O
-	O
3	O
'	O
)	O
in	O
combination	O
with	O
primer	O
3Gpromreverse	O
.	O

This	O
PCR	O
was	O
performed	O
with	O
an	O
annealing	O
temperature	O
of	O
65degreesC.	O
pGL3promE1	O
(	O
containing	O
nucleotides	O
-114/	O
-	O
85	O
)	O
and	O
pGL3promE2	O
(	O
containing	O
nucleotides	O
-92/	O
-	O
63	O
)	O
were	O
constructed	O
by	O
annealing	O
the	O
following	O
single	O
-	O
stranded	O
oligonucleotides	O
:	O
114_85Plus	O
(	O
5'	O
-	O
CGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGGA	O
-	O
3	O
'	O
)	O
and	O
114_85Minus	O
(	O
5'	O
-	O
GATCTCCAGCTGGAGCCTCCTCTCCACCATCAAGAA	O
-	O
3	O
'	O
)	O
or	O
92	O
-	O
63Plus	O
(	O
5'-CGCGTCCAGCTGGGCGGGACCACCAGGGGAGGGGCA	O
-	O
3	O
'	O
)	O
and	O
92_63Minus	O
(	O
5'-GATCTGCCCCTCCCCTGGTGGTCCCGCCCAGCTGGA	O
-	O
3	O
'	O
)	O
.	O

After	O
annealing	O
,	O
the	O
double	O
-	O
stranded	O
oligonucleotides	O
which	O
contained	O
the	O
respective	O
30	O
bp	O
of	O
the	O
APOBEC3G	O
promoter	O
and	O
sticky	O
ends	O
compatible	O
with	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
were	O
ligated	O
into	O
the	O
pGL3	O
-	O
Promoter	O
(	O
Promega	O
)	O
vector	O
.	O

The	O
sequences	O
of	O
all	O
constructed	O
plasmids	O
were	O
verified	O
by	O
sequence	O
analysis	O
.	O

Nucleotide	O
-	O
219	O
of	O
the	O
cloned	O
APOBEC3G	O
promoter	O
differs	O
from	O
the	O
sequence	O
in	O
the	O
database	O
(	O
GenBanktrade	O
accession	O
number	O
DQ147772	O
)	O
.	O

An	O
A-to	O
-	O
C	O
substitution	O
is	O
present	O
at	O
this	O
position	O
.	O

Numbering	O
is	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
we	O
identified	O
.	O

The	O
reporter	O
plasmids	O
pGL3	O
-	O
Control	O
and	O
phRG	O
-	O
TK	O
were	O
purchased	O
from	O
Promega.	O
pGL2	O
-	O
CVX	O
contains	O
two	O
repeats	O
of	O
the	O
IFN	O
-	O
responsive	O
GAS	O
(	O
gamma	O
activated	O
sequence	O
)	O
elements	O
(	O
GATCTGGATTTAGAGTAATATGAAACTGAAAGTACTTCG	O
)	O
of	O
the	O
guanylate	O
-	O
binding	O
protein	O
(	O
GBP	O
)	O
gene	O
in	O
front	O
of	O
a	O
CMV	O
minimal	O
promoter	O
and	O
was	O
kindly	O
provided	O
by	O
Ute	O
Pagelow	O
and	O
Mario	O
Koster	O
from	O
the	O
Helmholtz	O
-	O
Zentrum	O
fur	O
Infektionsforschung	O
.	O

Plasmid	O
pNL4	O
-	O
3	O
(	O
NIBSC	O
,	O
UK	O
)	O
contains	O
the	O
full	O
-	O
length	O
HIV-1NL4	O
-	O
3	O
genome	O
and	O
has	O
been	O
described	O
previously	O
(	O
34	O
)	O
.	O

pcDNA3.1Vif	O
was	O
generously	O
provided	O
by	O
Nathaniel	O
R	O
.	O

Landau	O
from	O
the	O
Salk	O
Institute	O
,	O
La	O
Jolla	O
.	O

It	O
was	O
generated	O
by	O
amplifying	O
the	O
Vif	O
gene	O
from	O
pNL4	O
-	O
3	O
and	O
ligating	O
it	O
into	O
the	O
pcDNA3.1	O
vector	O
via	O
BamHI	O
and	O
XhoI	O
restriction	O
sites	O
.	O

A	O
3'	O
-	O
WPRE	O
element	O
was	O
included	O
into	O
the	O
XhoI	O
site	O
.	O

pBS-kRSPA-TatHIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
was	O
constructed	O
by	O
amplifying	O
the	O
two	O
exons	O
of	O
Tat	O
via	O
PCR	O
reaction	O
using	O
the	O
molecular	O
clone	O
pNL4	O
-	O
3	O
as	O
template	O
and	O
the	O
following	O
primer	O
sets	O
:	O
exon1	O
,	O
5UXho1HIV	O
-	O
Tat	O
1Plus	O
(	O
5'-GCATGCTCGAGATGGAGCCAGTAGATCCTAG	O
-	O
3	O
'	O
)	O
and	O
HIV	O
-	O
Tat	O
1Minus	O
(	O
5'-TGCTTTGATAGAGAAGCTTGATG	O
-	O
3	O
'	O
)	O
;	O
exon2	O
,	O
15FHIV	O
-	O
Tat2Plus	O
(	O
5'-TTCTCTATCAAAGCAACCCACCTCCCAATCCCG	O
-	O
3	O
'	O
)	O
and	O
5USpe1HIV	O
-	O
Tat2Minus	O
(	O
5'-GACGTACTAGTCTATTCCTTCGGGCCTGTC	O
-	O
3	O
'	O
)	O
.	O

XhoI	O
and	O
SpeI	O
restriction	O
sites	O
were	O
introduced	O
via	O
the	O
primers	O
.	O

The	O
sense	O
-	O
primer	O
of	O
exon2	O
starts	O
with	O
a	O
15	O
-	O
mer	O
which	O
is	O
homologous	O
to	O
the	O
3	O
'	O
end	O
of	O
exon1	O
and	O
necessary	O
for	O
fusion	O
of	O
both	O
exons	O
.	O

PCRs	O
were	O
performed	O
with	O
Expand	O
High	O
Fidelity	O
PCR	O
System	O
(	O
Roche	O
)	O
using	O
the	O
following	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
3	O
min	O
;	O
35	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
55degreesC	O
for	O
45	O
s	O
,	O
68degreesC	O
for	O
45	O
s	O
;	O
one	O
cycle	O
68degreesC	O
for	O
7	O
min	O
.	O

For	O
fusion	O
of	O
both	O
exons	O
,	O
the	O
following	O
PCR	O
conditions	O
were	O
applied	O
:	O
one	O
cycle	O
94degreesC	O
for	O
3	O
min	O
;	O
35	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
58degreesC	O
for	O
45	O
s	O
,	O
68degreesC	O
for	O
60	O
s	O
.	O

After	O
10	O
cycles	O
without	O
primers	O
,	O
the	O
sense	O
-	O
primer	O
of	O
exon1	O
and	O
the	O
antisense	O
-	O
primer	O
of	O
exon2	O
were	O
added	O
for	O
the	O
remaining	O
cycles	O
.	O

The	O
resulting	O
amplicon	O
was	O
ligated	O
into	O
the	O
pBS	O
-	O
kRSPA	O
vector	O
(	O
35	O
)	O
via	O
XhoI	O
and	O
SpeI	O
restriction	O
sites	O
.	O

5'	O
-	O
Rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
(	O
RACE	O
)	O

Total	O
RNA	O
was	O
isolated	O
from	O
A3.01	O
T	O
cells	O
using	O
RNeasy	O
mini	O
kit	O
(	O
Qiagen	O
)	O
.	O

The	O
transcriptional	O
start	O
sites	O
of	O
A3G	O
were	O
identified	O
using	O
the	O
5'/3	O
'	O
RACE	O
Kit	O
,	O
2nd	O
Generation	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
following	O
primers	O
were	O
used	O
:	O
RACE	O
-	O
APO3G1	O
(	O
5'-TATCCCTTGTACACTTTGT	O
-	O
3	O
'	O
)	O
for	O
cDNA	O
synthesis	O
,	O
RACE	O
-	O
APO3G2	O
(	O
5'-CATACTCCTGGTCACGAT	O
-	O
3	O
'	O
)	O
for	O
the	O
first	O
PCR	O
and	O
RACE	O
-	O
APO3Gnest	O
(	O
5'-GAATACACCTGGCCTCGAA	O
-	O
3	O
'	O
)	O
for	O
the	O
nested	O
PCR	O
.	O

Reaction	O
products	O
were	O
analyzed	O
by	O
agarose	O
gel	O
electrophoresis	O
,	O
purified	O
using	O
QIAquick	O
gel	O
extraction	O
kit	O
(	O
Qiagen	O
)	O
,	O
T/A	O
-	O
cloned	O
into	O
vector	O
pCR4	O
-	O
TOPO	O
(	O
Invitrogen	O
)	O
and	O
sequenced	O
.	O

Luciferase	O
assay	O

For	O
transient	O
transfection	O
of	O
A3.01	O
and	O
U937	O
cells	O
,	O
DMRIE	O
-	O
C	O
transfection	O
reagent	O
(	O
Life	O
Technologies	O
)	O
was	O
used	O
(	O
36	O
)	O
.	O

Cells	O
were	O
seeded	O
in	O
6	O
-	O
well	O
tissue	O
culture	O
plates	O
(	O
5	O
x	O
105	O
cells	O
per	O
well	O
)	O
in	O
1.5	O
ml	O
Opti	O
-	O
MEM	O
(	O
Life	O
Technologies	O
)	O
containing	O
0.5	O
microg	O
firefly	O
luciferase	O
reporter	O
plasmid	O
and	O
3.5	O
microl	O
DMRIE	O
-	O
C	O
.	O

After	O
4	O
-	O
5	O
h	O
of	O
incubation	O
,	O
1.5	O
ml	O
complete	O
RPMI	O
medium	O
were	O
added	O
.	O

HepG2	O
and	O
Huh7	O
cell	O
lines	O
were	O
transfected	O
using	O
LipofectAMINE	O
Plus	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
Life	O
Technologies	O
)	O
.	O

Briefly	O
,	O
exponential	O
growing	O
cells	O
(	O
1.5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
5	O
microl	O
LipofectAMINE	O
,	O
6	O
microl	O
PLUS	O
reagent	O
and	O
the	O
required	O
amount	O
of	O
plasmid	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
Opti	O
-	O
MEM	O
.	O

Following	O
4	O
h	O
of	O
incubation	O
,	O
cells	O
were	O
washed	O
in	O
PBS	O
and	O
3	O
ml	O
of	O
complete	O
DMEM	O
medium	O
were	O
added	O
.	O

For	O
cotransfection	O
of	O
reporter	O
plasmids	O
and	O
siRNA	O
into	O
HeLa	O
cells	O
,	O
HiPerfect	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
for	O
cotransfection	O
of	O
adherent	O
cells	O
with	O
siRNA	O
and	O
plasmid	O
DNA	O
.	O

Two	O
days	O
after	O
transfection	O
of	O
the	O
respective	O
cell	O
lines	O
,	O
cells	O
were	O
harvested	O
in	O
100	O
microl	O
(	O
suspension	O
cells	O
)	O
or	O
300	O
microl	O
(	O
adherent	O
cells	O
)	O
of	O
Passive	O
Lysis	O
Buffer	O
(	O
Promega	O
)	O
and	O
luciferase	O
assay	O
was	O
performed	O
using	O
the	O
Dual	O
Luciferase	O
Assay	O
System	O
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

As	O
an	O
internal	O
control	O
,	O
50	O
ng	O
(	O
adherent	O
cells	O
)	O
or	O
100	O
ng	O
(	O
suspension	O
cells	O
)	O
of	O
ph-RG	O
-	O
TK	O
plasmid	O
(	O
Promega	O
)	O
,	O
which	O
constitutively	O
expresses	B-Gene_expression
renilla	O
luciferase	O
was	O
cotransfected	O
in	O
every	O
sample	O
and	O
firefly	O
luciferase	O
activities	O
were	O
normalized	O
to	O
renilla	O
luciferase	O
activities	O
.	O

Mean	O
values	O
(	O
+/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
in	O
the	O
figures	O
.	O

For	O
stimulation	O
of	O
cells	O
,	O
final	O
concentrations	O
of	O
20	O
ng/ml	O
TPA	O
(	O
Sigma	O
)	O
or	O
30	O
ng/ml	O
IFN	O
-	O
alpha	O
or	O
30	O
ng/ml	O
IFN	O
-	O
gamma	O
(	O
Tebu	O
-	O
Bio	O
)	O
were	O
applied	O
approximately	O
15	O
h	O
before	O
harvesting	O
for	O
luciferase	O
assay	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O

For	O
preparation	O
of	O
nuclear	O
extracts	O
,	O
5	O
x	O
106	O
A3.01	O
T	O
cells	O
were	O
washed	O
in	O
cold	O
PBS	O
and	O
resuspended	O
in	O
500	O
microl	O
buffer	O
A	O
(	O
10	O
mM	O
HEPES	O
pH7.9	O
,	O
10	O
mM	O
KCl	O
,	O
0.1	O
mM	O
EDTA	O
,	O
0.1	O
mM	O
EGTA	O
,	O
1	O
mM	O
DTT	O
,	O
0.5	O
mM	O
PMSF	O
)	O
.	O

After	O
incubation	O
for	O
15	O
min	O
on	O
ice	O
,	O
swollen	O
cells	O
were	O
pressed	O
10	O
times	O
through	O
a	O
syringe	O
with	O
a	O
26G	O
needle	O
and	O
centrifuged	O
at	O
5000	O
r.p.m	O
.	O

for	O
5	O
min	O
.	O

Pellets	O
contained	O
the	O
nuclei	O
and	O
were	O
washed	O
in	O
buffer	O
A	O
for	O
two	O
times	O
and	O
resuspended	O
in	O
50	O
microl	O
buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
pH	O
7.9	O
,	O
400	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
EGTA	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
)	O
.	O

After	O
shaking	O
for	O
30	O
min	O
at	O
4degreesC	O
and	O
centrifugation	O
for	O
10	O
min	O
at	O
13	O
000	O
r.p.m.	O
,	O
supernatants	O
were	O
used	O
as	O
nuclear	O
extracts	O
.	O

EMSA	O
probes	O
were	O
generated	O
by	O
annealing	O
the	O
following	O
complementary	O
oligonucleotides	O
:	O
APO	O
-	O
Sp1/3	O
,	O
5'	O
-	O
CCAGCTGGGCGGGACCACCAGGGGAGGGGC	O
-	O
3	O
'	O
and	O
5'-GCCCCTCCCCTGGTGGTCCCGCCCAGCTGG	O
-	O
3	O
'	O
;	O
APO	O
-	O
Sp1/3mut	O
,	O
5'	O
-	O
CCAGCTGTTCGGGACCACCAGGGGAGGGGC	O
-	O
3	O
'	O
and	O
5'	O
-	O
GCCCCTCCCCTGGTGGTCCCGAACAGCTGG	O
-	O
3	O
'	O
according	O
to	O
standard	O
procedures	O
.	O

Nucleotides	O
differing	O
from	O
the	O
original	O
promoter	O
sequence	O
are	O
shown	O
in	O
bold	O
type	O
.	O

A	O
commercially	O
available	O
Sp1	O
probe	O
(	O
sc	O
-	O
2502	O
,	O
referred	O
to	O
as	O
Sp1cons	O
)	O
was	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
.	O

The	O
double	O
-	O
stranded	O
oligonucleotides	O
were	O
5	O
'	O
end	O
-	O
labeled	O
using	O
T4	O
polynucleotide	O
kinase	O
(	O
New	O
England	O
Biolabs	O
)	O
and	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
(	O
3000	O
Ci/mmol	O
,	O
Amersham	O
)	O
and	O
purified	O
by	O
using	O
Nick	O
G50	O
columns	O
(	O
Amersham	O
)	O
.	O

For	O
EMSA	O
,	O
5	O
microg	O
of	O
nuclear	O
proteins	O
were	O
preincubated	O
on	O
ice	O
with	O
2	O
microg	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
(	O
Roche	O
)	O
as	O
an	O
unspecific	O
competitor	O
and	O
1	O
microg	O
of	O
bovine	O
serum	O
albumin	O
in	O
band	O
shift	O
buffer	O
(	O
50	O
mM	O
Tris	O
,	O
150	O
mM	O
KCl	O
,	O
5	O
mM	O
EDTA	O
,	O
2.5	O
mM	O
dithiothreitol	O
,	O
20	O
%	O
Ficoll	O
)	O
for	O
15	O
min	O
.	O

32P	O
-	O
labeled	O
oligonucleotides	O
(	O
50	O
000	O
c.p.m.	O
)	O
were	O
added	O
in	O
a	O
total	O
volume	O
of	O
20	O
microl	O
,	O
incubated	O
on	O
ice	O
for	O
20	O
min	O
and	O
loaded	O
onto	O
5	O
%	O
native	O
polyacrylamide	O
gels	O
in	O
0.5xTris-borate	O
-	O
EDTA	O
buffer	O
.	O

Upon	O
fractionation	O
,	O
gels	O
were	O
dried	O
and	O
exposed	O
for	O
autoradiography	O
.	O

For	O
competition	O
experiments	O
,	O
1	O
-	O
or	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
the	O
unlabeled	O
APO	O
-	O
Sp1/3	O
or	O
APO	O
-	O
Sp1/3mut	O
oligonucleotides	O
was	O
added	O
to	O
the	O
preincubation	O
mixture	O
.	O

For	O
supershift	O
experiments	O
,	O
2	O
microg	O
Sp1	O
antibody	O
(	O
sc	O
-	O
59x	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
or	O
Sp3	O
antibody	O
(	O
sc	O
-	O
644x	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
were	O
added	O
to	O
the	O
preincubation	O
mixture	O
and	O
preincubation	O
time	O
was	O
extended	O
to	O
30	O
min	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O

A3.01	O
cells	O
were	O
treated	O
with	O
RPMI	O
culture	O
medium	O
containing	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
.	O

at	O
37degreesC	O
.	O

Cells	O
were	O
washed	O
twice	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
incubated	O
for	O
10	O
min	O
.	O

on	O
ice	O
after	O
resuspension	O
in	O
SDS	O
lysis	O
buffer	O
(	O
ChIP	O
Assay	O
Kit	O
,	O
Upstate	O
)	O
.	O

After	O
centrifugation	O
,	O
pellets	O
were	O
resuspended	O
in	O
MNase	O
reaction	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7.5	O
,	O
10	O
mM	O
NaCl	O
,	O
3	O
mM	O
MgCl2	O
,	O
1	O
mM	O
CaCl2	O
,	O
4	O
%	O
NP	O
-	O
40	O
)	O
.	O

DNA	O
digestion	O
was	O
performed	O
using	O
50	O
U	O
Micrococcal	O
Nuclease	O
(	O
Fermentas	O
)	O
and	O
1	O
x	O
107	O
cells	O
per	O
tube	O
in	O
a	O
volume	O
of	O
1.5	O
ml	O
.	O

After	O
2	O
min	O
,	O
reaction	O
was	O
stopped	O
by	O
adding	O
30	O
microl	O
200	O
mM	O
EGTA	O
.	O

Further	O
steps	O
were	O
performed	O
using	O
the	O
Chromatin	O
Immunoprecipitation	O
Assay	O
Kit	O
(	O
Upstate	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

1	O
x	O
107	O
cells	O
and	O
2	O
microg	O
antibody	O
(	O
Sp1	O
(	O
Pep2	O
)	O
sc	O
-	O
59	O
,	O
Sp3	O
(	O
D	O
-	O
20	O
)	O
sc	O
-	O
644	O
or	O
actin	O
(	O
H	O
-	O
196	O
)	O
sc	O
-	O
7210	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
were	O
used	O
for	O
each	O
immunoprecipitation	O
.	O

All	O
buffers	O
were	O
freshly	O
supplied	O
with	O
protease	O
inhibitors	O
.	O

After	O
phenol/chloroform	O
extraction	O
and	O
ethanol	O
precipitation	O
,	O
DNA	O
was	O
resolved	O
in	O
16	O
microl	O
H2O	O
.	O

Immunoprecipitated	O
DNA	O
was	O
detected	O
by	O
nested	O
PCR	O
using	O
4	O
microl	O
of	O
the	O
resolved	O
DNA	O
in	O
the	O
first	O
PCR	O
,	O
and	O
1	O
microl	O
for	O
the	O
nested	O
PCR	O
.	O

For	O
amplification	O
of	O
the	O
A3G	O
promoter	O
,	O
the	O
following	O
primers	O
were	O
used	O
:	O
ChIP3Gplus	O
5'-ccacggtggcctccgagggtga	O
-	O
3	O
'	O
and	O
ChIP3Gminus	O
:	O
5'-ctctccaccatcaagacagac	O
-	O
3	O
'	O
(	O
1	O
.	O

PCR	O
)	O
;	O
ChIP3G2plus	O
:	O
5'-tactctccctccctgtcccca	O
-	O
3	O
'	O
and	O
ChIP3G	O
nested	O
minus	O
:	O
5'-aggctgatgcctccgcag	O
-	O
3	O
'	O
(	O
nested	O
PCR	O
)	O
.	O

Taq	O
polymerase	O
(	O
Qiagen	O
)	O
was	O
used	O
together	O
with	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
30	O
s	O
,	O
60degreesC	O
for	O
60	O
s	O
,	O
72degreesC	O
for	O
2	O
min	O
;	O
one	O
cycle	O
72degreesC	O
for	O
10	O
min	O
.	O

As	O
a	O
negative	O
control	O
,	O
a	O
region	O
in	O
the	O
A3G	O
gene	O
was	O
targeted	O
using	O
the	O
primers	O
ChIP3Gneg_plus	O
:	O
5'-taagtaccacccagagatgag	O
-	O
3	O
'	O
and	O
ChIP3Gneg_minus	O
:	O
5'-catgatcttcatggtggcacg	O
-	O
3	O
'	O
for	O
both	O
PCR	O
steps	O
.	O

PCR	O
conditions	O
were	O
the	O
same	O
as	O
for	O
the	O
A3G	O
promoter	O
sequence	O
,	O
with	O
the	O
exception	O
that	O
annealing	O
temperature	O
was	O
decreased	O
to	O
55degreesC	O
.	O

RNA	O
interference	O
and	O
western	O
blot	O
analysis	O

Sp1	O
and	O
Sp3	O
translation	O
was	O
silenced	O
in	O
HeLa	O
cells	O
using	O
the	O
siRNA	O
duplexes	O
Hs_SP1_1_HP	O
and	O
Hs_SP3_1_HP	O
(	O
Qiagen	O
)	O
.	O

A	O
nonspecific	O
siRNA	O
(	O
Qiagen	O
)	O
was	O
used	O
as	O
control	O
.	O

HeLa	O
cells	O
were	O
transfected	O
with	O
150	O
or	O
300	O
ng	O
siRNA	O
per	O
6	O
-	O
well	O
,	O
using	O
the	O
HiPerfect	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
for	O
reverse	O
transfection	O
of	O
adherent	O
cells	O
in	O
6	O
-	O
well	O
plates	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
HeLa	O
cells	O
were	O
harvested	O
for	O
detection	B-Gene_expression
of	O
Sp1	O
and	O
Sp3	O
proteins	O
.	O

Cells	O
were	O
washed	O
in	O
PBS	O
,	O
lysed	O
in	O
RIPA	O
(	O
25	O
mM	O
Tris	O
pH	O
8.0	O
,	O
137	O
mM	O
NaCl	O
,	O
1	O
%	O
Glycerol	O
,	O
0.5	O
%	O
sodium	O
deoxycholate	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
2	O
mM	O
EDTA	O
pH	O
8	O
,	O
0.1	O
%	O
SDS	O
and	O
protease	O
inhibitors	O
)	O
and	O
lysates	O
were	O
cleared	O
by	O
centrifugation	O
.	O

After	O
boiling	O
with	O
Laemmli	O
's	O
buffer	O
,	O
samples	O
were	O
subjected	O
to	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
transfer	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Sp1	O
and	O
Sp3	O
proteins	O
were	O
detected	B-Gene_expression
using	O
alpha	O
-	O
Sp1	O
(	O
Pep2	O
)	O
antibody	O
(	O
sc	O
-	O
59	O
,	O
Santa	O
Cruz	O
)	O
or	O
alpha	O
-	O
Sp3	O
(	O
D	O
-	O
20	O
)	O
antibody	O
(	O
sc	O
-	O
644	O
,	O
Santa	O
Cruz	O
)	O
followed	O
by	O
incubation	O
with	O
alpha-rabbit	O
-	O
HRP	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

For	O
detection	O
of	O
tubulin	O
,	O
alpha	O
-	O
tubulin	O
(	O
B5-1	O
-	O
2	O
,	O
Sigma	O
)	O
and	O
alpha-mouse	O
-	O
HRP	O
(	O
Amersham	O
Biosciences	O
)	O
antibodies	O
were	O
used	O
.	O

Signals	O
were	O
visualized	O
by	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
,	O
Amersham	O
Biosciences	O
)	O
.	O

Characterization	O
of	O
the	O
transcriptional	O
start	O
sites	O
of	O
APOBEC3G	O
by	O
5'	O
-	O
RACE	O

To	O
identify	O
the	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
of	O
APOBEC3G	O
(	O
A3G	O
)	O
in	O
A3.01	O
T	O
cells	O
,	O
we	O
performed	O
5'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
(	O
RACE	O
)	O
with	O
A3G	O
-	O
specific	O
primers	O
(	O
see	O
Figure	O
1	O
)	O
.	O

Agarose	O
gel	O
electrophoresis	O
resolved	O
the	O
nested	O
PCR	O
products	O
into	O
three	O
bands	O
of	O
different	O
electrophoretic	O
mobility	O
with	O
a	O
dominant	O
middle	O
band	O
(	O
Figure	O
2	O
)	O
.	O

For	O
each	O
band	O
,	O
the	O
DNA	O
was	O
cloned	O
and	O
sequence	O
analysis	O
of	O
six	O
or	O
seven	O
individual	O
transformants	O
was	O
performed	O
.	O

We	O
observed	O
that	O
the	O
transcriptional	O
start	O
sites	O
of	O
the	O
A3G	O
gene	O
were	O
located	O
between	O
58	O
and	O
361	O
nt	O
upstream	O
of	O
the	O
ATG	O
start	O
codon	O
(	O
Figure	O
1	O
)	O
.	O

Although	O
TSS	O
were	O
variable	O
and	O
most	O
sites	O
were	O
only	O
detected	O
once	O
among	O
the	O
19	O
clones	O
analyzed	O
,	O
one	O
TSS	O
was	O
identified	O
in	O
six	O
individual	O
clones	O
.	O

This	O
TSS	O
was	O
located	O
66	O
nt	O
upstream	O
of	O
the	O
start	O
of	O
the	O
published	O
A3G	O
mRNA	O
sequence	O
(	O
GenBanktrade	O
accession	O
number	O
NM021822	O
)	O
and	O
we	O
defined	O
this	O
position	O
as	O
the	O
major	O
transcriptional	O
start	O
site	O
of	O
the	O
A3G	O
gene	O
.	O

The	O
core	O
promoter	O
of	O
A3G	O
is	O
located	O
within	O
the	O
region	O
-	O
114/+66	O
relative	O
to	O
the	O
TSS	O

For	O
characterization	O
of	O
the	O
A3G	O
promoter	O
,	O
we	O
cloned	O
the	O
1025	O
bp	O
located	O
at	O
position	O
-	O
959/+66	O
relative	O
to	O
the	O
identified	O
transcription	O
start	O
into	O
the	O
promoterless	O
pGL3	O
-	O
Basic	O
luciferase	O
reporter	O
plasmid	O
and	O
designated	O
the	O
plasmid	O
pGL3-Basic	O
-	O
APOprom1025	O
.	O

Similarly	O
,	O
pGL3	O
-	O
APOprom502	O
(	O
containing	O
sequence	O
-	O
436/+66	O
)	O
,	O
pGL3	O
-	O
APOprom225	O
(	O
containing	O
sequence	O
-	O
159/+66	O
)	O
and	O
further	O
5	O
'	O
deletion	O
reporter	O
constructs	O
containing	O
180	O
,	O
150	O
,	O
120	O
or	O
60	O
bp	O
upstream	O
of	O
position	O
+65	O
were	O
generated	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
order	O
to	O
analyze	O
transcriptional	O
activity	O
,	O
the	O
luciferase	O
reporter	O
plasmids	O
were	O
transiently	O
transfected	O
into	O
A3.01	O
T	O
cells	O
.	O

Luciferase	O
assays	O
revealed	O
a	O
approximately20	O
-	O
fold	O
increased	B-Positive_regulation
transcriptional	B-Transcription
activity	I-Transcription
of	O
the	O
1025	O
bp	O
sequence	O
as	O
compared	O
to	O
the	O
empty	O
vector	O
,	O
indicating	O
that	O
we	O
had	O
identified	O
an	O
active	O
A3G	O
promoter	O
sequence	O
(	O
Figure	O
3B	O
)	O
.	O

This	O
transcription	O
rate	O
was	O
not	O
significantly	O
altered	B-Regulation
by	O
the	O
5	O
'	O
deletions	O
leading	O
to	O
the	O
502	O
,	O
225	O
and	O
180	O
bp	O
fragments	O
(	O
Figure	O
3B	O
)	O
.	O

In	O
contrast	O
,	O
a	O
drop	B-Negative_regulation
in	O
luciferase	O
activity	O
was	O
observed	O
in	O
the	O
case	O
of	O
the	O
150	O
bp	O
fragment	O
.	O

This	O
construct	O
only	O
retained	O
28	O
%	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
promoter	O
in	O
A3.01	O
T	O
cells	O
and	O
activity	O
of	O
the	O
120	O
bp	O
fragment	O
was	O
further	O
reduced	O
.	O

Comparable	O
reductions	O
relative	O
to	O
the	O
activity	O
of	O
180	O
bp	O
fragment	O
were	O
observed	O
in	O
the	O
myeloid	O
cell	O
line	O
U937	O
and	O
the	O
hepatic	O
cell	O
lines	O
HepG2	O
and	O
Huh7	O
(	O
Figure	O
3C	O
)	O
,	O
indicating	O
that	O
the	O
core	O
promoter	O
of	O
A3G	O
is	O
located	O
within	O
the	O
region	O
-	O
114/+66	O
relative	O
to	O
the	O
TSS	O
.	O

The	O
A3G	O
promoter	O
is	O
not	O
inducible	B-Positive_regulation
in	O
T	O
cells	O

According	O
to	O
the	O
current	O
knowledge	O
,	O
APOBEC3G	O
plays	O
a	O
role	O
in	O
the	O
innate	O
defence	O
against	O
pathogens	O
like	O
HIV	O
-	O
1	O
.	O

The	O
latter	O
has	O
evolved	O
a	O
mechanism	O
to	O
counteract	B-Negative_regulation
A3G	O
activity	O
by	O
expressing	B-Gene_expression
the	O
regulatory	O
protein	O
Vif	O
(	O
4	O
)	O
.	O

Vif	O
induces	B-Positive_regulation
proteasomal	O
degradation	B-Protein_catabolism
of	O
A3G	O
and	O
additionally	O
inhibits	B-Negative_regulation
A3G	O
activity	O
by	O
further	O
mechanisms	O
(	O
8	O
,	O
37	O
-	O
43	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
overexpression	O
of	O
HIV	O
-	O
1	O
proteins	O
also	O
influences	O
A3G	O
promoter	O
activity	O
,	O
we	O
either	O
expressed	B-Gene_expression
HIV	O
-	O
1	O
Vif	O
or	O
the	O
HIV	O
-	O
1	O
Tat	O
protein	O
,	O
the	O
latter	O
has	O
been	O
shown	O
to	O
activate	O
different	O
viral	O
and	O
cellular	O
promoters	O
(	O
44	O
,	O
45	O
)	O
.	O

In	O
addition	O
,	O
increasing	O
amounts	O
of	O
the	O
plasmid	O
pNL4	O
-	O
3	O
,	O
containing	O
the	O
full	O
-	O
length	O
genome	O
of	O
HIV	O
-	O
1	O
,	O
were	O
transfected	O
.	O

These	O
constructs	O
or	O
the	O
empty	O
vector	O
pcDNA3.1	O
were	O
cotransfected	O
with	O
the	O
1025	O
bp	O
construct	O
into	O
A3.01	O
T	O
cells	O
.	O

Luciferase	O
assays	O
showed	O
that	O
the	O
transcriptional	O
activity	O
of	O
the	O
A3G	O
promoter	O
was	O
not	O
significantly	O
altered	O
in	O
the	O
presence	O
of	O
Vif	O
,	O
Tat	O
or	O
HIV-1NL4	O
-	O
3	O
(	O
Figure	O
4A	O
)	O
,	O
suggesting	O
that	O
HIV	O
-	O
1	O
is	O
not	O
modulating	B-Regulation
A3G	O
expression	B-Gene_expression
on	O
the	O
transcriptional	O
level	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
amount	O
of	O
A3G	O
mRNA	O
in	O
T	O
cells	O
is	O
increased	B-Positive_regulation
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phorbol	O
ester	O
(	O
46	O
-	O
48	O
)	O
.	O

In	O
addition	O
,	O
interferons	O
have	O
been	O
described	O
to	O
upregulate	B-Positive_regulation
A3G	O
expression	B-Gene_expression
in	O
hepatocytes	O
and	O
macrophages	O
(	O
46	O
,	O
48	O
)	O
.	O

To	O
investigate	O
whether	O
these	O
stimuli	O
interfere	O
with	O
A3G	O
promoter	O
activity	O
in	O
T	O
cells	O
,	O
we	O
transfected	O
A3.01	O
T	O
cells	O
with	O
the	O
1025	O
bp	O
promoter	O
or	O
the	O
empty	O
vector	O
pGL3	O
-	O
Basic	O
(	O
vector	O
)	O
and	O
treated	O
the	O
cells	O
with	O
phorbol	O
ester	O
(	O
TPA	O
)	O
.	O

The	O
luciferase	O
assay	O
showed	O
that	O
the	O
approximately15	O
-	O
fold	O
increased	B-Positive_regulation
transcriptional	B-Transcription
activity	B-Positive_regulation
of	O
the	O
1025	O
bp	O
promoter	O
relative	O
to	O
the	O
empty	O
vector	O
was	O
not	O
further	O
enhanced	B-Positive_regulation
by	O
TPA	O
treatment	O
(	O
Figure	O
4B	O
)	O
,	O
although	O
the	O
functional	O
activity	O
of	O
TPA	O
was	O
confirmed	O
by	O
induction	O
of	O
the	O
SV40	O
promoter	O
-	O
containing	O
reporter	O
plasmid	O
pGL3	O
-	O
Control	O
(	O
data	O
not	O
shown	O
)	O
.	O

Similarly	O
,	O
treatment	O
of	O
A3.01	O
T	O
cells	O
transfected	O
with	O
the	O
A3G	O
promoter	O
deletion	O
constructs	O
with	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
showed	O
no	O
effect	O
(	O
Figure	O
4C	O
)	O
.	O

Interestingly	O
,	O
a	O
control	O
plasmid	O
(	O
pGL2	O
-	O
CVX	O
)	O
containing	O
twoIFN	O
-	O
responsive	O
GAS	O
(	O
gamma	O
activated	O
sequence	O
)	O
elements	O
upstream	O
of	O
the	O
luciferase	O
reporter	O
gene	O
was	O
only	O
induced	O
by	O
IFN	O
-	O
alpha	O
in	O
these	O
cells	O
(	O
Figure	O
4C	O
)	O
.	O

Since	O
two	O
reports	O
describe	O
A3G	O
upregulation	B-Positive_regulation
by	O
interferons	O
in	O
hepatocytes	O
(	O
47	O
,	O
48	O
)	O
,	O
we	O
additionally	O
performed	O
the	O
experiment	O
in	O
the	O
hepatic	O
cell	O
line	O
HepG2	O
.	O

In	O
line	O
with	O
these	O
publications	O
,	O
we	O
observed	O
an	O
induction	B-Positive_regulation
of	O
the	O
A3G	O
promoter	O
by	O
approximately	O
2	O
-	O
fold	O
after	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
stimulation	O
(	O
Figure	O
4D	O
)	O
with	O
IFN	O
-	O
gamma	O
being	O
slightly	O
more	O
potent	O
.	O

For	O
both	O
interferon	O
types	O
,	O
induction	O
of	O
A3G	O
promoter	O
activity	O
was	O
observed	O
for	O
all	O
deletion	O
constructs	O
except	O
for	O
the	O
60	O
bp	O
fragment	O
,	O
indicating	O
that	O
the	O
responsible	O
region	O
is	O
located	O
within	O
the	O
60	O
nt	O
present	O
in	O
the	O
120	O
bp	O
,	O
but	O
not	O
in	O
the	O
60	O
bp	O
fragment	O
.	O

A	O
GC	O
-	O
box	O
located	O
at	O
position	O
-87/	O
-	O
78	O
of	O
the	O
A3G	O
promoter	O
is	O
important	O
for	O
transcriptional	O
activity	O

The	O
reporter	O
studies	O
shown	O
in	O
Figure	O
3	O
had	O
demonstrated	O
a	O
drop	O
in	O
luciferase	O
activity	O
after	O
deletion	O
of	O
the	O
30	O
nt	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
.	O

We	O
therefore	O
inspected	O
the	O
30	O
bp	O
sequence	O
deleted	O
in	O
the	O
150	O
bp	O
fragment	O
and	O
identified	O
a	O
GC	O
-	O
box	O
at	O
position	O
-87/	O
-	O
78	O
(	O
see	O
Figure	O
1	O
)	O
.	O

The	O
sequence	O
TGGGCGGGAC	O
,	O
which	O
is	O
interrupted	O
in	O
the	O
150	O
bp	O
fragment	O
,	O
represents	O
a	O
variant	O
of	O
the	O
(	O
G/T	O
)	O
GGGCGG	O
(	O
G/A	O
)	O
(	O
G/A	O
)	O
(	O
C/T	O
)	O
consensus	O
motif	O
recognized	B-Binding
by	O
Sp1	O
and	O
Sp3	O
transcription	O
factors	O
.	O

To	O
analyze	O
whether	O
this	O
putative	O
Sp1/Sp3	O
-	O
binding	O
site	O
mediates	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
,	O
we	O
introduced	O
two	O
point	O
mutations	O
which	O
changed	O
the	O
sequence	O
from	O
TGGGCGGGAC	O
to	O
TGTTCGGGAC	O
(	O
mutations	O
shown	O
in	O
bold	O
)	O
.	O

This	O
resulted	O
in	O
a	O
71	O
%	O
reduction	O
of	O
the	O
transcriptional	O
activity	O
compared	O
to	O
the	O
unmodified	O
180	O
bp	O
promoter	O
(	O
Figure	O
5A	O
)	O
and	O
this	O
value	O
was	O
only	O
marginally	O
higher	O
than	O
the	O
luciferase	O
activity	O
of	O
the	O
150	O
bp	O
fragment	O
,	O
indicating	O
that	O
the	O
identified	O
motif	O
is	O
essential	O
for	O
basal	O
activity	O
of	O
the	O
A3G	O
core	O
promoter	O
.	O

To	O
further	O
examine	O
the	O
transcriptional	O
potency	O
of	O
the	O
30	O
nt	O
present	O
in	O
the	O
180	O
bp	O
promoter	O
,	O
we	O
cloned	O
the	O
region	O
-114/	O
-	O
85	O
(	O
containing	O
all	O
nucleotides	O
which	O
are	O
deleted	O
in	O
the	O
150	O
bp	O
fragment	O
,	O
designated	O
E1	O
)	O
or	O
the	O
region	O
-92/	O
-	O
63	O
(	O
containing	O
the	O
putative	O
Sp1/Sp3	O
motif	O
,	O
designated	O
E2	O
)	O
into	O
the	O
vector	O
pGL3	O
-	O
Promoter	O
(	O
see	O
Figure	O
1	O
)	O
.	O

This	O
vector	O
contains	O
a	O
luciferase	O
reporter	O
gene	O
under	B-Regulation
the	I-Regulation
control	I-Regulation
of	O
an	O
SV40	O
promoter	O
without	O
enhancer	O
sequences	O
,	O
and	O
putative	O
transcriptionally	O
active	O
sequences	O
can	O
be	O
cloned	O
upstream	O
of	O
the	O
SV40	O
promoter	O
.	O

Luciferase	O
assays	O
showed	O
that	O
the	O
E1	O
element	O
increased	O
SV40	O
promoter	O
activity	O
only	O
by	O
approximately2	O
-	O
fold	O
(	O
Figure	O
5B	O
)	O
.	O

In	O
contrast	O
,	O
the	O
30	O
nt	O
of	O
E2	O
enhanced	B-Positive_regulation
the	O
transcriptional	B-Transcription
activity	I-Transcription
of	O
the	O
SV40	O
promoter	O
by	O
approximately4.3	O
-	O
fold	O
,	O
indicating	O
that	O
the	O
intact	O
GC	O
-	O
box	O
present	O
in	O
the	O
E2	O
element	O
was	O
responsible	B-Positive_regulation
for	O
the	O
strongly	O
enhanced	B-Positive_regulation
transcriptional	B-Positive_regulation
activity	I-Positive_regulation
of	O
the	O
SV40	O
promoter	O
.	O

Sp1	O
and	O
Sp3	O
transcription	O
factors	O
bind	B-Binding
to	O
the	O
GC	O
-	O
box	O
at	O
position	O
-87/	O
-	O
78	O
of	O
the	O
A3G	O
promoter	O

To	O
investigate	O
whether	O
the	O
GC	O
-	O
box	O
represents	B-Binding
a	I-Binding
binding	I-Binding
site	I-Binding
for	O
the	O
transcription	O
factors	O
Sp1	O
and	O
Sp3	O
,	O
we	O
performed	O
EMSA	O
analyses	O
with	O
nuclear	O
extracts	O
isolated	O
from	O
A3.01	O
T	O
cells	O
.	O

As	O
probes	O
,	O
we	O
radioactively	O
labeled	O
the	O
unmodified	O
E2	O
sequence	O
(	O
nucleotides	O
-92/	O
-	O
63	O
of	O
the	O
A3G	O
promoter	O
,	O
probe	O
designated	O
APO	O
-	O
Sp1/3	O
)	O
or	O
the	O
same	O
region	O
carrying	O
the	O
two	O
point	O
mutations	O
described	O
above	O
(	O
probe	O
designated	O
APO	O
-	O
Sp1/3mut	O
)	O
.	O

As	O
control	O
,	O
we	O
used	O
a	O
commercially	O
available	O
Sp1	O
consensus	O
oligonucleotide	O
(	O
Sp1cons	O
)	O
,	O
which	O
is	O
known	O
to	O
be	O
recognized	B-Binding
by	O
Sp1	O
transcription	O
factors	O
.	O

Four	O
DNA	O
-	O
protein	O
complexes	O
were	O
observed	O
in	O
the	O
presence	O
of	O
the	O
APO	O
-	O
Sp1/3	O
probe	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
upper	O
two	O
complexes	O
were	O
specific	O
since	O
they	O
disappeared	O
in	O
the	O
presence	O
of	O
a	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
APO	O
-	O
Sp1/3	O
probe	O
(	O
Figure	O
6A	O
,	O
lane	O
7	O
)	O
.	O

Further	O
confirmation	O
of	O
the	O
specificity	O
of	O
these	O
DNA	O
-	O
protein	O
complexes	O
was	O
demonstrated	O
by	O
the	O
inability	O
of	O
the	O
unlabeled	O
APO	O
-	O
Sp1/3mut	O
probe	O
to	O
abolish	O
binding	O
(	O
Figure	O
6A	O
,	O
lanes	O
12	O
and	O
13	O
)	O
.	O

As	O
expected	O
,	O
the	O
two	O
specific	O
complexes	O
were	O
also	O
present	O
in	O
the	O
case	O
of	O
the	O
Sp1	O
cons	O
control	O
probe	O
(	O
Figure	O
6A	O
,	O
lanes	O
2	O
and	O
3	O
)	O
.	O

In	O
contrast	O
,	O
none	O
of	O
these	O
specific	O
complexes	O
was	O
observed	O
when	O
the	O
mutated	O
probe	O
was	O
used	O
(	O
Figure	O
6A	O
,	O
lanes	O
10	O
and	O
11	O
)	O
,	O
confirming	O
that	O
protein	O
binding	O
was	O
dependent	O
on	O
the	O
identified	O
GC	O
-	O
box	O
.	O

In	O
order	O
to	O
characterize	O
the	O
complexes	O
,	O
we	O
performed	O
supershift	O
experiments	O
using	O
Sp1	O
-	O
and	O
Sp3	O
-	O
specific	O
antibodies	O
.	O

The	O
upper	O
of	O
the	O
complexes	O
that	O
appeared	O
in	O
combination	O
with	O
the	O
Sp1cons	O
or	O
APO	O
-	O
Sp1/3	O
probes	O
,	O
shifted	O
in	O
the	O
presence	O
of	O
the	O
Sp1	O
antibody	O
(	O
Figure	O
6B	O
,	O
lanes	O
3	O
and	O
7	O
)	O
,	O
whereas	O
the	O
lower	O
complex	O
shifted	O
in	O
the	O
presence	O
of	O
the	O
Sp3	O
antibody	O
(	O
Figure	O
6B	O
,	O
lanes	O
4	O
and	O
8	O
)	O
.	O

Taken	O
together	O
,	O
the	O
EMSA	O
demonstrated	O
that	O
the	O
GC	O
-	O
box	O
located	O
on	O
the	O
A3G	O
core	O
promoter	O
serves	B-Binding
as	I-Binding
a	I-Binding
binding	I-Binding
site	I-Binding
for	O
Sp1	O
and	O
Sp3	O
.	O

To	O
show	O
binding	B-Binding
of	O
Sp1	O
and	O
Sp3	O
factors	O
also	O
in	O
the	O
context	O
of	O
the	O
endogenous	O
A3G	O
promoter	O
,	O
a	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
was	O
performed	O
.	O

Sp1	O
and	O
Sp3	O
antibodies	O
,	O
but	O
not	O
an	O
actin	O
antibody	O
,	O
immunoprecipitated	O
the	O
A3G	O
promoter	O
in	O
A3.01	O
T	O
cells	O
(	O
Figure	O
6C	O
,	O
upper	O
panel	O
)	O
.	O

In	O
contrast	O
,	O
no	O
PCR	O
signal	O
was	O
received	O
with	O
a	O
primer	O
pair	O
recognizing	O
a	O
region	O
in	O
the	O
A3G	O
gene	O
approximately4000	O
bp	O
downstream	O
of	O
the	O
Sp1/Sp3	O
-	O
binding	O
site	O
(	O
Figure	O
6C	O
,	O
lower	O
panel	O
)	O
.	O

Only	O
the	O
positive	O
controls	O
showed	O
a	O
DNA	O
band	O
,	O
with	O
an	O
A3G	O
expression	B-Gene_expression
plasmid	O
or	O
the	O
sheared	O
and	O
cross	O
-	O
linked	O
input	O
DNA	O
used	O
as	O
template	O
.	O

This	O
demonstrates	O
the	O
binding	B-Binding
of	O
Sp1	O
and	O
Sp3	O
transcription	O
factors	O
to	O
the	O
endogenous	O
A3G	O
promoter	O
.	O

Silencing	B-Negative_regulation
of	O
Sp1	O
and	O
Sp3	O
reduces	O
A3G	O
promoter	O
activity	O

To	O
confirm	O
the	O
role	O
of	O
Sp1	O
and	O
Sp3	O
in	O
regulation	O
of	O
A3G	O
promoter	O
activity	O
,	O
we	O
silenced	O
their	O
translation	O
via	O
RNA	O
interference	O
.	O

Functionality	O
of	O
the	O
siRNAs	O
directed	O
against	O
Sp1	O
or	O
Sp3	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
:	O
protein	B-Gene_expression
levels	I-Gene_expression
of	O
Sp1	O
as	O
well	O
as	O
the	O
long	O
and	O
short	O
isoforms	O
of	O
Sp3	O
were	O
strongly	O
reduced	B-Negative_regulation
in	O
the	O
presence	O
of	O
150	O
or	O
300	O
ng	O
specific	O
siRNA	O
(	O
Figure	O
7A	O
)	O
.	O

An	O
unspecific	O
control	O
siRNA	O
had	O
no	O
influence	O
(	O
Figure	O
7A	O
)	O
.	O

We	O
then	O
cotransfected	B-Gene_expression
the	O
luciferase	O
reporter	O
plasmid	O
containing	O
the	O
180	O
bp	O
A3G	O
promoter	O
together	O
with	O
100	O
ng	O
siRNA	O
using	O
an	O
optimized	O
protocol	O
for	O
the	O
cotransfection	O
of	O
plasmid	O
plus	O
siRNA	O
.	O

This	O
resulted	O
in	O
a	O
31	O
-	O
43	O
%	O
reduction	B-Negative_regulation
of	O
luciferase	O
activity	O
in	O
the	O
presence	O
of	O
Sp1	O
-	O
or	O
Sp3	O
-	O
specific	O
siRNA	B-Negative_regulation
compared	O
to	O
the	O
control	O
siRNA	O
.	O

In	O
contrast	O
,	O
no	O
influence	O
on	O
transcriptional	O
activity	O
of	O
the	O
150	O
bp	O
fragment	O
,	O
which	O
does	O
not	O
contain	O
the	O
Sp1/Sp3	O
-	O
binding	O
motif	O
,	O
was	O
observed	O
.	O

Thus	O
,	O
both	O
Sp1	O
and	O
Sp3	O
factors	O
are	O
mediating	O
transcriptional	O
activity	O
of	O
the	O
A3G	O
promoter	O
.	O

DISCUSSION	O

Shortly	O
after	O
the	O
discovery	O
of	O
APOBEC3G	O
,	O
it	O
became	O
clear	O
that	O
this	O
human	O
gene	O
plays	O
an	O
important	O
role	O
in	O
antiretroviral	O
defense	O
(	O
4	O
)	O
.	O

Originally	O
identified	O
as	O
a	O
restriction	O
factor	O
of	O
HIV	O
-	O
1	O
infection	O
,	O
expression	B-Gene_expression
of	O
APOBEC3G	O
was	O
found	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
,	O
which	O
represent	O
the	O
main	O
target	O
cells	O
for	O
HIV	O
-	O
1	O
(	O
32	O
)	O
.	O

In	O
addition	O
,	O
the	O
protein	O
was	O
detected	B-Gene_expression
in	O
lung	O
,	O
liver	O
,	O
spleen	O
,	O
testis	O
and	O
ovary	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
transcriptional	O
regulation	O
(	O
29	O
,	O
32	O
,	O
47	O
)	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
cloned	O
the	O
human	O
APOBEC3G	O
promoter	O
and	O
analyzed	O
its	O
regulation	B-Regulation
in	O
T	O
cells	O
.	O

Applying	O
5'	O
-	O
RACE	O
,	O
we	O
identified	O
multiple	O
start	O
sites	O
for	O
transcription	B-Transcription
of	O
the	O
A3G	O
gene	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
the	O
gene	O
appears	O
to	O
lack	O
canonical	O
CCAAT	O
and	O
TATA	O
boxes	O
(	O
32	O
)	O
,	O
a	O
condition	O
often	O
associated	O
with	O
multiple	O
transcriptional	O
start	O
sites	O
(	O
49	O
-	O
51	O
)	O
.	O

However	O
,	O
one	O
single	O
start	O
site	O
was	O
detected	O
in	O
6	O
of	O
19	O
clones	O
and	O
was	O
designated	O
as	O
+1	O
.	O

This	O
TSS	O
is	O
located	O
66	O
bp	O
upstream	O
of	O
the	O
start	O
of	O
the	O
published	O
mRNA	O
sequence	O
(	O
GenBanktrade	O
NM021822	O
)	O
.	O

We	O
cloned	O
a	O
1025	O
bp	O
promoter	O
,	O
which	O
ranges	O
from	O
position	O
-	O
959/+66	O
relative	O
to	O
the	O
identified	O
TSS	O
.	O

Luciferase	O
reporter	O
assays	O
showed	O
that	O
this	O
promoter	O
was	O
transcriptionally	O
active	O
in	O
A3.01	O
T	O
cells	O
.	O

Treatment	O
with	O
the	O
phorbol	O
ester	O
TPA	O
did	O
not	O
further	O
enhance	B-Positive_regulation
transcriptional	B-Transcription
activity	O
,	O
although	O
upregulation	B-Positive_regulation
of	O
A3G	O
mRNA	O
levels	O
in	O
T	O
cells	O
by	O
TPA	O
has	O
been	O
described	O
(	O
33	O
)	O
.	O

Rose	O
et	O
al.	O
used	O
actinomycin	O
D	O
to	O
block	B-Negative_regulation
further	O
transcription	B-Transcription
and	O
did	O
not	O
find	O
evidence	O
for	O
enhanced	O
mRNA	O
stability	O
.	O

Therefore	O
,	O
the	O
authors	O
suggested	O
that	O
an	O
enhanced	B-Positive_regulation
transcription	B-Transcription
rate	O
could	O
be	O
responsible	O
for	O
the	O
increased	B-Positive_regulation
amount	O
of	O
A3G	O
mRNA	O
after	O
TPA	O
treatment	O
.	O

However	O
,	O
the	O
promoter	O
analysis	O
we	O
performed	O
indicates	O
a	O
different	O
mechanism	O
that	O
is	O
independent	O
of	O
transcriptional	O
regulation	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
A3G	O
promoter	O
was	O
not	O
inducible	B-Positive_regulation
by	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
in	O
A3.01	O
T	O
cells	O
,	O
whereas	O
in	O
the	O
hepatic	O
cell	O
line	O
HepG2	O
,	O
a	O
moderate	O
induction	O
was	O
measured	O
.	O

It	O
has	O
been	O
described	O
previously	O
that	O
A3G	O
gene	O
expression	B-Gene_expression
is	O
upregulated	B-Positive_regulation
by	O
interferons	O
in	O
hepatocytes	O
and	O
macrophages	O
(	O
46	O
-	O
48	O
,	O
52	O
)	O
.	O

In	O
this	O
context	O
,	O
two	O
interferon	O
-	O
responsive	O
elements	O
have	O
been	O
identified	O
at	O
the	O
positions	O
-	O
6/+9	O
and	O
+1/+15	O
relative	O
to	O
the	O
TSS	O
(	O
48	O
)	O
.	O

Consistent	O
with	O
this	O
data	O
,	O
we	O
observed	O
an	O
interferon	O
induction	O
in	O
hepatocytes	O
for	O
the	O
fragments	O
ranging	O
between	O
1025	O
and	O
120	O
bp	O
length	O
.	O

The	O
activity	O
of	O
the	O
60	O
bp	O
fragment	O
that	O
does	O
not	O
contain	O
these	O
motifs	O
was	O
not	O
affected	B-Regulation
.	O

Thus	O
,	O
the	O
induction	O
we	O
observed	O
was	O
most	O
likely	O
mediated	O
by	O
the	O
described	O
interferon	O
-	O
responsive	O
elements	O
.	O

However	O
,	O
according	O
to	O
our	O
results	O
,	O
these	O
motifs	O
can	O
enhance	B-Positive_regulation
transcription	B-Transcription
in	O
hepatic	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

This	O
is	O
surprising	O
,	O
since	O
IFN-alpha	O
-	O
inducible	O
signaling	O
cascades	O
are	O
present	O
in	O
A3.01	O
T	O
cells	O
:	O
we	O
showed	O
that	O
the	O
control	O
plasmid	O
harboring	O
interferon	O
-	O
responsive	O
GAS	O
elements	O
was	O
markedly	O
induced	O
by	O
IFN	O
-	O
alpha	O
treatment	O
.	O

In	O
contrast	O
,	O
the	O
GAS	O
element	O
was	O
not	O
responsive	O
to	O
IFN	O
-	O
gamma	O
treatment	O
in	O
these	O
cells	O
,	O
suggesting	O
that	O
our	O
T	O
cell	O
line	O
was	O
not	O
able	O
to	O
mediate	O
IFN-gamma	O
-	O
induced	O
signals	O
.	O

So	O
far	O
,	O
enhanced	O
A3G	O
promoter	O
activity	O
by	O
interferons	O
is	O
clearly	O
described	O
in	O
hepatocytes	O
and	O
macrophages	O
,	O
whereas	O
the	O
situation	O
in	O
T	O
cells	O
is	O
still	O
unclear	O
.	O

A	O
recent	O
study	O
found	O
no	O
influence	B-Regulation
of	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
on	O
A3G	O
expression	B-Gene_expression
in	O
resting	O
primary	O
blood	O
lymphocytes	O
(	O
52	O
)	O
.	O

Another	O
publication	O
describes	O
an	O
enhanced	B-Positive_regulation
expression	B-Gene_expression
of	O
A3G	O
after	O
IFN	O
-	O
alpha	O
treatment	O
in	O
resting	O
primary	O
CD4	O
T	O
cells	O
,	O
but	O
not	O
in	O
activated	O
T	O
cells	O
(	O
53	O
)	O
.	O

This	O
observation	O
is	O
not	O
contradictory	O
to	O
our	O
results	O
since	O
T	O
cell	O
lines	O
are	O
mitotically	O
active	O
and	O
therefore	O
rather	O
in	O
an	O
activated	O
than	O
in	O
a	O
resting	O
state	O
.	O

In	O
conclusion	O
,	O
the	O
current	O
data	O
suggests	O
that	O
regulation	O
of	O
the	O
A3G	O
promoter	O
activity	O
by	O
interferons	O
is	O
dependent	O
on	O
the	O
cell	O
type	O
and	O
possibly	O
also	O
from	O
the	O
cellular	O
activation	O
status	O
.	O

We	O
additionally	O
analyzed	O
the	O
influence	O
of	O
HIV	O
-	O
1	O
proteins	O
on	O
A3G	O
promoter	O
activity	O
.	O

The	O
HIV	O
-	O
1	O
Vif	O
protein	O
is	O
neutralizing	O
the	O
antiviral	O
function	O
of	O
A3G	O
by	O
a	O
multitude	O
of	O
ways	O
.	O

Targeting	B-Positive_regulation
the	O
A3G	O
protein	O
for	O
proteasomal	B-Protein_catabolism
degradation	I-Protein_catabolism
is	O
considered	O
to	O
be	O
the	O
main	O
mode	O
of	O
action	O
(	O
37	O
-	O
41	O
)	O
,	O
but	O
it	O
becomes	O
more	O
and	O
more	O
clear	O
that	O
other	O
mechanisms	O
are	O
also	O
involved	O
.	O

There	O
is	O
evidence	O
that	O
Vif	O
also	O
promotes	O
exclusion	O
of	O
A3G	O
from	O
the	O
virus	O
particles	O
and	O
an	O
influence	O
on	O
the	O
A3G	O
translation	O
process	O
is	O
discussed	O
(	O
8	O
,	O
42	O
,	O
43	O
)	O
.	O

The	O
question	O
whether	O
Vif	O
alters	B-Regulation
transcription	B-Transcription
controlled	B-Regulation
by	O
the	O
A3G	O
promoter	O
has	O
not	O
been	O
analyzed	O
so	O
far	O
.	O

Our	O
analysis	O
indicates	O
that	O
transcription	B-Transcription
from	B-Positive_regulation
the	O
A3G	O
promoter	O
is	O
unaffected	B-Regulation
by	O
Vif	O
or	O
other	O
HIV	O
-	O
1	O
proteins	O
.	O

Taken	O
together	O
,	O
in	O
T	O
cell	O
lines	O
,	O
the	O
A3G	O
promoter	O
appears	O
constitutively	O
active	B-Positive_regulation
.	O

By	O
generating	O
a	O
series	O
of	O
5	O
'	O
deletions	O
,	O
we	O
showed	O
that	O
the	O
core	O
promoter	O
is	O
located	O
within	O
the	O
region	O
-	O
114/+66	O
relative	O
to	O
the	O
TSS	O
.	O

This	O
180	O
bp	O
promoter	O
was	O
transcriptionally	O
active	O
in	O
the	O
lymphoid	O
,	O
myeloid	O
and	O
hepatic	O
cell	O
lines	O
we	O
tested	O
,	O
indicating	O
that	O
ubiquitous	O
transcription	O
factors	O
are	O
involved	O
in	O
regulation	B-Regulation
of	O
A3G	O
gene	O
transcription	B-Transcription
.	O

A	O
GC	O
-	O
box	O
with	O
the	O
sequence	O
TGGGCGGGAC	O
was	O
identified	O
at	O
position	O
-87/	O
-	O
78	O
of	O
the	O
A3G	O
promoter	O
.	O

This	O
GC	O
-	O
box	O
is	O
essential	O
for	O
basal	O
promoter	O
activity	O
,	O
since	O
changing	O
the	O
motif	O
to	O
TGTTCGGGAC	O
by	O
introducing	O
two	O
point	O
mutations	O
strongly	O
reduced	O
A3G	O
promoter	O
activity	O
.	O

The	O
transcriptional	O
potency	O
of	O
the	O
GC	O
-	O
box	O
was	O
further	O
demonstrated	O
by	O
cloning	O
it	O
upstream	O
of	O
an	O
SV40	O
promoter	O
.	O

This	O
resulted	O
in	O
a	O
4	O
-	O
fold	O
enhanced	O
transcription	O
rate	O
.	O

The	O
hypothesis	O
that	O
a	O
general	O
transcription	O
factor	O
is	O
involved	O
in	O
regulation	B-Regulation
of	O
A3G	O
transcription	B-Transcription
was	O
confirmed	O
by	O
EMSA	O
.	O

Supershift	O
analysis	O
showed	O
that	O
the	O
transcription	O
factors	O
Sp1	O
and	O
Sp3	O
which	O
are	O
ubiquitously	O
expressed	B-Gene_expression
in	O
mammalian	O
cells	O
,	O
bind	B-Binding
specifically	O
to	O
the	O
identified	O
motif	O
.	O

In	O
addition	O
,	O
the	O
binding	B-Binding
of	O
Sp1	O
and	O
Sp3	O
to	O
the	O
endogenous	O
A3G	O
promoter	O
was	O
demonstrated	O
by	O
a	O
chromatin	O
immunoprecipitation	O
assay	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
results	O
of	O
the	O
5'	O
-	O
RACE	O
,	O
since	O
Sp1	O
is	O
known	O
to	O
play	B-Positive_regulation
an	I-Positive_regulation
important	I-Positive_regulation
role	I-Positive_regulation
for	O
RNA	O
polymerase	O
II	O
to	O
bind	B-Binding
to	O
the	O
transcription	O
initiation	O
site	O
in	O
TATA	O
-	O
boxless	O
promoters	O
and	O
is	O
associated	O
with	O
multiple	O
transcription	O
initiation	O
sites	O
(	O
54	O
-	O
56	O
)	O
.	O

We	O
also	O
tested	O
whether	O
overexpression	B-Gene_expression
of	O
Sp1	O
or	O
Sp3	O
proteins	O
had	O
an	O
influence	O
on	O
A3G	O
promoter	O
activity	O
.	O

Luciferase	O
assays	O
revealed	O
that	O
A3G	O
promoter	O
activities	O
remained	O
unchanged	O
(	O
data	O
not	O
shown	O
)	O
,	O
most	O
probably	O
due	O
to	O
the	O
high	O
basal	O
expression	B-Gene_expression
level	O
of	O
the	O
endogenous	O
Sp1	O
and/or	O
Sp3	O
proteins	O
.	O

The	O
Sp	O
family	O
of	O
transcription	O
factors	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
many	O
housekeeping	O
,	O
tissue	O
-	O
specific	O
,	O
viral	O
and	O
inducible	O
genes	O
(	O
57	O
)	O
.	O

Whereas	O
Sp1	O
typically	O
acts	O
as	O
an	O
activator	O
,	O
Sp3	O
can	O
serve	O
as	O
a	O
repressor	O
or	O
activator	O
(	O
57	O
)	O
.	O

However	O
,	O
in	O
the	O
context	O
of	O
the	O
A3G	O
promoter	O
,	O
both	O
transcription	O
factors	O
serve	B-Positive_regulation
as	I-Positive_regulation
activators	I-Positive_regulation
,	I-Positive_regulation
as	O
shown	O
by	O
siRNA	O
-	O
mediated	O
silencing	B-Negative_regulation
of	O
the	O
single	O
factors	O
.	O

Although	O
siRNAs	O
directed	O
against	O
Sp1	O
or	O
Sp3	O
significantly	O
reduced	B-Negative_regulation
transcription	B-Transcription
controlled	B-Regulation
by	O
the	O
180	O
bp	O
promoter	O
,	O
transcriptional	B-Transcription
activity	O
was	O
not	O
reduced	B-Negative_regulation
to	O
the	O
level	O
of	O
the	O
150	O
bp	O
fragment	O
.	O

This	O
can	O
be	O
explained	O
by	O
the	O
remaining	O
low	O
amounts	O
of	O
Sp1/Sp3	O
proteins	O
which	O
can	O
be	O
seen	O
in	O
the	O
western	O
blot	O
analysis	O
.	O

Alternatively	O
,	O
other	O
transcription	O
factors	O
could	O
be	O
involved	O
in	O
A3G	O
regulation	B-Regulation
.	O

Our	O
results	O
also	O
provide	O
information	O
about	O
the	O
regulation	B-Regulation
of	O
APOBEC3F	O
(	O
A3F	O
)	O
,	O
another	O
member	O
of	O
the	O
human	O
APOBEC3	O
family	O
.	O

A3F	O
is	O
expressed	B-Gene_expression
in	O
many	O
human	O
tissues	O
that	O
also	O
express	B-Gene_expression
A3G	O
and	O
both	O
proteins	O
have	O
been	O
shown	O
to	O
form	B-Binding
heteromultimers	I-Binding
,	O
which	O
are	O
most	O
likely	O
generated	O
through	O
binding	O
to	O
an	O
RNA	O
intermediate	O
(	O
26	O
,	O
29	O
,	O
30	O
)	O
.	O

A3F	O
only	O
differs	O
in	O
16	O
nt	O
from	O
the	O
560	O
nt	O
upstream	O
of	O
the	O
TSS	O
of	O
A3G	O
(	O
GenBanktrade	O
DQ146365	O
and	O
DQ147772	O
)	O
.	O

The	O
180	O
-	O
bp	O
core	O
promoter	O
region	O
,	O
which	O
we	O
identified	O
for	O
A3G	O
has	O
100	O
%	O
identity	O
with	O
the	O
A3F	O
sequence	O
.	O

Therefore	O
,	O
Sp1/Sp3	O
transcription	O
factors	O
are	O
most	O
likely	O
also	O
mediating	B-Positive_regulation
basal	O
transcription	B-Transcription
of	O
the	O
A3F	O
gene	O
.	O

Our	O
study	O
revealed	O
that	O
the	O
human	O
A3G	O
gene	O
is	O
controlled	B-Regulation
by	O
a	O
promoter	O
with	O
multiple	O
transcriptional	O
start	O
sites	O
.	O

In	O
A3.01	O
T	O
cells	O
,	O
the	O
A3G	O
promoter	O
appears	O
constitutively	O
active	B-Positive_regulation
and	O
is	O
not	O
inducible	B-Positive_regulation
by	O
TPA	O
,	O
type	O
I	O
or	O
II	O
interferons	O
or	O
by	O
HIV	O
-	O
1	O
proteins	O
.	O

The	O
core	O
promoter	O
is	O
located	O
within	O
a	O
region	O
of	O
180	O
bp	O
at	O
position	O
-	O
114/+66	O
relative	O
to	O
the	O
TSS	O
.	O

A	O
GC	O
-	O
box	O
is	O
crucial	B-Positive_regulation
to	O
the	O
function	O
of	O
the	O
core	O
promoter	O
and	O
represents	O
a	O
binding	B-Binding
site	O
for	O
Sp1	O
and	O
Sp3	O
transcription	O
factors	O
.	O

Our	O
results	O
can	O
serve	O
as	O
a	O
basis	O
for	O
future	O
studies	O
aimed	O
at	O
understanding	O
how	O
A3G	O
and	O
A3F	O
expression	B-Gene_expression
is	O
controlled	B-Regulation
in	O
different	O
tissues	O
and	O
how	O
these	O
restriction	O
factors	O
can	O
be	O
used	O
to	O
develop	O
novel	O
therapeutic	O
strategies	O
against	O
HIV	O
-	O
1	O
infection	O
.	O

Sequence	O
of	O
the	O
A3G	O
promoter	O
and	O
the	O
downstream	O
region	O
.	O

The	O
first	O
1000	O
bp	O
upstream	O
of	O
the	O
major	O
TSS	O
are	O
shown	O
in	O
lower	O
case	O
,	O
the	O
first	O
800	O
bp	O
of	O
the	O
transcribed	O
sequence	O
are	O
shown	O
in	O
upper	O
case	O
.	O

Introns	O
are	O
removed	O
,	O
but	O
their	O
positions	O
are	O
indicated	O
.	O

Arrows	O
refer	O
to	O
transcriptional	O
start	O
sites	O
and	O
their	O
observed	O
frequency	O
is	O
given	O
by	O
the	O
numbers	O
above	O
.	O

The	O
primer	O
binding	O
sites	O
for	O
5'	O
-	O
RACE	O
analysis	O
and	O
cloning	O
of	O
the	O
luciferase	O
reporter	O
constructs	O
are	O
underlined	O
and	O
the	O
names	O
of	O
the	O
primers	O
are	O
annotated	O
.	O

Gray	O
and	O
black	O
arrowheads	O
define	O
the	O
regions	O
designated	O
E1	O
and	O
E2	O
which	O
were	O
cloned	O
into	O
vector	O
pGL3	O
-	O
Promoter	O
and	O
used	O
as	O
EMSA	O
probes	O
.	O

The	O
ATG	O
start	O
codon	O
and	O
the	O
identified	O
Sp1/Sp3	O
transcription	O
factor	O
binding	O
site	O
are	O
shown	O
in	O
bold	O
.	O

5'	O
-	O
RACE	O
analysis	O
of	O
the	O
A3G	O
cDNA	O
.	O

Agarose	O
gel	O
electrophoresis	O
of	O
size	O
marker	O
and	O
A3G	O
5'	O
-	O
RACE	O
products	O
after	O
nested	O
PCR	O
with	O
primer	O
RACE	O
-	O
APO3Gnest	O
(	O
see	O
Figure	O
1	O
for	O
primer	O
details	O
)	O
.	O

Arrowheads	O
indicate	O
the	O
three	O
resulting	O
DNA	O
bands	O
which	O
were	O
cloned	O
and	O
sequenced	O
.	O

Luciferase	O
activities	B-Positive_regulation
of	O
A3G	O
promoter	O
constructs	O
in	O
different	O
cell	O
lines	O
.	O

(	O
A	O
)	O
A3G	O
promoter	O
5	O
'	O
deletion	O
constructs	O
of	O
different	O
sizes	O
were	O
cloned	O
into	O
pGL3	O
-	O
Basic	O
luciferase	O
reporter	O
plasmids	O
.	O

Numbering	O
is	O
relative	O
to	O
the	O
major	O
TSS	O
.	O

A	O
putative	O
Sp1/Sp3	O
consensus	O
site	O
(	O
gray	O
square	O
)	O
is	O
depicted	O
.	O

(	O
B	O
)	O
A3.01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
the	O
A3G	O
promoter	O
deletion	O
constructs	O
.	O

Numbers	O
on	O
the	O
x	O
-	O
axis	O
refer	O
to	O
the	O
length	O
of	O
the	O
A3G	O
promoter	O
fragments	O
in	O
bp	O
.	O

(	O
C	O
)	O
A3G	O
promoter	O
plasmids	O
were	O
transfected	O
into	O
U937	O
,	O
HepG2	O
and	O
Huh7	O
cell	O
lines	O
.	O

Numbers	O
in	O
the	O
legends	O
refer	O
to	O
the	O
length	O
of	O
the	O
A3G	O
promoter	O
fragments	O
in	O
bp	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	O
assay	O
.	O

Firefly	O
luciferase	O
activities	O
were	O
normalized	O
to	O
coexpressed	B-Gene_expression
renilla	O
luciferase	O
activities	O
.	O

Mean	O
values	O
(	O
+/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

A3G	O
promoter	O
activities	O
after	O
coexpression	O
of	O
HIV	O
-	O
1	O
proteins	O
or	O
treatment	O
with	O
TPA	O
or	O
interferons	O
.	O

(	O
A	O
)	O
A3.01	O
T	O
cells	O
were	O
cotransfected	O
with	O
pGL3	O
-	O
Basic	O
reporter	O
plasmid	O
containing	O
the	O
1025	O
bp	O
A3G	O
promoter	O
and	O
1	O
microg	O
of	O
Vif	O
expression	O
plasmid	O
,	O
1	O
microg	O
Tat	O
expression	O
plasmid	O
or	O
increasing	O
amounts	O
of	O
HIV-1NL4	O
-	O
3	O
(	O
0.1	O
,	O
0.5	O
and	O
1	O
microg	O
)	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	O
assay	O
.	O

Firefly	O
luciferase	O
activities	O
were	O
normalized	O
to	O
coexpressed	B-Gene_expression
renilla	O
luciferase	O
activities	O
.	O

(	O
B	O
)	O
A3.01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
pGL3	O
-	O
Basic	O
reporter	O
plasmid	O
containing	O
the	O
1025	O
bp	O
A3G	O
promoter	O
or	O
with	O
empty	O
vector	O
.	O

Fifteen	O
hour	O
before	O
harvesting	O
for	O
luciferase	O
assay	O
,	O
a	O
subset	O
of	O
the	O
cell	O
culture	O
was	O
stimulated	O
with	O
20	O
ng/ml	O
TPA	O
.	O

Forty	O
-	O
eight	O
hour	O
after	O
transfection	O
,	O
luciferase	O
assay	O
was	O
performed	O
.	O

Firefly	O
luciferase	O
activities	O
were	O
normalized	O
to	O
coexpressed	B-Gene_expression
renilla	O
luciferase	O
activities	O
and	O
the	O
values	O
for	O
the	O
empty	O
vectors	O
(	O
untreated	O
and	O
TPA	O
-	O
stimulated	O
)	O
were	O
set	O
as	O
1	O
.	O

(	O
C	O
)	O
A3.01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
the	O
A3G	O
promoter	O
constructs	O
or	O
with	O
the	O
interferon	O
-	O
responsive	O
reporter	O
plasmid	O
pGL2	O
-	O
CVX	O
(	O
GAS	O
)	O
.	O

Fifteen	O
hour	O
before	O
harvesting	O
for	O
luciferase	O
assay	O
,	O
a	O
subset	O
of	O
the	O
cell	O
culture	O
was	O
stimulated	O
with	O
30	O
ng/ml	O
IFN	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
.	O

Forty	O
-	O
eight	O
hour	O
after	O
transfection	O
,	O
luciferase	O
assay	O
was	O
performed	O
.	O

Firefly	O
luciferase	O
activities	O
were	O
normalized	O
to	O
coexpressed	B-Gene_expression
renilla	O
luciferase	O
activities	O
.	O

(	O
D	O
)	O
HepG2	O
cells	O
were	O
used	O
for	O
transfection	O
.	O

The	O
experiment	O
was	O
performed	O
as	O
described	O
in	O
(	O
C	O
)	O
.	O

Mean	O
values	O
(	O
+/	O
-	O
SD	O
)	O
of	O
representative	O
experiments	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

A	O
GC	O
-	O
box	O
mediates	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
.	O

(	O
A	O
)	O
A3.01	O
T	O
cells	O
were	O
transfected	O
with	O
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
containing	O
180	O
,	O
150	O
or	O
120	O
bp	O
of	O
the	O
A3G	O
promoter	O
.	O

The	O
two	O
G-to	O
-	O
T	O
substitutions	O
introduced	O
into	O
the	O
GC	O
-	O
box	O
of	O
the	O
180	O
bp	O
fragment	O
(	O
180mut	O
)	O
are	O
specified	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	O
assay	O
.	O

Firefly	O
luciferase	O
activities	O
were	O
normalized	O
to	O
coexpressed	B-Gene_expression
renilla	O
luciferase	O
activities	O
.	O

Mean	O
values	O
(	O
+/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

(	O
B	O
)	O
pGL3	O
-	O
Promoter	O
reporter	O
plasmids	O
containing	O
the	O
regions	O
E1	O
or	O
E2	O
(	O
see	O
Figure	O
1	O
)	O
upstream	O
of	O
the	O
SV40	O
promoter	O
were	O
transfected	O
into	O
A3.01	O
T	O
cells	O
.	O

Firefly	O
luciferase	O
activities	O
after	O
48	O
h	O
were	O
normalized	O
to	O
coexpressed	B-Gene_expression
renilla	O
luciferase	O
activities	O
.	O

Mean	O
values	O
(	O
+/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

Sp1	O
and	O
Sp3	O
bind	B-Binding
to	O
the	O
GC	O
-	O
box	O
present	O
in	O
the	O
A3G	O
promoter	O
.	O

(	O
A	O
)	O
Nuclear	O
extracts	O
of	O
A3.01	O
T	O
cells	O
were	O
incubated	O
with	O
a	O
32P	O
-	O
labeled	O
commercial	O
Sp1	O
oligonucleotide	O
probe	O
(	O
Sp1cons	O
)	O
or	O
labeled	O
probes	O
homologous	O
to	O
the	O
unmodified	O
or	O
mutated	O
E2	O
region	O
(	O
see	O
Figure	O
1	O
)	O
of	O
the	O
A3G	O
promoter	O
(	O
APO	O
-	O
Sp1/3	O
and	O
APO	O
-	O
Sp1/3mut	O
)	O
.	O

Protein	O
-	O
DNA	O
complexes	O
were	O
separated	O
by	O
polyacrylamide	O
electrophoresis	O
and	O
detected	O
by	O
autoradiography	O
.	O

EMSA	O
was	O
performed	O
with	O
a	O
1	O
-	O
or	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
APO	O
-	O
Sp1/3	O
probe	O
(	O
competitor	O
,	O
lanes	O
6	O
and	O
7	O
)	O
or	O
APO	O
-	O
Sp1/3mut	O
probe	O
(	O
competitor	O
mut.	O
,	O
lanes	O
12	O
and	O
13	O
)	O
.	O

(	O
B	O
)	O
Sp1	O
-	O
and	O
Sp3	O
-	O
specific	O
antibodies	O
were	O
added	O
to	O
the	O
EMSA	O
reactions	O
resulting	O
in	O
a	O
supershift	O
(	O
ss	O
)	O
of	O
the	O
respective	O
antibody-protein	O
-	O
oligo	O
complexes	O
(	O
lanes	O
3	O
,	O
4	O
,	O
7	O
,	O
8	O
,	O
11	O
,	O
12	O
)	O
.	O

(	O
C	O
)	O
ChIP	O
assay	O
was	O
performed	O
with	O
DNA	O
from	O
A3.01	O
T	O
cells	O
.	O

Immunoprecipitation	O
was	O
performed	O
with	O
antibodies	O
against	O
Sp1	O
,	O
Sp3	O
or	O
actin	O
.	O

PCR	O
primer	O
pairs	O
specific	O
for	O
the	O
A3G	O
promoter	O
(	O
upper	O
panel	O
)	O
or	O
the	O
A3G	O
gene	O
(	O
lower	O
panel	O
)	O
were	O
used	O
.	O

As	O
positive	O
controls	O
,	O
the	O
sheared	O
and	O
cross	O
-	O
linked	O
DNA	O
before	O
the	O
immunoprecipitation	O
step	O
(	O
input	O
)	O
or	O
a	O
plasmid	O
carrying	O
the	O
target	O
sequence	O
(	O
plasmid	O
)	O
was	O
used	O
as	O
template	O
.	O

Silencing	B-Negative_regulation
of	O
Sp1	O
and	O
Sp3	O
reduces	O
A3G	O
promoter	O
activity	O
.	O

(	O
A	O
)	O
HeLa	O
cells	O
were	O
transfected	O
with	O
150	O
and	O
300	O
ng	O
of	O
unspecific	O
,	O
Sp1	O
-	O
specific	O
or	O
Sp3	O
-	O
specific	O
siRNA	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
and	O
Sp1	O
and	O
Sp3	O
proteins	O
were	O
detected	O
by	O
western	O
blot	O
analysis	O
.	O

As	O
loading	O
control	O
,	O
protein	O
levels	O
of	O
tubulin	O
are	O
shown	O
.	O

(	O
B	O
)	O
HeLa	O
cells	O
were	O
cotransfected	O
with	O
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
containing	O
180	O
or	O
150	O
bp	O
of	O
the	O
A3G	O
promoter	O
and	O
siRNA	O
.	O

Hundred	O
nanogram	O
of	O
unspecific	O
siRNA	O
(	O
control	O
)	O
,	O
Sp1	O
-	O
specific	O
siRNA	O
(	O
Sp1	O
)	O
,	O
Sp3	O
-	O
specific	O
siRNA	O
(	O
Sp3	O
)	O
or	O
a	O
mixture	O
of	O
50	O
ng	O
Sp1	O
-	O
specific	O
plus	O
50	O
ng	O
Sp3	O
-	O
specific	O
siRNA	O
(	O
Sp1+Sp3	O
)	O
were	O
used	O
.	O

Firefly	O
luciferase	O
activities	O
after	O
48	O
h	O
were	O
normalized	O
to	O
coexpressed	B-Gene_expression
renilla	O
luciferase	O
activities	O
.	O

Mean	O
values	O
(	O
+/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

Protein	O
kinase	O
D	O
enzymes	O
are	O
dispensable	O
for	O
proliferation	O
,	O
survival	O
and	O
antigen	O
receptor	O
-	O
regulated	O
NFkappaB	O
activity	O
in	O
vertebrate	O
B	O
-	O
cells	O

Abstract	O

To	O
investigate	O
the	O
importance	O
of	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
enzymes	O
we	O
generated	O
a	O
PKD	O
-	O
null	O
DT40	O
B	O
-	O
lymphocyte	O
cell	O
line	O
.	O

Previously	O
we	O
have	O
shown	O
that	O
PKDs	O
have	O
an	O
essential	O
role	O
in	O
regulating	O
class	O
II	O
histone	O
deacetylases	O
in	O
DT40	O
B	O
-	O
cells	O
[	O
Matthews	O
,	O
S.A.	O
,	O
Liu	O
,	O
P.	O
,	O
Spitaler	O
,	O
M.	O
,	O
Olson	O
,	O
E.N.	O
,	O
McKinsey	O
,	O
T.A.	O
,	O
Cantrell	O
,	O
D.A.	O
and	O
Scharenberg	O
,	O
A.M	O
.	O

(	O
2006	O
)	O
Essential	O
role	O
for	O
protein	O
kinase	O
D	O
family	O
kinases	O
in	O
the	O
regulation	O
of	O
class	O
II	O
histone	O
deacetylases	O
in	O
B	O
lymphocytes	O
.	O

Mol	O
.	O

Cell	O
Biol	O
.	O

26	O
,	O
1569	O
-	O
1577	O
]	O
.	O

We	O
now	O
show	O
that	O
PKDs	O
are	O
also	O
required	B-Positive_regulation
to	O
regulate	B-Regulation
HSP27	O
phosphorylation	B-Phosphorylation
in	O
DT40	O
B	O
-	O
cells	O
.	O

However	O
,	O
in	O
contrast	O
to	O
previous	O
observations	O
in	O
other	O
cell	O
types	O
,	O
PKD	O
enzymes	O
do	O
not	O
regulate	O
basic	O
cellular	O
processes	O
such	O
as	O
proliferation	O
or	O
survival	O
responses	O
,	O
nor	O
NFkappaB	O
transcriptional	O
activity	O
downstream	O
of	O
the	O
B	O
cell	O
antigen	O
receptor	O
.	O

Thus	O
,	O
PKDs	O
have	O
a	O
selective	O
role	O
in	O
DT40	O
B	O
-	O
cell	O
biology	O
.	O

Introduction	O

The	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
serine/threonine	O
kinase	O
family	O
has	O
three	O
members	O
:	O
PKD1	O
,	O
PKD2	O
and	O
PKD3	O
.	O

Most	O
cell	O
types	O
express	O
at	O
least	O
two	O
PKD	O
isoforms	O
but	O
PKD	O
enzymes	O
are	O
especially	O
highly	O
expressed	O
in	O
haematopoietic	O
cells	O
,	O
where	O
they	O
are	O
activated	O
in	O
response	O
to	O
antigen	O
receptors	O
stimulation	O
[	O
2	O
,	O
3	O
]	O
.	O

A	O
conserved	O
signalling	O
pathway	O
linking	O
antigen	O
receptors	O
to	O
PKDs	O
involves	O
the	O
activation	O
of	O
PLCgamma	O
and	O
the	O
subsequent	O
production	O
of	O
diacylglycerol	O
(	O
DAG	O
)	O
which	O
stimulates	O
classical	O
and/or	O
novel	O
protein	O
kinase	O
Cs	O
(	O
PKC	O
)	O
that	O
phosphorylate	O
two	O
key	O
regulatory	O
serine	O
residues	O
in	O
the	O
activation	O
loop	O
of	O
PKD	O
kinases	O
[	O
3	O
-	O
6	O
]	O
.	O

The	O
N	O
-	O
terminal	O
regulatory	O
region	O
of	O
PKD	O
enzymes	O
contains	O
a	O
DAG	O
binding	O
domain	O
and	O
direct	O
binding	B-Binding
of	O
DAG	O
also	O
contributes	B-Positive_regulation
to	O
PKD1	O
activation	B-Positive_regulation
[	O
7	O
]	O
as	O
well	O
as	O
regulating	O
the	O
spatial	O
location	O
of	O
PKD	O
enzymes	O
within	O
cells	O
[	O
8	O
-	O
12	O
]	O
.	O

PKD	O
enzymes	O
have	O
been	O
proposed	O
to	O
regulate	O
numerous	O
cellular	O
functions	O
,	O
including	O
cell	O
proliferation	O
[	O
13	O
-	O
16	O
]	O
,	O
anti	O
-	O
apoptotic	O
signals	O
[	O
17	O
,	O
18	O
]	O
and	O
thymocyte	O
development	O
[	O
19	O
]	O
.	O

Expression	O
of	O
mutant	O
catalytically	O
inactive	O
and	O
constitutively	O
activated	O
PKDs	O
can	O
also	O
modify	O
Golgi	O
function	O
,	O
cell	O
adhesion	O
and	O
cell	O
motility	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
.	O

In	O
particular	O
,	O
PKDs	O
have	O
been	O
widely	O
linked	O
to	O
the	O
activation	O
of	O
the	O
NFkappaB	O
transcription	O
factor	O
and	O
in	O
regulating	O
cell	O
survival	O
during	O
oxidative	O
stress	O
[	O
17	O
,	O
21	O
-	O
23	O
]	O
.	O

Another	O
recently	O
proposed	O
PKD1	O
substrate	O
is	O
HSP27	O
[	O
24	O
]	O
,	O
a	O
small	O
heat	O
shock	O
protein	O
involved	O
in	O
regulating	O
cell	O
migration	O
and	O
cell	O
survival	O
[	O
25	O
]	O
.	O

An	O
essential	O
role	O
for	O
PKD	O
enzymes	O
in	O
regulating	O
class	O
II	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
,	O
enzymes	O
that	O
repress	O
MEF2	O
-	O
dependent	O
gene	O
transcription	O
,	O
has	O
also	O
been	O
demonstrated	O
[	O
1	O
,	O
26	O
-	O
28	O
]	O
.	O

To	O
investigate	O
the	O
biological	O
role	O
of	O
PKDs	O
we	O
have	O
generated	O
DT40	O
B	O
cell	O
lines	O
that	O
lack	O
expression	O
of	O
one	O
or	O
more	O
members	O
of	O
the	O
PKD	O
family	O
[	O
1	O
]	O
,	O
allowing	O
us	O
to	O
investigate	O
the	O
function	O
(	O
s	O
)	O
of	O
PKD	O
isoforms	O
following	O
B	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
stimulation	O
,	O
as	O
well	O
addressing	O
the	O
issue	O
of	O
functional	O
redundancy	O
between	O
the	O
different	O
PKD	O
family	O
members	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
PKDs	O
are	O
indispensable	O
for	O
HDAC	O
regulation	O
in	O
B	O
cells	O
[	O
1	O
]	O
.	O

Herein	O
we	O
show	O
that	O
PKDs	O
are	O
also	O
indispensable	B-Positive_regulation
for	O
HSP27	O
phosphorylation	B-Phosphorylation
in	O
B	O
cells	O
.	O

However	O
,	O
PKD	O
-	O
null	O
DT40	O
B	O
cells	O
are	O
viable	O
and	O
proliferate	O
normally	O
.	O

Moreover	O
,	O
loss	O
of	O
the	O
entire	O
cellular	O
pool	O
of	O
PKD	O
does	O
not	O
critically	O
affect	O
oxidative	O
stress	O
responses	O
in	O
B	O
cells	O
nor	O
do	O
PKD	O
kinases	O
play	O
an	O
essential	O
role	O
in	O
regulating	O
NFkappaB	O
transcriptional	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
reveal	O
that	O
in	O
B	O
lymphocytes	O
,	O
PKD	O
kinases	O
are	O
not	O
critical	O
regulators	O
of	O
many	O
of	O
the	O
cellular	O
processes	O
previously	O
ascribed	O
to	O
them	O
in	O
other	O
cellular	O
systems	O
.	O

Cell	O
culture	O
,	O
transient	O
transfections	O
and	O
cell	O
stimulation	O

The	O
generation	O
,	O
culture	O
and	O
activation	O
of	O
PKD1-/	O
-	O
,	O
PKD3-/	O
-	O
and	O
PKD1/3-/	O
-	O
knockout	B-Negative_regulation
DT40	O
B	O
cell	O
lines	O
have	O
been	O
described	O
previously	O
[	O
1	O
]	O
.	O

Cells	O
were	O
lysed	O
and	O
protein	O
extracts	O
were	O
analysed	O
in	O
Western	O
blotting	O
experiments	O
as	O
previously	O
described	O
[	O
1	O
]	O
.	O

Chloramphenicol	O
acetyl	O
transferase	O
assays	O
have	O
been	O
described	O
previously	O
[	O
29	O
]	O
.	O

sIgM	O
staining	O

DT40	O
B	O
cells	O
(	O
2x106	O
cells	O
per	O
point	O
)	O
were	O
resuspended	O
in	O
200mul	O
buffer	O
(	O
RPMI	O
1640	O
media	O
,	O
1	O
%	O
foetal	O
calf	O
serum	O
)	O
containing	O
anti	O
-	O
chicken	O
M1	O
monoclonal	O
antibody	O
conjugated	O
to	O
FITC	O
for	O
20min	O
on	O
ice	O
.	O

The	O
cells	O
were	O
washed	O
twice	O
and	O
fluorescent	O
intensity	O
was	O
analysed	O
by	O
flow	O
cytometry	O
.	O

All	O
results	O
shown	O
are	O
representative	O
of	O
at	O
two	O
to	O
four	O
independent	O
experiments	O
unless	O
otherwise	O
indicated	O
.	O

Loss	B-Negative_regulation
of	O
HSP27	O
phosphorylation	B-Phosphorylation
in	O
DT40	O
B	O
cells	O
lacking	O
expression	O
of	O
PKD	O
family	O
kinases	O

DT40	O
B	O
cells	O
express	B-Gene_expression
two	O
PKD	O
isoforms	O
,	O
PKD1	O
and	O
PKD3	O
,	O
and	O
as	O
previously	O
described	O
we	O
have	O
recently	O
generated	O
DT40	O
B	O
cell	O
lines	O
that	O
lack	B-Negative_regulation
expression	B-Gene_expression
of	O
either	O
PKD1	O
or	O
PKD3	O
or	O
both	O
enzymes	O
[	O
1	O
]	O
.	O

In	O
generating	O
the	O
double	O
knockout	O
cell	O
lines	O
we	O
targeted	O
the	O
PKD1	O
loci	O
in	O
a	O
PKD3-/	O
-	O
cell	O
line	O
that	O
expressed	B-Gene_expression
a	O
Flag	O
-	O
PKD3	O
transgene	O
under	O
the	O
control	O
of	O
a	O
doxycycline	O
-	O
inducible	O
promoter	O
.	O

Hence	O
,	O
in	O
the	O
presence	O
of	O
doxycycline	O
,	O
Flag	O
-	O
PKD3	O
expression	B-Gene_expression
in	O
PKD1/3	O
double	B-Negative_regulation
knockout	I-Negative_regulation
cells	O
is	O
comparable	O
to	O
endogenous	O
PKD3	O
present	O
in	O
wild	O
-	O
type	O
DT40	O
cells	O
and	O
removal	O
of	O
doxycycline	O
from	O
the	O
culture	O
media	O
for	O
5	O
days	O
results	O
in	O
a	O
completely	O
null	O
PKD	O
phenotype	O
(	O
Fig	O
.	O

1A	O
)	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
phosphorylation	O
and	O
nuclear	O
exclusion	O
of	O
class	O
II	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
during	O
BCR	O
engagement	O
is	O
defective	O
in	O
PKD1/3-/	O
-	O
B	O
cells	O
and	O
can	O
restored	O
upon	O
re	O
-	O
expression	O
of	O
a	O
single	O
PKD	O
isoform	O
[	O
1	O
]	O
.	O

The	O
small	O
heat	O
shock	O
protein	O
HSP27	O
has	O
recently	O
been	O
proposed	O
as	O
a	O
PKD1	O
substrate	O
[	O
24	O
]	O
and	O
we	O
accordingly	O
assessed	O
whether	O
PKD	O
-	O
null	O
DT40	O
cells	O
have	O
defective	B-Negative_regulation
phosphorylation	B-Phosphorylation
of	O
HSP27	O
on	O
serine	O
82	O
,	O
the	O
proposed	O
PKD1	O
substrate	O
sequence	O
.	O

We	O
initially	O
investigated	O
the	O
regulation	B-Regulation
of	O
HSP27	O
phosphorylation	B-Phosphorylation
in	O
single	O
knockout	O
DT40	O
B	O
cells	O
lacking	B-Negative_regulation
either	O
PKD1	O
or	O
PKD3	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

1B	O
,	O
activation	O
of	O
the	O
BCR	O
or	O
treatment	O
with	O
the	O
DAG	O
-	O
mimetic	O
PdBu	O
increased	B-Positive_regulation
the	O
levels	O
of	O
HSP27	O
phosphorylation	B-Phosphorylation
at	O
S82	O
in	O
wild	O
-	O
type	O
DT40	O
B	O
cells	O
.	O

BCR	O
and	O
phorbol	O
ester	O
signals	O
were	O
also	O
able	O
to	O
increase	B-Positive_regulation
HSP27	O
phosphorylation	B-Phosphorylation
in	O
PKD1	O
or	O
PKD3	O
single	O
knockout	B-Negative_regulation
DT40	O
B	O
cells	O
(	O
Fig	O
.	O

1B	O
)	O
.	O

However	O
,	O
BCR	O
-	O
and	O
phorbol	O
ester	O
-	O
induced	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
HSP27	O
on	O
S82	O
was	O
abolished	B-Negative_regulation
in	O
B	O
cells	O
that	O
lacked	B-Negative_regulation
both	O
PKD1	O
and	O
PKD3	O
(	O
Fig	O
.	O

1C	O
)	O
.	O

Significantly	O
,	O
doxycycline	O
-	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
Flag	O
-	O
PKD3	O
transgene	O
in	O
the	O
double	O
knockout	O
cells	O
was	O
sufficient	B-Positive_regulation
to	I-Positive_regulation
restore	I-Positive_regulation
normal	O
regulation	B-Regulation
of	O
HSP27	O
phosphorylation	B-Phosphorylation
(	O
Fig	O
.	O

1C	O
)	O
.	O

In	O
contrast	O
,	O
expression	B-Gene_expression
of	O
a	O
kinase	O
-	O
deficient	B-Negative_regulation
PKD3	O
mutant	O
protein	O
in	O
the	O
double	O
knockout	O
cells	O
was	O
not	O
able	O
to	O
restore	B-Positive_regulation
BCR	O
-	O
or	O
phorbol	O
ester	O
-	O
induced	B-Positive_regulation
HSP27	O
phosphorylation	B-Phosphorylation
(	O
Fig	O
.	O

1D	O
)	O
.	O

Hence	O
,	O
PKD3	O
as	O
well	O
as	O
PKD1	O
can	O
regulate	B-Regulation
HSP27	O
phosphorylation	B-Phosphorylation
and	O
in	O
DT40	O
B	O
cells	O
they	O
are	O
functionally	O
redundant	O
as	O
HSP27	O
kinases	O
.	O

Cellular	O
proliferation	O
and	O
survival	O
in	O
DT40	O
B	O
cells	O
lacking	O
expression	O
of	O
PKD	O
family	O
kinases	O

PKD	O
enzymes	O
have	O
previously	O
been	O
linked	O
to	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
survival	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
.	O

To	O
investigate	O
the	O
effect	O
that	O
loss	O
of	O
PKD	O
kinases	O
had	O
on	O
B	O
cell	O
survival	O
and/or	O
proliferation	O
we	O
cultured	O
wild	O
-	O
type	O
and	O
PKD	O
-	O
null	O
cells	O
in	O
the	O
presence	O
(	O
PKD1/3-/	O
-	O
:	O
Flag	O
-	O
PKD3+ve	O
)	O
or	O
absence	O
(	O
PKD1/3-/	O
-	O
)	O
of	O
doxycycline	O
and	O
monitored	O
exponential	O
growth	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2A	O
,	O
PKD1/3-/	O
-	O
cells	O
proliferated	O
exponentially	O
and	O
re	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
of	O
Flag	O
-	O
PKD3	O
in	O
these	O
cells	O
had	O
no	O
impact	O
on	O
the	O
rate	O
of	O
proliferation	O
.	O

Furthermore	O
,	O
the	O
viability	O
of	O
PKD1/3-/	O
-	O
B	O
cells	O
during	O
routine	O
culturing	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
wild	O
-	O
type	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
was	O
noted	O
that	O
the	O
population	O
doubling	O
time	O
of	O
PKD1/3-/	O
-	O
cells	O
was	O
slightly	O
slower	O
than	O
that	O
of	O
wild	O
type	O
DT40	O
cells	O
(	O
12.7+/	O
-	O
2.8h	O
versus	O
10.2+/	O
-	O
0.4h	O
)	O
but	O
the	O
failure	O
of	O
PKD3	O
re	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
to	O
modify	O
the	O
proliferation	O
rate	O
of	O
PKD1/3-/	O
-	O
cells	O
suggests	O
that	O
these	O
small	O
differences	O
were	O
most	O
likely	O
the	O
result	O
of	O
clonal	O
variation	O
and	O
were	O
not	O
caused	O
specifically	O
by	O
loss	O
of	O
PKD	O
enzymes	O
.	O

Thus	O
,	O
PKD	O
family	O
enzymes	O
are	O
not	O
essential	O
for	O
regulating	O
basal	O
survival	O
and	O
proliferation	O
of	O
DT40	O
B	O
cells	O
.	O

PKD	O
enzymes	O
,	O
specifically	O
PKD1	O
and	O
PKD2	O
,	O
have	O
previously	O
been	O
linked	O
to	O
a	O
protective	O
role	O
against	O
oxidative	O
stress	O
-	O
induced	O
injury	O
in	O
3T3	O
fibroblast	O
,	O
HeLa	O
and	O
epithelial	O
cell	O
lines	O
[	O
17	O
,	O
30	O
-	O
32	O
]	O
.	O

We	O
therefore	O
addressed	O
the	O
role	O
of	O
PKD	O
family	O
kinases	O
in	O
regulating	O
B	O
cell	O
survival	O
in	O
response	O
to	O
oxidative	O
stress	O
and	O
other	O
stress	O
stimuli	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2B	O
,	O
loss	B-Negative_regulation
of	O
PKD1/3	O
expression	B-Gene_expression
had	O
no	O
significant	O
impact	O
on	O
the	O
survival	O
of	O
DT40	O
B	O
cells	O
in	O
response	O
to	O
mitochondrial	O
stress	O
stimuli	O
(	O
H2O2	O
or	O
serum	O
deprivation	O
)	O
;	O
DNA	O
damaging	O
agents	O
(	O
etoposide	O
or	O
doxorubicin	O
)	O
;	O
ER	O
pathway	O
stress	O
due	O
to	O
calcium	O
overload	O
(	O
thapsigargin	O
)	O
or	O
following	O
prolonged	O
treatment	O
with	O
phorbol	O
esters	O
or	O
Trichostatin	O
A	O
,	O
an	O
inhibitor	O
of	O
class	O
I/II	O
HDACs	O
.	O

Thus	O
,	O
PKD	O
kinases	O
do	O
not	O
play	O
an	O
essential	O
role	O
in	O
regulating	O
B	O
cell	O
survival	O
in	O
response	O
to	O
a	O
range	O
of	O
different	O
stress	O
stimuli	O
.	O

Antigen	O
receptor	O
regulated	O
signalling	O
pathways	O
in	O
PKD	O
-	O
null	O
DT40	O
B	O
cells	O

To	O
further	O
explore	O
the	O
contribution	O
of	O
PKD	O
kinases	O
to	O
DT40	O
B	O
cell	O
biology	O
we	O
investigated	O
whether	O
specific	O
BCR	O
-	O
regulated	O
signalling	O
events	O
were	O
defective	O
in	O
the	O
PKD	O
-	O
null	O
B	O
cells	O
.	O

Initial	O
experiments	O
revealed	O
that	O
surface	O
expression	O
of	O
the	O
BCR	O
was	O
reduced	O
in	O
PKD1/3-/	O
-	O
(	O
and	O
in	O
PKD1/3-/	O
-	O
:	O
Flag	O
-	O
PKD3+ve	O
)	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O

3A	O
and	O
data	O
not	O
shown	O
)	O
.	O

Nevertheless	O
,	O
BCR	O
-	O
crosslinking	O
of	O
PKD1/3-/	O
-	O
cells	O
was	O
sufficient	O
to	O
induce	O
the	O
activation	O
of	O
a	O
number	O
of	O
signalling	O
cascades	O
,	O
similar	O
to	O
that	O
observed	O
in	O
wild	O
-	O
type	O
cells	O
(	O
Fig	O
.	O

3B	O
)	O
.	O

Hence	O
,	O
BCR	O
-	O
induced	B-Positive_regulation
activation	B-Positive_regulation
of	O
the	O
Akt	O
,	O
mTOR/p70	O
S6	O
kinase	O
(	O
as	O
shown	O
by	O
S6	O
ribosomal	O
protein	O
phosphorylation	B-Phosphorylation
)	O
and	O
MAPK	O
signalling	O
pathways	O
was	O
clearly	O
detectable	B-Negative_regulation
in	O
PKD1/3	O
-	O
null	B-Negative_regulation
B	O
cells	O
(	O
Fig	O
.	O

3B	O
)	O
.	O

Furthermore	O
,	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
cellular	O
proteins	O
as	O
well	O
as	O
an	O
increase	O
in	O
intracellular	O
calcium	O
levels	O
was	O
also	O
observed	O
following	O
BCR	O
stimulation	O
of	O
PKD1/3	O
-	O
null	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
did	O
observe	O
that	O
the	O
strength	O
of	O
BCR	O
(	O
but	O
not	O
phorbol	O
ester	O
)	O
-	O
induced	O
regulation	O
of	O
the	O
Erk1	O
-	O
RSK1	O
signalling	O
pathway	O
was	O
reduced	O
in	O
PKD1/3-/	O
-	O
B	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
B	O
cells	O
(	O
Fig	O
.	O

3B	O
)	O
.	O

One	O
interpretation	O
of	O
this	O
data	O
is	O
that	O
PKD	O
enzymes	O
may	O
modulate	O
Erk	O
activation	O
.	O

Indeed	O
,	O
PKD	O
enzymes	O
have	O
previously	O
been	O
linked	O
to	O
the	O
growth	O
factor	O
-	O
regulated	O
Erk	O
signalling	O
in	O
fibroblast	O
and	O
endothelial	O
cell	O
lines	O
[	O
33	O
-	O
35	O
]	O
.	O

However	O
,	O
BCR	O
-	O
induced	O
Erk	O
phosphorylation	O
was	O
also	O
reduced	O
in	O
PKD1/3	O
-	O
/	O
-	O
-	O
Flag	O
-	O
PKD3+	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
suggesting	O
that	O
reduced	O
BCR	O
levels	O
on	O
the	O
surface	O
of	O
PKD1/3-/	O
-	O
(	O
and	O
PKD1/3	O
-	O
/	O
-	O
-	O
Flag	O
-	O
PKD3+	O
)	O
B	O
cells	O
may	O
itself	O
impact	O
on	O
the	O
strength	O
of	O
activation	O
of	O
this	O
specific	O
intracellular	O
signalling	O
pathway	O
.	O

To	O
search	O
for	O
other	O
potential	O
PKD	O
targets	O
that	O
may	O
show	O
defective	O
regulation	O
in	O
PKD1/3-/	O
-	O
DT40	O
B	O
cells	O
,	O
we	O
used	O
a	O
PKD	O
substrate	O
phospho	O
-	O
antibody	O
that	O
recognises	O
consensus	O
phosphorylation	O
sequences	O
targeted	O
by	O
PKD	O
enzymes	O
(	O
LxRxxpS/T	O
)	O
[	O
36	O
]	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

3C	O
,	O
phorbol	O
ester	O
-	O
and	O
BCR	O
-	O
induced	O
phosphorylation	O
of	O
cellular	O
substrates	O
detected	O
by	O
this	O
phospho	O
-	O
antibody	O
was	O
similar	O
in	O
wild	O
-	O
type	O
and	O
PKD1/3-/	O
-	O
cells	O
and	O
is	O
therefore	O
independent	O
of	O
PKD	O
enzymes	O
.	O

However	O
,	O
pretreatment	O
of	O
both	O
wild	O
-	O
type	O
and	O
PKD1/3-/	O
-	O
DT40	O
B	O
cells	O
with	O
GF109203X	O
,	O
a	O
bisindoylmaleimide	O
derivative	O
that	O
inhibits	O
PKCs	O
prevented	O
the	O
induction	O
of	O
proteins	O
that	O
contain	O
phosphorylated	O
LxRxxS/T	O
motifs	O
.	O

Thus	O
loss	B-Negative_regulation
of	O
PKD1/3	O
enzymes	O
does	O
not	O
globally	O
disrupt	O
the	O
phosphorylation	O
of	O
cellular	O
proteins	O
that	O
contain	O
LxRxxpS/T	O
motifs	O
.	O

This	O
result	O
is	O
perhaps	O
not	O
surprising	O
as	O
LxRxxS/T	O
motifs	O
also	O
act	O
as	O
good	O
substrates	O
for	O
other	O
serine/threonine	O
kinases	O
such	O
as	O
MAPKAPK2	O
.	O

However	O
these	O
experiments	O
do	O
provide	O
further	O
evidence	O
that	O
phosphospecific	O
antisera	O
are	O
not	O
sufficiently	O
selective	O
to	O
be	O
designated	O
kinase	O
specific	O
substrate	O
antisera	O
.	O

BCR	O
-	O
induced	O
signalling	O
pathways	O
culminate	O
in	O
the	O
activation	O
of	O
gene	O
transcription	O
events	O
that	O
control	O
B	O
cell	O
survival	O
,	O
proliferation	O
and	O
function	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
proposed	O
that	O
PKD	O
family	O
members	O
control	O
of	O
gene	O
transcription	O
through	O
activation	O
of	O
the	O
NFkappaB	O
transcription	O
factor	O
.	O

Thus	O
,	O
PKD	O
-	O
mediated	O
activation	O
of	O
NFkappaB	O
occurs	O
downstream	O
of	O
a	O
variety	O
of	O
different	O
signals	O
,	O
including	O
mROS/oxidative	O
stress	O
,	O
lysophosphatidic	O
acid	O
and	O
the	O
Bcr	O
-	O
Abl	O
oncogene	O
[	O
17	O
,	O
21	O
,	O
23	O
,	O
30	O
,	O
37	O
]	O
.	O

Furthermore	O
,	O
expression	B-Positive_regulation
of	I-Positive_regulation
an	I-Positive_regulation
activated	I-Positive_regulation
PKD1	O
mutant	O
enhances	O
HPK1	O
-	O
mediated	O
NFkappaB	O
activation	O
[	O
38	O
]	O
.	O

In	O
B	O
cells	O
,	O
NFkappaB	O
is	O
known	O
to	O
be	O
regulated	O
via	O
DAG	O
and	O
PKCbeta	O
[	O
39	O
,	O
40	O
]	O
but	O
whether	O
PKDs	O
are	O
key	O
intermediaries	O
for	O
NFkappaB	O
regulation	O
has	O
not	O
been	O
explored	O
.	O

The	O
data	O
(	O
Fig	O
.	O

4A	O
)	O
show	O
that	O
NFkappaB	O
transcriptional	O
activity	O
was	O
strongly	O
induced	O
in	O
both	O
wild	O
-	O
type	O
and	O
PKD1/3-/	O
-	O
DT40	O
B	O
cells	O
in	O
response	O
to	O
either	O
phorbol	O
ester	O
or	O
BCR	O
stimulation	O
.	O

In	O
contrast	O
,	O
BCR	O
and	O
phorbol	O
ester	O
-	O
induced	O
NFkappaB	O
transcriptional	O
activity	O
was	O
abolished	O
in	O
PKCbeta-/	O
-	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O

4A	O
)	O
,	O
although	O
strong	O
activation	O
of	O
PKD	O
kinases	O
(	O
as	O
assessed	O
by	O
autophosphorylation	B-Phosphorylation
of	O
PKD1	O
at	O
S916	O
)	O
was	O
observed	B-Positive_regulation
in	O
the	O
PKCbeta-/	O
-	O
cells	O
(	O
Fig	O
.	O

4B	O
)	O
.	O

Thus	O
,	O
PKD	O
kinases	O
are	O
neither	O
essential	O
nor	O
sufficient	O
to	O
mediate	O
BCR	O
-	O
induced	O
NFkappaB	O
activation	O
in	O
DT40	O
B	O
cells	O
and	O
hence	O
do	O
not	O
participate	O
in	O
DAG/PKC	O
mediated	O
control	O
of	O
NFkappaB	O
.	O

Discussion	O

Protein	O
kinase	O
D	O
serine	O
kinases	O
have	O
been	O
proposed	O
to	O
regulate	B-Regulation
diverse	O
cellular	O
functions	O
including	O
the	O
phosphorylation	O
and	O
nuclear	O
localisation	O
of	O
class	O
II	O
HDACs	O
and	O
the	O
phosphorylation	B-Phosphorylation
of	O
HSP27	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
PKDs	O
act	O
as	O
mitochondrial	O
sensors	O
for	O
oxidative	O
stress	O
and	O
play	O
a	O
role	O
in	O
regulating	O
NFkappaB	O
transcription	O
factors	O
[	O
41	O
]	O
.	O

Most	O
of	O
the	O
data	O
about	O
the	O
function	O
of	O
PKDs	O
has	O
come	O
from	O
experiments	O
that	O
ectopically	O
express	O
active	O
or	O
inhibitory	O
PKD	O
mutants	O
or	O
that	O
use	O
RNAi	O
to	O
reduce	O
PKD	O
expression	O
.	O

We	O
have	O
used	O
gene	O
targeting	O
to	O
specifically	O
delete	O
PKD	O
alleles	O
in	O
DT40	O
chicken	O
B	O
cells	O
and	O
can	O
thus	O
use	O
PKD	O
-	O
null	O
DT40	O
cells	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
individual	O
PKD	O
isoforms	O
in	O
class	O
II	O
HDAC	O
control	O
versus	O
oxidative	O
stress	O
responses	O
and	O
NFkappaB	O
regulation	O
in	O
lymphocytes	O
.	O

We	O
have	O
previously	O
used	O
these	O
PKD	O
-	O
null	O
DT40	O
cells	O
to	O
define	O
an	O
essential	O
role	O
for	O
PKDs	O
in	O
regulation	O
of	O
class	O
II	O
HDACs	O
,	O
the	O
present	O
report	O
now	O
describes	O
an	O
indispensable	O
role	O
for	O
PKDs	O
in	O
regulating	B-Regulation
the	O
phosphorylation	B-Phosphorylation
of	O
HSP27	O
on	O
serine	O
82	O
,	O
a	O
site	O
previously	O
identified	O
as	O
a	O
target	B-Regulation
for	O
the	O
p38	O
-	O
MAPKAPK2	O
signalling	O
cascade	O
[	O
42	O
]	O
.	O

However	O
,	O
studies	O
of	O
PKD	O
-	O
null	O
DT40	O
cells	O
reveal	O
that	O
PKD	O
family	O
kinases	O
are	O
not	O
essential	O
for	O
oxidative	O
stress	O
survival	O
responses	O
nor	O
are	O
they	O
required	O
for	O
activation	O
of	O
NFkappaB	O
transcription	O
factors	O
.	O

These	O
latter	O
findings	O
are	O
in	O
striking	O
contrast	O
to	O
previous	O
observations	O
in	O
HeLa	O
and	O
epithelial	O
cell	O
lines	O
where	O
overexpression/RNAi	O
approaches	O
have	O
implicated	O
PKD1/2	O
in	O
the	O
control	O
of	O
proliferation	O
,	O
survival	O
and	O
NFkappaB	O
activation	O
[	O
20	O
,	O
23	O
]	O
.	O

Hence	O
,	O
the	O
present	O
report	O
shows	O
that	O
the	O
proposed	O
roles	O
for	O
PKDs	O
as	O
key	O
sensors	O
that	O
modulate	O
survival	O
pathways	O
in	O
response	O
to	O
oxidative	O
stress	O
and	O
regulate	O
cell	O
survival	O
and	O
proliferation	O
are	O
not	O
ubiquitous	O
and	O
may	O
be	O
restricted	O
to	O
certain	O
cell	O
lineages	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
loss	O
of	O
expression	O
of	O
PKD	O
family	O
members	O
does	O
not	O
globally	O
impact	O
on	O
early	O
BCR	O
-	O
regulated	O
signalling	O
pathways	O
.	O

GATA3	O
-	O
Driven	O
Th2	O
Responses	O
Inhibit	B-Negative_regulation
TGF-beta1	O
-	O
Induced	B-Positive_regulation
FOXP3	O
Expression	B-Gene_expression
and	O
the	O
Formation	O
of	O
Regulatory	O
T	O
Cells	O

Transcription	O
factors	O
act	O
in	O
concert	O
to	O
induce	O
lineage	O
commitment	O
towards	O
Th1	O
,	O
Th2	O
,	O
or	O
T	O
regulatory	O
(	O
Treg	O
)	O
cells	O
,	O
and	O
their	O
counter	O
-	O
regulatory	O
mechanisms	O
were	O
shown	O
to	O
be	O
critical	O
for	O
polarization	O
between	O
Th1	O
and	O
Th2	O
phenotypes	O
.	O

FOXP3	O
is	O
an	O
essential	O
transcription	O
factor	O
for	O
natural	O
,	O
thymus	O
-	O
derived	O
(	O
nTreg	O
)	O
and	O
inducible	O
Treg	O
(	O
iTreg	O
)	O
commitment	O
;	O
however	O
,	O
the	O
mechanisms	O
regulating	B-Regulation
its	O
expression	B-Gene_expression
are	O
as	O
yet	O
unknown	O
.	O

We	O
describe	O
a	O
mechanism	O
controlling	O
iTreg	O
polarization	O
,	O
which	O
is	O
overruled	O
by	O
the	O
Th2	O
differentiation	O
pathway	O
.	O

We	O
demonstrated	O
that	O
interleukin	O
4	O
(	O
IL	O
-	O
4	O
)	O
present	O
at	O
the	O
time	O
of	O
T	O
cell	O
priming	O
inhibits	B-Negative_regulation
FOXP3	O
.	O

This	O
inhibitory	O
mechanism	O
was	O
also	O
confirmed	O
in	O
Th2	O
cells	O
and	O
in	O
T	O
cells	O
of	O
transgenic	O
mice	O
overexpressing	B-Gene_expression
GATA	O
-	O
3	O
in	O
T	O
cells	O
,	O
which	O
are	O
shown	O
to	O
be	O
deficient	B-Negative_regulation
in	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-beta	O
-	O
mediated	B-Positive_regulation
FOXP3	O
induction	B-Positive_regulation
.	O

This	O
inhibition	O
is	O
mediated	B-Positive_regulation
by	O
direct	O
binding	B-Binding
of	O
GATA3	O
to	O
the	O
FOXP3	O
promoter	O
,	O
which	O
represses	O
its	O
transactivation	O
process	O
.	O

Therefore	O
,	O
this	O
study	O
provides	O
a	O
new	O
understanding	O
of	O
tolerance	O
development	O
,	O
controlled	O
by	O
a	O
type	O
2	O
immune	O
response	O
.	O

IL	O
-	O
4	O
treatment	O
in	O
mice	O
reduces	O
iTreg	O
cell	O
frequency	O
,	O
highlighting	O
that	O
therapeutic	O
approaches	O
that	O
target	B-Regulation
IL	O
-	O
4	O
or	O
GATA3	O
might	O
provide	O
new	O
preventive	O
strategies	O
facilitating	O
tolerance	O
induction	O
particularly	O
in	O
Th2	O
-	O
mediated	O
diseases	O
,	O
such	O
as	O
allergy	O
.	O

Author	O
Summary	O

Specific	O
immune	O
responses	O
against	O
foreign	O
or	O
autologous	O
antigens	O
are	O
driven	O
by	O
specialized	O
epitope	O
-	O
specific	O
T	O
cells	O
,	O
whose	O
numbers	O
expand	O
upon	O
recognition	O
of	O
antigen	O
found	O
on	O
professional	O
antigen	O
-	O
presenting	O
cells	O
.	O

The	O
subsequent	O
maturation	O
process	O
involves	O
the	O
differentiation	O
of	O
certain	O
T	O
cell	O
phenotypes	O
such	O
as	O
pro	O
-	O
inflammatory	O
cells	O
(	O
Th1	O
,	O
Th2	O
,	O
Th17	O
)	O
or	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	O
,	O
which	O
serve	O
to	O
keep	O
the	O
immune	O
response	O
in	O
check	O
.	O

The	O
current	O
study	O
focuses	O
on	O
the	O
role	O
of	O
two	O
key	O
transcription	O
factors	O
-	O
FOXP3	O
and	O
GATA3	O
-	O
in	O
controlling	O
the	O
commitment	O
of	O
these	O
cells	O
.	O

We	O
demonstrate	O
that	O
the	O
Th2	O
cytokine	O
IL	O
-	O
4	O
inhibits	B-Negative_regulation
the	O
induction	B-Positive_regulation
of	O
FOXP3	O
and	O
thus	O
inhibits	O
the	O
generation	O
of	O
inducible	O
Treg	O
cells	O
.	O

We	O
show	O
that	O
IL-4	O
-	O
induced	B-Positive_regulation
GATA3	O
mediates	B-Positive_regulation
FOXP3	O
inhibition	B-Negative_regulation
by	O
directly	O
binding	B-Binding
to	O
a	O
GATA	O
element	O
in	O
the	O
FOXP3	O
promoter	O
.	O

We	O
hypothesize	O
that	O
therapeutic	O
agents	O
aimed	O
at	O
neutralizing	B-Negative_regulation
IL	O
-	O
4	O
could	O
be	O
a	O
novel	O
strategy	O
to	O
facilitate	O
inducible	O
Treg	O
cell	O
generation	O
and	O
thus	O
promotion	O
of	O
tolerance	O
in	O
allergies	O
and	O
other	O
Th2	O
-	O
dominated	O
diseases	O
.	O

It	O
is	O
shown	O
that	O
Th2	O
responses	O
prevent	O
the	O
generation	O
of	O
inducible	O
Tregs	O
.	O

This	O
is	O
mediated	O
by	O
IL	O
-	O
4	O
induction	B-Positive_regulation
of	O
GATA3	O
,	O
which	O
binds	B-Binding
directly	O
to	O
and	O
represses	B-Negative_regulation
the	O
FOXP3	O
promoter	O
.	O

This	O
mechanism	O
is	O
likely	O
to	O
be	O
relevant	O
in	O
the	O
induction	O
of	O
immunotolerance	O
,	O
particularly	O
in	O
allergic	O
diseases	O
.	O

Introduction	O

Effective	O
immune	O
responses	O
are	O
characterized	O
by	O
T	O
cell	O
activation	O
,	O
which	O
directs	O
adaptive	O
and	O
innate	O
immune	O
responses	O
to	O
kill	O
pathogens	O
efficiently	O
.	O

Dependent	O
on	O
the	O
pathogen	O
,	O
T	O
cells	O
differentiate	O
into	O
different	O
subtypes	O
,	O
such	O
as	O
Th1	O
or	O
Th2	O
cells	O
,	O
which	O
are	O
most	O
efficient	O
in	O
defeating	O
microbial	O
or	O
parasitic	O
invaders	O
respectively	O
.	O

A	O
hallmark	O
of	O
Th1	O
and	O
Th2	O
differentiation	O
pathways	O
is	O
the	O
exclusiveness	O
of	O
the	O
individual	O
phenotype	O
leading	O
to	O
either	O
Th1	O
or	O
Th2	O
,	O
but	O
not	O
to	O
mixed	O
populations	O
.	O

The	O
exclusiveness	O
of	O
this	O
mechanism	O
is	O
provided	O
by	O
a	O
polarization	O
process	O
,	O
where	O
Th2	O
differentiation	O
inhibits	O
Th1	O
commitment	O
and	O
vice	O
versa	O
.	O

Specifically	O
interleukin	O
4	O
(	O
IL	O
-	O
4	O
)	O
-	O
induced	B-Positive_regulation
STAT6	O
and	O
GATA3	O
inhibit	O
differentiation	O
into	O
Th1	O
cells	O
in	O
the	O
early	O
phase	O
of	O
commitment	O
[	O
1	O
,	O
2	O
]	O
.	O

GATA3	O
is	O
sufficient	O
to	O
induce	O
a	O
Th2	O
phenotype	O
[	O
3	O
]	O
and	O
acts	O
not	O
only	O
through	O
the	O
induction	B-Positive_regulation
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
and	O
IL	O
-	O
13	O
,	O
the	O
Th2	O
cytokines	O
,	O
but	O
also	O
through	O
the	O
inhibition	O
of	O
Th1	O
cell	O
-	O
specific	O
factors	O
[	O
3	O
]	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
T	O
-	O
bet	O
directly	O
modulates	B-Regulation
GATA3	O
function	O
,	O
suggesting	O
that	O
transcription	O
factors	O
compete	O
in	O
the	O
early	O
differentiation	O
phase	O
of	O
T	O
cells	O
,	O
potentially	O
integrating	O
environmental	O
signals	O
to	O
finally	O
imprint	O
the	O
T	O
cell	O
phenotype	O
[	O
4	O
,	O
5	O
]	O
.	O

A	O
GATA3	O
-	O
dominated	O
immune	O
response	O
has	O
been	O
shown	O
to	O
be	O
essential	O
in	O
airway	O
hyperresonsiveness	O
[	O
6	O
]	O
and	O
IL-4	O
-	O
dominated	O
responses	O
can	O
break	O
antigen	O
-	O
specific	O
immune	O
tolerance	O
[	O
7	O
]	O
.	O

Overexpression	B-Negative_regulation
of	I-Negative_regulation
a	I-Negative_regulation
dominant	I-Negative_regulation
negative	I-Negative_regulation
form	I-Negative_regulation
of	O
GATA3	O
[	O
8	O
]	O
or	O
treatment	O
with	O
antisense	O
-	O
mediated	O
GATA3	O
blockade	B-Negative_regulation
[	O
9	O
]	O
decreased	O
the	O
severity	O
of	O
the	O
allergic	O
airway	O
hyper	O
-	O
responsiveness	O
.	O

The	O
discovery	O
of	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	O
highlights	O
another	O
phenotype	O
of	O
T	O
cells	O
,	O
which	O
is	O
essential	O
for	O
tolerance	O
against	O
self	O
-	O
antigens	O
.	O

Naturally	O
occurring	O
,	O
thymus	O
-	O
derived	O
Treg	O
(	O
nTreg	O
)	O
cells	O
are	O
generated	O
in	O
the	O
thymus	O
and	O
are	O
assumed	O
to	O
protect	O
against	O
the	O
activity	O
of	O
autoreactive	O
T	O
cells	O
in	O
the	O
periphery	O
.	O

These	O
cells	O
express	B-Gene_expression
the	O
forkhead	O
transcription	O
factor	O
FOXP3	O
and	O
constitutively	O
express	B-Gene_expression
CD25	O
on	O
their	O
surface	O
,	O
but	O
they	O
lack	O
expression	O
of	O
Th1	O
or	O
Th2	O
cytokines	O
.	O

Particularly	O
interesting	O
are	O
those	O
Treg	O
cells	O
that	O
are	O
generated	O
in	O
the	O
periphery	O
and	O
thus	O
are	O
potential	O
targets	O
for	O
therapeutic	O
interventions	O
.	O

These	O
induced	O
Treg	O
(	O
iTreg	O
)	O
cells	O
were	O
reported	O
to	O
express	B-Gene_expression
FOXP3	O
[	O
10	O
]	O
.	O

The	O
exact	O
mechanisms	O
of	O
iTreg	O
generation	O
are	O
unclear	O
,	O
but	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
triggering	O
has	O
been	O
shown	O
to	O
induce	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
and	O
suppressive	O
cells	O
in	O
human	O
[	O
11	O
,	O
12	O
]	O
,	O
however	O
the	O
phenotype	O
appears	O
to	O
be	O
of	O
transient	O
nature	O
[	O
13	O
,	O
14	O
]	O
.	O

TGF	O
-	O
beta	O
has	O
been	O
demonstrated	O
to	O
be	O
important	O
for	O
the	O
persistent	O
induction	O
of	O
these	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
animals	O
lacking	B-Negative_regulation
the	O
TGF	O
-	O
betaRII	O
on	O
T	O
cells	O
have	O
fewer	O
peripherally	O
iTreg	O
cells	O
[	O
15	O
]	O
and	O
suffer	O
from	O
a	O
T	O
cell	O
-	O
dependent	O
multiorgan	O
inflammatory	O
disease	O
[	O
16	O
]	O
.	O

Although	O
the	O
effect	O
of	O
TGF	O
-	O
beta	O
on	O
natural	O
and	O
inducible	O
Treg	O
cell	O
induction	O
has	O
been	O
demonstrated	O
repeatedly	O
[	O
15	O
,	O
17	O
]	O
,	O
its	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
identified	O
.	O

The	O
current	O
study	O
provides	O
evidence	O
that	O
GATA3	O
and	O
FOXP3	O
play	O
a	O
competitive	O
role	O
in	O
iTreg	O
cell	O
commitment	O
as	O
T	O
-	O
bet	O
and	O
GATA3	O
for	O
Th1	O
and	O
Th2	O
differentiation	O
,	O
respectively	O
.	O

We	O
show	O
that	O
GATA3	O
inhibits	B-Negative_regulation
FOXP3	O
induction	B-Positive_regulation
and	O
that	O
IL	O
-	O
4	O
limits	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
in	O
a	O
GATA3	O
-	O
mediated	B-Positive_regulation
way	I-Positive_regulation
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
show	O
that	O
GATA3	O
directly	O
binds	B-Binding
to	O
the	O
FOXP3	O
promoter	O
and	O
thereby	O
prevents	B-Negative_regulation
the	O
induction	B-Positive_regulation
of	O
this	O
gene	O
,	O
demonstrating	O
that	O
Th2	O
differentiation	O
overrules	O
iTreg	O
induction	O
.	O

FOXP3	O
Induction	B-Positive_regulation
in	O
T	O
Cell	O
Subsets	O

It	O
is	O
assumed	O
that	O
FOXP3	O
expression	B-Gene_expression
can	O
be	O
induced	B-Positive_regulation
in	O
nonregulatory	O
T	O
cells	O
,	O
which	O
is	O
an	O
important	O
step	O
in	O
iTreg	O
cell	O
differentiation	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
all	O
CD4+	O
T	O
cells	O
have	O
the	O
same	O
capacity	O
to	O
express	B-Gene_expression
FOXP3	O
.	O

To	O
investigate	O
whether	O
FOXP3	O
can	O
be	O
expressed	B-Gene_expression
by	O
any	O
T	O
cell	O
subset	O
or	O
if	O
expression	B-Gene_expression
is	O
restricted	B-Regulation
to	O
a	O
distinct	O
lineage	O
,	O
FOXP3	O
mRNA	B-Transcription
expression	I-Transcription
was	O
analyzed	O
in	O
freshly	O
isolated	O
T	O
cells	O
such	O
as	O
CD25	O
-	O
depleted	O
CD4+	O
cells	O
,	O
CD45RA+	O
naive	O
or	O
CD45RO+	O
memory	O
T	O
cells	O
(	O
Figure	O
1A	O
)	O
,	O
as	O
well	O
as	O
T	O
cells	O
driven	O
in	O
vitro	O
toward	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
phenotypes	O
(	O
Figure	O
1B	O
;	O
phenotype	O
on	O
Figure	O
S1	O
)	O
.	O

The	O
CD4+CD25	O
-	O
,	O
CD45RA+	O
,	O
CD45RO+	O
,	O
and	O
CD4+CD45RO+CD25	O
-	O
were	O
able	O
to	O
significantly	O
induce	B-Positive_regulation
FOXP3	O
mRNA	O
up	O
to	O
30	O
-	O
fold	O
upon	O
TCR	O
activation	O
and	O
addition	O
of	O
TGF	O
-	O
beta	O
.	O

Th1	O
cells	O
showed	O
only	O
a	O
10	O
-	O
fold	O
increase	O
.	O

In	O
contrast	O
,	O
Th2	O
cells	O
stimulated	O
under	O
the	O
same	O
conditions	O
did	O
not	O
increase	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
.	O

The	O
in	O
vitro	O
generated	O
iTreg	O
cells	O
were	O
unable	O
to	O
further	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
FOXP3	O
,	O
which	O
was	O
already	O
at	O
high	O
levels	O
under	O
the	O
resting	O
conditions	O
(	O
Figure	O
1B	O
,	O
right	O
panel	O
)	O
.	O

Th2	O
cells	O
are	O
known	O
to	O
produce	B-Gene_expression
IL	O
-	O
4	O
upon	O
activation	O
,	O
which	O
may	O
interact	O
with	O
TGF	O
-	O
beta	O
signaling	O
and	O
thus	O
prevent	B-Negative_regulation
FOXP3	O
induction	B-Positive_regulation
.	O

However	O
,	O
the	O
neutralization	B-Negative_regulation
of	O
IL	O
-	O
4	O
with	O
a	O
blocking	O
IL	O
-	O
4	O
antibody	O
did	O
not	O
rescue	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
in	O
the	O
differentiated	O
Th2	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
data	O
demonstrated	O
that	O
Th2	O
cells	O
have	O
a	O
limited	O
capacity	O
to	O
express	B-Gene_expression
FOXP3	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
inability	B-Negative_regulation
of	O
Th2	O
cells	O
to	O
express	B-Gene_expression
FOXP3	O
was	O
also	O
documented	O
at	O
the	O
single	O
-	O
cell	O
level	O
,	O
confirming	O
that	O
Th2	O
cells	O
lack	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
(	O
Figure	O
2A	O
)	O
.	O

Only	O
iTreg	O
cells	O
expressed	B-Gene_expression
FOXP3	O
in	O
resting	O
conditions	O
.	O

Interestingly	O
,	O
we	O
observed	O
that	O
resting	O
iTreg	O
cells	O
express	B-Gene_expression
FOXP3	O
but	O
show	O
low	B-Positive_regulation
CD25	O
surface	O
expression	B-Gene_expression
.	O

Repeated	O
exposure	O
to	O
TGF	O
-	O
beta	O
did	O
not	O
further	O
increase	B-Positive_regulation
the	O
FOXP3	O
expression	B-Gene_expression
in	O
the	O
iTreg	O
lineage	O
but	O
transiently	O
induced	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
in	O
Th1	O
cells	O
.	O

Naturally	O
occurring	O
Th2	O
cells	O
such	O
as	O
CRTH2+	O
T	O
cells	O
,	O
T	O
cells	O
isolated	O
according	O
to	O
their	O
IL	O
-	O
4	O
secretion	B-Gene_expression
,	O
or	O
an	O
IL-4	O
-	O
producing	B-Gene_expression
T	O
cell	O
clone	O
(	O
BR8	O
)	O
were	O
also	O
lacking	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
(	O
Figure	O
2B	O
)	O
.	O

Furthermore	O
TGF-beta	O
-	O
mediated	O
FOXP3	O
induction	B-Positive_regulation
failed	B-Negative_regulation
in	O
these	O
cells	O
in	O
contrast	O
to	O
the	O
naive	O
T	O
cells	O
(	O
Figure	O
2B	O
)	O
.	O

Because	O
IL	O
-	O
4	O
is	O
the	O
key	O
Th2	O
cytokine	O
,	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
4	O
and	O
FOXP3	O
in	O
freshly	O
isolated	O
CD4+	O
T	O
cells	O
was	O
analyzed	O
by	O
fluorescence	O
activated	O
cell	O
sorting	O
(	O
FACS	O
)	O
.	O

IL-4	O
-	O
expressing	B-Gene_expression
cells	O
were	O
most	O
abundant	O
among	O
CD45RO+CD25	O
-	O
cells	O
,	O
which	O
did	O
not	O
co	B-Gene_expression
-	I-Gene_expression
express	I-Gene_expression
FOXP3	O
(	O
Figure	O
3A	O
,	O
left	O
panel	O
)	O
.	O

In	O
contrast	O
,	O
CD45RO+CD25+	O
cells	O
abundantly	O
expressed	B-Gene_expression
FOXP3	O
,	O
while	O
lacking	B-Negative_regulation
IL	O
-	O
4	O
(	O
Figure	O
3A	O
,	O
right	O
panel	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
the	O
frequency	O
of	O
the	O
IL	O
-	O
4+	O
cells	O
was	O
always	O
below	O
1	O
%	O
in	O
the	O
FOXP3+	O
cells	O
close	O
to	O
the	O
background	O
.	O

The	O
IL	O
-	O
4+	O
cells	O
were	O
confined	O
to	O
the	O
FOXP3	O
-	O
cells	O
,	O
as	O
shown	O
for	O
the	O
CD45RO+CD25	O
-	O
,	O
CD45RO+CD25+	O
,	O
and	O
CD45RO+CD25+high	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

In	O
addition	O
,	O
neither	O
the	O
Th2	O
clone	O
(	O
BR8	O
)	O
nor	O
CRTH2	O
cells	O
significantly	O
expressed	B-Gene_expression
FOXP3	O
(	O
Figure	O
3C	O
)	O
.	O

Cells	O
enriched	O
for	O
their	O
IL	O
-	O
4	O
secretion	B-Gene_expression
using	O
the	O
magnetic	O
cell	O
isolation	O
technology	O
contained	O
some	O
FOXP3	O
-	O
expressing	B-Gene_expression
cells	O
,	O
but	O
importantly	O
,	O
the	O
expression	O
did	O
not	O
overlap	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
FOXP3	O
was	O
not	O
expressed	B-Gene_expression
by	O
Th2	O
cells	O
and	O
was	O
not	O
inducible	B-Positive_regulation
in	O
those	O
cells	O
.	O

FOXP3	O
and	O
GATA3	O
Kinetics	O
in	O
Differentiating	O
Cells	O

The	O
limited	O
capacity	O
of	O
differentiated	O
effector	O
cells	O
to	O
induce	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
suggests	O
that	O
iTreg	O
induction	O
has	O
to	O
occur	O
before	O
effector	O
T	O
cell	O
differentiation	O
occurs	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	B-Gene_expression
of	O
FOXP3	O
and	O
GATA3	O
during	O
the	O
differentiation	O
of	O
naive	O
CD4	O
T	O
cells	O
into	O
Th0	O
(	O
neutral	O
,	O
anti-IL	O
-	O
4	O
,	O
anti-IFN	O
-	O
gamma	O
,	O
and	O
anti	O
IL	O
-	O
12	O
)	O
,	O
Th2	O
,	O
and	O
iTreg	O
phenotypes	O
.	O

After	O
initiation	O
of	O
the	O
differentiation	O
process	O
,	O
FOXP3	O
and	O
GATA3	O
showed	O
a	O
similar	O
expression	B-Gene_expression
kinetic	O
within	O
the	O
first	O
3	O
d	O
,	O
which	O
are	O
considered	O
to	O
be	O
critical	O
in	O
T	O
cell	O
commitment	O
[	O
18	O
]	O
.	O

Under	O
Th2	O
differentiation	O
conditions	O
,	O
FOXP3	O
mRNA	B-Transcription
expression	I-Transcription
increased	B-Positive_regulation
only	O
marginally	O
(	O
Figure	O
4A	O
,	O
left	O
panel	O
)	O
.	O

Thus	O
,	O
although	O
GATA3	O
and	O
FOXP3	O
showed	O
similar	O
kinetics	O
,	O
their	O
expression	B-Gene_expression
polarizes	O
at	O
the	O
end	O
of	O
the	O
differentiation	O
process	O
when	O
cells	O
were	O
cultured	O
towards	O
Th2	O
or	O
iTreg	O
cells	O
,	O
respectively	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Interestingly	O
,	O
the	O
Th0	O
cells	O
were	O
expressing	B-Gene_expression
more	B-Positive_regulation
FOXP3	O
than	O
the	O
Th2	O
cells	O
,	O
but	O
expressed	B-Gene_expression
low	B-Positive_regulation
levels	O
of	O
GATA3	O
;	O
however	O
,	O
the	O
protein	O
expression	O
slightly	O
differed	O
from	O
mRNA	O
expression	O
,	O
suggesting	O
also	O
posttranslational	O
regulation	O
and	O
degradation	O
as	O
potential	O
additional	O
mechanisms	O
in	O
the	O
differentiation	O
process	O
.	O

The	O
phenotype	O
of	O
iTreg	O
cells	O
included	O
an	O
anergic	O
phenotype	O
upon	O
anti	O
-	O
CD3	O
re	O
-	O
stimulation	O
(	O
Figure	O
S1A	O
)	O
,	O
CD103	O
,	O
CTLA	O
-	O
4	O
,	O
GITR	O
,	O
and	O
PD	O
-	O
1	O
surface	O
expression	B-Gene_expression
(	O
Figure	O
S1B	O
)	O
.	O

On	O
the	O
single	O
-	O
cell	O
level	O
,	O
it	O
can	O
be	O
seen	O
that	O
cells	O
progress	O
through	O
a	O
transition	O
phase	O
,	O
where	O
GATA3	O
and	O
FOXP3	O
expression	B-Gene_expression
coexist	O
to	O
some	O
degree	O
in	O
the	O
same	O
cells	O
,	O
which	O
is	O
resolved	B-Negative_regulation
in	O
iTreg	O
cells	O
after	O
7	O
d	O
(	O
Figure	O
4B	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrated	O
that	O
Th2	O
cells	O
have	O
lost	B-Negative_regulation
their	O
capacity	O
to	O
express	B-Gene_expression
FOXP3	O
and	O
showed	O
that	O
Th2	O
and	O
iTreg	O
cells	O
arise	O
from	O
two	O
different	O
differentiation	O
pathways	O
.	O

IL	O
-	O
4	O
Inhibits	O
TGF-beta	O
-	O
Mediated	O
iTreg	O
Commitment	O

IL	O
-	O
4	O
induces	O
differentiation	O
of	O
naive	O
T	O
cells	O
,	O
upon	O
antigen	O
encounter	O
,	O
into	O
the	O
Th2	O
cell	O
lineage	O
.	O

We	O
therefore	O
asked	O
whether	O
IL	O
-	O
4	O
is	O
able	O
to	O
inhibit	B-Negative_regulation
TGF	O
-	O
beta	O
induction	B-Positive_regulation
of	O
FOXP3	O
during	O
the	O
priming	O
of	O
naive	O
T	O
cells	O
.	O

Human	O
CD4+CD45RA+	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
and/or	O
IL	O
-	O
4	O
and	O
harvested	O
after	O
5	O
d	O
.	O

IL	O
-	O
4	O
efficiently	O
repressed	B-Negative_regulation
the	O
TGF-beta	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
FOXP3	O
expression	B-Gene_expression
(	O
Figure	O
5A	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
5B	O
)	O
.	O

Low	O
levels	O
of	O
GATA3	O
were	O
induced	B-Negative_regulation
also	O
in	O
the	O
absence	B-Negative_regulation
of	O
IL	O
-	O
4	O
,	O
as	O
it	O
was	O
previously	O
observed	O
[	O
3	O
]	O
.	O

However	O
,	O
at	O
low	O
concentration	O
,	O
IL	O
-	O
4	O
was	O
able	O
to	O
marginally	O
induce	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
.	O

Of	O
note	O
,	O
GATA3	O
was	O
also	O
induced	B-Positive_regulation
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
at	O
high	O
IL	O
-	O
4	O
concentration	O
(	O
Figure	O
5A	O
and	O
5B	O
)	O
.	O

The	O
IL-4	O
-	O
mediated	O
prevention	B-Negative_regulation
of	O
FOXP3	O
expression	B-Gene_expression
was	O
not	O
caused	B-Positive_regulation
by	O
interferences	O
of	O
the	O
receptor	O
signaling	O
,	O
because	O
the	O
phosphorylation	B-Phosphorylation
of	O
SMAD2	O
or	O
STAT6	O
was	O
not	O
affected	B-Regulation
by	O
the	O
addition	O
of	O
IL	O
-	O
4	O
and/or	O
TGF	O
-	O
beta	O
,	O
which	O
demonstrates	O
that	O
IL	O
-	O
4	O
as	O
well	O
as	O
TGF	O
-	O
beta	O
signaling	O
were	O
functional	O
under	O
these	O
conditions	O
(	O
Figure	O
5C	O
)	O
.	O

Increasing	B-Positive_regulation
amounts	I-Positive_regulation
of	O
IL	O
-	O
4	O
increase	B-Positive_regulation
intracellular	O
GATA3	O
,	O
whereas	O
FOXP3	O
decreased	B-Negative_regulation
,	O
which	O
is	O
consistent	O
with	O
the	O
mRNA	O
analysis	O
(	O
Figure	O
5D	O
)	O
.	O

Furthermore	O
,	O
injection	O
of	O
IL	O
-	O
4	O
into	O
wild	O
-	O
type	O
B6	O
mice	O
decreased	O
the	O
inducible	O
or	O
natural	O
Treg	O
number	O
in	O
vivo	O
.	O

A	O
distinction	O
of	O
the	O
Treg	O
subsets	O
is	O
not	O
possible	O
,	O
because	O
recently	O
activated	O
iTreg	O
cells	O
also	O
express	B-Gene_expression
surface	O
CD25	O
.	O

We	O
used	O
complexes	O
of	O
recombinant	O
mouse	O
IL	O
-	O
4	O
(	O
rmIL	O
-	O
4	O
)	O
plus	O
anti-IL	O
-	O
4	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
,	O
which	O
have	O
been	O
shown	O
to	O
dramatically	O
increase	O
the	O
potency	O
of	O
the	O
cytokine	O
in	O
vivo	O
[	O
19	O
]	O
.	O

In	O
these	O
mice	O
,	O
the	O
percentage	O
of	O
CD4+CD25+	O
and	O
FOXP3+	O
T	O
cells	O
dramatically	O
decreased	O
when	O
the	O
antibody	O
-	O
cytokine	O
immune	O
complexes	O
were	O
injected	O
(	O
Figure	O
S2	O
)	O
.	O

Upon	O
administration	O
of	O
rmIL	O
-	O
4	O
plus	O
anti-IL	O
-	O
4	O
mAb	O
complexes	O
,	O
the	O
total	O
number	O
of	O
CD4+CD25+	O
T	O
cell	O
,	O
as	O
well	O
as	O
the	O
Foxp3+	O
T	O
cells	O
diminished	O
by	O
half	O
(	O
Figure	O
S2G	O
and	O
S2H	O
)	O
,	O
confirming	O
that	O
the	O
lower	O
percentage	O
was	O
not	O
due	O
to	O
an	O
increase	O
in	O
the	O
CD4+CD25	O
-	O
cells	O
,	O
but	O
a	O
real	O
decrease	O
of	O
CD4+CD25+	O
T	O
cells	O
.	O

In	O
conclusion	O
,	O
IL	O
-	O
4	O
negatively	O
regulates	O
the	O
natural	O
or	O
inducible	O
Treg	O
cell	O
turnover	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo	O
.	O

To	O
study	O
the	O
effects	O
of	O
IL	O
-	O
4	O
on	O
already	O
-	O
existing	O
human	O
natural	O
or	O
inducible	O
Treg	O
cells	O
,	O
we	O
exposed	O
sorted	O
CD25+	O
T	O
cells	O
(	O
nTreg	O
cells	O
)	O
to	O
IL	O
-	O
4	O
and	O
analyzed	O
FOXP3	O
expression	B-Gene_expression
and	O
suppressive	B-Negative_regulation
capacity	I-Negative_regulation
.	O

In	O
already	O
-	O
existing	O
Treg	O
cells	O
,	O
IL	O
-	O
4	O
failed	O
to	O
inhibit	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
(	O
Figure	O
S3A	O
)	O
,	O
and	O
the	O
suppressive	O
capacity	O
was	O
not	O
altered	B-Regulation
(	O
Figure	O
S3C	O
)	O
.	O

Similarly	O
pre	O
-	O
existing	O
iTreg	O
cells	O
did	O
not	O
decrease	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
upon	O
IL	O
-	O
4	O
exposure	O
(	O
Figure	O
S3B	O
)	O
.	O

The	O
Role	O
of	O
TGF	O
-	O
beta	O
in	O
T	O
Cell	O
Differentiation	O

Although	O
TGF-beta	O
-	O
reduced	B-Negative_regulation
CD25	O
,	O
IL	O
-	O
4	O
expression	B-Gene_expression
,	O
and	O
CD25	O
expression	B-Gene_expression
(	O
Figure	O
6B	O
)	O
,	O
IL	O
-	O
4	O
significantly	O
inhibited	B-Negative_regulation
TGF-beta	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
FOXP3	O
in	O
naive	O
T	O
cells	O
driven	O
toward	O
FOXP3+	O
T	O
cells	O
,	O
as	O
shown	O
by	O
FACS	O
analysis	O
(	O
Figure	O
6A	O
)	O
.	O

It	O
is	O
known	O
that	O
IL	O
-	O
4	O
is	O
a	O
potent	O
growth	O
factor	O
and	O
may	O
therefore	O
favor	O
the	O
proliferation	O
of	O
FOXP3	O
-	O
cells	O
and	O
thus	O
decrease	O
the	O
relative	O
percentage	O
of	O
FOXP3+	O
cells	O
.	O

However	O
,	O
analysis	O
of	O
cell	O
division	O
kinetics	O
by	O
CFSE	O
-	O
labeling	O
demonstrated	O
that	O
IL	O
-	O
4	O
did	O
not	O
differentially	O
promote	O
cell	O
growth	O
of	O
FOXP3+	O
over	O
that	O
of	O
FOXP3	O
-	O
.	O

In	O
fact	O
both	O
populations	O
showed	O
similarly	O
enhanced	O
proliferation	O
(	O
Figure	O
6A	O
)	O
.	O

Furthermore	O
the	O
TGF-beta	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
FOXP3	O
expression	B-Gene_expression
was	O
not	O
caused	B-Positive_regulation
by	O
overgrowth	O
of	O
a	O
CD25	O
-	O
FOXP3+	O
minority	O
,	O
since	O
the	O
number	O
of	O
FOXP3+	O
cells	O
was	O
low/absent	O
in	O
the	O
purified	O
CD4+CD45RA+	O
T	O
cells	O
(	O
between	O
0	O
%	O
and	O
1	O
%	O
)	O
,	O
and	O
the	O
FOXP3+	O
cells	O
were	O
not	O
confined	O
to	O
the	O
highly	O
divided	O
cells	O
.	O

CD25	O
was	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
TGF-beta	O
-	O
treated	O
cells	O
compare	O
to	O
activated	O
T	O
cells	O
,	O
which	O
was	O
even	O
more	O
pronounced	B-Positive_regulation
in	O
cells	O
cultured	O
with	O
TGF	O
-	O
beta	O
and	O
IL	O
-	O
4	O
.	O

The	O
addition	O
of	O
IL	O
-	O
4	O
to	O
iTreg	O
-	O
driving	O
conditions	O
decreased	O
the	O
number	O
of	O
FOXP3+	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

In	O
line	O
with	O
the	O
previous	O
findings	O
,	O
the	O
IL-4	O
-	O
producing	B-Gene_expression
cells	O
and	O
the	O
FOXP3	O
expressing	B-Gene_expression
cells	O
are	O
nonoverlapping	O
populations	O
.	O

Since	O
FOXP3	O
is	O
known	O
to	O
act	O
as	O
a	O
repressor	O
of	O
cytokine	O
expression	O
[	O
20	O
]	O
,	O
we	O
therefore	O
analyzed	O
GATA3	O
and	O
FOXP3	O
expression	B-Gene_expression
.	O

The	O
expression	O
kinetic	O
of	O
naive	O
T	O
cells	O
exposed	O
to	O
IL	O
-	O
4	O
and	O
TGF	O
-	O
beta	O
demonstrated	B-Positive_regulation
that	O
GATA3	O
and	O
FOXP3	O
are	O
initially	O
found	O
in	O
separate	O
populations	O
(	O
day	O
2	O
)	O
,	O
but	O
transiently	O
co	B-Gene_expression
-	I-Gene_expression
express	I-Gene_expression
both	O
factors	O
(	O
days	O
4	O
-	O
8	O
)	O
,	O
before	O
establishing	O
separate	O
populations	O
at	O
the	O
end	O
of	O
the	O
differentiation	O
process	O
(	O
day	O
10	O
;	O
Figure	O
6C	O
)	O
,	O
suggesting	O
that	O
GATA3	O
inhibits	O
the	O
development	O
of	O
iTreg	O
cells	O
by	O
repressing	B-Negative_regulation
FOXP3	O
.	O

These	O
results	O
showed	O
that	O
IL	O
-	O
4	O
acts	B-Negative_regulation
in	I-Negative_regulation
vitro	I-Negative_regulation
as	I-Negative_regulation
an	I-Negative_regulation
inhibitor	I-Negative_regulation
of	O
FOXP3	O
expression	B-Gene_expression
,	O
without	O
interfering	O
with	O
TGF	O
-	O
beta	O
signaling	O
,	O
probably	O
acting	B-Positive_regulation
at	O
the	O
level	O
of	O
transcription	O
factors	O
,	O
and	O
possibly	O
by	O
a	O
GATA3	O
-	O
dependent	B-Regulation
mechanism	O
.	O

GATA3	O
Is	O
a	O
Negative	B-Negative_regulation
Regulator	I-Negative_regulation
of	O
FOXP3	O
Expression	B-Gene_expression

FOXP3	O
expression	B-Gene_expression
decreased	B-Negative_regulation
once	O
GATA3	O
expression	B-Gene_expression
is	O
high	B-Positive_regulation
;	O
therefore	O
,	O
we	O
hypothesized	O
a	O
potential	O
role	B-Regulation
for	O
GATA3	O
in	O
repressing	B-Negative_regulation
FOXP3	O
.	O

Besides	O
GATA3	O
's	O
well	O
-	O
known	O
positive	O
effect	O
on	O
gene	O
regulation	O
,	O
GATA3	O
's	O
repressive	O
capabilities	O
were	O
previously	O
shown	O
to	O
restrict	O
Th1	O
commitment	O
by	O
inhibiting	B-Negative_regulation
STAT4	O
expression	B-Gene_expression
[	O
2	O
,	O
21	O
]	O
,	O
and	O
therefore	O
GATA3	O
prevents	O
differentiation	O
into	O
Th1	O
cells	O
.	O

To	O
investigate	O
whether	O
GATA3	O
can	O
directly	O
inhibit	B-Negative_regulation
FOXP3	O
induction	B-Positive_regulation
,	O
we	O
transduced	O
GATA3	O
or	O
a	O
truncated	O
GATA3	O
lacking	B-Negative_regulation
the	O
DNA	O
-	O
binding	O
domain	O
in	O
human	O
primary	O
CD4+CD45RA+	O
T	O
cells	O
using	O
a	O
TAT	O
-	O
fused	O
,	O
recombinantly	O
expressed	O
GATA3	O
.	O

After	O
transduction	O
,	O
the	O
cells	O
were	O
activated	O
with	O
soluble	O
anti	O
-	O
CD3/CD28	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TGF	O
-	O
beta	O
.	O

TAT	O
-	O
GATA3	O
was	O
successfully	O
transduced	O
in	O
a	O
homogeneous	O
and	O
dose	O
-	O
dependent	O
manner	O
into	O
human	O
CD4+	O
T	O
cells	O
(	O
Figure	O
7A	O
,	O
upper	O
panel	O
)	O
.	O

TAT	O
-	O
GATA3	O
reduced	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
a	O
DNA	O
-	O
binding	O
domain	O
truncated	B-Negative_regulation
version	O
(	O
TAT-DeltaDBD	O
-	O
GATA3	O
)	O
did	O
not	O
affect	B-Regulation
FOXP3	O
expression	B-Gene_expression
as	O
compared	O
with	O
expression	O
in	O
untransduced	O
cells	O
(	O
Figure	O
7A	O
)	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
inhibitory	B-Negative_regulation
effect	I-Negative_regulation
of	O
GATA3	O
on	O
FOXP3	O
in	O
transgenic	O
DO11.10	O
mice	O
,	O
constitutively	O
overexpressing	B-Positive_regulation
GATA3	O
under	O
the	O
control	O
of	O
the	O
CD2	O
locus	O
control	O
region	O
(	O
DO11.10xCD2	O
-	O
GATA3	O
)	O
.	O

The	O
thymic	O
selection	O
into	O
the	O
CD4	O
lineage	O
is	O
largely	O
intact	O
in	O
DO11.10xCD2	O
-	O
GATA3	O
(	O
RW	O
Hendriks	O
,	O
unpublished	O
data	O
)	O
.	O

These	O
mice	O
develop	O
lymphomas	O
at	O
an	O
older	O
age	O
,	O
but	O
signs	O
of	O
autoimmune	O
disease	O
were	O
not	O
described	O
[	O
22	O
]	O
.	O

To	O
investigate	O
the	O
effect	B-Regulation
of	O
GATA3	O
on	O
iTreg	O
,	O
CD4+CD62L+CD25	O
-	O
cells	O
were	O
isolated	O
,	O
activated	O
with	O
OVA	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TGF	O
-	O
beta	O
,	O
and	O
Foxp3	O
expression	B-Gene_expression
was	O
analyzed	O
after	O
4	O
d	O
.	O

The	O
naive	O
CD4+CD25	O
-	O
cells	O
were	O
Foxp3	O
-	O
(	O
unpublished	O
data	O
)	O
.	O

As	O
described	O
for	O
the	O
human	O
cells	O
,	O
TGF	O
-	O
beta	O
dramatically	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
Foxp3	O
in	O
the	O
DO11.10	O
littermate	O
control	O
mice	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
the	O
CD2	O
-	O
GATA3xDO11.10	O
mice	O
showed	O
dramatically	O
reduced	B-Negative_regulation
Foxp3	O
expression	B-Gene_expression
when	O
activated	B-Positive_regulation
with	O
TGF	O
-	O
beta	O
and	O
OVA	O
(	O
Figure	O
7B	O
)	O
.	O

All	O
mice	O
produced	B-Gene_expression
similar	O
amounts	O
of	O
TGF	O
-	O
beta	O
;	O
in	O
addition	O
,	O
Smad7	O
was	O
equally	O
expressed	B-Gene_expression
[	O
23	O
]	O
in	O
T	O
cells	O
of	O
both	O
mice	O
strains	O
(	O
Figure	O
7C	O
)	O
,	O
indicating	O
intact	O
TGF	O
-	O
beta	O
signaling	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
a	O
repressive	O
role	O
of	O
IL-4	O
-	O
induced	B-Positive_regulation
GATA3	O
transcription	O
factor	O
in	O
the	O
generation	O
of	O
iTreg	O
cells	O
.	O

GATA3	O
Represses	B-Negative_regulation
the	O
FOXP3	O
Promoter	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
GATA3	O
-	O
mediated	O
repression	B-Negative_regulation
of	O
human	O
FOXP3	O
,	O
the	O
human	O
FOXP3	O
promoter	O
was	O
studied	O
and	O
a	O
palindromic	O
binding	O
site	O
for	O
GATA3	O
was	O
discovered	O
.	O

The	O
GATA	O
-	O
binding	O
site	O
is	O
located	O
303	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
[	O
24	O
]	O
.	O

This	O
site	O
is	O
highly	O
conserved	O
between	O
humans	O
,	O
mice	O
,	O
and	O
rats	O
(	O
Figure	O
S4	O
)	O
and	O
may	O
therefore	O
play	B-Regulation
an	I-Regulation
important	I-Regulation
role	I-Regulation
in	O
FOXP3	O
regulation	B-Regulation
.	O

The	O
functional	O
relevance	O
of	O
this	O
site	O
was	O
studied	O
using	O
a	O
FOXP3	O
-	O
promoter	O
construct	O
[	O
24	O
]	O
.	O

We	O
transfected	O
human	O
primary	O
CD4+	O
T	O
cells	O
,	O
in	O
vitro	O
differentiated	O
Th2	O
cells	O
,	O
and	O
Jurkat	O
cells	O
(	O
Jurkat	O
cells	O
are	O
known	O
to	O
constitutively	O
express	B-Gene_expression
GATA3	O
[	O
25	O
,	O
26	O
]	O
)	O
,	O
and	O
we	O
measured	O
FOXP3	O
promoter	O
activity	O
.	O

The	O
promoter	O
was	O
not	O
active	O
in	O
the	O
GATA3	O
-	O
expressing	B-Gene_expression
cell	O
line	O
Jurkat	O
or	O
in	O
the	O
in	O
vitro	O
-	O
differentiated	O
Th2	O
cells	O
,	O
whereas	O
the	O
construct	O
was	O
active	B-Positive_regulation
in	O
the	O
CD4	O
cells	O
,	O
which	O
express	B-Gene_expression
a	O
lower	O
amount	O
of	O
GATA3	O
(	O
Figure	O
8A	O
)	O
.	O

Overexpression	B-Positive_regulation
of	O
GATA3	O
in	O
naive	O
T	O
cells	O
diminished	O
luciferase	O
activity	O
of	O
the	O
FOXP3	O
promoter	O
compared	O
with	O
the	O
control	O
vector	O
(	O
Figure	O
8B	O
)	O
.	O

To	O
further	O
address	O
the	O
function	O
of	O
the	O
GATA3	O
site	O
,	O
we	O
inserted	O
a	O
site	O
-	O
specific	O
mutation	O
deleting	B-Negative_regulation
the	O
GATA3	O
-	O
binding	O
site	O
.	O

This	O
mutation	O
increased	O
luciferase	O
activity	O
by	O
3	O
-	O
fold	O
in	O
memory	O
CD4+CD45RO+	O
T	O
cells	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
naive	O
(	O
GATA3	O
-	O
)	O
CD4+CD45RA+	O
T	O
cells	O
,	O
revealing	O
a	O
repressor	B-Negative_regulation
activity	O
of	O
GATA3	O
on	O
the	O
FOXP3	O
promoter	O
(	O
Figure	O
8C	O
)	O
.	O

Furthermore	O
GATA3	O
binds	B-Binding
directly	O
to	O
the	O
FOXP3	O
promoter	O
as	O
investigated	O
by	O
pull	O
-	O
down	O
assay	O
.	O

HEK	O
cells	O
were	O
transiently	O
transfected	O
with	O
GATA3	O
or	O
a	O
control	O
vector	O
,	O
and	O
increasing	O
amounts	O
of	O
lysates	O
were	O
incubated	O
with	O
oligonucleotides	O
containing	O
the	O
GATA3	O
site	O
of	O
the	O
FOXP3	O
promoter	O
or	O
a	O
control	O
oligonucleotide	O
with	O
a	O
mutated	O
GATA3	O
-	O
binding	O
site	O
.	O

After	O
the	O
pull	O
-	O
down	O
,	O
GATA3	O
binding	B-Binding
was	O
detected	O
by	O
Western	O
blot	O
.	O

Similarly	O
,	O
GATA3	O
-	O
expressing	B-Gene_expression
Th2	O
cells	O
and	O
iTreg	O
cells	O
were	O
subjected	O
to	O
this	O
approach	O
.	O

Only	O
HEK	O
cells	O
overexpressing	B-Gene_expression
GATA3	O
and	O
Th2	O
cells	O
showed	O
GATA3	O
-	O
binding	B-Binding
activity	O
(	O
Figure	O
8D	O
and	O
8E	O
)	O
.	O

These	O
experiments	O
demonstrated	O
that	O
GATA3	O
binds	B-Binding
the	O
palindromic	O
FOXP3	O
promoter	O
.	O

To	O
gain	O
insights	O
into	O
the	O
in	O
vivo	O
situation	O
,	O
we	O
performed	O
a	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
using	O
an	O
anti	O
-	O
GATA3	O
antibody	O
and	O
showed	O
that	O
GATA3	O
binds	B-Binding
to	O
the	O
FOXP3	O
promoter	O
region	O
in	O
Th2	O
cells	O
,	O
but	O
not	O
in	O
iTreg	O
cells	O
(	O
Figure	O
7F	O
)	O
.	O

Taken	O
together	O
these	O
data	O
demonstrate	O
that	O
the	O
GATA3	O
-	O
binding	B-Binding
to	O
the	O
FOXP3	O
promoter	O
is	O
repressing	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
.	O

Discussion	O

The	O
current	O
study	O
reveals	O
that	O
FOXP3	O
induction	B-Positive_regulation
,	O
an	O
important	O
step	O
in	O
iTreg	O
commitment	O
,	O
is	O
inhibited	B-Negative_regulation
by	O
GATA3	O
,	O
which	O
is	O
the	O
key	O
regulator	O
for	O
polarization	O
toward	O
Th2	O
cells	O
.	O

After	O
differentiation	O
,	O
the	O
effector	O
Th2	O
cells	O
become	O
refractory	O
to	O
conversion	O
into	O
a	O
FOXP3+	O
phenotype	O
.	O

In	O
accordance	O
with	O
other	O
studies	O
,	O
we	O
found	O
that	O
CD4+CD25	O
-	O
cells	O
were	O
able	O
to	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
FOXP3	O
[	O
12	O
,	O
27	O
]	O
.	O

Already	O
-	O
committed	O
cells	O
such	O
as	O
memory	O
T	O
cells	O
and	O
Th1	O
cells	O
showed	O
only	O
moderate	O
and	O
transient	O
FOXP3	O
induction	B-Positive_regulation
,	O
which	O
is	O
not	O
sufficient	O
to	O
change	O
the	O
phenotype	O
toward	O
a	O
regulatory	O
T	O
cell	O
profile	O
.	O

In	O
contrast	O
,	O
naive	O
T	O
cells	O
could	O
efficiently	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
FOXP3	O
when	O
treated	O
with	O
TGF	O
-	O
beta	O
to	O
induce	O
iTreg	O
cells	O
[	O
10	O
,	O
28	O
-	O
34	O
]	O
,	O
suggesting	O
that	O
FOXP3	O
plays	O
an	O
important	O
role	O
in	O
the	O
early	O
differentiation	O
process	O
and	O
may	O
act	O
in	O
a	O
way	O
similar	O
to	O
that	O
known	O
for	O
the	O
Th1/Th2	O
decision	O
factors	O
T	O
-	O
bet	O
and	O
GATA3	O
.	O

This	O
commitment	O
is	O
characterized	O
by	O
competitive	O
expression	B-Gene_expression
of	O
these	O
factors	O
[	O
35	O
,	O
36	O
]	O
,	O
which	O
we	O
also	O
observed	O
in	O
differentiating	O
FOXP3+	O
iTreg	O
cells	O
including	O
a	O
phase	O
of	O
co	B-Gene_expression
-	I-Gene_expression
expression	I-Gene_expression
,	O
which	O
turns	O
into	O
nonoverlapping	O
expression	B-Gene_expression
upon	O
completed	O
differentiation	O
.	O

In	O
this	O
competitive	O
process	O
TGF	O
-	O
beta	O
appeared	O
to	O
be	O
mandatory	O
for	O
the	O
induction	O
of	O
FOXP3	O
,	O
possibly	O
by	O
keeping	O
the	O
expression	B-Gene_expression
of	O
GATA3	O
and	O
T	O
-	O
bet	O
low	B-Negative_regulation
[	O
37	O
,	O
38	O
]	O
.	O

In	O
contrast	O
,	O
differentiating	O
naive	O
T	O
cells	O
in	O
the	O
absence	B-Negative_regulation
of	O
polarization	O
factors	O
(	O
Th0	O
)	O
such	O
as	O
IL	O
-	O
4	O
,	O
IL	O
-	O
12	O
,	O
or	O
TGF	O
-	O
beta	O
showed	O
only	O
a	O
transient	O
FOXP3	O
expression	B-Gene_expression
and	O
failed	O
to	O
generate	O
a	O
population	O
of	O
FOXP3	O
-	O
expressing	B-Gene_expression
cells	O
,	O
but	O
GATA3	O
and	O
T	O
-	O
bet	O
were	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
(	O
unpublished	O
data	O
)	O
.	O

Interestingly	O
,	O
as	O
we	O
and	O
others	O
previously	O
described	O
,	O
FOXP3	O
-	O
promoting	B-Positive_regulation
factors	O
,	O
such	O
as	O
dexamethasone	O
[	O
39	O
]	O
,	O
CTLA	O
-	O
4	O
[	O
40	O
]	O
,	O
and	O
estrogens	O
[	O
41	O
]	O
,	O
are	O
also	O
known	O
as	O
inhibitors	B-Negative_regulation
of	O
GATA3	O
expression	B-Gene_expression
[	O
42	O
-	O
45	O
]	O
.	O

Therefore	O
GATA3	O
not	O
only	O
induces	O
differentiation	O
into	O
Th2	O
cells	O
but	O
also	O
inhibits	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
and	O
commitment	O
into	O
iTreg	O
cells	O
.	O

The	O
Th2	O
cytokine	O
IL	O
-	O
4	O
but	O
not	O
IL	O
-	O
13	O
(	O
unpublished	O
data	O
)	O
was	O
able	O
to	O
inhibit	B-Negative_regulation
TGF-beta	O
-	O
mediated	O
FOXP3	O
induction	B-Positive_regulation
and	O
therefore	O
prevented	O
conversion	O
into	O
the	O
regulatory	O
phenotype	O
.	O

To	O
prove	O
the	O
inhibitory	O
effect	O
of	O
IL	O
-	O
4	O
on	O
inducible	O
or	O
natural	O
Treg	O
commitment	O
in	O
vivo	O
,	O
we	O
treated	O
mice	O
with	O
IL	O
-	O
4	O
and	O
anti-IL	O
-	O
4	O
.	O

This	O
has	O
been	O
shown	O
to	O
increase	O
the	O
effect	O
of	O
the	O
cytokine	O
in	O
vivo	O
[	O
19	O
]	O
.	O

Only	O
the	O
IL-4/IL	O
-	O
4	O
mAb	O
complex	O
resulted	O
in	O
a	O
decrease	O
of	O
the	O
amount	O
of	O
natural	O
or	O
inducible	O
Treg	O
(	O
CD25+	O
and	O
Foxp3+	O
)	O
cells	O
7	O
d	O
after	O
treatment	O
.	O

Our	O
results	O
suggest	O
that	O
IL	O
-	O
4	O
is	O
only	O
interfering	O
with	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
into	O
iTreg	O
cells	O
.	O

But	O
since	O
a	O
distinction	O
of	O
nTreg	O
and	O
iTreg	O
cells	O
is	O
currently	O
not	O
possible	O
,	O
because	O
iTreg	O
cells	O
also	O
transiently	O
express	B-Gene_expression
CD25	O
after	O
activation	O
,	O
we	O
can	O
not	O
exclude	O
that	O
IL	O
-	O
4	O
may	O
also	O
inhibit	B-Negative_regulation
Foxp3	O
expression	B-Gene_expression
in	O
nTreg	O
cells	O
in	O
vivo	O
or	O
that	O
additional	O
effects	O
may	O
contribute	B-Positive_regulation
to	O
the	O
observed	O
drop	B-Negative_regulation
in	O
Foxp3	O
expression	B-Gene_expression
.	O

IL	O
-	O
4	O
has	O
already	O
been	O
shown	O
to	O
negatively	O
regulate	O
the	O
development	O
of	O
naive	O
T	O
cells	O
into	O
Th1	O
or	O
the	O
IL-17	O
-	O
producing	B-Gene_expression
T	O
cells	O
(	O
Th17	O
)	O
[	O
46	O
,	O
47	O
]	O
.	O

Similar	O
effects	O
have	O
been	O
recently	O
described	O
for	O
IL	O
-	O
6	O
,	O
which	O
,	O
combined	O
with	O
TGF	O
-	O
beta	O
,	O
inhibits	O
the	O
generation	O
of	O
iTreg	O
cells	O
and	O
induces	O
differentiation	O
into	O
the	O
Th17	O
cells	O
by	O
an	O
unknown	O
mechanism	O
[	O
48	O
,	O
49	O
]	O
.	O

Thus	O
the	O
polarization	O
into	O
iTreg	O
cells	O
is	O
negatively	O
regulated	O
by	O
the	O
effector	O
cytokines	O
IL	O
-	O
4	O
and	O
IL	O
-	O
6	O
.	O

IL	O
-	O
4	O
has	O
been	O
previously	O
shown	O
to	O
induce	O
the	O
generation	O
of	O
FOXP3+	O
Treg	O
cells	O
out	O
of	O
CD4+CD25	O
-	O
[	O
50	O
]	O
.	O

In	O
those	O
experiments	O
,	O
the	O
concentrations	O
of	O
IL	O
-	O
4	O
used	O
were	O
low	O
,	O
and	O
as	O
we	O
also	O
observed	O
,	O
IL	O
-	O
4	O
at	O
low	O
concentration	O
slightly	O
enhanced	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
.	O

Importantly	O
,	O
these	O
concentrations	O
were	O
not	O
sufficient	O
to	O
induce	B-Positive_regulation
GATA3	O
expression	B-Gene_expression
.	O

IL	O
-	O
4	O
may	O
favor	O
proliferation	O
of	O
nTreg	O
cells	O
[	O
47	O
]	O
or	O
directly	O
regulate	B-Regulation
FOXP3	O
expression	B-Gene_expression
in	O
a	O
STAT	O
-	O
dependent	O
fashion	O
[	O
51	O
]	O
.	O

Since	O
IL	O
-	O
13	O
does	O
not	O
effectively	O
reduce	B-Negative_regulation
FOXP3	O
and	O
fails	O
to	O
induce	B-Positive_regulation
GATA3	O
,	O
we	O
hypothesized	O
that	O
the	O
IL-4	O
-	O
dependent	O
inhibition	B-Negative_regulation
of	O
FOXP3	O
could	O
be	O
mediated	B-Positive_regulation
by	O
GATA3	O
.	O

In	O
fact	O
,	O
GATA3	O
-	O
inducing	B-Positive_regulation
IL	O
-	O
4	O
concentrations	O
repressed	B-Negative_regulation
TGF-beta	O
-	O
mediated	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
,	O
whereas	O
IL	O
-	O
4	O
as	O
well	O
as	O
TGF	O
-	O
beta	O
signaling	O
were	O
intact	O
.	O

This	O
result	O
suggested	O
a	O
competitive	O
mechanism	O
between	O
GATA3	O
and	O
FOXP3	O
transcription	O
factors	O
in	O
determining	O
lineage	O
commitment	O
during	O
the	O
early	O
phase	O
of	O
differentiation	O
.	O

Accordingly	O
,	O
we	O
investigated	O
naturally	O
high	B-Positive_regulation
GATA3	O
-	O
expressing	B-Gene_expression
cells	O
and	O
confirmed	O
the	O
absence	B-Negative_regulation
of	O
FOXP3	O
.	O

Protein	O
transduction	O
of	O
GATA3	O
into	O
naive	O
T	O
cells	O
inhibited	B-Negative_regulation
FOXP3	O
induction	B-Positive_regulation
in	O
human	O
,	O
differentiating	O
,	O
naive	O
T	O
cells	O
.	O

This	O
inhibitory	O
effect	O
of	O
GATA3	O
was	O
further	O
confirmed	O
in	O
BALB/c	O
transgenic	O
mice	O
,	O
expressing	B-Gene_expression
GATA3	O
in	O
T	O
cells	O
(	O
DO11.10	O
:	O
CD2	O
-	O
GATA3	O
transgenic	O
mice	O
)	O
.	O

In	O
line	O
with	O
the	O
transient	O
overexpression	B-Positive_regulation
of	O
GATA3	O
in	O
human	O
T	O
cells	O
,	O
cells	O
of	O
these	O
mice	O
failed	B-Negative_regulation
to	O
induce	B-Positive_regulation
FOXP3	O
expression	B-Gene_expression
upon	O
exposure	O
with	O
antigen	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

Strikingly	O
,	O
the	O
DO11.10	O
:	O
CD2	O
-	O
GATA3	O
mice	O
do	O
have	O
peripheral	O
FOXP3+	O
cells	O
,	O
which	O
however	O
displayed	O
a	O
10	O
%	O
-	O
25	O
%	O
lower	O
frequency	O
compared	O
to	O
wild	O
-	O
type	O
DO11.10	O
mice	O
.	O

Thus	O
GATA3	O
restrains	O
the	O
development	O
of	O
certain	O
Treg	O
subsets	O
,	O
presumably	O
the	O
inducible	O
,	O
peripheral	O
population	O
and	O
not	O
those	O
of	O
thymic	O
origin	O
.	O

Thymic	O
T	O
cells	O
undergo	O
a	O
different	O
maturation	O
process	O
,	O
which	O
may	O
explain	O
the	O
insensitivity	O
of	O
nTreg	O
to	O
GATA3	O
overexpression	B-Positive_regulation
[	O
52	O
]	O
.	O

In	O
contrast	O
to	O
the	O
Th2	O
-	O
differentiating	O
and	O
iTreg	O
-	O
inhibiting	O
function	O
of	O
GATA3	O
in	O
peripheral	O
T	O
cells	O
,	O
GATA3	O
acts	O
in	O
the	O
thymus	O
together	O
with	O
other	O
transcription	O
factors	O
such	O
as	O
the	O
Repressor	O
of	O
GATA3	O
(	O
ROG	O
)	O
in	O
the	O
differentiation	O
process	O
toward	O
CD8	O
cells	O
[	O
53	O
,	O
54	O
]	O
or	O
participates	O
in	O
complex	O
transcriptional	O
feedback	O
network	O
to	O
regulate	O
sympathoadrenal	O
differentiation	O
[	O
55	O
]	O
.	O

Therefore	O
,	O
the	O
role	O
of	O
GATA3	O
appears	O
to	O
be	O
tissue	O
specific	O
and	O
can	O
not	O
be	O
generalized	O
.	O

Our	O
study	O
demonstrates	O
that	O
GATA3	O
repressed	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
directly	O
by	O
binding	B-Binding
to	O
the	O
FOXP3	O
promoter	O
region	O
.	O

A	O
palindromic	O
GATA	O
-	O
site	O
is	O
located	O
303	O
bp	O
upstream	O
of	O
the	O
TSS	O
in	O
a	O
highly	O
conserved	O
region	O
,	O
which	O
we	O
have	O
previously	O
identified	O
as	O
the	O
FOXP3	O
promoter	O
[	O
24	O
]	O
.	O

Site	O
-	O
specific	O
mutation	O
of	O
this	O
site	O
increased	O
the	O
activity	O
of	O
the	O
promoter	O
constructs	O
,	O
thus	O
revealing	O
the	O
repressive	O
nature	O
of	O
this	O
GATA	O
element	O
in	O
memory	O
T	O
cells	O
,	O
which	O
naturally	O
express	B-Gene_expression
GATA3	O
,	O
whereas	O
no	O
difference	O
was	O
seen	O
in	O
naive	O
T	O
cells	O
,	O
which	O
do	O
not	O
express	B-Gene_expression
GATA3	O
.	O

This	O
palindromic	O
GATA	O
element	O
is	O
bound	B-Binding
by	O
GATA3	O
protein	O
as	O
proven	O
with	O
pull	O
-	O
down	O
experiments	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
by	O
ChIP	O
that	O
GATA3	O
binds	B-Binding
this	O
element	O
also	O
in	O
intact	O
cells	O
.	O

It	O
is	O
known	O
that	O
GATA3	O
can	O
induce	O
transcription	O
by	O
chromatin	O
remodeling	O
[	O
56	O
]	O
,	O
by	O
directly	O
transactivating	O
promoters	O
[	O
36	O
]	O
,	O
or	O
,	O
as	O
shown	O
in	O
the	O
current	O
study	O
,	O
acts	O
as	O
a	O
repressor	O
of	O
gene	O
expression	O
[	O
21	O
,	O
57	O
-	O
59	O
]	O
.	O

Therefore	O
keeping	O
GATA3	O
expression	B-Gene_expression
low	B-Negative_regulation
might	O
be	O
required	O
to	O
induce	O
efficient	O
FOXP3+	O
iTreg	O
cell	O
generation	O
.	O

The	O
molecular	O
interactions	O
enabling	O
GATA3	O
to	O
inhibit	B-Negative_regulation
FOXP3	O
are	O
not	O
identified	O
yet	O
,	O
but	O
the	O
GATA	O
-	O
binding	O
site	O
is	O
located	O
adjacent	O
to	O
positive	O
,	O
inducing	O
sites	O
,	O
composed	O
of	O
AP-1	O
-	O
NFATc2	O
sites	O
[	O
24	O
]	O
,	O
and	O
GATA3	O
may	O
compete	B-Negative_regulation
with	O
the	O
binding	B-Binding
of	O
AP	O
-	O
1/NFAT	O
to	O
the	O
promoter	O
(	O
unpublished	O
observations	O
)	O
.	O

In	O
summary	O
,	O
we	O
demonstrated	O
that	O
FOXP3	O
is	O
negatively	B-Negative_regulation
regulated	I-Negative_regulation
by	O
cytokines	O
such	O
as	O
IL	O
-	O
4	O
.	O

GATA3	O
acts	B-Negative_regulation
as	I-Negative_regulation
an	I-Negative_regulation
inhibitor	I-Negative_regulation
of	O
FOXP3	O
expression	B-Gene_expression
in	O
early	O
T	O
cell	O
differentiation	O
,	O
as	O
well	O
as	O
in	O
differentiated	O
Th2	O
cells	O
by	O
directly	O
binding	B-Binding
and	O
repressing	B-Negative_regulation
the	O
FOXP3	O
promoter	O
.	O

We	O
therefore	O
describe	O
a	O
new	O
mechanism	O
of	O
how	O
Il	O
-	O
4	O
avoids	O
tolerance	O
induction	O
by	O
repressing	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
.	O

These	O
findings	O
will	O
give	O
new	O
perspectives	O
toward	O
understanding	O
molecular	O
mechanisms	O
of	O
iTreg	O
induction	O
and	O
thus	O
pathways	O
of	O
peripheral	O
tolerance	O
induction	O
,	O
particularly	O
in	O
allergy	O
and	O
asthma	O
.	O

Mice	O
.	O

Normal	O
B6	O
mice	O
were	O
purchased	O
from	O
the	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
.	O

Transgenic	O
DO11.10	O
mice	O
,	O
expressing	O
a	O
T	O
cell	O
receptor	O
for	O
OVA323	O
-	O
339	O
peptide	O
in	O
the	O
context	O
of	O
H	O
-	O
2d	O
,	O
were	O
backcrossed	O
with	O
mice	O
expressing	B-Gene_expression
GATA	O
-	O
3	O
,	O
driven	O
by	O
the	O
human	O
CD2	O
locus	O
control	O
region	O
(	O
CD2	O
-	O
GATA3	O
)	O
[	O
22	O
]	O
,	O
resulting	O
in	O
DO11.10xCD2	O
-	O
GATA3	O
mice	O
.	O

Mice	O
used	O
for	O
experiments	O
were	O
backcrossed	O
on	O
a	O
BALB/c	O
background	O
for	O
a	O
minimum	O
of	O
eight	O
generations	O
and	O
used	O
at	O
an	O
age	O
of	O
8	O
-	O
12	O
wk	O
.	O

Mice	O
were	O
housed	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
and	O
all	O
animal	O
studies	O
were	O
performed	O
according	O
to	O
institutional	O
and	O
state	O
guidelines	O
.	O

Isolation	O
of	O
CD4+	O
T	O
cells	O
.	O

CD4+	O
T	O
cells	O
were	O
isolated	O
from	O
blood	O
of	O
healthy	O
human	O
volunteers	O
using	O
the	O
anti	O
-	O
CD4	O
magnetic	O
beads	O
(	O
Dynal	O
,	O
Hamburg	O
,	O
Germany	O
)	O
as	O
previously	O
described	O
[	O
60	O
]	O
.	O

The	O
purity	O
of	O
CD4+	O
T	O
cells	O
was	O
initially	O
tested	O
by	O
FACS	O
and	O
was	O
>	O
/=	O
95	O
%	O
.	O

Monoclonality	O
of	O
T	O
cell	O
clones	O
was	O
confirmed	O
by	O
TCR	O
-	O
chain	O
mapping	O
and	O
was	O
identified	O
to	O
be	O
Vbeta8	O
positive	O
.	O

The	O
clones	O
were	O
characterized	O
by	O
high	B-Positive_regulation
IL	O
-	O
4	O
secretion	B-Gene_expression
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
PCR	O
primers	O
and	O
probes	O
were	O
designed	O
based	O
on	O
the	O
sequences	O
reported	O
in	O
GenBank	O
with	O
the	O
Primer	O
Express	O
software	O
version	O
1.2	O
(	O
Applied	O
Biosystems	O
)	O
as	O
follows	O
:	O
FOXP3	O
forward	O
primer	O
5'	O
-	O
GAA	O
ACA	O
GCA	O
CAT	O
TCC	O
CAG	O
AGT	O
TC	O
-	O
3	O
'	O
;	O
FOXP3	O
reverse	O
primer	O
5'	O
-	O
ATG	O
GCC	O
CAG	O
CGG	O
ATG	O
AG	O
-	O
3	O
'	O
;	O
EF	O
-	O
1alpha	O
forward	O
primer	O
and	O
reverse	O
primer	O
as	O
described	O
[	O
61	O
]	O
;	O
GATA3	O
forward	O
primer	O
5'	O
-	O
GCG	O
GGC	O
TCT	O
ATC	O
ACA	O
AAA	O
TGA	O
-	O
3	O
'	O
and	O
rwd	O
5'	O
-	O
GCT	O
CTC	O
CTG	O
GCT	O
GCA	O
GAC	O
AGC	O
-	O
3	O
'	O
.	O

The	O
prepared	O
cDNAs	O
were	O
amplified	O
using	O
SYBR	O
-	O
PCR	O
mastermix	O
(	O
Biorad	O
)	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
manufacturer	O
in	O
an	O
ABI	O
PRISM	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Quantitative	O
PCR	O
of	O
murine	O
samples	O
was	O
performed	O
with	O
Brilliant	O
SYBR	O
Green	O
QPCR	O
master	O
mix	O
(	O
Stratagene	O
)	O
and	O
the	O
following	O
primers	O
:	O
Ubiquitin	O
C	O
,	O
5'	O
-	O
AGG	O
TCA	O
AAC	O
AGG	O
AAG	O
ACA	O
GAC	O
GTA	O
-	O
3	O
'	O
and	O
5'-TCACACCCAAGAACAAGCACA	O
-	O
3	O
'	O
;	O
Smad	O
-	O
7	O
,	O
5'	O
-	O
GAA	O
ACC	O
GGG	O
GGA	O
ACG	O
AAT	O
TAT	O
-	O
3	O
'	O
and	O
5'	O
-	O
CGC	O
GAG	O
TCT	O
TCT	O
CCT	O
CCC	O
A	O
-	O
3	O
'	O
;	O
TGF	O
-	O
ss1	O
,	O
5'	O
-	O
TGA	O
CGT	O
CAC	O
TGG	O
AGT	O
TGT	O
ACG	O
G	O
-	O
3	O
'	O
and	O
5'	O
-	O
GGT	O
TCA	O
TGT	O
CAT	O
GGA	O
TGG	O
TGC	O
-	O
3	O
'	O
.	O

Primer	O
pairs	O
were	O
evaluated	O
for	O
integrity	O
by	O
analysis	O
of	O
the	O
amplification	O
plot	O
,	O
dissociation	O
curves	O
,	O
and	O
efficiency	O
of	O
PCR	O
amplification	O
.	O

PCR	O
conditions	O
were	O
10	O
min	O
at	O
95	O
degreesC	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
15	O
s	O
at	O
95	O
degreesC	O
and	O
60	O
degreesC	O
for	O
1	O
min	O
using	O
an	O
7300	O
real	O
-	O
time	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
amplification	O
of	O
the	O
housekeeping	O
gene	O
encoding	O
ubiquitin	O
C	O
was	O
performed	O
during	O
each	O
run	O
for	O
each	O
sample	O
to	O
allow	O
normalization	O
between	O
samples	O
.	O

Relative	O
quantification	O
and	O
calculation	O
of	O
the	O
range	O
of	O
confidence	O
was	O
performed	O
using	O
the	O
comparative	O
DeltaDeltaCT	O
method	O
.	O

Inducible	O
murine	O
Treg	O
culture	O
.	O

Naive	O
CD4+	O
T	O
cells	O
(	O
CD4+	O
,	O
CD62L+	O
,	O
and	O
CD25	O
-	O
)	O
were	O
isolated	O
from	O
pooled	O
lymph	O
nodes	O
and	O
spleens	O
by	O
FACS	O
(	O
FACS	O
Aria	O
,	O
BD	O
Biosciences	O
)	O
.	O

5	O
x	O
105	O
T	O
cells	O
were	O
co	O
-	O
cultured	O
with	O
2.5	O
x	O
104	O
bone	O
marrow	O
-	O
derived	O
dendritic	O
cells	O
[	O
62	O
]	O
and	O
0.01	O
mug/ml	O
OVA323	O
-	O
339	O
peptide	O
(	O
Ansynth	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
-	O
ng/mul	O
rhTGF	O
-	O
ss1	O
(	O
Peprotech	O
)	O
in	O
48	O
-	O
well	O
plates	O
.	O

After	O
4	O
d	O
,	O
cells	O
were	O
harvested	O
and	O
analyzed	O
for	O
intracellular	O
FOXP3	O
expression	B-Gene_expression
by	O
FACS	O
or	O
gene	O
expression	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

In	O
vitro	O
T	O
cell	O
differentiation	O
.	O

CD4+	O
CD45RA+	O
magnetically	O
-	O
sorted	O
(	O
CD45RO	O
depletion	B-Negative_regulation
,	O
MACS	O
,	O
according	O
to	O
the	O
protocol	O
of	O
the	O
manufacturer	O
)	O
cells	O
were	O
stimulated	O
with	O
immobilized	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	O
(	O
1	O
mug/ml	O
,	O
Okt3	O
,	O
IgG1	O
)	O
and	O
anti	O
-	O
CD28	O
(	O
2	O
mug/ml	O
)	O
in	O
Th1	O
conditions	O
:	O
25	O
ng/ml	O
IL	O
-	O
12	O
,	O
5	O
mug/ml	O
anti-IL	O
-	O
4	O
(	O
R	O
&	O
D	O
systems	O
)	O
;	O
in	O
Th2	O
conditions	O
:	O
25	O
ng/ml	O
IL	O
-	O
4	O
,	O
5	O
mug/ml	O
anti-IFN	O
-	O
gamma	O
,	O
5	O
mug/ml	O
anti-IL	O
-	O
12	O
(	O
R	O
&	O
D	O
systems	O
)	O
;	O
or	O
in	O
Treg	O
conditions	O
:	O
10	O
ng/ml	O
TGF	O
-	O
beta	O
,	O
5	O
mug/ml	O
anti-IFN	O
-	O
gamma	O
,	O
5	O
mug/ml	O
anti-IL	O
-	O
12	O
,	O
5	O
mug/ml	O
anti-IL	O
-	O
4	O
.	O

Proliferating	O
cells	O
were	O
expanded	O
in	O
medium	O
containing	O
IL	O
-	O
2	O
(	O
30	O
ng/ml	O
)	O
.	O

Cloning	O
of	O
the	O
FOXP3	O
promoter	O
and	O
construction	O
of	O
mutant	O
constructs	O
.	O

The	O
FOXP3	O
promoter	O
was	O
cloned	O
into	O
the	O
pGL3	O
basic	O
vector	O
(	O
Promega	O
Biotech	O
)	O
to	O
generate	O
the	O
pGL3	O
FOXP3	O
-	O
511/+176	O
[	O
24	O
]	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
in	O
the	O
FOXP3	O
promoter	O
region	O
were	O
introduced	O
using	O
the	O
QuickChange	O
kit	O
(	O
Stratagene	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
following	O
primer	O
and	O
its	O
complementary	O
strand	O
were	O
used	O
:	O
GTT	O
TCT	O
CAT	O
GAG	O
CCC	O
TAT	O
TAA	O
GTC	O
ATT	O
CTT	O
ACC	O
TCT	O
CAC	O
CTC	O
TGT	O
GGT	O
GA	O
.	O

Transfections	O
and	O
reporter	O
gene	O
assays	O
.	O

T	O
cells	O
were	O
rested	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
(	O
Life	O
Technologies	O
)	O
overnight	O
.	O

3.5	O
mug	O
of	O
the	O
FOXP3	O
promoter	O
luciferase	O
reporter	O
vector	O
and	O
0.5	O
mug	O
phRL	O
-	O
TK	O
were	O
added	O
to	O
3	O
x	O
106	O
CD4+	O
T	O
cells	O
resuspended	O
in	O
100	O
muL	O
of	O
Nucleofector	O
solution	O
(	O
Amaxa	O
Biosystems	O
)	O
and	O
electroporated	O
using	O
the	O
U	O
-	O
15	O
program	O
of	O
the	O
Nucleofector	O
.	O

After	O
a	O
24	O
-	O
h	O
culture	O
in	O
serum	O
-	O
free	O
conditions	O
and	O
stimuli	O
as	O
indicated	O
in	O
the	O
figures	O
,	O
luciferase	O
activity	O
was	O
measured	O
by	O
the	O
dual	O
luciferase	O
assay	O
system	O
(	O
Promega	O
Biotech	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Data	O
were	O
normalized	O
by	O
the	O
activity	O
of	O
renilla	O
luciferase	O
.	O

RNA	O
isolation	O
and	O
cDNA	O
synthesis	O
.	O

RNA	O
was	O
isolated	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Reverse	O
transcription	O
of	O
human	O
samples	O
was	O
performed	O
with	O
TaqMan	O
reverse	O
-	O
transcription	O
reagents	O
(	O
Applied	O
Biosystems	O
)	O
with	O
random	O
hexamers	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Recombinant	O
TAT	O
proteins	O
.	O

The	O
cDNAs	O
encoding	O
GATA3	O
protein	O
or	O
the	O
truncated	O
GATA3	O
(	O
lacking	B-Negative_regulation
the	O
two	O
zinc	O
fingers	O
)	O
were	O
cloned	O
in	O
frame	O
into	O
an	O
expression	O
vector	O
along	O
with	O
the	O
TAT	O
sequence	O
as	O
previously	O
described	O
[	O
63	O
]	O
.	O

Proteins	O
were	O
expressed	O
in	O
BL21	O
Star	O
(	O
DE3	O
)	O
pLysS	O
(	O
Invitrogen	O
)	O
and	O
lysates	O
were	O
purified	O
by	O
Ni2+	O
-	O
chelate	O
column	O
chromatography	O
.	O

Both	O
TAT	O
-	O
linked	O
proteins	O
were	O
more	O
than	O
95	O
%	O
pure	O
,	O
based	O
on	O
Coomassie	O
blue	O
staining	O
of	O
sodium	O
disulfate	O
acrylamide	O
gels	O
.	O

TAT	O
-	O
GATA3	O
transduction	O
.	O

CD4+CD45RA+	O
cells	O
were	O
cultured	O
in	O
AIMV	O
medium	O
and	O
transduced	O
with	O
20	O
nM	O
,	O
10	O
nM	O
,	O
or	O
500	O
nM	O
of	O
full	O
-	O
length	O
or	O
truncated	O
GATA3	O
over	O
the	O
course	O
of	O
4	O
h	O
.	O

After	O
4	O
h	O
,	O
the	O
cells	O
were	O
washed	O
and	O
activated	O
with	O
soluble	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
and	O
TGF	O
-	O
beta	O
(	O
10	O
ng/ml	O
)	O
.	O

Each	O
day	O
,	O
the	O
TAT	O
proteins	O
were	O
freshly	O
added	O
to	O
the	O
medium	O
.	O

FOXP3	O
expression	B-Gene_expression
was	O
measured	O
after	O
5	O
d	O
by	O
intracellular	O
staining	O
.	O

Intracellular	O
cytokine	O
staining	O
.	O

T	O
cells	O
were	O
stimulated	O
with	O
2	O
x	O
10	O
-	O
7	O
M	O
PMA	O
and	O
1	O
mug/ml	O
of	O
ionomycin	O
(	O
Sigma	O
Chemicals	O
)	O
for	O
4	O
h	O
.	O

The	O
following	O
mAb	O
was	O
used	O
:	O
anti-IL-4	O
-	O
PE	O
(	O
8D4	O
-	O
8	O
,	O
BD	O
)	O
.	O

Matched	O
isotype	O
controls	O
were	O
used	O
at	O
the	O
same	O
protein	O
concentration	O
as	O
the	O
respective	O
antibodies	O
.	O

Four	O
-	O
color	O
FACS	O
was	O
performed	O
using	O
an	O
EPICS	O
XL	O
-	O
MCL	O
(	O
Beckman	O
Coulter	O
)	O
using	O
the	O
software	O
Expo32	O
version	O
for	O
data	O
acquisition	O
and	O
evaluation	O
.	O

Flow	O
cytometry	O
.	O

For	O
analysis	O
of	O
FOXP3	O
expression	B-Gene_expression
at	O
the	O
single	O
-	O
cell	O
level	O
,	O
cells	O
were	O
first	O
stained	O
with	O
the	O
monoclonal	O
antibody	O
CD25	O
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
after	O
fixation	O
and	O
permeabilization	O
,	O
cells	O
were	O
incubated	O
with	O
PE	O
-	O
conjugated	O
monoclonal	O
antibody	O
PCH101	O
(	O
anti	O
-	O
human	O
FOXP3	O
;	O
eBioscience	O
)	O
based	O
on	O
the	O
manufacturer	O
's	O
recommendations	O
and	O
subjected	O
to	O
FACS	O
(	O
EPICS	O
XL	O
-	O
MCL	O
)	O
.	O

For	O
cell	O
surface	O
marker	O
staining	O
,	O
cells	O
were	O
incubated	O
for	O
20	O
min	O
at	O
4degreesC	O
in	O
staining	O
buffer	O
with	O
the	O
following	O
antibodies	O
:	O
anti-CD152	O
-	O
PE	O
(	O
CTLA	O
-	O
4	O
;	O
BD	O
)	O
,	O
anti-PD	O
-	O
1	O
(	O
eBiosciences	O
)	O
,	O
anti	O
-	O
GITR	O
(	O
R	O
&	O
D	O
Systems	O
)	O
,	O
anti	O
-	O
CD69	O
(	O
Beckman	O
Coulter	O
)	O
,	O
anti	O
-	O
CD103	O
(	O
DakoCytomation	O
)	O
,	O
anti	O
-	O
CD62L	O
(	O
Beckman	O
Coulter	O
)	O
,	O
or	O
anti-HLA	O
-	O
DR	O
(	O
Beckman	O
Coulter	O
)	O
.	O

The	O
controls	O
were	O
FITC	O
,	O
PE	O
,	O
or	O
ECD	O
-	O
conjugated	O
mouse	O
IgG1	O
or	O
rat	O
IgG2a	O
.	O

For	O
staining	O
of	O
mouse	O
cells	O
,	O
the	O
following	O
mAbs	O
from	O
BD	O
Biosciences	O
were	O
used	O
following	O
standard	O
techniques	O
as	O
described	O
above	O
:	O
anti	O
-	O
CD3	O
,	O
anti	O
-	O
CD4	O
,	O
and	O
anti	O
-	O
CD25	O
.	O

Anti	O
-	O
FcgammaRII/III	O
antibody	O
(	O
2.4G2	O
,	O
ATCC	O
)	O
was	O
included	O
in	O
all	O
stainings	O
to	O
reduce	O
nonspecific	O
antibody	O
binding	O
.	O

To	O
isolate	O
naive	O
murine	O
CD4	O
T	O
cells	O
from	O
murine	O
DO11.10	O
or	O
DO11.10xCD2	O
-	O
GATA3	O
T	O
cells	O
,	O
cells	O
were	O
stained	O
with	O
anti-CD25	O
-	O
FITC	O
,	O
anti-CD62L	O
-	O
PE	O
,	O
and	O
anti-CD4	O
-	O
APC	O
prior	O
to	O
sorting	O
.	O

Dead	O
cells	O
were	O
excluded	O
with	O
4''	O
,	O
6-Diamidino-2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
.	O

To	O
analyze	O
murine	O
Foxp3	O
expression	B-Gene_expression
in	O
inducible	O
Treg	O
cultures	O
,	O
cells	O
were	O
stained	O
intracellularly	O
with	O
anti-Foxp3	O
-	O
PE	O
according	O
to	O
manufacturer	O
's	O
instruction	O
,	O
in	O
conjunction	O
with	O
anti-CD4	O
-	O
APC	O
and	O
LIVE/DEAD	O
fixable	O
dead	O
cell	O
stain	O
kit	O
(	O
Invitrogen	O
)	O
to	O
discriminate	O
live	O
cells	O
.	O

All	O
monoclonal	O
antibodies	O
for	O
murine	O
cell	O
stainings	O
were	O
purchased	O
from	O
eBioscience	O
or	O
BD	O
Biosciences	O
.	O

Western	O
blotting	O
.	O

For	O
FOXP3	O
analysis	O
on	O
the	O
protein	O
level	O
,	O
1	O
x	O
106	O
CD4+CD25	O
-	O
cells	O
were	O
lysed	O
and	O
loaded	O
next	O
to	O
a	O
protein	O
-	O
mass	O
ladder	O
(	O
Magicmark	O
,	O
Invitrogen	O
)	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
bis	O
-	O
tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
Amersham	O
Life	O
Science	O
)	O
.	O

Unspecific	O
binding	O
was	O
blocked	O
with	O
BSA	O
,	O
and	O
the	O
membranes	O
were	O
subsequently	O
incubated	O
with	O
an	O
1	O
:	O
200	O
dilution	O
of	O
goat	O
anti	O
-	O
FOXP3	O
in	O
blocking	O
buffer	O
(	O
Abcam	O
)	O
overnight	O
at	O
4	O
degreesC	O
.	O

The	O
blots	O
were	O
developed	O
using	O
an	O
anti	O
-	O
goat	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
visualized	O
with	O
a	O
LAS	O
1000	O
camera	O
(	O
Fuji	O
)	O
.	O

Membranes	O
were	O
incubated	O
in	O
stripping	O
buffer	O
and	O
re	O
-	O
blocked	O
for	O
1	O
h	O
.	O

The	O
membranes	O
were	O
re	O
-	O
probed	O
using	O
anti	O
-	O
GATA3	O
(	O
HG3	O
-	O
31	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
anti-T	O
-	O
bet	O
(	O
4B10	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
anti	O
-	O
GAPDH	O
(	O
6C5	O
,	O
Ambion	O
)	O
,	O
anti-phospho	O
-	O
SMAD2	O
(	O
138D4	O
)	O
,	O
anti-phospho	O
-	O
STAT6	O
(	O
5A4	O
)	O
,	O
and	O
anti	O
-	O
STAT6	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
,	O

Administration	O
of	O
cytokines	O
and	O
antibodies	O
in	O
vivo	O
.	O

Age	O
-	O
and	O
gender	O
-	O
matched	O
normal	O
B6	O
mice	O
received	O
every	O
other	O
day	O
intraperitoneal	O
(	O
ip	O
)	O
injections	O
of	O
PBS	O
,	O
1.5	O
mug	O
rmIL	O
-	O
4	O
,	O
50	O
mug	O
anti-IL	O
-	O
4	O
mAb	O
(	O
11B11	O
or	O
MAB404	O
)	O
,	O
or	O
a	O
mixture	O
of	O
1.5	O
mug	O
rmIL	O
-	O
4	O
plus	O
50	O
mug	O
anti-IL	O
-	O
4	O
mAb	O
(	O
11B11	O
or	O
MAB404	O
)	O
for	O
7	O
d	O
.	O

Thereafter	O
,	O
spleen	O
and	O
lymph	O
node	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
for	O
CD3	O
,	O
CD4	O
,	O
and	O
CD25	O
expression	B-Gene_expression
.	O

The	O
anti	O
-	O
mouse	O
IL	O
-	O
4	O
mAb	O
MAB404	O
was	O
obtained	O
from	O
R	O
&	O
D	O
Systems	O
,	O
the	O
second	O
anti	O
-	O
mouse	O
IL	O
-	O
4	O
mAb	O
11B11	O
was	O
purchased	O
from	O
eBioscience	O
.	O

ChIP	O
.	O

ChIP	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
(	O
Upstate	O
Biotechnology	O
)	O
with	O
the	O
following	O
modifications	O
.	O

iTreg	O
and	O
Th2	O
cells	O
were	O
fixed	O
with	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

The	O
chromatin	O
was	O
sheared	O
to	O
200	O
-	O
1000	O
bp	O
of	O
length	O
by	O
sonication	O
with	O
five	O
pulses	O
of	O
10	O
s	O
at	O
30	O
%	O
power	O
(	O
Bandelin	O
)	O
.	O

The	O
chromatin	O
was	O
pre	O
-	O
cleared	O
for	O
2	O
h	O
with	O
normal	O
mouse	O
IgG	O
beads	O
and	O
then	O
incubated	O
with	O
anti-GATA3	O
-	O
agarose	O
beads	O
(	O
HG3	O
-	O
31	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
for	O
2	O
h	O
.	O

Washing	O
and	O
elution	O
buffers	O
were	O
used	O
according	O
to	O
the	O
protocol	O
of	O
Upstate	O
Biotechnology	O
.	O

Crosslinks	O
were	O
reversed	O
by	O
incubation	O
at	O
65	O
degreesC	O
for	O
4	O
h	O
in	O
the	O
presence	O
of	O
0.2	O
M	O
NaCl	O
,	O
and	O
the	O
DNA	O
was	O
purified	O
by	O
phenol/chloroform	O
extraction	O
.	O

The	O
amount	O
of	O
DNA	O
was	O
determined	O
by	O
conventional	O
PCR	O
.	O

The	O
PCR	O
addressed	O
for	O
the	O
FOXP3	O
promoter	O
region	O
-	O
246	O
to	O
-	O
511	O
and	O
was	O
performed	O
using	O
the	O
following	O
primers	O
:	O
5'	O
-	O
gtgccctttacgagt	O
catctg	O
-	O
3	O
'	O
and	O
5'-gtgccctttacgagtcatctg	O
-	O
3	O
'	O
.	O

The	O
PCR	O
products	O
were	O
visualized	O
using	O
an	O
ethidium	O
bromide	O
gel	O
.	O

Pull	O
-	O
down	O
assay	O
.	O

CD4+	O
T	O
cells	O
were	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
2	O
h	O
at	O
37degreesC	O
.	O

The	O
cells	O
were	O
pelleted	O
,	O
resuspended	O
in	O
buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
[	O
pH	O
7.9	O
]	O
,	O
420	O
mM	O
NaCl	O
,	O
1.5	O
mM	O
MgCl2	O
,	O
0.2	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
protease	O
inhibitors	O
[	O
Sigma	O
]	O
.	O
and	O
0.1	O
%	O
NP	O
-	O
40	O
)	O
and	O
lysed	O
on	O
ice	O
for	O
15	O
min	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

The	O
supernatant	O
was	O
diluted	O
1	O
:	O
3	O
with	O
buffer	O
D	O
(	O
as	O
buffer	O
C	O
,	O
but	O
without	O
NaCl	O
)	O
.	O

The	O
lysates	O
were	O
incubated	O
with	O
10	O
mug	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
(	O
Sigma	O
)	O
and	O
70	O
mul	O
of	O
streptavidin	O
-	O
agarose	O
(	O
Amersham	O
Biosciences	O
)	O
carrying	O
biotinylated	O
oligonucleotides	O
,	O
for	O
3	O
h	O
at	O
4	O
degreesC	O
.	O

The	O
beads	O
were	O
washed	O
twice	O
with	O
buffer	O
C	O
:	O
D	O
(	O
1	O
:	O
3	O
)	O
and	O
resuspended	O
in	O
DTT	O
-	O
containing	O
loading	O
buffer	O
(	O
NuPAGE	O
;	O
Invitrogen	O
)	O
,	O
heated	O
to	O
70	O
degreesC	O
for	O
10	O
min	O
,	O
and	O
the	O
eluants	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
bis	O
-	O
tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
detected	O
using	O
an	O
anti	O
-	O
GATA3	O
mAb	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
.	O

Accumulated	O
signals	O
were	O
analyzed	O
using	O
AIDA	O
software	O
(	O
Raytest	O
)	O
.	O

Supporting	O
Information	O

Phenotype	O
of	O
In	O
Vitro	O
Differentiated	O
T	O
Cells	O

After	O
two	O
round	O
of	O
differentiation	O
cultures	O
,	O
T	O
cells	O
were	O
stimulated	O
by	O
plate	O
-	O
immobilized	O
anti	O
-	O
CD3/CD28	O
and	O
3H	O
-	O
thymidine	O
incorporation	O
as	O
measurement	O
of	O
proliferation	O
was	O
analyzed	O
after	O
3	O
d	O
of	O
culture	O
(	O
A	O
)	O
.	O

In	O
parallel	O
,	O
T	O
cells	O
were	O
analyzed	O
for	O
Treg	O
relevant	O
surface	O
receptor	O
expression	O
as	O
indicated	O
on	O
the	O
x	O
-	O
axis	O
(	O
B	O
)	O
.	O

(	O
1.0	O
MB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

In	O
Vivo	O
Treatment	O
of	O
Mice	O
with	O
IL	O
-	O
4	O
Antibody	O
-	O
Cytokine	O
Complexes	O

B6	O
mice	O
were	O
given	O
every	O
other	O
day	O
ip	O
injections	O
of	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
,	O
recombinant	O
mouse	O
IL	O
-	O
4	O
(	O
rmIL	O
-	O
4	O
)	O
,	O
anti-IL	O
-	O
4	O
mAb	O
(	O
anti-IL	O
-	O
4	O
mAb	O
,	O
11B11	O
,	O
or	O
MAB404	O
)	O
,	O
or	O
a	O
mixture	O
of	O
rmIL	O
-	O
4	O
plus	O
anti-IL	O
-	O
4	O
mAbs	O
(	O
11B11	O
or	O
MAB404	O
)	O
.	O

Mice	O
were	O
analyzed	O
on	O
day	O
7	O
by	O
flow	O
cytometry	O
for	O
CD3	O
,	O
CD4	O
,	O
and	O
CD25	O
expression	B-Gene_expression
.	O

Shown	O
is	O
CD25	O
versus	O
CD4	O
expression	B-Gene_expression
in	O
CD3+	O
CD4+	O
spleen	O
cells	O
(	O
A	O
-	O
F	O
)	O
.	O

Numbers	O
indicate	O
percentages	O
of	O
CD4+	O
CD25high	O
CD3+	O
cells	O
.	O

Total	O
cell	O
counts	O
(	O
G	O
)	O
of	O
CD4+	O
CD25high	O
cells	O
in	O
spleen	O
from	O
mice	O
in	O
(	O
A	O
-	O
F	O
)	O
are	O
shown	O
as	O
mean	O
+/	O
-	O
SD	O
.	O

The	O
data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
369	O
KB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Effect	O
of	O
IL	O
-	O
4	O
on	O
Already	O
Existing	O
Natural	O
or	O
Inducible	O
Treg	O
Cells	O

(	O
A	O
)	O
CD4+CD25high	O
nTreg	O
cells	O
were	O
FACS	O
-	O
sorted	O
and	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
plus	O
IL	O
-	O
2	O
during	O
3	O
d	O
and	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	O
-	O
4	O
(	O
100	O
ng/ml	O
)	O
and	O
harvested	O
for	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

The	O
results	O
shown	O
represent	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
iTreg	O
cells	O
were	O
induced	O
in	O
vitro	O
.	O

FOXP3	O
espression	B-Gene_expression
was	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
analysis	O
in	O
resting	O
cells	O
,	O
in	O
cells	O
re	O
-	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
,	O
with	O
or	O
without	O
TGF	O
-	O
beta	O
,	O
plus	O
IL	O
-	O
2	O
during	O
3	O
d	O
and	O
in	O
the	O
presence	O
(	O
black	O
bar	O
)	O
or	O
absence	O
(	O
white	O
bar	O
)	O
of	O
IL	O
-	O
4	O
(	O
100	O
ng/ml	O
)	O
.	O

(	O
C	O
)	O
Activation	O
dramatically	O
increases	O
CD4+CD25+	O
Treg	O
cells	O
suppressive	O
capacity	O
of	O
CD4+CD25+	O
nTreg	O
cells	O
.	O

CD4+CD25+	O
nTreg	O
cells	O
were	O
preactivated	O
during	O
2	O
d	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
increasing	B-Positive_regulation
IL	O
-	O
4	O
concentration	O
.	O

After	O
vigorous	O
washing	O
,	O
their	O
suppressive	O
capacity	O
on	O
responder	O
CD4+CD25	O
-	O
was	O
tested	O
.	O

IL	O
-	O
4	O
pretreatment	O
did	O
not	O
affect	O
the	O
suppressive	O
capacity	O
of	O
FACS	O
-	O
sorted	O
CD4+CD25high	O
cells	O
.	O

1	O
x	O
104	O
CD4+CD25+	O
nTreg	O
cells	O
were	O
added	O
to	O
5	O
x	O
104	O
CD4+CD25	O
-	O
and	O
5	O
x	O
104	O
irradiated	O
PBMCs	O
.	O

The	O
results	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
269	O
KB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Schematic	O
Structure	O
of	O
the	O
FOXP3	O
Gene	O
and	O
Location	O
of	O
the	O
GATA3	O
Sites	O

The	O
scheme	O
shows	O
the	O
location	O
of	O
the	O
11	O
exons	O
spaced	O
by	O
a	O
large	O
intron	O
(	O
6000	O
bp	O
)	O
from	O
the	O
5'untranslated	O
region	O
(	O
UTR	O
)	O
.	O

Human	O
,	O
murine	O
,	O
and	O
rat	O
sequences	O
are	O
aligned	O
and	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
is	O
indicated	O
with	O
an	O
arrow	O
.	O

(	O
529	O
KB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Th2	O
Cells	O
Can	O
not	O
Induce	B-Positive_regulation
FOXP3	O
Expression	B-Gene_expression

(	O
A	O
)	O
Human	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
with	O
or	O
without	O
TGF	O
-	O
beta	O
as	O
indicated	O
on	O
the	O
x	O
-	O
axis	O
of	O
(	O
B	O
)	O
.	O

Cells	O
were	O
harvested	O
after	O
5	O
days	O
and	O
FOXP3	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
4	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
In	O
vitro	O
differentiated	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
cells	O
were	O
activated	O
with	O
anti	O
-	O
CD3/CD28	O
,	O
TGF	O
-	O
beta	O
,	O
or	O
anti-IL	O
-	O
4	O
as	O
indicated	O
.	O

The	O
phenotype	O
of	O
these	O
cells	O
was	O
confirmed	O
by	O
FACS	O
and	O
proliferation	O
analysis	O
(	O
Figure	O
S1	O
)	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
four	O
independent	O
experiments	O
.	O

Th2	O
Cells	O
Do	O
Not	O
Express	B-Gene_expression
FOXP3	O

(	O
A	O
)	O
Intracellular	O
FACS	O
analysis	O
of	O
FOXP3	O
expression	B-Gene_expression
in	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
-	O
differentiated	O
cells	O
(	O
two	O
rounds	O
,	O
phenotype	O
see	O
Figure	O
S1	O
)	O
,	O
rested	O
or	O
activated	O
,	O
with	O
or	O
without	O
TGF	O
-	O
beta	O
.	O

FOXP3	O
expression	B-Gene_expression
was	O
measured	O
after	O
5	O
d	O
in	O
culture	O
.	O

The	O
dot	O
blots	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Shows	O
the	O
same	O
experimental	O
setup	O
,	O
but	O
naturally	O
occurring	O
Th2	O
cells	O
were	O
analyzed	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Th2	O
-	O
or	O
IL-4	O
-	O
Producing	B-Gene_expression
Cells	O
Lack	B-Negative_regulation
FOXP3	O

(	O
A	O
)	O
FACS	O
analysis	O
of	O
intracellular	O
FOXP3	O
and	O
IL	O
-	O
4	O
expression	B-Gene_expression
following	O
PMA/Ionomycin	O
stimulation	O
.	O

CD4+	O
T	O
cells	O
were	O
gated	O
on	O
the	O
basis	O
of	O
CD45RO	O
and	O
CD25	O
surface	O
expression	B-Gene_expression
(	O
upper	O
panel	O
)	O
,	O
and	O
gated	O
cells	O
are	O
shown	O
below	O
for	O
the	O
CD45RO+CD25	O
-	O
(	O
A	O
,	O
left	O
panel	O
)	O
,	O
the	O
CD45RO+CD25+	O
(	O
right	O
panel	O
)	O
,	O
and	O
the	O
CD45RO-CD25	O
-	O
subsets	O
(	O
central	O
panel	O
)	O
.	O

A	O
statistical	O
analysis	O
of	O
eight	O
independent	O
donors	O
after	O
subtraction	O
of	O
the	O
isotype	O
control	O
are	O
shown	O
in	O
(	O
B	O
)	O
.	O

The	O
dotted	O
gray	O
line	O
indicates	O
the	O
IC	O
background	O
level	O
.	O

The	O
error	O
bars	O
show	O
the	O
error	O
of	O
the	O
mean	O
.	O

(	O
C	O
)	O
Similarly	O
,	O
a	O
Th2	O
clone	O
(	O
BR8	O
)	O
,	O
CRTH2+	O
Th2	O
cells	O
,	O
IL-4	O
-	O
secreting	B-Gene_expression
cells	O
,	O
and	O
memory	O
T	O
cells	O
(	O
CD45RO	O
)	O
were	O
stained	B-Gene_expression
for	O
FOXP3	O
and	O
IL	O
-	O
4	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

FOXP3	O
Induction	B-Positive_regulation
During	O
the	O
Differentiation	O
Process	O

(	O
A	O
)	O
Human	O
CD4+CD45RA+	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
(	O
5	O
ng/ml	O
)	O
or	O
IL	O
-	O
4	O
(	O
25	O
ng/ml	O
)	O
.	O

The	O
cells	O
were	O
harvested	O
at	O
different	O
time	O
points	O
,	O
and	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
for	O
FOXP3	O
and	O
GATA3	O
expression	B-Gene_expression
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Intracellular	O
GATA3	O
and	O
FOXP3	O
staining	B-Gene_expression
is	O
shown	O
after	O
exposure	O
of	O
CD4+CD45RA+	O
T	O
cells	O
to	O
differentiating	O
conditions	O
as	O
in	O
part	O
A	O
of	O
the	O
figure	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Effect	B-Regulation
of	O
IL	O
-	O
4	O
on	O
FOXP3	O
Induction	B-Positive_regulation

(	O
A	O
)	O
A	O
statistical	O
analysis	O
was	O
performed	O
with	O
six	O
donors	O
on	O
day	O
5	O
(	O
TGF	O
-	O
beta	O
(	O
10	O
ng/ml	O
)	O
and	O
with	O
or	O
without	O
IL	O
-	O
4	O
(	O
100	O
ng/ml	O
)	O
)	O
;	O
Shown	O
is	O
the	O
mean	O
,	O
and	O
error	O
bars	O
indicated	O
the	O
SD	O
of	O
six	O
donors	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Dunnett	O
test	O
.	O

Statistical	O
significance	O
is	O
indicated	O
by	O
asterisks	O
(	O
*p	O
<	O
/=	O
0.05	O
,	O
**p	O
<	O
/=	O
0.01	O
,	O
Dunnett	O
)	O
.	O

(	O
B	O
)	O
CD4+CD45RA+	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
a	O
constant	O
concentration	O
of	O
TGF	O
-	O
beta	O
(	O
5	O
ng/ml	O
)	O
with	O
an	O
increasing	B-Positive_regulation
concentration	O
of	O
IL	O
-	O
4	O
,	O
as	O
indicated	O
.	O

Cells	O
were	O
harvested	O
for	O
mRNA	O
quantification	O
after	O
5	O
d	O
.	O

(	O
C	O
)	O
CD4+CD45RA+	O
cells	O
were	O
stimulated	O
in	O
vitro	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
,	O
TGF	O
-	O
beta	O
(	O
10ng/ml	O
)	O
,	O
and	O
IL	O
-	O
4	O
(	O
100	O
ng/ml	O
)	O
as	O
indicated	O
.	O

After	O
1	O
h	O
,	O
cell	O
lysates	O
were	O
prepared	O
and	O
analyzed	O
by	O
Western	O
blot	O
for	O
phosphorylated	B-Phosphorylation
SMAD2	O
and	O
STAT6	O
.	O

Total	O
STAT6	O
and	O
GAPDH	O
served	O
as	O
internal	O
control	O
.	O

(	O
D	O
)	O
Intracellular	O
GATA3	O
and	O
FOXP3	O
staining	B-Gene_expression
are	O
shown	O
after	O
exposure	O
of	O
CD4+CD45RA+	O
T	O
cells	O
to	O
IL	O
-	O
4	O
as	O
described	O
for	O
panel	O
B	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

IL	O
-	O
4	O
Inhibits	O
TGF-beta	O
-	O
Mediated	O
iTreg	O
Commitment	O

CFSE	O
-	O
labeled	O
CD4+CD45RA+	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
,	O
TGF	O
-	O
beta	O
,	O
and	O
IL	O
-	O
4	O
,	O
as	O
indicated	O
.	O

After	O
5	O
d	O
,	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
A	O
)	O
and	O
results	O
of	O
six	O
independent	O
experiments	O
are	O
shown	O
in	O
the	O
bar	O
graph	O
below	O
(	O
B	O
)	O
.	O

Statistical	O
significance	O
(	O
one	O
-	O
way	O
Anova	O
,	O
Newman	O
-	O
Keuls	O
)	O
is	O
indicated	O
by	O
asterisks	O
(	O
**p	O
<	O
/=	O
0.01	O
,	O
***p	O
<	O
/=	O
0.001	O
)	O
.	O

(	O
C	O
)	O
Kinetic	O
analysis	O
of	O
intracellular	O
GATA3	O
and	O
FOXP3	O
staining	B-Gene_expression
is	O
shown	O
in	O
panel	O
C	O
following	O
exposure	O
of	O
CD4+CD45RA+	O
T	O
cells	O
to	O
anti	O
-	O
CD3/28	O
,	O
IL	O
-	O
4	O
and	O
TGF	O
-	O
beta	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

GATA3	O
Acts	O
as	O
a	O
Negative	O
Regulator	O
of	O
FOXP3	O
Expression	O

(	O
A	O
)	O
Human	O
naive	O
CD4+CDRA+	O
T	O
cells	O
were	O
transduced	O
with	O
0	O
,	O
20	O
,	O
100	O
,	O
and	O
500	O
nM	O
of	O
TAT	O
-	O
GATA3	O
protein	O
,	O
and	O
intracellular	O
presence	B-Gene_expression
of	O
GATA3	O
was	O
analyzed	O
using	O
FACS	O
following	O
anti	O
-	O
CD3/CD28	O
activation	O
of	O
the	O
cells	O
.	O

GFP	O
-	O
positive	O
cells	O
were	O
gated	O
and	O
analyzed	O
for	O
intracellular	O
FOXP3	O
expression	B-Gene_expression
following	O
a	O
2	O
-	O
d	O
incubation	O
period	O
(	O
lower	O
panel	O
)	O
.	O

Data	O
are	O
representative	O
of	O
four	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
CD4+CD25	O
-	O
T	O
cells	O
were	O
isolated	O
from	O
D011.10	O
and	O
D011.10xCD2	O
-	O
GATA3	O
mice	O
and	O
treated	O
with	O
OVA	O
and	O
TGF	O
-	O
beta	O
for	O
96	O
h	O
.	O

Surface	O
CD4	O
and	O
intracellular	O
FOXP3	O
were	O
measured	O
by	O
FACS	O
.	O

These	O
data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
The	O
cells	O
treated	O
as	O
in	O
(	O
B	O
)	O
were	O
harvested	O
and	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
for	O
SMAD7	O
and	O
TGF	O
-	O
beta	O
expression	B-Gene_expression
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

GATA3	O
Represses	B-Negative_regulation
the	O
Human	O
FOXP3	O
Promoter	O

(	O
A	O
)	O
Jurkat	O
,	O
Th2	O
cells	O
,	O
and	O
human	O
primary	O
CD4	O
cells	O
were	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
basic	O
)	O
or	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	O
promoter	O
region	O
fused	O
to	O
the	O
luciferase	O
reporter	O
gene	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
arbitrary	O
light	O
units	O
normalized	O
for	O
renilla	O
luciferase	O
of	O
four	O
independent	O
experiments	O
;	O
samples	O
were	O
measured	O
in	O
triplicates	O
.	O

(	O
B	O
)	O
Naive	O
CD4	O
T	O
cells	O
were	O
transfected	O
with	O
the	O
FOXP3	O
promoter	O
reporter	O
construct	O
together	O
with	O
a	O
GATA3	O
expression	B-Gene_expression
vector	O
or	O
an	O
empty	O
vector	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Naive	O
(	O
left	O
panel	O
)	O
or	O
memory	O
(	O
right	O
panel	O
)	O
CD4	O
T	O
cells	O
were	O
transfected	O
with	O
wild	O
-	O
type	O
or	O
a	O
GATA3	O
mutated	O
511	O
-	O
FOXP3	O
promoter	O
reporter	O
construct	O
and	O
activated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
arbitrary	O
light	O
units	O
normalized	O
for	O
renilla	O
luciferase	O
of	O
eight	O
independent	O
experiments	O
;	O
samples	O
were	O
measured	O
in	O
triplicates	O
.	O

(	O
D	O
)	O
Nuclear	O
extracts	O
were	O
prepared	O
from	O
HEK	O
cells	O
transfected	O
with	O
GATA3	O
or	O
an	O
empty	O
vector	O
,	O
(	O
E	O
)	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
cells	O
and	O
binding	O
factors	O
precipitated	O
using	O
biotinylated	O
oligonucleotides	O
.	O

The	O
oligonucleotides	O
-	O
transcription	O
factor	O
complexes	O
were	O
separated	O
on	O
a	O
SDS	O
-	O
PAGE	O
gel	O
.	O

The	O
amounts	B-Gene_expression
of	O
GATA3	O
protein	O
in	O
the	O
precipitates	O
were	O
assessed	O
by	O
immunoblotting	O
with	O
anti	O
-	O
GATA3	O
mAb	O
.	O

Total	O
nuclear	O
extracts	O
were	O
also	O
run	O
as	O
controls	O
.	O

Data	O
are	O
representative	O
of	O
three	O
different	O
experiments	O
.	O

(	O
F	O
)	O
iTreg	O
or	O
Th2	O
cells	O
were	O
analyzed	O
by	O
ChIP	O
for	O
GATA3	O
binding	B-Binding
to	O
the	O
FOXP3	O
promoter	O
.	O

The	O
"	O
input	O
"	O
represents	O
PCR	O
amplification	O
of	O
the	O
total	O
sample	O
,	O
which	O
was	O
not	O
subjected	O
to	O
any	O
precipitation	O
.	O

Results	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Phenotype	O
of	O
In	O
Vitro	O
Differentiated	O
T	O
Cells	O

After	O
two	O
round	O
of	O
differentiation	O
cultures	O
,	O
T	O
cells	O
were	O
stimulated	O
by	O
plate	O
-	O
immobilized	O
anti	O
-	O
CD3/CD28	O
and	O
3H	O
-	O
thymidine	O
incorporation	O
as	O
measurement	O
of	O
proliferation	O
was	O
analyzed	O
after	O
3	O
d	O
of	O
culture	O
(	O
A	O
)	O
.	O

In	O
parallel	O
,	O
T	O
cells	O
were	O
analyzed	O
for	O
Treg	O
relevant	O
surface	O
receptor	O
expression	O
as	O
indicated	O
on	O
the	O
x	O
-	O
axis	O
(	O
B	O
)	O
.	O

(	O
1.0	O
MB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

In	O
Vivo	O
Treatment	O
of	O
Mice	O
with	O
IL	O
-	O
4	O
Antibody	O
-	O
Cytokine	O
Complexes	O

B6	O
mice	O
were	O
given	O
every	O
other	O
day	O
ip	O
injections	O
of	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
,	O
recombinant	O
mouse	O
IL	O
-	O
4	O
(	O
rmIL	O
-	O
4	O
)	O
,	O
anti-IL	O
-	O
4	O
mAb	O
(	O
anti-IL	O
-	O
4	O
mAb	O
,	O
11B11	O
,	O
or	O
MAB404	O
)	O
,	O
or	O
a	O
mixture	O
of	O
rmIL	O
-	O
4	O
plus	O
anti-IL	O
-	O
4	O
mAbs	O
(	O
11B11	O
or	O
MAB404	O
)	O
.	O

Mice	O
were	O
analyzed	O
on	O
day	O
7	O
by	O
flow	O
cytometry	O
for	O
CD3	O
,	O
CD4	O
,	O
and	O
CD25	O
expression	B-Gene_expression
.	O

Shown	O
is	O
CD25	O
versus	O
CD4	O
expression	B-Gene_expression
in	O
CD3+	O
CD4+	O
spleen	O
cells	O
(	O
A	O
-	O
F	O
)	O
.	O

Numbers	O
indicate	O
percentages	O
of	O
CD4+	O
CD25high	O
CD3+	O
cells	O
.	O

Total	O
cell	O
counts	O
(	O
G	O
)	O
of	O
CD4+	O
CD25high	O
cells	O
in	O
spleen	O
from	O
mice	O
in	O
(	O
A	O
-	O
F	O
)	O
are	O
shown	O
as	O
mean	O
+/	O
-	O
SD	O
.	O

The	O
data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
369	O
KB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Effect	O
of	O
IL	O
-	O
4	O
on	O
Already	O
Existing	O
Natural	O
or	O
Inducible	O
Treg	O
Cells	O

(	O
A	O
)	O
CD4+CD25high	O
nTreg	O
cells	O
were	O
FACS	O
-	O
sorted	O
and	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
plus	O
IL	O
-	O
2	O
during	O
3	O
d	O
and	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	O
-	O
4	O
(	O
100	O
ng/ml	O
)	O
and	O
harvested	O
for	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

The	O
results	O
shown	O
represent	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
iTreg	O
cells	O
were	O
induced	O
in	O
vitro	O
.	O

FOXP3	O
espression	B-Gene_expression
was	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
analysis	O
in	O
resting	O
cells	O
,	O
in	O
cells	O
re	O
-	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3/CD28	O
,	O
with	O
or	O
without	O
TGF	O
-	O
beta	O
,	O
plus	O
IL	O
-	O
2	O
during	O
3	O
d	O
and	O
in	O
the	O
presence	O
(	O
black	O
bar	O
)	O
or	O
absence	O
(	O
white	O
bar	O
)	O
of	O
IL	O
-	O
4	O
(	O
100	O
ng/ml	O
)	O
.	O

(	O
C	O
)	O
Activation	O
dramatically	O
increases	O
CD4+CD25+	O
Treg	O
cells	O
suppressive	O
capacity	O
of	O
CD4+CD25+	O
nTreg	O
cells	O
.	O

CD4+CD25+	O
nTreg	O
cells	O
were	O
preactivated	O
during	O
2	O
d	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
increasing	B-Positive_regulation
IL	O
-	O
4	O
concentration	O
.	O

After	O
vigorous	O
washing	O
,	O
their	O
suppressive	O
capacity	O
on	O
responder	O
CD4+CD25	O
-	O
was	O
tested	O
.	O

IL	O
-	O
4	O
pretreatment	O
did	O
not	O
affect	O
the	O
suppressive	O
capacity	O
of	O
FACS	O
-	O
sorted	O
CD4+CD25high	O
cells	O
.	O

1	O
x	O
104	O
CD4+CD25+	O
nTreg	O
cells	O
were	O
added	O
to	O
5	O
x	O
104	O
CD4+CD25	O
-	O
and	O
5	O
x	O
104	O
irradiated	O
PBMCs	O
.	O

The	O
results	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
269	O
KB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Schematic	O
Structure	O
of	O
the	O
FOXP3	O
Gene	O
and	O
Location	O
of	O
the	O
GATA3	O
Sites	O

The	O
scheme	O
shows	O
the	O
location	O
of	O
the	O
11	O
exons	O
spaced	O
by	O
a	O
large	O
intron	O
(	O
6000	O
bp	O
)	O
from	O
the	O
5'untranslated	O
region	O
(	O
UTR	O
)	O
.	O

Human	O
,	O
murine	O
,	O
and	O
rat	O
sequences	O
are	O
aligned	O
and	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
is	O
indicated	O
with	O
an	O
arrow	O
.	O

(	O
529	O
KB	O
AI	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Transcription	O
factors	O
RUNX1	O
and	O
RUNX3	O
in	O
the	O
induction	O
and	O
suppressive	O
function	O
of	O
Foxp3+	O
inducible	O
regulatory	O
T	O
cells	O

Forkhead	O
box	O
P3	O
(	O
FOXP3	O
)	O
+CD4+CD25+	O
inducible	O
regulatory	O
T	O
(	O
iT	O
reg	O
)	O
cells	O
play	O
an	O
important	O
role	O
in	O
immune	O
tolerance	O
and	O
homeostasis	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
the	O
Runt	O
-	O
related	O
transcription	O
factors	O
RUNX1	O
and	O
RUNX3	O
in	O
CD4+	O
T	O
cells	O
.	O

This	O
induction	O
seems	O
to	O
be	O
a	O
prerequisite	B-Positive_regulation
for	O
the	O
binding	B-Binding
of	O
RUNX1	O
and	O
RUNX3	O
to	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	O
promoter	O
.	O

Inactivation	B-Negative_regulation
of	O
the	O
gene	O
encoding	O
RUNX	O
cofactor	O
core	O
-	O
binding	O
factor	O
-	O
beta	O
(	O
CBFbeta	O
)	O
in	O
mice	O
and	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
mediated	B-Positive_regulation
suppression	B-Negative_regulation
of	O
RUNX1	O
and	O
RUNX3	O
in	O
human	O
T	O
cells	O
resulted	O
in	O
reduced	B-Negative_regulation
expression	B-Gene_expression
of	O
Foxp3	O
.	O

The	O
in	O
vivo	O
conversion	O
of	O
naive	O
CD4+	O
T	O
cells	O
into	O
Foxp3+	O
iT	O
reg	O
cells	O
was	O
significantly	O
decreased	O
in	O
adoptively	O
transferred	O
CbfbF/F	O
CD4	O
-	O
cre	O
naive	O
T	O
cells	O
into	O
Rag2-/	O
-	O
mice	O
.	O

Both	O
RUNX1	O
and	O
RUNX3	O
siRNA	B-Negative_regulation
silenced	O
human	O
T	O
reg	O
cells	O
and	O
CbfbF/F	O
CD4	O
-	O
cre	O
mouse	O
T	O
reg	O
cells	O
showed	O
diminished	O
suppressive	O
function	O
in	O
vitro	O
.	O

Circulating	O
human	O
CD4+	O
CD25high	O
CD127	O
-	O
T	O
reg	O
cells	O
significantly	O
expressed	B-Transcription
higher	O
levels	O
of	O
RUNX3	O
,	O
FOXP3	O
,	O
and	O
TGF	O
-	O
beta	O
mRNA	O
compared	O
with	O
CD4+CD25	O
-	O
cells	O
.	O

Furthermore	O
,	O
FOXP3	O
and	O
RUNX3	O
were	O
colocalized	B-Localization
in	O
human	O
tonsil	O
T	O
reg	O
cells	O
.	O

These	O
data	O
demonstrate	O
Runx	O
transcription	O
factors	O
as	O
a	O
molecular	O
link	B-Regulation
in	O
TGF-beta	O
-	O
induced	B-Positive_regulation
Foxp3	O
expression	B-Gene_expression
in	O
iT	O
reg	O
cell	O
differentiation	O
and	O
function	O
.	O

INTRODUCTION	O

Regulatory	O
T	O
(	O
T	O
reg	O
)	O
cells	O
expressing	B-Gene_expression
the	O
transcription	O
factor	O
forkhead	O
box	O
P3	O
(	O
FOXP3	O
,	O
human	O
;	O
Foxp3	O
,	O
mouse	O
)	O
play	O
an	O
essential	O
role	O
in	O
controlling	O
immune	O
responses	O
to	O
autoantigens	O
,	O
allergens	O
,	O
tumor	O
antigens	O
,	O
transplantation	O
antigens	O
,	O
and	O
infectious	O
agents	O
(	O
Hori	O
et	O
al.	O
,	O
2003	O
;	O
Akdis	O
,	O
2006	O
)	O
.	O

Foxp3	O
is	O
a	O
member	O
of	O
the	O
forkhead/winged	O
-	O
helix	O
family	O
of	O
transcriptional	O
regulators	O
,	O
and	O
its	O
expression	B-Gene_expression
in	O
T	O
reg	O
cells	O
is	O
essential	O
for	O
their	O
development	O
and	O
function	O
(	O
Fontenot	O
et	O
al.	O
,	O
2003	O
;	O
Williams	O
and	O
Rudensky	O
,	O
2007	O
)	O
.	O

A	O
spontaneous	O
mutation	O
of	O
the	O
X	O
-	O
linked	O
Foxp3	O
gene	O
in	O
scurfy	O
mice	O
causes	O
an	O
autoimmune	O
-	O
like	O
disease	O
,	O
whereas	O
the	O
mutation	O
in	O
humans	O
leads	O
to	O
immunodysregulation	O
,	O
polyendocrinopathy	O
,	O
enteropathy	O
,	O
and	O
X	O
-	O
linked	O
syndrome	O
that	O
is	O
also	O
a	O
severe	O
multiorgan	O
autoimmune	O
disease	O
with	O
hyper	O
-	O
IgE	O
(	O
Ziegler	O
,	O
2006	O
)	O
.	O

Although	O
the	O
essential	O
role	O
of	O
Foxp3	O
in	O
central	O
and	O
peripheral	O
tolerance	O
has	O
been	O
extensively	O
studied	O
,	O
its	O
regulation	B-Regulation
,	O
cooperation	O
with	O
other	O
transcription	O
factors	O
,	O
and	O
how	O
it	O
functions	O
in	O
inducible	O
T	O
reg	O
(	O
iT	O
reg	O
)	O
cells	O
to	O
suppress	O
various	O
target	O
genes	O
is	O
mostly	O
not	O
yet	O
understood	O
.	O

It	O
is	O
known	O
that	O
Foxp3	O
cooperates	O
with	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
or	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
to	O
regulate	O
the	O
transcription	O
of	O
different	O
target	O
genes	O
(	O
Schubert	O
et	O
al.	O
,	O
2001	O
;	O
Bettelli	O
et	O
al.	O
,	O
2005	O
;	O
Wu	O
et	O
al.	O
,	O
2006	O
)	O
.	O

The	O
Th2	O
cytokine	O
IL	O
-	O
4	O
inhibits	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
during	O
T	O
cell	O
priming	O
.	O

GATA3	O
binds	B-Binding
to	O
the	O
FOXP3	O
promoter	O
and	O
can	O
repress	B-Negative_regulation
the	O
FOXP3	O
trans	B-Positive_regulation
-	I-Positive_regulation
activation	I-Positive_regulation
process	O
directly	O
in	O
Th2	O
cells	O
(	O
Mantel	O
et	O
al.	O
,	O
2007	O
)	O
.	O

It	O
was	O
further	O
demonstrated	O
that	O
both	O
Th1	O
and	O
Th2	O
transcription	O
factors	O
T	O
-	O
bet	O
and	O
GATA3	O
oppose	B-Negative_regulation
peripheral	O
induction	B-Positive_regulation
of	O
Foxp3+	O
T	O
reg	O
cells	O
in	O
mice	O
through	O
STAT1	O
-	O
,	O
STAT4	O
-	O
,	O
and	O
STAT6	O
-	O
dependent	B-Positive_regulation
pathways	O
(	O
Wei	O
et	O
al.	O
,	O
2007	O
)	O
.	O

Although	O
natural	O
T	O
reg	O
(	O
nT	O
reg	O
)	O
cells	O
that	O
differentiate	O
in	O
the	O
thymus	O
are	O
characterized	O
by	O
their	O
stable	O
Foxp3	O
expression	B-Gene_expression
,	O
the	O
generation	O
of	O
iT	O
reg	O
cells	O
specific	O
for	O
allergens	O
,	O
alloantigens	O
,	O
and	O
autoantigens	O
in	O
the	O
periphery	O
has	O
been	O
associated	O
with	O
a	O
transient	O
Foxp3+	O
phenotype	O
(	O
Fontenot	O
et	O
al.	O
,	O
2003	O
;	O
Hori	O
et	O
al.	O
,	O
2003	O
)	O
.	O

The	O
crucial	O
role	O
of	O
TGF	O
-	O
beta	O
in	O
their	O
generation	O
has	O
been	O
demonstrated	O
.	O

The	O
RUNX	O
gene	O
family	O
(	O
Runt	O
-	O
related	O
transcription	O
factor	O
,	O
acute	O
myeloid	O
leukemia	O
[	O
AML	O
]	O
,	O
core	O
-	O
binding	O
factor	O
-	O
alpha	O
[	O
CBFalpha	O
]	O
,	O
and	O
polyoma	O
enhancer	O
-	O
binding	O
protein	O
-	O
2alpha	O
[	O
PEBP2alpha	O
]	O
)	O
contains	O
three	O
members	O
,	O
RUNX1	O
(	O
AML1/CBFA2/PEBP2alphaB	O
)	O
,	O
RUNX2	O
(	O
AML3/CBFA1/	O
PEBP2alphaA	O
)	O
,	O
and	O
RUNX3	O
(	O
AML2/CBFA3/PEBP2alphaC	O
)	O
.	O

They	O
are	O
essential	O
transcriptional	O
regulators	O
of	O
different	O
developmental	O
pathways	O
.	O

RUNX2	O
is	O
mostly	O
important	O
for	O
bone	O
development	O
and	O
osteoblast	O
differentiation	O
(	O
Komori	O
et	O
al.	O
,	O
1997	O
)	O
.	O

RUNX1	O
plays	O
an	O
important	O
role	O
in	O
hematopoiesis	O
during	O
development	O
,	O
and	O
RUNX3	O
has	O
important	O
functions	O
in	O
thymogenesis	O
and	O
neurogenesis	O
(	O
Wang	O
et	O
al.	O
,	O
1996	O
;	O
Inoue	O
et	O
al.	O
,	O
2002	O
;	O
Levanon	O
et	O
al.	O
,	O
2002	O
)	O
.	O

RUNX1	O
and	O
RUNX3	O
also	O
work	O
together	O
in	O
the	O
establishment	O
of	O
lineage	O
specification	O
of	O
T	O
lymphocytes	O
(	O
Taniuchi	O
et	O
al.	O
,	O
2002	O
;	O
Egawa	O
et	O
al.	O
,	O
2007	O
)	O
.	O

RUNX1	O
is	O
a	O
frequent	O
target	O
for	O
chromosomal	O
translocations	O
associated	O
with	O
leukemias	O
(	O
Look	O
,	O
1997	O
)	O
,	O
and	O
RUNX3	O
methylation	O
and	O
silencing	O
is	O
observed	O
in	O
various	O
human	O
epithelial	O
cancers	O
(	O
Blyth	O
et	O
al.	O
,	O
2005	O
)	O
.	O

RUNX	O
family	O
members	O
share	O
the	O
Runt	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
DNA	O
binding	O
(	O
Ito	O
,	O
1999	O
)	O
.	O

The	O
Runt	O
domain	O
-	O
containing	O
protein	O
constitutes	O
the	O
alpha	O
-	O
chain	O
partner	O
of	O
the	O
heterodimeric	O
CBF	O
complex	O
.	O

RUNX	O
proteins	O
heterodimerize	B-Binding
with	O
the	O
non-DNA	O
-	O
binding	O
partner	O
,	O
CBFbeta	O
,	O
which	O
increases	O
the	O
affinity	O
for	O
DNA	O
binding	O
and	O
stabilizes	O
the	O
complex	O
by	O
preventing	O
ubiquitin	O
-	O
dependent	O
degradation	O
(	O
Wang	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
CBF	O
complexes	O
regulate	O
the	O
expression	O
of	O
cellular	O
genes	O
through	O
binding	B-Binding
to	O
promoters	O
or	O
enhancer	O
elements	O
.	O

The	O
effects	O
of	O
the	O
RUNX	O
-	O
CBFbeta	O
complex	O
regulation	O
are	O
clearly	O
cell	O
lineage	O
and	O
stage	O
specific	O
.	O

They	O
include	O
the	O
crucial	O
choices	O
between	O
cell	O
-	O
cycle	O
exit	O
and	O
continued	O
proliferation	O
,	O
as	O
well	O
as	O
between	O
cell	O
differentiation	O
and	O
self	O
-	O
renewal	O
(	O
Blyth	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Because	O
of	O
the	O
involvement	O
of	O
RUNX	O
mutations	O
in	O
different	O
autoimmune	O
diseases	O
and	O
the	O
known	O
interaction	B-Binding
with	O
TGF	O
-	O
beta	O
,	O
we	O
investigated	O
the	O
impact	B-Regulation
of	O
RUNX1	O
and	O
RUNX3	O
on	O
the	O
expression	B-Gene_expression
of	O
FOXP3	O
and	O
subsequently	O
on	O
the	O
development	O
and	O
function	O
of	O
iT	O
reg	O
cells	O
.	O

This	O
study	O
demonstrates	O
that	O
RUNX1	O
and	O
RUNX3	O
induced	B-Positive_regulation
by	O
TGF	O
-	O
beta	O
are	O
involved	O
in	O
the	O
development	O
and	O
suppressive	O
function	O
of	O
Foxp3+	O
iT	O
reg	O
cells	O
.	O

The	O
role	O
of	O
RUNX1	O
and	O
RUNX3	O
transcription	O
factors	O
in	O
TGF-beta	O
-	O
mediated	O
iT	O
reg	O
cell	O
generation	O

To	O
investigate	O
the	O
role	O
of	O
RUNX	O
transcription	O
factors	O
in	O
the	O
development	O
of	O
iT	O
reg	O
cells	O
,	O
we	O
cultured	O
naive	O
CD4+	O
T	O
cells	O
,	O
isolated	O
from	O
human	O
PBMCs	O
,	O
in	O
conditions	O
that	O
enable	O
the	O
development	O
of	O
iT	O
reg	O
cells	O
.	O

Stimulation	O
with	O
anti	O
-	O
CD2/3/28	O
mAbs	O
or	O
TGF	O
-	O
beta	O
alone	O
resulted	O
in	O
a	O
minimal	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
RUNX1	O
and	O
RUNX3	O
mRNA	B-Transcription
(	O
Fig	O
.	O

1	O
A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
combination	O
of	O
both	O
TGF	O
-	O
beta	O
and	O
anti	O
-	O
CD2/3/28	O
mAbs	O
induced	B-Positive_regulation
RUNX1	O
and	O
RUNX3	O
mRNAs	B-Transcription
,	O
as	O
well	O
as	O
FOXP3	O
mRNA	B-Transcription
,	O
within	O
48	O
h	O
in	O
naive	O
CD4+	O
T	O
cells	O
.	O

This	O
result	O
suggested	O
further	O
experiments	O
to	O
investigate	O
whether	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
RUNX1	O
and	O
RUNX3	O
might	O
be	O
a	O
feature	O
of	O
iT	O
reg	O
cells	O
during	O
their	O
development	O
or	O
even	O
a	O
prerequisite	O
for	O
their	O
induction	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
RUNX1	O
and	O
RUNX3	O
expression	B-Gene_expression
was	O
knocked	B-Negative_regulation
down	I-Negative_regulation
in	O
human	O
naive	O
CD4+	O
T	O
cells	O
by	O
transfection	O
of	O
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
;	O
Fig	O
.	O

1	O
B	O
)	O
.	O

Deficiency	B-Negative_regulation
of	O
RUNX1	O
or	O
RUNX3	O
resulted	O
in	O
markedly	O
reduced	B-Negative_regulation
TGF-beta	O
-	O
mediated	B-Positive_regulation
induction	B-Transcription
of	O
FOXP3	O
mRNA	O
in	O
naive	O
CD4+	O
T	O
cells	O
compared	O
with	O
control	O
cells	O
transfected	O
with	O
scrambled	O
siRNA	O
.	O

The	O
level	O
of	O
FOXP3	O
mRNA	B-Transcription
was	O
further	O
reduced	B-Negative_regulation
when	O
both	O
RUNX1	O
and	O
RUNX3	O
were	O
knocked	B-Negative_regulation
down	I-Negative_regulation
in	O
naive	O
CD4+	O
T	O
cells	O
during	O
their	O
differentiation	O
to	O
iT	O
reg	O
cells	O
(	O
Fig	O
.	O

1	O
B	O
)	O
.	O

The	O
influence	O
of	O
RUNX1	O
and	O
RUNX3	O
on	O
the	O
development	O
of	O
other	O
T	O
cell	O
subsets	O
and	O
their	O
specific	O
transcription	O
factor	O
expression	O
was	O
further	O
investigated	O
.	O

Naive	O
CD4+	O
T	O
cells	O
were	O
cultured	O
under	O
Th1	O
,	O
Th2	O
,	O
T	O
reg	O
cell	O
,	O
and	O
Th17	O
differentiation	O
conditions	O
and	O
the	O
mRNA	O
expression	O
of	O
the	O
predominant	O
transcription	O
factor	O
for	O
each	O
cell	O
type	O
was	O
subsequently	O
analyzed	O
.	O

We	O
observed	O
no	O
change	B-Regulation
in	O
GATA3	O
expression	B-Transcription
in	O
Th2	O
cells	O
,	O
T	O
-	O
bet	O
expression	B-Transcription
in	O
Th1	O
cells	O
,	O
or	O
RORC2	O
mRNA	B-Transcription
expression	I-Transcription
in	O
Th17	O
cells	O
in	O
which	O
RUNX1	O
and	O
RUNX3	O
were	O
knocked	B-Negative_regulation
down	I-Negative_regulation
compared	O
with	O
control	O
cells	O
.	O

On	O
the	O
contrary	O
,	O
FOXP3	O
mRNA	B-Transcription
was	O
significantly	O
decreased	B-Negative_regulation
in	O
RUNX1	O
-	O
and	O
RUNX3	O
-	O
deficient	B-Negative_regulation
T	O
reg	O
cells	O
compared	O
with	O
control	O
cells	O
(	O
Fig	O
.	O

1	O
C	O
)	O
.	O

The	O
effect	B-Regulation
of	O
RUNX	O
silencing	B-Negative_regulation
on	O
the	O
expression	B-Gene_expression
level	O
of	O
intracellular	O
FOXP3	O
during	O
naive	O
CD4+	O
T	O
cell	O
differentiation	O
to	O
iT	O
reg	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
.	O

FOXP3	O
was	O
only	O
slightly	O
reduced	B-Negative_regulation
after	O
RUNX1	O
silencing	B-Negative_regulation
.	O

Transfection	B-Negative_regulation
of	I-Negative_regulation
siRNA	I-Negative_regulation
for	O
RUNX3	O
had	O
a	O
stronger	B-Negative_regulation
effect	I-Negative_regulation
.	O

The	O
most	O
striking	O
FOXP3	O
reduction	B-Negative_regulation
was	O
observed	O
when	O
RUNX1	O
and	O
RUNX3	O
were	O
silenced	B-Negative_regulation
together	O
(	O
Fig	O
.	O

1	O
D	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
total	O
CD4+	O
T	O
cells	O
(	O
Fig	O
.	O

S1	O
and	O
Fig	O
.	O

S2	O
)	O
.	O

The	O
increased	O
impact	O
of	O
combined	O
RUNX1	O
and	O
RUNX3	O
knockdown	B-Negative_regulation
implies	O
that	O
RUNX1	O
and	O
RUNX3	O
might	O
have	O
redundant	O
functions	B-Regulation
in	O
the	O
induction	B-Positive_regulation
of	O
FOXP3	O
.	O

In	O
addition	O
,	O
the	O
levels	B-Gene_expression
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
13	O
,	O
and	O
IFN	O
-	O
gamma	O
in	O
control	O
siRNA	O
-	O
transfected	O
or	O
RUNX1	O
and	O
RUNX3	O
siRNA	B-Negative_regulation
-	I-Negative_regulation
transfected	I-Negative_regulation
CD4+	O
T	O
cells	O
that	O
were	O
cultured	O
with	O
or	O
without	O
anti	O
-	O
CD2/3/28	O
mAb	O
and	O
TGF	O
-	O
beta	O
did	O
not	O
show	B-Regulation
any	I-Regulation
significant	I-Regulation
difference	I-Regulation
(	O
Fig	O
.	O

S3	O
)	O
.	O

To	O
determine	O
whether	O
RUNX1	O
and	O
RUNX3	O
are	O
also	O
expressed	B-Gene_expression
in	O
human	O
T	O
reg	O
cells	O
in	O
vivo	O
,	O
we	O
isolated	O
peripheral	O
blood	O
CD4+	O
CD127	O
-	O
CD25high	O
T	O
reg	O
cells	O
and	O
compared	O
them	O
with	O
CD4+	O
CD127+	O
CD25	O
-	O
T	O
cells	O
.	O

Circulating	O
T	O
reg	O
cells	O
expressed	B-Transcription
significantly	O
higher	O
levels	O
of	O
RUNX3	O
mRNA	O
compared	O
with	O
CD4+CD25	O
-	O
cells	O
.	O

As	O
expected	O
,	O
IL	O
-	O
10	O
,	O
TGF	O
-	O
beta	O
,	O
and	O
FOXP3	O
mRNAs	O
are	O
also	O
expressed	B-Transcription
in	O
circulating	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O

2	O
A	O
)	O
.	O

There	O
was	O
no	O
difference	B-Regulation
in	O
RUNX1	O
mRNA	B-Transcription
expression	I-Transcription
between	O
these	O
two	O
cell	O
subsets	O
.	O

We	O
also	O
performed	O
an	O
analysis	O
of	O
human	O
tonsils	O
,	O
which	O
contain	O
high	O
numbers	O
of	O
FOXP3+	O
T	O
reg	O
cells	O
(	O
Verhagen	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Staining	O
of	O
tonsil	O
sections	O
for	O
FOXP3	O
and	O
RUNX3	O
demonstrated	O
in	O
vivo	O
coexpression	B-Gene_expression
of	O
these	O
two	O
molecules	O
in	O
a	O
subset	O
of	O
T	O
reg	O
cells	O
,	O
whereas	O
there	O
was	O
low	B-Negative_regulation
RUNX1	O
expression	B-Gene_expression
in	O
all	O
tonsil	O
cells	O
(	O
Fig	O
.	O

2	O
B	O
)	O
.	O

RUNX1	O
and	O
RUNX3	O
bind	B-Binding
to	O
the	O
FOXP3	O
promoter	O

Transcription	O
element	O
search	O
system	O
analysis	O
of	O
the	O
human	O
FOXP3	O
promoter	O
predicted	O
3	O
putative	O
RUNX	O
binding	O
sites	O
at	O
333	O
,	O
287	O
,	O
and	O
53	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
.	O

All	O
three	O
binding	O
sites	O
are	O
conserved	O
between	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
(	O
Fig	O
.	O

S4	O
)	O
.	O

To	O
verify	O
the	O
putative	O
binding	O
sites	O
in	O
the	O
FOXP3	O
promoter	O
,	O
we	O
transiently	O
transfected	B-Gene_expression
HEK293T	O
cells	O
with	O
RUNX1	O
and	O
RUNX3	O
.	O

After	O
the	O
pull	O
-	O
down	O
with	O
oligonucleotides	O
containing	O
the	O
wild	O
-	O
type	O
binding	O
sequences	O
,	O
but	O
not	O
mutant	O
sequences	O
,	O
RUNX	O
binding	B-Binding
to	O
the	O
FOXP3	O
promoter	O
oligonucleotides	O
was	O
detected	O
by	O
Western	O
blot	O
(	O
Fig	O
.	O

3	O
A	O
)	O
.	O

To	O
confirm	O
these	O
results	O
and	O
test	O
the	O
ability	O
of	O
single	O
binding	O
site	O
sequences	O
to	O
bind	B-Binding
either	O
RUNX1	O
or	O
RUNX3	O
,	O
we	O
used	O
the	O
promoter	O
enzyme	O
immunoassay	O
.	O

Cell	O
lysates	O
were	O
obtained	O
from	O
HEK293T	O
cells	O
that	O
had	O
been	O
transiently	O
transfected	B-Positive_regulation
with	O
RUNX1	O
or	O
RUNX3	O
expression	B-Gene_expression
vectors	O
.	O

The	O
biotinylated	O
FOXP3	O
promoter	O
oligonucleotides	O
were	O
linked	O
to	O
a	O
streptavidin	O
-	O
coated	O
microtiter	O
plate	O
,	O
and	O
bound	B-Binding
RUNX1	O
or	O
RUNX3	O
was	O
detected	O
by	O
using	O
anti	O
-	O
RUNX	O
antibodies	O
and	O
a	O
peroxidase	O
-	O
labeled	O
secondary	O
antibody	O
.	O

We	O
showed	O
binding	B-Binding
of	O
RUNX1	O
and	O
RUNX3	O
to	O
the	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
binding	O
sites	O
,	O
whereas	O
there	O
was	O
no	O
binding	B-Binding
detectable	O
when	O
a	O
combination	O
of	O
the	O
mutated	O
oligonucleotides	O
was	O
used	O
in	O
the	O
assay	O
(	O
Fig	O
.	O

3	O
B	O
)	O
.	O

Although	O
there	O
was	O
a	O
similar	O
and	O
high	O
degree	O
of	O
binding	B-Binding
to	O
the	O
-	O
333	O
and	O
-	O
287	O
sites	O
,	O
a	O
lower	O
degree	O
of	O
binding	B-Binding
was	O
detected	O
when	O
the	O
oligonucleotide	O
containing	O
the	O
-	O
53	O
site	O
in	O
the	O
Foxp3	O
promoter	O
was	O
used	O
.	O

This	O
effect	O
was	O
observed	O
both	O
for	O
binding	B-Binding
to	O
RUNX1	O
and	O
RUNX3	O
(	O
Fig	O
.	O

3	O
B	O
)	O
.	O

The	O
binding	B-Binding
to	O
the	O
two	O
single	O
binding	O
sites	O
at	O
-	O
333	O
and	O
-	O
287	O
was	O
comparable	O
to	O
the	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
results	O
confirmed	O
the	O
binding	B-Binding
of	O
RUNX1	O
and	O
RUNX3	O
complexes	O
containing	O
CBFbeta	O
to	O
FOXP3	O
promoter	O
during	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
toward	O
T	O
reg	O
cells	O
.	O

Here	O
,	O
naive	O
CD4+	O
T	O
cells	O
were	O
cultured	O
with	O
IL	O
-	O
2	O
,	O
anti	O
-	O
CD2/3/28	O
mAb	O
,	O
and	O
TGF	O
-	O
beta	O
as	O
a	O
Foxp3	O
-	O
inducing	B-Positive_regulation
stimulation	O
.	O

Amplification	O
of	O
PCR	O
products	O
from	O
the	O
FOXP3	O
promoter	O
region	O
with	O
the	O
predicted	O
RUNX	O
binding	O
sites	O
showed	O
that	O
RUNX1	O
,	O
RUNX3	O
,	O
and	O
CBFbeta	O
were	O
immunoprecipitated	B-Binding
together	I-Binding
with	O
the	O
FOXP3	O
promoter	O
(	O
Fig	O
.	O

3	O
C	O
)	O
.	O

Negative	O
control	O
primer	O
targeting	O
open	O
reading	O
frame	O
-	O
free	O
intergenic	O
DNA	O
,	O
IGX1A	O
did	O
not	O
show	O
any	O
significant	O
change	O
in	O
site	O
occupancy	O
.	O

Regulation	B-Regulation
of	O
FOXP3	O
promoter	O
activity	B-Positive_regulation
and	O
FOXP3	O
protein	O
expression	B-Gene_expression
by	O
RUNX1	O
and	O
RUNX3	O

To	O
investigate	O
the	O
effect	O
of	O
RUNX1	O
and	O
RUNX3	O
binding	B-Binding
to	O
the	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	O
promoter	O
,	O
we	O
transfected	B-Positive_regulation
human	O
peripheral	O
blood	O
CD4+	O
T	O
cells	O
with	O
a	O
FOXP3	O
promoter	O
luciferase	O
reporter	O
vector	O
and	O
RUNX1	O
or	O
RUNX3	O
expression	B-Gene_expression
vectors	O
.	O

An	O
increase	B-Positive_regulation
in	O
luciferase	O
activity	O
was	O
observed	O
only	O
when	O
the	O
FOXP3	O
promoter	O
(	O
-	O
511	O
to	O
+176	O
)	O
luciferase	O
construct	O
was	O
cotransfected	B-Positive_regulation
with	O
RUNX1	O
or	O
RUNX3	O
expression	B-Gene_expression
vectors	O
(	O
Fig	O
.	O

4	O
A	O
)	O
.	O

The	O
increase	B-Positive_regulation
in	O
promoter	O
activity	O
was	O
greater	O
upon	O
cotransfection	B-Gene_expression
of	O
RUNX3	O
compared	O
with	O
RUNX1	O
.	O

Luciferase	O
expression	B-Gene_expression
was	O
abrogated	B-Negative_regulation
when	O
the	O
Runx	O
binding	O
sites	O
in	O
the	O
FOXP3	O
promoter	O
(	O
-	O
511	O
to	O
+176	O
)	O
luciferase	O
construct	O
were	O
mutated	O
(	O
Fig	O
.	O

4	O
A	O
)	O
.	O

In	O
these	O
experiments	O
,	O
the	O
overexpression	B-Gene_expression
of	O
RUNX1	O
and	O
RUNX3	O
eliminated	O
the	O
need	B-Positive_regulation
of	O
TGF	O
-	O
beta	O
for	O
FOXP3	O
promoter	O
activation	B-Positive_regulation
and	O
PMA/ionomycin	O
stimulation	O
was	O
sufficient	O
.	O

To	O
examine	O
the	O
role	O
of	O
each	O
of	O
the	O
three	O
RUNX	O
binding	O
sites	O
for	O
the	O
FOXP3	O
promoter	O
activity	O
,	O
we	O
mutated	O
each	O
individually	O
or	O
in	O
combination	O
.	O

No	O
reduction	B-Negative_regulation
in	O
luciferase	O
activity	O
was	O
observed	O
when	O
the	O
-	O
53	O
site	O
was	O
mutated	O
and	O
only	O
a	O
slight	O
reduction	B-Negative_regulation
when	O
either	O
the	O
-	O
287	O
or	O
-	O
333	O
site	O
was	O
mutated	O
(	O
Fig	O
.	O

4	O
B	O
)	O
.	O

However	O
,	O
mutating	O
the	O
-	O
53	O
site	O
in	O
combination	O
with	O
one	O
of	O
the	O
other	O
two	O
sites	O
led	O
to	O
a	O
significant	O
decrease	B-Negative_regulation
in	O
luciferase	O
activity	O
,	O
with	O
the	O
greatest	O
reduction	B-Negative_regulation
observed	O
when	O
all	O
three	O
binding	O
sites	O
were	O
mutated	O
(	O
Fig	O
.	O

4	O
B	O
)	O
,	O
suggesting	O
that	O
the	O
identified	O
binding	O
sites	O
have	O
redundant	O
functions	O
and	O
RUNX	O
binding	B-Binding
to	O
more	O
than	O
one	O
site	O
is	O
necessary	B-Positive_regulation
for	O
the	O
full	O
activation	B-Positive_regulation
of	O
the	O
FOXP3	O
promoter	O
.	O

Supporting	O
these	O
findings	O
,	O
the	O
overexpression	B-Gene_expression
of	O
RUNX1	O
in	O
human	O
primary	O
CD4+	O
T	O
cells	O
resulted	O
in	O
significantly	O
elevated	B-Positive_regulation
levels	O
of	O
FOXP3	O
protein	O
measured	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
.	O

This	O
was	O
achieved	O
without	O
any	O
requirement	B-Positive_regulation
for	O
anti	O
-	O
CD3	O
,	O
anti	O
-	O
CD28	O
stimulation	O
,	O
or	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

Although	O
there	O
was	O
a	O
trend	O
,	O
the	O
transfection	B-Gene_expression
of	O
CD4+	O
T	O
cells	O
with	O
RUNX3	O
did	O
not	O
lead	O
to	O
statistically	O
significant	O
increase	B-Positive_regulation
in	O
FOXP3	O
(	O
Fig	O
.	O

S5	O
)	O
.	O

Role	B-Positive_regulation
of	O
CBFbeta	O
in	O
the	O
induction	B-Gene_expression
of	O
Foxp3	O

CBFbeta	O
,	O
a	O
common	O
cofactor	O
of	O
all	O
RUNX	O
proteins	O
,	O
stabilizes	O
and	O
increases	O
the	O
binding	O
of	O
the	O
runt	O
domain	O
to	O
target	O
DNA	O
sequences	O
.	O

To	O
target	O
all	O
Runx	O
proteins	O
that	O
might	O
be	O
involved	B-Regulation
in	O
the	O
induction	B-Positive_regulation
of	O
Foxp3	O
,	O
we	O
used	O
mice	O
in	O
which	O
loxP	O
-	O
flanked	O
Cbfb	O
alleles	O
were	O
inactivated	B-Negative_regulation
in	O
T	O
cells	O
through	O
expression	B-Gene_expression
of	O
a	O
CD4	O
-	O
cre	O
transgene	O
.	O

Retinoic	O
acid	O
and	O
TGF	O
-	O
beta	O
synergize	B-Positive_regulation
in	O
the	O
induction	B-Gene_expression
of	O
Foxp3	O
in	O
naive	O
T	O
cells	O
(	O
Kang	O
et	O
al.	O
,	O
2007	O
)	O
.	O

To	O
investigate	O
whether	O
Runx	O
-	O
mediated	B-Positive_regulation
induction	B-Gene_expression
of	O
Foxp3	O
is	O
dependent	B-Positive_regulation
on	O
the	O
expression	B-Gene_expression
of	O
CBFbeta	O
,	O
naive	O
CD4+	O
CD8	O
-	O
T	O
cells	O
from	O
CbfbF/F	O
CD4	O
-	O
cre	O
and	O
control	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3/28	O
mAbs	O
,	O
retinoic	O
acid	O
,	O
and	O
increasing	O
concentrations	O
of	O
TGF	O
-	O
beta	O
.	O

After	O
3	O
d	O
in	O
culture	O
,	O
the	O
cells	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
and	O
analyzed	O
for	O
intracellular	O
Foxp3	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
.	O

TGF	O
-	O
beta	O
induced	B-Positive_regulation
Foxp3	O
in	O
CbfbF/+	O
CD4	O
-	O
cre	O
cells	O
in	O
a	O
dose	O
dependent	O
manner	O
,	O
and	O
this	O
was	O
significantly	O
reduced	B-Negative_regulation
in	O
CbfbF/F	O
CD4	O
-	O
cre	O
cells	O
.	O

Retinoic	O
acid	O
enhanced	B-Positive_regulation
Foxp3	O
expression	B-Gene_expression
even	O
in	O
20	O
pg/ml	O
of	O
TGF	O
-	O
beta	O
and	O
more	O
than	O
95	O
%	O
of	O
the	O
CD4+	O
T	O
cells	O
from	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
became	O
Foxp3+	O
in	O
100	O
and	O
500	O
pg/ml	O
TGF	O
-	O
beta	O
doses	O
.	O

The	O
induction	B-Gene_expression
of	O
Foxp3	O
was	O
again	O
significantly	O
lower	B-Negative_regulation
in	O
CbfbF/F	O
CD4	O
-	O
cre	O
CD4+	O
T	O
cells	O
even	O
in	O
the	O
presence	O
of	O
retinoic	O
acid	O
,	O
demonstrating	O
that	O
deficiency	O
in	O
Runx	O
binding	B-Binding
to	O
DNA	O
affects	B-Regulation
the	O
TGF	O
-	O
beta	O
induction	B-Positive_regulation
of	O
Foxp3	O
in	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O

5	O
A	O
)	O
.	O

There	O
was	O
no	O
difference	B-Regulation
in	O
the	O
induction	B-Gene_expression
of	O
Foxp3	O
when	O
endogenous	O
IL	O
-	O
4	O
and	O
IFN	O
-	O
gamma	O
were	O
neutralized	B-Negative_regulation
(	O
Fig	O
.	O

S6	O
)	O
.	O

The	O
importance	O
of	O
RUNX	O
transcription	O
factors	O
for	O
the	O
in	O
vivo	O
conversion	O
of	O
naive	O
CD4+	O
T	O
cells	O
into	O
iT	O
reg	O
cells	O
was	O
examined	O
.	O

Control	O
CbfbF/F	O
or	O
CbfbF/F	O
CD4	O
-	O
cre	O
naive	O
T	O
cells	O
,	O
harboring	O
a	O
Foxp3-IRES	O
-	O
GFP	O
allele	O
were	O
adoptively	O
transferred	O
into	O
Rag2-/	O
-	O
mice	O
.	O

6	O
wk	O
later	O
,	O
CD4+	O
T	O
cells	O
in	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
were	O
analyzed	O
for	O
Foxp3	O
-	O
GFP	O
expression	B-Gene_expression
(	O
Fig	O
.	O

5	O
B	O
)	O
.	O

There	O
was	O
a	O
consistently	O
lower	O
percentage	O
of	O
CD4+	O
T	O
cells	O
that	O
had	O
developed	O
Foxp3	O
expression	B-Gene_expression
in	O
the	O
mesenteric	O
lymph	O
node	O
and	O
lamina	O
propria	O
of	O
mice	O
transferred	O
with	O
CbfbF/F	O
CD4	O
-	O
cre	O
cells	O
compared	O
with	O
control	O
cells	O
(	O
Fig	O
.	O

5	O
,	O
B	O
and	O
C	O
)	O
.	O

These	O
data	O
affirm	O
the	O
significance	B-Positive_regulation
of	O
RUNX	O
proteins	O
for	O
the	O
in	O
vivo	O
generation	B-Gene_expression
of	O
CD4+	O
Foxp3+	O
T	O
cells	O
.	O

CBFbeta	O
,	O
RUNX1	O
,	O
and	O
RUNX3	O
are	O
important	O
for	O
the	O
suppressive	O
activity	O
of	O
CD25+	O
Foxp3+	O
T	O
reg	O
cells	O

Even	O
though	O
Cbfb	O
-	O
deficient	B-Negative_regulation
CD4+	O
T	O
cells	O
had	O
impaired	B-Negative_regulation
induction	B-Positive_regulation
of	O
Foxp3	O
after	O
stimulation	O
with	O
anti	O
-	O
CD3/28	O
mAbs	O
and	O
TGF	O
-	O
beta	O
,	O
sufficient	O
numbers	O
of	O
Foxp3+	O
cells	O
could	O
be	O
generated	O
to	O
permit	O
analysis	O
of	O
their	O
suppressive	O
activity	O
.	O

Purified	O
naive	O
CD4+	O
T	O
cells	O
from	O
CbfbF/F	O
CD4	O
-	O
cre	O
and	O
control	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
(	O
Cd45.2	O
)	O
harboring	O
a	O
Foxp3-ires	O
-	O
GFP	O
allele	O
(	O
Bettelli	O
et	O
al.	O
,	O
2006	O
)	O
were	O
stimulated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3/28	O
mAbs	O
,	O
IL	O
-	O
2	O
,	O
and	O
TGF	O
-	O
beta	O
.	O

After	O
3	O
d	O
,	O
Foxp3+	O
-	O
GFP+	O
cells	O
were	O
sorted	O
by	O
flow	O
cytometry	O
and	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
naive	O
CD45.1+	O
CD4+	O
cells	O
at	O
ratios	O
of	O
1	O
:	O
4	O
,	O
1	O
:	O
2	O
,	O
and	O
1	O
:	O
1	O
.	O

The	O
cells	O
were	O
then	O
incubated	O
with	O
inactivated	O
splenocytes	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
for	O
four	O
more	O
days	O
.	O

CD45.1+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
(	O
Fig	O
.	O

6	O
A	O
)	O
.	O

CbfbF/+	O
CD4	O
-	O
cre	O
CD4+	O
T	O
cells	O
activated	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
showed	O
a	O
clear	O
suppression	O
of	O
T	O
cell	O
proliferation	O
that	O
became	O
even	O
more	O
apparent	O
when	O
an	O
increased	O
ratio	O
of	O
FOXP3+/CD25	O
-	O
cells	O
was	O
used	O
(	O
Fig	O
.	O

6	O
B	O
)	O
.	O

The	O
suppression	O
was	O
significantly	O
reduced	O
when	O
cells	O
from	O
CbfbF/F	O
CD4	O
-	O
cre	O
mice	O
were	O
used	O
,	O
demonstrating	O
that	O
TGF-beta	O
-	O
induced	O
Runx	O
complexes	O
are	O
important	O
for	O
the	O
suppressive	O
activity	O
of	O
Foxp3+	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O

6	O
B	O
)	O
.	O

As	O
a	O
control	O
,	O
CbfbF/+	O
CD4	O
-	O
cre	O
CD4+	O
T	O
cells	O
activated	O
in	O
absence	O
of	O
TGF	O
-	O
beta	O
were	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
naive	O
CD45.1+	O
CD4+	O
cells	O
.	O

No	O
suppression	O
could	O
be	O
observed	O
in	O
all	O
control	O
groups	O
without	O
TGF	O
-	O
beta	O
at	O
all	O
tested	O
ratios	O
(	O
Fig	O
.	O

6	O
C	O
)	O
.	O

The	O
decreased	O
suppression	O
capacity	O
of	O
CbfbF/F	O
CD4	O
-	O
cre	O
iT	O
reg	O
cells	O
was	O
unlikely	O
to	O
be	O
caused	O
by	O
decreased	O
survival	O
or	O
proliferation	O
.	O

Foxp3+	O
and	O
Foxp3	O
-	O
cells	O
generated	O
from	O
both	O
CbfbF/F	O
CD4	O
-	O
cre	O
and	O
control	O
cells	O
all	O
displayed	O
similar	O
proliferation	O
rates	O
and	O
cell	O
death	O
as	O
measured	O
by	O
CFSE	O
dilution	O
and	O
annexin	O
V	O
staining	O
,	O
respectively	O
(	O
Fig	O
.	O

S7	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
we	O
tested	O
the	O
requirement	O
of	O
RUNX1	O
and	O
RUNX3	O
for	O
the	O
development	O
of	O
the	O
suppressive	O
capacity	O
in	O
human	O
iT	O
reg	O
cells	O
.	O

We	O
isolated	O
human	O
naive	O
CD4+	O
T	O
cells	O
and	O
transfected	O
them	O
with	O
a	O
combination	O
of	O
RUNX1	O
and	O
RUNX3	O
siRNA	B-Negative_regulation
,	O
or	O
with	O
a	O
scrambled	O
control	O
siRNA	O
.	O

Cells	O
were	O
cultured	O
under	O
T	O
reg	O
conditions	O
,	O
and	O
then	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
autologous	O
CD4+	O
T	O
cells	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
.	O

Cells	O
in	O
which	O
RUNX1	O
and	O
RUNX3	O
were	O
knocked	B-Negative_regulation
down	I-Negative_regulation
showed	O
markedly	O
lower	O
suppressive	O
activity	O
compared	O
with	O
control	O
iT	O
reg	O
cells	O
at	O
a	O
T	O
reg/CD4+	O
T	O
responder	O
cell	O
ratio	O
of	O
1	O
:	O
20	O
,	O
but	O
not	O
when	O
the	O
T	O
reg/CD4+	O
T	O
responder	O
cell	O
ratio	O
was	O
increased	O
to	O
1	O
:	O
5	O
(	O
Fig	O
.	O

6	O
D	O
)	O
.	O

These	O
results	O
demonstrate	O
the	O
important	B-Positive_regulation
role	O
of	O
RUNX1	O
and	O
RUNX3	O
not	O
only	O
for	O
the	O
induction	B-Gene_expression
of	O
FOXP3	O
,	O
but	O
also	O
for	O
the	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
both	O
in	O
humans	O
and	O
in	O
mice	O
.	O

The	O
data	O
suggest	O
both	O
quantity	O
and	O
quality	O
of	O
T	O
reg	O
cells	O
are	O
hampered	O
.	O

Reduced	O
intrinsic	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
was	O
demonstrated	O
in	O
mice	O
,	O
because	O
Foxp3	O
-	O
GFP+	O
cells	O
were	O
FACS	O
sorted	O
and	O
same	O
numbers	O
of	O
iT	O
reg	O
cells	O
are	O
included	O
in	O
control	O
experiments	O
.	O

In	O
the	O
suppression	O
experiment	O
with	O
human	O
cells	O
,	O
reduced	O
suppressive	O
activity	O
was	O
caused	O
by	O
reduced	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
in	O
T	O
cells	O
by	O
siRNA	O
inhibition	B-Negative_regulation
of	O
RUNX1	O
and	O
RUNX3	O
.	O

DISCUSSION	O

This	O
study	O
demonstrates	O
that	O
RUNX	O
transcription	O
factors	O
1	O
and	O
3	O
play	O
an	O
important	O
role	O
in	O
the	O
generation	O
of	O
FOXP3+	O
iT	O
reg	O
cells	O
by	O
TGF	O
-	O
beta	O
.	O

TGF	O
-	O
beta	O
mediates	B-Positive_regulation
RUNX	O
induction	B-Gene_expression
and	O
FOXP3	O
is	O
efficiently	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
by	O
RUNX1	O
and	O
RUNX3	O
in	O
human	O
CD4+	O
T	O
cells	O
.	O

There	O
are	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
proximal	O
FOXP3	O
promoter	O
.	O

One	O
binding	O
site	O
was	O
predicted	O
as	O
a	O
binding	O
site	O
for	O
RUNX2	O
.	O

Promoter	O
enzyme	O
immunoassay	O
results	O
showed	O
that	O
binding	B-Binding
of	O
RUNX1	O
and	O
RUNX3	O
also	O
occurred	O
at	O
this	O
site	O
(	O
as	O
well	O
as	O
at	O
the	O
other	O
two	O
)	O
,	O
which	O
were	O
initially	O
identified	O
as	O
RUNX1	O
binding	O
sites	O
.	O

This	O
finding	O
is	O
not	O
surprising	O
because	O
RUNX	O
proteins	O
bind	B-Binding
to	O
promoter	O
or	O
enhancer	O
elements	O
of	O
their	O
target	O
genes	O
via	O
the	O
runt	O
domain	O
,	O
which	O
is	O
conserved	O
between	O
members	O
of	O
the	O
RUNX	O
family	O
.	O

The	O
RUNX	O
protein	O
that	O
actually	O
induces	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
FOXP3	O
might	O
therefore	O
be	O
dependent	B-Regulation
on	O
the	O
availability	O
of	O
the	O
specific	O
RUNX	O
family	O
member	O
at	O
certain	O
stages	O
of	O
T	O
cell	O
development	O
.	O

RUNX	O
proteins	O
are	O
able	O
to	O
increase	O
or	O
inhibit	O
transcriptional	O
activity	O
of	O
their	O
target	O
genes	O
depending	O
on	O
the	O
cell	O
type	O
and	O
the	O
target	O
gene	O
(	O
Otto	O
et	O
al.	O
,	O
2003	O
)	O
.	O

Mutation	O
of	O
only	O
one	O
of	O
the	O
three	O
binding	O
sites	O
had	O
only	O
a	O
little	O
effect	O
on	O
the	O
promoter	O
activity	O
;	O
however	O
,	O
when	O
two	O
binding	O
sites	O
were	O
mutated	O
,	O
the	O
FOXP3	O
promoter	O
activity	O
dropped	O
to	O
a	O
greater	O
extent	O
.	O

The	O
most	O
striking	O
effect	O
was	O
observed	O
when	O
all	O
three	O
binding	O
sites	O
were	O
mutated	O
.	O

We	O
therefore	O
assume	O
that	O
these	O
binding	O
sites	O
have	O
partially	O
redundant	O
functions	O
,	O
but	O
binding	B-Binding
to	O
at	O
least	O
two	O
sites	O
seems	O
to	O
be	O
necessary	B-Positive_regulation
for	O
full	O
promoter	O
activation	B-Positive_regulation
.	O

TGF	O
-	O
beta	O
promotes	O
or	O
inhibits	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
of	O
a	O
wide	O
array	O
of	O
different	O
cells	O
.	O

It	O
is	O
also	O
produced	B-Gene_expression
in	O
activated	O
T	O
cells	O
and	O
it	O
inhibits	O
T	O
cell	O
proliferation	O
(	O
Kehrl	O
et	O
al.	O
,	O
1986	O
;	O
Siegel	O
and	O
Massague	O
,	O
2003	O
)	O
.	O

It	O
was	O
shown	O
that	O
TGF	O
-	O
beta	O
is	O
mandatory	B-Positive_regulation
for	O
the	O
maintenance	O
of	O
peripheral	O
T	O
reg	O
cells	O
and	O
their	O
expression	B-Gene_expression
of	O
Foxp3	O
(	O
Marie	O
et	O
al.	O
,	O
2005	O
;	O
Rubtsov	O
and	O
Rudensky	O
,	O
2007	O
)	O
.	O

RUNX	O
transcription	O
factors	O
are	O
targets	B-Regulation
of	O
the	O
TGF	O
-	O
beta	O
superfamily	O
and	O
they	O
are	O
involved	B-Regulation
in	O
the	O
TGF	O
-	O
beta	O
pathway	O
.	O

They	O
interact	B-Binding
directly	O
with	O
regulatory	O
SMADs	O
(	O
Miyazawa	O
et	O
al.	O
,	O
2002	O
;	O
Ito	O
and	O
Miyazono	O
,	O
2003	O
)	O
.	O

TGF	O
-	O
beta	O
can	O
activate	B-Positive_regulation
RUNX	O
genes	O
at	O
the	O
transcriptional	B-Transcription
level	O
,	O
and	O
at	O
the	O
posttranscriptional	O
level	O
through	O
activation	B-Positive_regulation
or	O
stabilization	O
of	O
RUNX	O
proteins	O
(	O
Jin	O
et	O
al.	O
,	O
2004	O
)	O
.	O

It	O
was	O
shown	O
that	O
RUNX2	O
regulates	B-Regulation
the	O
expression	B-Gene_expression
of	O
TGF	O
-	O
beta	O
type	O
I	O
receptor	O
(	O
Ji	O
et	O
al.	O
,	O
2001	O
)	O
,	O
suggesting	O
that	O
other	O
mechanisms	O
for	O
their	O
function	O
could	O
be	O
involved	O
.	O

The	O
fusion	O
proteins	O
RUNX1	O
-	O
EVI1	O
and	O
RUNX1	O
-	O
ETO	O
block	O
TGF	O
-	O
beta	O
inhibition	O
of	O
leukemic	O
cell	O
growth	O
.	O

RUNX3	O
plays	O
an	O
important	O
role	O
in	O
TGF-beta	O
-	O
mediated	O
growth	O
control	O
in	O
epithelial	O
cells	O
,	O
as	O
loss	B-Negative_regulation
of	O
RUNX3	O
leads	O
to	O
decreased	O
sensitivity	O
to	O
TGF	O
-	O
beta	O
and	O
hyperproliferation	O
of	O
the	O
gastric	O
mucosa	O
(	O
Blyth	O
et	O
al.	O
,	O
2005	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
RUNX3	O
expression	B-Gene_expression
is	O
more	O
dominant	O
in	O
circulating	O
human	O
T	O
reg	O
cells	O
and	O
tonsil	O
T	O
reg	O
cells	O
compared	O
with	O
RUNX1	O
.	O

This	O
could	O
be	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
cells	O
and	O
organ	O
from	O
which	O
they	O
were	O
isolated	O
.	O

We	O
observed	O
that	O
single	O
siRNA	O
interference	B-Negative_regulation
of	O
either	O
RUNX1	O
or	O
RUNX3	O
alone	O
shows	O
a	O
slight	O
decrease	B-Negative_regulation
in	O
Foxp3+	O
T	O
reg	O
cell	O
induction	B-Positive_regulation
,	O
which	O
could	O
be	O
caused	O
by	O
redundancy	O
of	O
these	O
proteins	O
.	O

For	O
this	O
reason	O
,	O
we	O
decided	O
to	O
use	O
CbfbetaF/F	O
CD4	O
-	O
cre	O
mice	O
.	O

Foxp3	O
induction	B-Positive_regulation
by	O
TGF	O
-	O
beta	O
is	O
reduced	B-Negative_regulation
in	O
CD4+	O
T	O
cells	O
of	O
CbfbF/F	O
CD4	O
-	O
cre	O
mice	O
compared	O
with	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
.	O

Retinoic	O
acid	O
is	O
secreted	O
by	O
a	O
subset	O
of	O
dendritic	O
cells	O
in	O
the	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
.	O

It	O
inhibits	O
the	O
IL-6	O
-	O
driven	O
induction	O
of	O
Th17	O
cells	O
and	O
facilitates	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
to	O
Foxp3+	O
T	O
reg	O
cells	O
(	O
Mucida	O
et	O
al.	O
,	O
2007	O
)	O
.	O

We	O
observed	O
an	O
increased	B-Positive_regulation
number	O
of	O
Foxp3+	O
cells	O
by	O
retinoic	O
acid	O
and	O
TGF	O
-	O
beta	O
compared	O
with	O
TGF	O
-	O
beta	O
treatment	O
alone	O
in	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
and	O
CbfbF/F	O
CD4	O
-	O
cre	O
mice	O
.	O

In	O
addition	O
,	O
we	O
showed	O
a	O
defective	O
in	O
vivo	O
generation	O
of	O
T	O
reg	O
cells	O
from	O
Cbfb	O
-	O
deficient	B-Negative_regulation
CD4+	O
T	O
cells	O
in	O
Rag2-/	O
-	O
mice	O
.	O

These	O
data	O
in	O
mice	O
confirm	O
the	O
human	O
data	O
that	O
RUNX	O
proteins	O
play	O
an	O
important	B-Positive_regulation
role	I-Positive_regulation
for	O
TGF-beta	O
-	O
dependent	B-Positive_regulation
FOXP3	O
induction	B-Gene_expression
,	O
as	O
well	O
as	O
in	O
the	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
.	O

As	O
an	O
additional	O
support	O
for	O
this	O
concept	O
,	O
the	O
overexpression	B-Gene_expression
of	O
RUNX1	O
induced	B-Positive_regulation
increased	B-Positive_regulation
FOXP3	O
protein	O
expression	B-Gene_expression
without	O
any	O
requirement	B-Positive_regulation
of	O
TGF	O
-	O
beta	O
and	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
stimulation	O
in	O
human	O
primary	O
CD4+	O
cells	O
.	O

In	O
both	O
human	O
and	O
mouse	O
systems	O
,	O
reduced	B-Negative_regulation
Foxp3	O
expression	B-Gene_expression
was	O
associated	O
with	O
reduced	O
T	O
reg	O
cell	O
suppressive	O
activity	O
.	O

In	O
a	O
recent	O
study	O
,	O
the	O
role	O
of	O
Runx	O
-	O
CBFbeta	O
was	O
investigated	O
in	O
nT	O
reg	O
cell	O
development	O
in	O
the	O
thymus	O
(	O
Rudra	O
et	O
al.	O
,	O
2009	O
)	O
.	O

It	O
was	O
reported	O
that	O
Foxp3	O
expression	B-Gene_expression
in	O
nT	O
reg	O
cells	O
is	O
unstable	O
in	O
the	O
absence	O
of	O
Runx	O
-	O
CBFbeta	O
complexes	O
.	O

Cbfb	O
-	O
deficient	B-Negative_regulation
nT	O
reg	O
cells	O
progressively	O
lose	B-Negative_regulation
Foxp3	O
upon	O
division	O
,	O
and	O
there	O
is	O
no	O
evidence	O
of	O
increased	O
death	O
of	O
Cbfb	O
-	O
deficient	B-Negative_regulation
nT	O
reg	O
cells	O
in	O
that	O
study	O
.	O

The	O
experiments	O
in	O
Cbfb	O
-	O
deficient	B-Negative_regulation
CD4	O
-	O
cre	O
T	O
cells	O
in	O
mice	O
and	O
the	O
knockdown	O
experiments	O
in	O
humans	O
in	O
this	O
study	O
suggest	O
that	O
the	O
induction	B-Positive_regulation
of	O
Foxp3	O
expression	B-Gene_expression
is	O
a	O
major	O
contributing	O
factor	O
in	O
the	O
in	O
vivo	O
conversion	O
experiment	O
.	O

Here	O
,	O
we	O
observed	O
that	O
there	O
is	O
a	O
twofold	O
increased	B-Positive_regulation
Foxp3+	O
iT	O
reg	O
cell	O
generation	O
in	O
vivo	O
.	O

This	O
is	O
in	O
the	O
same	O
range	O
with	O
previously	O
published	O
studies	O
targeting	O
different	O
mechanisms	O
in	O
Foxp3	O
induction	B-Positive_regulation
(	O
Maynard	O
et	O
al.	O
,	O
2007	O
;	O
Sun	O
et	O
al.	O
,	O
2007	O
)	O
.	O

Whether	O
the	O
diminished	B-Negative_regulation
capacity	O
of	O
Cbfb	O
-	O
deficient	B-Negative_regulation
CD4	O
-	O
cre	O
T	O
cells	O
in	O
the	O
generation	B-Gene_expression
of	O
Foxp3	O
may	O
be	O
caused	B-Positive_regulation
by	O
peripheral	O
expansion	O
of	O
Cbfb	O
-	O
deficient	B-Negative_regulation
non	O
-	O
T	O
reg	O
cells	O
or	O
survival	O
problems	O
faced	O
by	O
Cbfb	O
-	O
deficient	B-Negative_regulation
iT	O
reg	O
cells	O
after	O
Foxp3	O
induction	B-Positive_regulation
remains	O
to	O
be	O
elucidated	O
.	O

The	O
involvement	B-Regulation
of	O
RUNX	O
proteins	O
in	O
autoimmune	O
diseases	O
has	O
been	O
previously	O
suggested	O
(	O
Alarcon	O
-	O
Riquelme	O
,	O
2003	O
)	O
.	O

A	O
mutation	O
in	O
the	O
RUNX1	O
binding	O
site	O
in	O
the	O
promoter	O
of	O
programmed	O
cell	O
death	O
1	O
gene	O
(	O
PDCD	O
-	O
1	O
)	O
has	O
been	O
implicated	O
in	O
systemic	O
lupus	O
erythematosus	O
pathogenesis	O
(	O
Prokunina	O
et	O
al.	O
,	O
2002	O
)	O
.	O

Polymorphisms	O
that	O
alter	B-Regulation
RUNX1	O
binding	B-Binding
to	O
other	O
genes	O
have	O
also	O
been	O
described	O
in	O
rheumatoid	O
arthritis	O
linkage	O
at	O
5q31	O
in	O
Japanese	O
patients	O
(	O
Tokuhiro	O
et	O
al.	O
,	O
2003	O
)	O
and	O
in	O
a	O
psoriasis	O
linkage	O
at	O
17q25	O
(	O
Prokunina	O
et	O
al.	O
,	O
2002	O
;	O
Helms	O
et	O
al.	O
,	O
2003	O
)	O
.	O

RUNX3	O
-	O
deficient	B-Negative_regulation
mice	O
spontaneously	O
develop	O
inflammatory	O
bowel	O
disease	O
and	O
hyperplastic	O
gastritis	O
-	O
like	O
lesions	O
(	O
Brenner	O
et	O
al.	O
,	O
2004	O
)	O
.	O

These	O
disease	O
symptoms	O
resemble	O
those	O
occurring	O
after	O
depletion	B-Negative_regulation
of	O
Foxp3	O
-	O
expressing	B-Gene_expression
T	O
reg	O
cells	O
(	O
Sakaguchi	O
,	O
2004	O
)	O
.	O

Derepression	O
of	O
Th2	O
cytokines	O
might	O
also	O
account	O
for	O
some	O
of	O
the	O
observed	O
disease	O
symptoms	O
,	O
as	O
it	O
was	O
shown	O
that	O
T	O
-	O
bet	O
first	O
induces	B-Positive_regulation
Runx3	O
in	O
Th1	O
cells	O
and	O
then	O
partners	B-Binding
with	O
Runx3	O
to	O
direct	O
lineage	O
-	O
specific	O
gene	O
activation	O
.	O

Runx3/Cbfbeta	O
are	O
both	O
required	B-Positive_regulation
for	O
the	O
activation	B-Positive_regulation
of	O
the	O
Ifng	O
gene	O
and	O
silencing	B-Negative_regulation
of	O
the	O
Il4	O
gene	O
in	O
Th1	O
cells	O
(	O
Djuretic	O
et	O
al.	O
,	O
2007	O
;	O
Naoe	O
et	O
al.	O
,	O
2007	O
)	O
.	O

Runx	O
proteins	O
also	O
play	O
an	O
essential	O
role	O
during	O
T	O
lymphocyte	O
differentiation	O
in	O
the	O
thymus	O
(	O
Taniuchi	O
et	O
al.	O
,	O
2002	O
)	O
.	O

Runx1	O
regulates	O
the	O
transitions	O
of	O
developing	O
thymocytes	O
from	O
the	O
CD4	O
-	O
CD8	O
-	O
double	O
-	O
negative	O
stage	O
to	O
the	O
CD4+	O
CD8+	O
double	O
-	O
positive	O
stage	O
and	O
from	O
the	O
DP	O
stage	O
to	O
the	O
mature	O
single	O
-	O
positive	O
stage	O
(	O
Egawa	O
et	O
al.	O
,	O
2007	O
)	O
.	O

Runx1	O
and	O
Runx3	O
deficiencies	B-Negative_regulation
caused	O
marked	O
reductions	O
in	O
mature	O
thymocytes	O
and	O
T	O
cells	O
of	O
the	O
CD4+	O
helper	O
and	O
CD8+	O
cytotoxic	O
T	O
cell	O
lineages	O
.	O

In	O
addition	O
,	O
inactivation	B-Negative_regulation
of	O
both	O
Runx1	O
and	O
Runx3	O
at	O
the	O
double	O
-	O
positive	O
stages	O
resulted	O
in	O
a	O
severe	O
blockage	O
in	O
the	O
development	O
of	O
CD8+	O
mature	O
thymocytes	O
.	O

These	O
results	O
indicate	O
that	O
Runx	O
proteins	O
have	O
important	O
roles	O
at	O
multiple	O
stages	O
of	O
T	O
cell	O
development	O
and	O
in	O
the	O
homeostasis	O
of	O
mature	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
they	O
may	O
play	O
a	O
role	O
in	O
nT	O
reg	O
cell	O
development	O
,	O
which	O
remains	O
to	O
be	O
elucidated	O
.	O

Furthermore	O
,	O
it	O
was	O
shown	O
that	O
Runx1	O
activates	B-Positive_regulation
IL	O
-	O
2	O
and	O
IFN	O
-	O
gamma	O
gene	O
expression	B-Gene_expression
in	O
conventional	O
CD4+	O
T	O
cells	O
by	O
binding	B-Binding
to	O
their	O
respective	O
promoter	O
.	O

RUNX1	O
interacts	B-Binding
physically	O
with	O
Foxp3	O
protein	O
,	O
and	O
it	O
was	O
demonstrated	O
that	O
this	O
interaction	O
might	O
be	O
responsible	B-Positive_regulation
for	O
the	O
suppression	B-Negative_regulation
of	O
IL	O
-	O
2	O
and	O
IFN	O
-	O
gamma	O
production	B-Gene_expression
and	O
up	O
-	O
regulation	O
of	O
T	O
reg	O
cell	O
-	O
associated	O
molecules	O
(	O
Ono	O
et	O
al.	O
,	O
2007	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
Foxp3	O
also	O
influences	O
Th17	O
differentiation	O
.	O

Specifically	O
,	O
Foxp3	O
physically	O
interacts	B-Binding
with	O
RORgammat	O
,	O
and	O
this	O
interaction	O
inhibits	B-Negative_regulation
RORgammat	O
function	O
(	O
Zhou	O
et	O
al.	O
,	O
2008	O
)	O
.	O

This	O
relationship	O
of	O
RORgammat	O
and	O
Foxp3	O
and	O
probably	O
yet	O
unknown	O
mechanisms	O
might	O
be	O
the	O
basis	O
of	O
the	O
observation	O
that	O
the	O
differentiation	O
of	O
Th17	O
cells	O
and	O
T	O
reg	O
cells	O
is	O
often	O
reciprocal	O
(	O
Bettelli	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Recently	O
,	O
data	O
suggests	O
that	O
Runx1	O
may	O
also	O
be	O
involved	O
in	O
regulating	B-Regulation
Il17	O
transcription	B-Transcription
,	O
functioning	O
in	O
complex	O
with	O
RORgammat	O
to	O
activate	O
transcription	O
(	O
Zhang	O
et	O
al.	O
,	O
2008	O
)	O
.	O

The	O
Runx3	O
-	O
deficient	B-Negative_regulation
mice	O
develop	O
spontaneous	O
Th2	O
-	O
dominated	O
autoimmune	O
colitis	O
and	O
asthma	O
(	O
Brenner	O
et	O
al.	O
,	O
2004	O
;	O
Fainaru	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Cbfbf/f	O
Cd4	O
mice	O
also	O
show	O
a	O
spontaneous	O
Th2	O
dominated	O
disease	O
,	O
with	O
increased	O
serum	O
IgA	O
,	O
IgG1	O
,	O
and	O
IgE	O
titers	O
and	O
lymphocyte	O
and	O
eosinophil	O
infiltration	O
of	O
the	O
lung	O
(	O
Naoe	O
et	O
al.	O
,	O
2007	O
)	O
.	O

All	O
these	O
phenotypes	O
were	O
previously	O
attributed	O
to	O
a	O
loss	O
of	O
Th2	O
silencing	O
whereas	O
our	O
findings	O
additionally	O
suggest	O
that	O
loss	O
of	O
T	O
reg	O
function	O
plays	O
a	O
role	O
.	O

We	O
have	O
shown	O
a	O
link	O
between	O
Foxp3	O
induction	B-Gene_expression
in	O
iT	O
reg	O
cells	O
and	O
RUNX1	O
and	O
RUNX3	O
.	O

RUNX	O
proteins	O
play	O
a	O
central	O
role	O
in	O
pathways	O
regulating	O
cell	O
growth	O
and	O
differentiation	O
,	O
and	O
their	O
interaction	B-Binding
with	O
the	O
TGF	O
-	O
beta	O
pathway	O
is	O
of	O
particular	O
interest	O
.	O

Foxp3	O
protein	O
interacts	B-Binding
not	O
only	O
with	O
RUNX	O
proteins	O
but	O
also	O
with	O
several	O
other	O
transcriptional	O
partners	O
,	O
such	O
as	O
NFAT	O
and	O
possibly	O
NF	O
-	O
kappaB	O
;	O
with	O
histone	O
acetyl	O
transferases	O
,	O
such	O
as	O
TIP60	O
;	O
and	O
histone	O
deacetyl	O
transferase	O
(	O
HDAC	O
)	O
complexes	O
,	O
such	O
as	O
HDAC7	O
and	O
HDAC9	O
(	O
Wu	O
et	O
al.	O
,	O
2006	O
;	O
Sakaguchi	O
et	O
al.	O
,	O
2008	O
)	O
.	O

NFAT	O
forms	B-Binding
a	I-Binding
complex	I-Binding
with	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
and	O
regulates	B-Regulation
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
2	O
,	O
IL	O
-	O
4	O
,	O
IFN	O
-	O
gamma	O
,	O
and	O
CTLA4	O
in	O
conventional	O
T	O
cells	O
,	O
which	O
leads	O
to	O
the	O
activation	O
and	O
differentiation	O
to	O
effector	O
T	O
cells	O
(	O
Dolganov	O
et	O
al.	O
,	O
1996	O
;	O
Hu	O
et	O
al.	O
,	O
2007	O
)	O
.	O

The	O
NFAT-AP	O
-	O
1	O
complex	O
also	O
binds	B-Binding
to	O
the	O
Foxp3	O
promoter	O
after	O
TCR	O
triggering	O
and	O
regulates	B-Positive_regulation
its	O
gene	O
expression	B-Gene_expression
positively	O
(	O
Mantel	O
et	O
al.	O
,	O
2006	O
)	O
.	O

It	O
was	O
shown	O
that	O
NFAT	O
and	O
Smad3	O
cooperate	O
to	O
induce	B-Positive_regulation
Foxp3	O
expression	B-Gene_expression
through	O
its	O
enhancer	O
(	O
Tone	O
et	O
al.	O
,	O
2008	O
)	O
,	O
but	O
no	O
TGF	O
-	O
beta	O
response	O
element	O
was	O
identified	O
in	O
the	O
Foxp3	O
gene	O
or	O
in	O
the	O
surrounding	O
regions	O
.	O

The	O
initial	O
induction	B-Positive_regulation
of	O
RUNX1	O
and	O
RUNX3	O
and	O
the	O
subsequent	O
binding	B-Binding
of	O
these	O
transcription	O
factors	O
to	O
the	O
Foxp3	O
promoter	O
that	O
we	O
showed	O
here	O
might	O
explain	O
the	O
relatively	O
late	O
induction	B-Transcription
of	O
Foxp3	O
mRNA	O
that	O
peaks	O
24	O
-	O
48	O
h	O
after	O
stimulation	O
.	O

The	O
interaction	B-Binding
of	O
Foxp3	O
and	O
NFAT	O
is	O
dependent	B-Regulation
on	O
their	O
cooperative	O
binding	B-Binding
to	O
DNA	O
(	O
Wu	O
et	O
al.	O
,	O
2006	O
)	O
.	O

RUNX1	O
alone	O
,	O
or	O
together	O
with	O
its	O
interacting	B-Binding
partners	O
p300	O
and	O
CREB	O
-	O
binding	B-Binding
protein	O
,	O
may	O
cooperate	O
with	O
the	O
NFAT	O
transcription	O
complex	O
to	O
activate	B-Positive_regulation
the	O
IL	O
-	O
2	O
promoter	O
(	O
Sakaguchi	O
et	O
al.	O
,	O
2008	O
)	O
.	O

Similar	O
to	O
this	O
interaction	O
,	O
NFAT	O
may	O
also	O
cooperate	O
with	O
RUNX1	O
or	O
RUNX3	O
to	O
activate	B-Positive_regulation
Foxp3	O
,	O
but	O
further	O
studies	O
are	O
necessary	O
to	O
elaborate	O
on	O
this	O
concept	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
elucidate	O
the	O
role	O
of	O
RUNX	O
proteins	O
in	O
iT	O
reg	O
cell	O
development	O
and	O
function	O
.	O

The	O
induction	B-Positive_regulation
of	O
the	O
transcription	O
factors	O
RUNX1	O
and	O
RUNX3	O
by	O
TGF	O
-	O
beta	O
and	O
the	O
subsequent	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
Foxp3	O
play	O
a	O
role	O
in	O
iT	O
reg	O
cell	O
generation	O
and	O
its	O
suppressive	O
capacity	O
.	O

Mice	O
.	O

CbfbF/F	O
CD4	O
-	O
cre	O
and	O
Foxp3GFP	O
mice	O
have	O
previously	O
been	O
described	O
(	O
Bettelli	O
et	O
al.	O
,	O
2006	O
;	O
Naoe	O
et	O
al.	O
,	O
2007	O
)	O
.	O

Cd45.1	O
and	O
Rag2-/	O
-	O
mice	O
were	O
purchased	O
from	O
Jackson	O
ImmunoResearch	O
Laboratories	O
and	O
Taconic	O
,	O
respectively	O
.	O

For	O
the	O
in	O
vivo	O
Foxp3	O
conversion	O
assay	O
,	O
naive	O
CD4+	O
T	O
cells	O
from	O
Cbfb	O
CD4	O
-	O
cre	O
or	O
control	O
mice	O
(	O
harboring	O
a	O
Foxp3-IRES	O
-	O
GFP	O
allele	O
)	O
were	O
adoptively	O
transferred	O
into	O
Rag	O
-	O
deficient	B-Negative_regulation
mice	O
.	O

5	O
x	O
106	O
cells	O
were	O
used	O
per	O
transfer	O
.	O

6	O
wk	O
later	O
,	O
TCRbeta+CD4+	O
gated	O
cells	O
from	O
the	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
(	O
MLN	O
)	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
were	O
analyzed	O
for	O
Foxp3	O
-	O
GFP	O
expression	B-Gene_expression
.	O

All	O
analyses	O
and	O
experiments	O
were	O
performed	O
on	O
animals	O
at	O
6	O
-	O
8	O
wk	O
of	O
age	O
.	O

Animals	O
were	O
housed	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
at	O
the	O
animal	O
facility	O
of	O
the	O
Skirball	O
Institute	O
,	O
and	O
experiments	O
were	O
performed	O
in	O
accordance	O
with	O
approved	O
protocols	O
for	O
the	O
New	O
York	O
University	O
Institutional	O
Animal	O
Care	O
and	O
Usage	O
Committee	O
.	O

Isolation	O
of	O
PBMCs	O
,	O
CD4+	O
T	O
cells	O
,	O
and	O
culture	O
conditions	O
.	O

Human	O
PBMCs	O
were	O
isolated	O
by	O
Ficoll	O
(	O
Biochrom	O
)	O
density	O
gradient	O
centrifugation	O
and	O
CD4+	O
T	O
cells	O
were	O
then	O
isolated	O
using	O
the	O
Dynal	O
CD4+	O
Isolation	O
kit	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
purity	O
of	O
CD4+	O
T	O
cells	O
was	O
initially	O
tested	O
by	O
flow	O
cytometry	O
and	O
was	O
>	O
/=95	O
%	O
.	O

Cells	O
were	O
stimulated	O
with	O
the	O
following	O
combination	O
of	O
mAbs	O
to	O
T	O
cell	O
surface	O
molecules	O
(	O
Meiler	O
et	O
al.	O
,	O
2008	O
)	O
:	O
anti	O
-	O
CD2	O
(	O
clone	O
4B2	O
and	O
6G4	O
;	O
0.5	O
microg/ml	O
)	O
,	O
anti	O
-	O
CD3	O
(	O
clone	O
OKT3	O
;	O
0.5	O
microg/ml	O
)	O
,	O
and	O
anti	O
-	O
CD28	O
mAb	O
(	O
clone	O
B7G5	O
;	O
0.5	O
microg/ml	O
;	O
all	O
from	O
Sanquin	O
)	O
and	O
cultured	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
(	O
Life	O
Technologies	O
)	O
with	O
the	O
addition	O
of	O
1	O
nmol/liter	O
IL	O
-	O
2	O
(	O
Roche	O
)	O
.	O

TGF	O
-	O
beta	O
(	O
R	O
&	O
D	O
Systems	O
)	O
was	O
used	O
at	O
5	O
ng/ml	O
,	O
if	O
not	O
stated	O
otherwise	O
.	O

A	O
combination	O
of	O
PMA	O
(	O
25	O
ng/ml	O
)	O
and	O
ionomycin	O
(	O
1	O
mg/ml	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
used	O
.	O

Human	O
CD4+	O
CD127	O
-	O
CD25high	O
and	O
CD4+	O
CD127+	O
CD25neg	O
cells	O
were	O
purified	O
by	O
flow	O
cytometry	O
using	O
anti	O
-	O
CD127	O
,	O
anti-CD25	O
-	O
PC5	O
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
anti-CD4	O
-	O
FITC	O
antibodies	O
(	O
Dako	O
)	O
.	O

Mouse	O
naive	O
(	O
CD62Lhi44lo25	O
-	O
)	O
CD4+	O
T	O
cells	O
were	O
purified	O
by	O
flow	O
cytometry	O
and	O
activated	O
in	O
vitro	O
with	O
5	O
microg/ml	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	O
and	O
1	O
microg/ml	O
soluble	O
anti	O
-	O
CD28	O
antibodies	O
(	O
eBioscience	O
)	O
in	O
RPMI	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
5	O
mM	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
antibiotics	O
.	O

Neutralizing	O
anti-IFN	O
-	O
gamma	O
and	O
anti-IL	O
-	O
4	O
mAbs	O
(	O
BD	O
)	O
were	O
used	O
at	O
1	O
microg/ml	O
concentrations	O
when	O
indicated	O
.	O

In	O
vitro	O
T	O
cell	O
differentiation	O
.	O

CD4+	O
CD45RA+	O
magnetically	O
sorted	O
(	O
CD45RO	O
depletion	B-Negative_regulation
with	O
AutoMACS	O
;	O
Miltenyi	O
Biotec	O
)	O
cells	O
were	O
stimulated	O
with	O
immobilized	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	O
(	O
1	O
microg/ml	O
;	O
OKT3	O
;	O
IgG1	O
)	O
and	O
anti	O
-	O
CD28	O
(	O
2	O
microg/ml	O
)	O
.	O

For	O
Th1	O
differentiation	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng/ml	O
IL	O
-	O
2	O
,	O
5	O
microg/ml	O
anti-IL	O
-	O
4	O
,	O
and	O
25	O
ng/ml	O
IL	O
-	O
12	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
Th2	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng/ml	O
IL	O
-	O
2	O
,	O
25	O
ng/ml	O
IL	O
-	O
4	O
,	O
and	O
5	O
microg/ml	O
anti-IL	O
-	O
12	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
T	O
reg	O
cell	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng/ml	O
IL	O
-	O
2	O
,	O
5	O
ng/ml	O
TGF	O
-	O
beta	O
,	O
5	O
microg/ml	O
anti-IL	O
-	O
12	O
,	O
5	O
microg/ml	O
anti-IL	O
-	O
4	O
.	O

For	O
Th17	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng/ml	O
IL	O
-	O
2	O
,	O
20	O
ng/ml	O
IL	O
-	O
6	O
,	O
5	O
ng/ml	O
TGF	O
-	O
beta	O
,	O
20	O
ng/ml	O
IL	O
-	O
23	O
(	O
Alexis	O
Biochemicals	O
Corp.	O
)	O
,	O
10	O
ng/ml	O
IL	O
-	O
1beta	O
,	O
5	O
microg/ml	O
anti-IL	O
-	O
4	O
,	O
and	O
5	O
microg/ml	O
anti-IL	O
-	O
12	O
were	O
used	O
.	O

Proliferating	O
cells	O
were	O
expanded	O
in	O
medium	O
containing	O
IL	O
-	O
2	O
.	O

The	O
cytokine	O
profile	O
of	O
these	O
cells	O
demonstrated	O
that	O
IFN	O
-	O
gamma	O
is	O
the	O
predominant	O
cytokine	O
in	O
Th1	O
cells	O
,	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
in	O
Th2	O
cells	O
,	O
and	O
IL	O
-	O
17	O
in	O
Th17	O
cells	O
(	O
Akdis	O
et	O
al.	O
,	O
2000	O
;	O
Burgler	O
et	O
al.	O
,	O
2009	O
)	O
.	O

Immunohistochemistry	O
.	O

Human	O
tonsils	O
were	O
obtained	O
from	O
tonsillectomy	O
samples	O
of	O
hypertrophic	O
and	O
obstructive	O
tonsils	O
without	O
a	O
current	O
infection	O
.	O

Ethical	O
permission	O
was	O
obtained	O
from	O
Cantonal	O
Ethics	O
Commission	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
patients	O
.	O

Paraformaldehyde	O
-	O
fixed	O
tonsil	O
cryosections	O
were	O
stained	O
with	O
unconjugated	O
rabbit	O
IgG	O
polyclonal	O
antibody	O
to	O
human	O
RUNX1	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
or	O
unconjugated	O
mouse	O
IgG1	O
mAb	O
to	O
human	O
RUNX3	O
(	O
Abcam	O
)	O
.	O

After	O
a	O
washing	O
step	O
,	O
the	O
sections	O
were	O
stained	O
with	O
the	O
corresponding	O
secondary	O
antibodies	O
.	O

RUNX1	O
-	O
binding	B-Binding
antibodies	O
were	O
detected	O
by	O
using	O
Alexa	O
Fluor	O
633	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
and	O
RUNX3	O
-	O
binding	B-Binding
antibodies	O
were	O
detected	O
by	O
using	O
Alexa	O
Fluor	O
532	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG1	O
.	O

Afterward	O
,	O
the	O
sections	O
were	O
washed	O
and	O
in	O
the	O
case	O
of	O
RUNX3	O
staining	O
a	O
blocking	O
step	O
with	O
an	O
unconjugated	O
mouse	O
IgG1	O
mAb	O
was	O
used	O
.	O

Finally	O
,	O
the	O
sections	O
were	O
stained	O
with	O
Alexa	O
Fluor	O
488	O
-	O
conjugated	O
mouse	O
IgG1	O
mAb	O
to	O
human	O
FOXP3	O
(	O
eBioscience	O
)	O
or	O
the	O
corresponding	O
isotype	O
control	O
.	O

Tissue	O
sections	O
were	O
stained	O
with	O
DAPI	O
for	O
the	O
demonstration	O
of	O
nuclei	O
and	O
mounted	O
with	O
Prolong	O
antifade	O
(	O
Invitrogen	O
)	O
.	O

Images	O
were	O
acquired	O
and	O
analyzed	O
using	O
the	O
confocal	O
microscope	O
DMI	O
4000B	O
and	O
the	O
TCS	O
SPE	O
system	O
(	O
both	O
from	O
Leica	O
)	O
.	O

In	O
vitro	O
suppression	O
assays	O
.	O

Mouse	O
Foxp3+	O
CD4+	O
CD8	O
-	O
T	O
cells	O
were	O
FACS	O
purified	O
based	O
on	O
GFP	O
expressed	B-Gene_expression
from	O
a	O
Foxp3-IRES	O
-	O
GFP	O
knock	O
-	O
in	O
allele	O
(	O
Foxp3GFP	O
)	O
.	O

Naive	O
(	O
CD62Lhi44lo25	O
-	O
)	O
CD4+	O
T	O
cells	O
(	O
effectors	O
)	O
were	O
FACS	O
-	O
purified	O
from	O
Cd45.1	O
mice	O
,	O
then	O
loaded	O
with	O
5	O
microM	O
CFSE	O
(	O
Invitrogen	O
)	O
.	O

Total	O
splenocytes	O
from	O
C57BL/6	O
mice	O
inactivated	O
with	O
50	O
microg/ml	O
mitomycin	O
C	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
for	O
45	O
min	O
were	O
used	O
as	O
APCs	O
.	O

A	O
total	O
of	O
4	O
x	O
105	O
CD4+	O
cells	O
(	O
CFSE	O
-	O
loaded	O
CD25	O
-	O
plus	O
Foxp3	O
-	O
GFP+	O
)	O
was	O
mixed	O
with	O
105	O
APCs	O
+	O
1	O
microg/ml	O
anti	O
-	O
CD3	O
mAb	O
per	O
well	O
of	O
a	O
96	O
well	O
round	O
bottom	O
plate	O
.	O

Proliferation	O
of	O
the	O
effector	O
cells	O
was	O
analyzed	O
by	O
CFSE	O
dilution	O
.	O

Apoptosis	O
of	O
the	O
cells	O
was	O
investigated	O
by	O
annexin	O
V	O
staining	O
and	O
flow	O
cytometry	O
.	O

Positive	O
and	O
negative	O
control	O
gates	O
were	O
made	O
according	O
to	O
T	O
cells	O
cultured	O
only	O
in	O
the	O
presence	O
of	O
IL	O
-	O
2	O
without	O
anti	O
-	O
CD3/28	O
stimulation	O
.	O

Human	O
naive	O
CD4+	O
T	O
cells	O
were	O
isolated	O
by	O
negative	O
selection	O
by	O
MACS	O
from	O
PBMCs	O
and	O
either	O
transfected	O
with	O
a	O
scrambled	O
siRNA	O
or	O
with	O
a	O
combination	O
of	O
RUNX1	O
and	O
RUNX3	O
siRNA	B-Negative_regulation
.	O

Cells	O
were	O
then	O
cultured	O
under	O
iT	O
reg	O
cell	O
differentiating	O
conditions	O
and	O
mixed	O
with	O
2	O
x	O
105	O
autologous	O
irradiated	O
PBMCs	O
that	O
were	O
used	O
as	O
APCs	O
and	O
autologous	O
CFSE	O
-	O
labeled	O
CD4+	O
T	O
cells	O
.	O

T	O
reg	O
cell	O
to	O
responder	O
cell	O
ratio	O
was	O
1	O
:	O
20	O
,	O
1	O
:	O
10	O
,	O
and	O
1	O
:	O
5	O
.	O

To	O
check	O
the	O
proliferation	O
of	O
the	O
CD4+	O
T	O
cells	O
without	O
suppression	O
,	O
no	O
T	O
reg	O
cells	O
were	O
added	O
in	O
a	O
control	O
group	O
.	O

Cells	O
were	O
stimulated	O
with	O
2.5	O
microg/ml	O
anti	O
-	O
CD3	O
mAb	O
,	O
cultured	O
in	O
a	O
96	O
-	O
well	O
plate	O
and	O
the	O
proliferation	O
of	O
the	O
effector	O
cells	O
was	O
determined	O
by	O
analyzing	O
the	O
CFSE	O
dilution	O
by	O
flow	O
cytometry	O
after	O
5	O
d	O
of	O
culture	O
.	O

Gating	O
on	O
the	O
CD4+CFSE+	O
T	O
cells	O
enabled	O
the	O
exclusion	O
of	O
APCs	O
and	O
T	O
reg	O
cells	O
.	O

Cloning	O
of	O
the	O
FOXP3	O
promoter	O
,	O
construction	O
of	O
mutant	O
FOXP3	O
promoter	O
,	O
and	O
RUNX	O
expression	B-Gene_expression
plasmids	O
.	O

The	O
FOXP3	O
promoter	O
was	O
cloned	O
into	O
the	O
pGL3	O
basic	O
vector	O
(	O
Promega	O
Biotech	O
)	O
to	O
generate	O
pGL3	O
FOXP3	O
-	O
511/+176	O
(	O
Mantel	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
for	O
the	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	O
promoter	O
region	O
was	O
introduced	O
using	O
the	O
QuickChange	O
kit	O
(	O
Stratagene	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
and	O
confirmed	O
by	O
sequencing	O
the	O
DNA	O
.	O

The	O
following	O
primers	O
and	O
their	O
complementary	O
strands	O
were	O
used	O
:	O
foxp	O
runx	O
-	O
333	O
,	O
forward	O
5'-CACTTTTGTTTTAAAAACTGTCCTTTCTCATGAGCCCTATTATC	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
333	O
reverse	O
5'-GATAATAGGGCTCATGAGAAAGGACAGTTTTTAAAACAAAAGTG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
287	O
forward	O
5'-CCTCTCACCTCTGTCCTGAGGGGAAGAAATC	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
287	O
reverse	O
5'-GATTTCTTCCCCTCAGGACAGAGGTGAGAGG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
53	O
forward	O
5'-GCTTCCACACCGTACAGCGTCCTTTTTCTTCTCGGTATAAAAG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
53	O
reverse	O
5'-CTTTTATACCGAGAAGAAAAAGGACGCTGTACGGTGTGGAAGC	O
-	O
3	O
'	O
.	O

The	O
human	O
RUNX1	O
fragment	O
from	O
the	O
Addgene	O
plasmid	O
12504	O
(	O
Biggs	O
et	O
al.	O
,	O
2006	O
)	O
pFlagCMV2	O
-	O
AML1B	O
was	O
sub	O
-	O
cloned	O
in	O
the	O
pEGFPN1	O
vector	O
(	O
Clontech	O
Laboratories	O
)	O
.	O

The	O
RUNX3	O
vector	O
pCMV	O
human	O
RUNX3	O
,	O
which	O
was	O
a	O
gift	O
from	O
K	O
.	O

Ito	O
(	O
Institute	O
of	O
Molecular	O
and	O
Cell	O
Biology	O
,	O
Proteos	O
,	O
Singapore	O
)	O
was	O
subcloned	O
into	O
pEGFPN1	O
vector	O
(	O
Clontech	O
Laboratories	O
;	O
Yamamura	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Transfections	O
and	O
reporter	O
gene	O
assays	O
.	O

T	O
cells	O
were	O
rested	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
overnight	O
.	O

3.5	O
microg	O
of	O
the	O
FOXP3	O
promoter	O
luciferase	O
reporter	O
vector	O
or	O
a	O
combination	O
together	O
with	O
the	O
RUNX1	O
,	O
RUNX3	O
pEGFPN1	O
vector	O
,	O
and	O
0.5	O
microg	O
phRL	O
-	O
TK	O
were	O
added	O
to	O
3	O
x	O
106	O
CD4+	O
T	O
cells	O
resuspended	O
in	O
100	O
microl	O
of	O
Nucleofector	O
solution	O
(	O
Lonza	O
)	O
and	O
electroporated	O
using	O
the	O
program	O
U	O
-	O
15	O
.	O

After	O
a	O
24	O
-	O
h	O
culture	O
in	O
serum	O
-	O
free	O
conditions	O
and	O
stimuli	O
as	O
indicated	O
in	O
the	O
figures	O
,	O
luciferase	O
activity	O
was	O
measured	O
by	O
the	O
dual	O
luciferase	O
assay	O
system	O
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

PMA/ionomycin	O
was	O
used	O
to	O
stimulate	O
the	O
cells	O
,	O
because	O
the	O
transfection	O
was	O
only	O
transient	O
and	O
the	O
luciferase	O
assay	O
required	O
a	O
strong	O
and	O
fast	O
stimulation	O
of	O
the	O
cells	O
.	O

To	O
evaluate	O
the	O
effect	B-Regulation
of	O
overexpression	B-Gene_expression
of	O
RUNX1	O
or	O
RUNX3	O
on	O
FOXP3	O
protein	O
levels	O
,	O
CD4+	O
T	O
cells	O
were	O
preactivated	O
with	O
2	O
microg/ml	O
phytohemagglutinin	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
in	O
the	O
presence	O
of	O
1	O
nmol/liter	O
IL	O
-	O
2	O
(	O
Roche	O
)	O
for	O
12	O
h	O
,	O
and	O
then	O
transfected	B-Gene_expression
with	O
the	O
vector	O
pEGFPN1	O
containing	O
the	O
RUNX1	O
or	O
RUNX3	O
fragment	O
using	O
the	O
Nucleofector	O
system	O
(	O
Amaxa	O
Biosystems	O
)	O
and	O
the	O
program	O
T	O
-	O
23	O
.	O

FOXP3	O
expression	B-Gene_expression
was	O
evaluated	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
of	O
culture	O
in	O
AIM	O
-	O
V	O
medium	O
containing	O
1	O
nmol/liter	O
IL	O
-	O
2	O
.	O

RNA	O
interference	O
.	O

CD4+	O
or	O
naive	O
CD4+	O
T	O
cells	O
were	O
resuspended	O
in	O
100	O
microl	O
of	O
Nucleofector	O
solution	O
(	O
Lonza	O
)	O
and	O
electroporated	O
with	O
2	O
microM	O
siRNA	O
using	O
the	O
Nucleofector	O
technology	O
program	O
U	O
-	O
14	O
(	O
Lonza	O
)	O
.	O

Five	O
different	O
Silencer	O
or	O
Silencer	O
Select	O
Pre	O
-	O
designed	O
siRNAs	B-Negative_regulation
for	O
RUNX1	O
(	O
Applied	O
Biosystems	O
)	O
and	O
three	O
Silencer	O
Pre	O
-	O
designed	O
siRNAs	B-Negative_regulation
for	O
RUNX3	O
(	O
Applied	O
Biosystems	O
)	O
were	O
tested	O
,	O
and	O
the	O
best	O
was	O
selected	O
for	O
all	O
further	O
experiments	O
.	O

The	O
Silencer	O
Negative	O
Control	O
#	O
1	O
siRNA	O
(	O
Applied	O
Biosystems	O
)	O
was	O
used	O
for	O
normalization	O
.	O

Cells	O
were	O
then	O
left	O
unstimulated	O
or	O
were	O
stimulated	O
after	O
12	O
h	O
with	O
anti	O
-	O
CD2	O
,	O
anti	O
-	O
CD3	O
,	O
and	O
anti	O
-	O
CD28	O
.	O

Cells	O
were	O
cultured	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
with	O
the	O
addition	O
of	O
1	O
nmol/l	O
IL	O
-	O
2	O
(	O
Roche	O
)	O
.	O

Cells	O
were	O
harvested	O
for	O
mRNA	O
detection	O
of	O
the	O
target	O
genes	O
after	O
24	O
h	O
and	O
for	O
protein	O
detection	O
after	O
48	O
h	O
.	O

RNA	O
isolation	O
and	O
cDNA	O
synthesis	O
.	O

RNA	O
was	O
isolated	O
using	O
the	O
RNeasy	O
Mini	O
kit	O
(	O
QIAGEN	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Reverse	O
transcription	O
of	O
human	O
samples	O
was	O
performed	O
with	O
reverse	O
-	O
transcription	O
reagents	O
(	O
Fermentas	O
)	O
with	O
random	O
hexamers	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Real	O
-	O
time	O
PCR	O
.	O

PCR	O
primers	O
and	O
probes	O
were	O
designed	O
based	O
on	O
the	O
sequences	O
reported	O
in	O
GenBank	O
with	O
the	O
Primer	O
Express	O
software	O
version	O
1.2	O
(	O
Applied	O
Biosystems	O
)	O
as	O
follows	O
:	O
FOXP3	O
forward	O
primer	O
,	O
5'-GAAACAGCACATTCCCAGAGTTC	O
-	O
3	O
'	O
;	O
FOXP3	O
reverse	O
primer	O
,	O
5'-ATGGCCCAGCGGATGAG	O
-	O
3	O
'	O
;	O
EF	O
-	O
1a	O
forward	O
primer	O
,	O
5'-CTGAACCATCCAGGCCAAAT	O
-	O
3	O
'	O
;	O
and	O
EF	O
-	O
1a	O
reverse	O
primer	O
,	O
5'-GCCGTGTGGCAATCCAAT	O
-	O
3	O
'	O
,	O
as	O
previously	O
described	O
(	O
Mantel	O
et	O
al.	O
,	O
2007	O
)	O
.	O

GATA3	O
forward	O
primer	O
,	O
5'-GCGGGCTCTATCACAAAATGA	O
-	O
3	O
'	O
;	O
and	O
GATA3	O
reverse	O
primer	O
5'-GCTCTCCTGGCTGCAGACAGC	O
-	O
3	O
'	O
(	O
Mantel	O
et	O
al.	O
,	O
2007	O
)	O
.	O

T	O
-	O
bet	O
forward	O
primer	O
,	O
5'-GATGCGCCAGGAAGTTTCAT	O
-	O
3	O
'	O
;	O
T	O
-	O
bet	O
reverse	O
primer	O
,	O
5'-GCACAATCATCTGGGTCACATT	O
-	O
3	O
'	O
;	O
RORC2	O
forward	O
primer	O
,	O
5'-CAGTCATGAGAACACAAATTGAAGTG	O
-	O
3	O
'	O
;	O
and	O
RORC2	O
reverse	O
primer	O
5'-CAGGTGATAACCCCGTAGTGGAT	O
-	O
3	O
'	O
.	O

The	O
prepared	O
cDNAs	O
were	O
amplified	O
using	O
SYBR	O
green	O
PCR	O
master	O
mix	O
(	O
Fermentas	O
)	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
manufacturer	O
in	O
an	O
ABI	O
PRISM	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

RUNX1	O
and	O
RUNX3	O
mRNA	B-Transcription
was	O
detected	O
by	O
using	O
TaqMan	O
Gene	O
Expression	O
Assays	O
from	O
Applied	O
Biosystems	O
and	O
used	O
according	O
to	O
the	O
manufacturer	O
's	O
instruction	O
using	O
TaqMan	O
master	O
mix	O
using	O
a	O
7000	O
real	O
-	O
time	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
amplification	O
of	O
the	O
housekeeping	O
gene	O
encoding	O
elongation	O
factor	O
(	O
EF	O
)	O
-	O
1alpha	O
or	O
by	O
using	O
the	O
18S	O
rRNA	O
Gene	O
Expression	O
Assay	O
(	O
Applied	O
Biosystems	O
)	O
was	O
performed	O
to	O
allow	O
normalization	O
between	O
samples	O
.	O

Relative	O
quantification	O
and	O
calculation	O
of	O
the	O
range	O
of	O
confidence	O
was	O
performed	O
using	O
the	O
comparative	O
DeltaDeltaCT	O
method	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
percentage	O
of	O
FOXP3	O
mRNA	B-Transcription
in	O
siRNA	O
-	O
mediated	B-Positive_regulation
RUNX	O
knockdown	B-Negative_regulation
cells	O
was	O
calculated	O
in	O
relation	O
to	O
cells	O
,	O
which	O
were	O
transfected	O
with	O
scrambled	O
control	O
siRNA	O
.	O

Arbitrary	O
units	O
show	O
the	O
2	O
-	O
(	O
Deltact	O
)	O
values	O
multiplied	O
by	O
10	O
,	O
000	O
incorporating	O
the	O
ct	O
values	O
of	O
the	O
gene	O
of	O
interest	O
and	O
the	O
housekeeping	O
gene	O
.	O

Flow	O
cytometry	O
.	O

For	O
analysis	O
of	O
human	O
FOXP3	O
expression	B-Gene_expression
on	O
the	O
single	O
-	O
cell	O
level	O
,	O
cells	O
were	O
first	O
stained	O
with	O
the	O
monoclonal	O
CD4	O
mAb	O
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
after	O
fixation	O
and	O
permeabilization	O
,	O
they	O
were	O
incubated	O
with	O
anti	O
-	O
human	O
Foxp3	O
-	O
Alexa	O
Fluor	O
488	O
antibody	O
(	O
BioLegend	O
)	O
based	O
on	O
the	O
manufacturer	O
's	O
recommendations	O
and	O
subjected	O
to	O
FACS	O
(	O
EPICS	O
XL	O
-	O
MCL	O
;	O
Beckman	O
Coulter	O
)	O
.	O

A	O
mouse	O
IgG1	O
antibody	O
(	O
BioLegend	O
)	O
was	O
used	O
as	O
an	O
isotype	O
control	O
.	O

Data	O
were	O
analyzed	O
with	O
the	O
CXP	O
software	O
(	O
Beckman	O
Coulter	O
)	O
.	O

Cells	O
were	O
cultured	O
with	O
IL	O
-	O
2	O
,	O
and	O
then	O
left	O
unstimulated	O
or	O
stimulated	O
with	O
anti-CD2/-CD3/	O
-	O
CD28	O
mAb	O
.	O

Flow	O
cytometry	O
analyses	O
of	O
the	O
mouse	O
cells	O
were	O
performed	O
on	O
an	O
LSRII	O
(	O
BD	O
)	O
and	O
cell	O
sorting	O
was	O
performed	O
on	O
a	O
FACSAria	O
(	O
BD	O
)	O
.	O

All	O
antibodies	O
for	O
these	O
experiments	O
were	O
purchased	O
from	O
eBioscience	O
or	O
BD	O
.	O

Western	O
blotting	O
.	O

For	O
human	O
RUNX1	O
and	O
RUNX3	O
analysis	O
on	O
the	O
protein	B-Gene_expression
level	I-Gene_expression
,	O
106	O
cells	O
were	O
lysed	O
and	O
loaded	O
next	O
to	O
a	O
protein	O
-	O
mass	O
ladder	O
(	O
Invitrogen	O
)	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
GE	O
Healthcare	O
)	O
.	O

Unspecific	O
binding	O
was	O
blocked	O
with	O
3	O
%	O
milk	O
in	O
TBS	O
Tween	O
,	O
and	O
the	O
membranes	O
were	O
subsequently	O
incubated	O
with	O
a	O
1	O
:	O
1	O
,	O
000	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX1	O
(	O
ab11903	O
;	O
Abcam	O
)	O
or	O
1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX3	O
(	O
H	O
-	O
50	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
in	O
blocking	O
buffer	O
containing	O
3	O
%	O
milk	O
in	O
TBS	O
Tween	O
overnight	O
at	O
4degreesC	O
.	O

The	O
blots	O
were	O
developed	O
using	O
an	O
anti	O
-	O
rabbit	O
IgG	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
visualized	O
with	O
a	O
LAS	O
-	O
1000	O
gel	O
documentation	O
system	O
(	O
Fujifilm	O
)	O
.	O

To	O
confirm	O
sample	O
loading	O
and	O
transfer	O
membranes	O
were	O
incubated	O
in	O
stripping	O
buffer	O
and	O
reblocked	O
for	O
1	O
h	O
and	O
reprobed	O
using	O
anti	O
-	O
GAPDH	O
(	O
6C5	O
;	O
Ambion	O
)	O
and	O
developed	O
using	O
an	O
anti	O
-	O
mouse	O
IgG	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

Pull	O
-	O
down	O
assay	O
.	O

HEK293T	O
cells	O
were	O
transfected	B-Gene_expression
with	O
RUNX1	O
or	O
RUNX3	O
using	O
the	O
Lipofectamine	O
2000	O
reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instruction	O
.	O

Cells	O
were	O
lysed	O
by	O
sonication	O
in	O
HKMG	O
buffer	O
(	O
10	O
mM	O
Hepes	O
,	O
pH	O
7.9	O
,	O
100	O
mM	O
KCl	O
,	O
5	O
mM	O
MgCl2	O
,	O
10	O
%	O
glycerol	O
,	O
1	O
mM	O
DTT	O
,	O
0.5	O
%	O
Nonidet	O
P	O
-	O
40	O
)	O
containing	O
a	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
Diagnostics	O
)	O
.	O

The	O
cell	O
lysate	O
was	O
precleared	O
using	O
streptavidin	O
-	O
agarose	O
beads	O
(	O
GE	O
Healthcare	O
)	O
,	O
incubated	O
with	O
biotinylated	O
double	O
-	O
stranded	O
oligonucleotides	O
containing	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
RUNX	O
binding	O
sites	O
,	O
and	O
polydeoxyinosinicdeoxycytidylic	O
acid	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

A	O
combination	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
mutated	O
or	O
the	O
wild	O
-	O
type	O
binding	O
sites	O
was	O
used	O
in	O
the	O
assay	O
.	O

DNA	O
-	O
bound	O
proteins	O
were	O
collected	O
with	O
streptavidin	O
-	O
agarose	O
beads	O
,	O
washed	O
with	O
HKMG	O
buffer	O
,	O
and	O
finally	O
resuspended	O
in	O
NuPAGE	O
loading	O
buffer	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
,	O
heated	O
to	O
70degreesC	O
for	O
10	O
min	O
,	O
and	O
separated	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
gel	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
GE	O
Healthcare	O
)	O
and	O
detected	O
using	O
RUNX1	O
or	O
RUNX3	O
antibodies	O
described	O
in	O
the	O
previous	O
section	O
.	O

Promoter	O
enzyme	O
immuno	O
assay	O
.	O

As	O
performed	O
in	O
the	O
pull	O
-	O
down	O
assay	O
,	O
HEK293T	O
cells	O
were	O
transfected	B-Gene_expression
with	O
RUNX1	O
or	O
RUNX3	O
and	O
subsequently	O
lysed	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

384	O
-	O
well	O
plates	O
,	O
precoated	O
with	O
streptavidin	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
were	O
washed	O
3	O
times	O
with	O
washing	O
buffer	O
(	O
PBS	O
and	O
0.05	O
%	O
Tween	O
20	O
)	O
.	O

Biotinylated	O
FOXP3	O
promoter/oligonucleotides	O
probes	O
containing	O
the	O
RUNX	O
binding	O
sites	O
were	O
added	O
(	O
1	O
pmol	O
per	O
well	O
;	O
50	O
fmol/microl	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Either	O
a	O
combination	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
mutated	O
or	O
the	O
wild	O
-	O
type	O
binding	O
sites	O
was	O
used	O
or	O
single	O
oligonucleotides	O
were	O
used	O
in	O
the	O
assay	O
.	O

After	O
3	O
washing	O
steps	O
with	O
washing	O
buffer	O
,	O
the	O
nuclear	O
extract	O
was	O
added	O
(	O
concentration	O
>	O
0.2	O
microg/microl	O
)	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
.	O

The	O
lysates	O
were	O
incubated	O
with	O
10	O
microg	O
of	O
poly-deoxyinosinic	O
-	O
deoxycytidylic	O
acid	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

The	O
plate	O
was	O
washed	O
with	O
HKMG	O
buffer	O
and	O
incubated	O
with	O
a	O
1	O
:	O
1000	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX1	O
(	O
ab11903	O
,	O
Abcam	O
)	O
or	O
1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX3	O
(	O
H	O
-	O
50	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
at	O
4degreesC	O
for	O
2	O
h	O
.	O

After	O
three	O
washing	O
steps	O
with	O
HKMG	O
buffer	O
,	O
a	O
secondary	O
antibody	O
(	O
anti	O
-	O
rabbit	O
IgG	O
-	O
HRP	O
,	O
1	O
:	O
3	O
,	O
000	O
in	O
HKMG	O
buffer	O
,	O
Cell	O
Signaling	O
Technology	O
)	O
was	O
added	O
,	O
and	O
the	O
plate	O
was	O
incubated	O
for	O
1	O
h	O
at	O
4degreesC	O
.	O

The	O
wells	O
were	O
washed	O
4	O
times	O
with	O
HKMG	O
buffer	O
before	O
adding	O
the	O
substrate	O
reagent	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

The	O
colorimetric	O
reaction	O
was	O
stopped	O
by	O
adding	O
2	O
M	O
H2SO4	O
.	O

Absorbance	O
at	O
450	O
nm	O
was	O
measured	O
using	O
a	O
microplate	O
reader	O
(	O
Berthold	O
Technologies	O
)	O
.	O

ChIP	O
.	O

Human	O
naive	O
CD4+	O
T	O
cells	O
were	O
cultured	O
either	O
with	O
IL	O
-	O
2	O
only	O
or	O
with	O
IL	O
-	O
2	O
,	O
anti	O
-	O
CD2/3/28	O
,	O
and	O
TGF	O
-	O
beta	O
for	O
72	O
h	O
,	O
and	O
protein	O
-	O
DNA	O
complexes	O
were	O
fixed	O
by	O
cross	O
-	O
linking	O
with	O
formaldehyde	O
in	O
a	O
final	O
concentration	O
of	O
1.42	O
%	O
for	O
15	O
min	O
.	O

Formaldehyde	O
was	O
quenched	O
with	O
125	O
mM	O
glycine	O
for	O
5	O
min	O
,	O
and	O
cells	O
were	O
subsequently	O
harvested	O
.	O

The	O
ChIP	O
assay	O
was	O
performed	O
as	O
described	O
in	O
the	O
fast	O
chromatin	O
immunoprecipitation	O
method	O
(	O
Nelson	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Cells	O
were	O
lysed	O
with	O
immunoprecipitation	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7.5	O
,	O
5	O
mM	O
EDTA	O
,	O
NP	O
-	O
40	O
[	O
0.5	O
%	O
vol/vol	O
]	O
)	O
containing	O
phosphatase	O
(	O
Roche	O
)	O
and	O
protease	O
inhibitors	O
cocktails	O
(	O
Roche	O
)	O
,	O
the	O
nuclear	O
pellet	O
was	O
washed	O
,	O
the	O
chromatin	O
was	O
sheared	O
by	O
sonication	O
and	O
incubated	O
with	O
antibodies	O
for	O
RUNX1	O
(	O
H	O
-	O
65	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
,	O
RUNX3	O
(	O
H	O
-	O
50	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
,	O
CBFbeta	O
(	O
PEBP2beta	O
;	O
FL	O
-	O
182	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
,	O
and	O
as	O
controls	O
normal	O
rabbit	O
IgG	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc.	O
)	O
,	O
anti	O
-	O
human	O
RNA	O
polymerase	O
II	O
antibody	O
,	O
and	O
mouse	O
control	O
IgG	O
(	O
both	O
from	O
SA	O
Biosciences	O
)	O
.	O

The	O
cleared	O
chromatin	O
was	O
incubated	O
with	O
protein	O
A	O
agarose	O
beads	O
and	O
,	O
after	O
several	O
washing	O
steps	O
,	O
DNA	O
was	O
isolated	O
with	O
10	O
%	O
(	O
wt/vol	O
)	O
Chelex	O
100	O
resin	O
.	O

Samples	O
were	O
treated	O
with	O
proteinase	O
K	O
at	O
55degreesC	O
for	O
30	O
min	O
.	O

The	O
proteinase	O
K	O
was	O
then	O
inactivated	O
by	O
boiling	O
the	O
samples	O
for	O
10	O
min	O
.	O

The	O
purified	O
DNA	O
was	O
used	O
in	O
a	O
real	O
-	O
time	O
PCR	O
reaction	O
.	O

Specific	O
primers	O
for	O
the	O
FOXP3	O
promoter	O
,	O
spanning	O
the	O
region	O
from	O
-	O
87	O
to	O
-	O
3	O
,	O
FOXP3	O
promoter	O
forward	O
primer	O
5'-AGAGGTCTGCGGCTTCCA	O
-	O
3	O
'	O
,	O
FOXP3	O
promoter	O
reverse	O
primer	O
5'-GGAAACTGTCACGTATCAAAAACAA	O
-	O
3	O
'	O
,	O
or	O
control	O
GAPDH	O
primer	O
(	O
SA	O
Biosciences	O
)	O
for	O
the	O
RNA	O
polymerase	O
II	O
were	O
used	O
.	O

A	O
negative	O
control	O
PCR	O
for	O
each	O
immunoprecipitation	O
using	O
IGX1A	O
negative	O
control	O
primer	O
targeting	O
ORF	O
-	O
free	O
intergenic	O
DNA	O
(	O
SA	O
Biosciences	O
)	O
was	O
used	O
.	O

The	O
fold	O
enrichment	O
in	O
site	O
occupancy	O
was	O
calculated	O
incorporating	O
IgG	O
control	O
values	O
and	O
input	O
DNA	O
values	O
using	O
the	O
ChampionChIP	O
qPCR	O
data	O
analysis	O
file	O
(	O
SA	O
Biosciences	O
)	O
.	O

Quantification	O
of	O
cytokine	O
levels	O
.	O

IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
13	O
,	O
IL	O
-	O
17	O
,	O
and	O
IFN	O
-	O
gamma	O
secretion	B-Localization
was	O
assessed	O
using	O
fluorescent	O
bead	O
-	O
based	O
technology	O
.	O

The	O
Bio-Plex	O
-	O
hu	O
Cytokine	O
Panel	O
,	O
17	O
-	O
Plex	O
Group	O
1	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Fluorescent	O
signals	O
were	O
read	O
and	O
analyzed	O
using	O
the	O
Bio	O
-	O
Plex	O
200	O
System	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Online	O
supplemental	O
material	O
.	O

Fig.	O
S1	O
shows	O
the	O
induction	B-Positive_regulation
of	O
RUNX1	O
,	O
RUNX3	O
,	O
and	O
FOXP3	O
mRNA	B-Transcription
in	O
human	O
CD4+	O
T	O
cells	O
after	O
anti	O
-	O
CD2/3/28	O
mAb	O
and	O
TGF	O
-	O
beta	O
stimulation	O
.	O

Fig	O
.	O

S2	O
shows	O
decreased	B-Negative_regulation
RUNX1	O
and	O
RUNX3	O
mRNA	B-Transcription
and	O
protein	O
expression	O
after	O
siRNA	O
-	O
mediated	B-Positive_regulation
knockdown	B-Negative_regulation
and	O
decreased	B-Negative_regulation
FOXP3	O
expression	B-Gene_expression
in	O
human	O
CD4+	O
T	O
cells	O
after	O
RUNX1	O
and	O
RUNX3	O
knockdown	B-Negative_regulation
.	O

Fig	O
.	O

S3	O
shows	O
the	O
quantification	O
of	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
13	O
,	O
and	O
IFN	O
-	O
gamma	O
levels	O
in	O
control	O
siRNA	O
transfected	O
or	O
RUNX1	O
and	O
RUNX3	O
siRNA	B-Negative_regulation
transfected	O
human	O
CD4+	O
T	O
cells	O
.	O

Fig	O
.	O

S4	O
shows	O
the	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	O
core	O
promoter	O
sequence	O
of	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
.	O

Fig	O
.	O

S5	O
shows	O
the	O
induction	B-Positive_regulation
of	O
FOXP3	O
protein	O
after	O
overexpression	B-Gene_expression
of	O
RUNX1	O
and	O
RUNX3	O
in	O
human	O
CD4+	O
T	O
cells	O
.	O

Fig	O
.	O

S6	O
shows	O
that	O
endogenous	O
IL	O
-	O
4	O
and	O
IFN	O
-	O
gamma	O
do	O
not	O
effect	B-Regulation
Foxp3	O
expression	B-Gene_expression
in	O
naive	O
CD4+	O
T	O
cells	O
of	O
CbfbF/F	O
CD4	O
-	O
cre	O
and	O
CbfbF/F	O
control	O
mice	O
,	O
which	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
mAbs	O
,	O
IL	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
in	O
the	O
absence	O
or	O
presence	O
of	O
anti-IL	O
-	O
4	O
and	O
anti-IFN	O
-	O
gamma	O
neutralizing	O
mAbs	O
.	O

Fig	O
.	O

S7	O
shows	O
similar	O
cell	O
death	O
(	O
A	O
)	O
and	O
proliferation	O
(	O
B	O
)	O
of	O
Foxp3+	O
and	O
Foxp3	O
-	O
cells	O
in	O
CbfbF/F	O
CD4	O
-	O
cre	O
and	O
CbfbF/F	O
control	O
mice	O
cultures	O
.	O

Online	O
supplemental	O
material	O
is	O
available	O
at	O
http	O
:	O
//www.jem.org/cgi/content/full/jem.20090596/DC1	O
.	O

Supplementary	O
Material	O

[	O
Supplemental	O
Material	O
]	O

RUNX1	O
and	O
RUNX3	O
are	O
involved	B-Regulation
in	O
the	O
induction	B-Gene_expression
of	O
Foxp3	O
in	O
iT	O
reg	O
cells	O
.	O

(	O
A	O
)	O
RUNX1	O
,	O
RUNX3	O
,	O
and	O
FOXP3	O
mRNA	B-Transcription
induction	B-Positive_regulation
in	O
human	O
naive	O
CD4+	O
T	O
cells	O
after	O
alone	O
or	O
combined	O
anti	O
-	O
CD2/3/28	O
mAb	O
and	O
TGF	O
-	O
beta	O
stimulation	O
in	O
the	O
presence	O
of	O
IL	O
-	O
2	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
human	O
naive	O
CD4+	O
T	O
cells	O
after	O
48	O
h	O
of	O
culture	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
FOXP3	O
mRNA	B-Transcription
induction	B-Positive_regulation
by	O
anti	O
-	O
CD2/3/28	O
mAb	O
and	O
TGF	O
-	O
beta	O
in	O
human	O
naive	O
CD4+	O
T	O
cells	O
is	O
reduced	B-Negative_regulation
after	O
siRNA	O
-	O
mediated	B-Positive_regulation
RUNX1/3	O
knockdown	B-Negative_regulation
.	O

Real	O
-	O
time	O
PCR	O
of	O
RNA	O
from	O
human	O
naive	O
CD4+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	O
and/or	O
RUNX3	O
siRNA	B-Negative_regulation
or	O
with	O
a	O
control	O
siRNA	O
and	O
cultured	O
with	O
anti	O
-	O
CD2/3/28	O
,	O
TGF	O
-	O
beta	O
and	O
IL	O
-	O
2	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
FOXP3	O
mRNA	B-Transcription
is	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
in	O
iT	O
reg	O
cells	O
after	O
siRNA	O
-	O
mediated	B-Positive_regulation
knockdown	B-Negative_regulation
of	O
RUNX1	O
and	O
RUNX3	O
.	O

Real	O
-	O
time	O
PCR	O
for	O
FOXP3	O
,	O
T	O
-	O
bet	O
,	O
GATA3	O
,	O
and	O
RORC2	O
from	O
human	O
naive	O
CD4+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	O
and	O
RUNX3	O
siRNA	B-Negative_regulation
or	O
with	O
scrambled	O
siRNA	O
(	O
control	O
)	O
and	O
cultured	O
under	O
iT	O
reg	O
,	O
Th1	O
,	O
Th2	O
,	O
or	O
Th17	O
-	O
driving	O
conditions	O
for	O
12	O
d	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
D	O
)	O
FOXP3	O
protein	O
induction	B-Gene_expression
in	O
iT	O
reg	O
cells	O
is	O
reduced	B-Negative_regulation
after	O
siRNA	O
-	O
mediated	B-Positive_regulation
RUNX1/3	O
knockdown	B-Negative_regulation
.	O

Human	O
naive	O
CD4+	O
T	O
cells	O
were	O
transfected	O
with	O
RUNX1	O
and/or	O
RUNX3	O
siRNA	B-Negative_regulation
or	O
with	O
a	O
control	O
siRNA	O
and	O
stimulated	O
with	O
anti	O
-	O
CD2/3/28	O
and	O
TGF	O
-	O
beta	O
in	O
the	O
presence	O
of	O
IL	O
-	O
2	O
.	O

CD4	O
and	O
intracellular	O
FOXP3	O
analysis	O
by	O
flow	O
cytometry	O
after	O
72	O
h	O
.	O

One	O
of	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
's	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0.05	O
;	O
**	O
,	O
P	O
<	O
0.01	O
.	O

RUNX1	O
and	O
RUNX3	O
expression	B-Gene_expression
in	O
Foxp3+	O
T	O
reg	O
cells	O
and	O
in	O
human	O
CD4+	O
,	O
CD127	O
-	O
,	O
CD25high	O
cells	O
.	O

(	O
A	O
)	O
Real	O
-	O
time	O
PCR	O
analysis	O
of	O
CD4+	O
,	O
CD127	O
-	O
,	O
and	O
CD25high	O
T	O
reg	O
cells	O
and	O
CD4+	O
,	O
CD127+	O
,	O
and	O
CD25neg	O
T	O
cells	O
isolated	O
from	O
human	O
peripheral	O
blood	O
showed	O
an	O
increased	B-Positive_regulation
expression	B-Transcription
of	O
IL	O
-	O
10	O
,	O
TGF	O
-	O
beta	O
,	O
FOXP3	O
,	O
and	O
RUNX3	O
mRNA	O
in	O
CD25+	O
compared	O
with	O
CD25	O
-	O
cells	O
.	O

Bars	O
show	O
the	O
mean	O
+/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Human	O
tonsil	O
sections	O
were	O
analyzed	O
by	O
confocal	O
microscopy	O
.	O

Tissue	O
sections	O
were	O
stained	O
for	O
FOXP3	O
,	O
RUNX1	O
,	O
RUNX3	O
,	O
and	O
DAPI	O
or	O
isotype	O
controls	O
.	O

HEK	O
cells	O
RUNX1	O
-	O
transfected	B-Gene_expression
or	O
not	O
transfected	B-Gene_expression
served	O
as	O
additional	O
control	O
for	O
RUNX1	O
staining	O
.	O

Data	O
shown	O
are	O
representative	O
from	O
one	O
of	O
the	O
three	O
tissue	O
samples	O
with	O
similar	O
results	O
.	O

Bars	O
,	O
5	O
microm	O
.	O

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
's	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0.05	O
;	O
**	O
,	O
P	O
<	O
0.01	O
.	O

Binding	B-Binding
of	O
RUNX1	O
and	O
RUNX3	O
proteins	O
to	O
the	O
predicted	O
binding	O
sites	O
in	O
the	O
FOXP3	O
promoter	O
.	O

(	O
A	O
)	O
Mutated	O
and	O
wild	O
-	O
type	O
oligonucleotides	O
are	O
shown	O
.	O

The	O
predicted	O
RUNX	O
binding	O
sites	O
are	O
accentuated	O
(	O
boxed	O
and	O
in	O
green	O
letters	O
)	O
and	O
stars	O
mark	O
mutations	O
introduced	O
into	O
the	O
binding	O
site	O
of	O
the	O
control	O
oligonucleotides	O
.	O

Nuclear	O
extracts	O
from	O
HEK293T	O
cells	O
were	O
incubated	O
with	O
biotinylated	O
oligonucleotides	O
.	O

The	O
precipitated	O
oligonucleotide	O
-	O
transcription	O
factor	O
complexes	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
identified	O
by	O
Western	O
blotting	O
with	O
anti	O
-	O
RUNX1	O
and	O
anti	O
-	O
RUNX3	O
antibodies	O
.	O

A	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
with	O
the	O
predicted	O
binding	O
sites	O
or	O
with	O
the	O
inserted	O
mutation	O
into	O
the	O
predicted	O
sites	O
was	O
used	O
.	O

Data	O
shown	O
are	O
one	O
representative	O
of	O
three	O
independent	O
experiments	O
with	O
similar	O
results	O
.	O

(	O
B	O
)	O
Promoter	O
enzyme	O
immunoassay	O
using	O
wild	O
-	O
type	O
and	O
mutated	O
oligonucleotides	O
within	O
the	O
FOXP3	O
promoter	O
.	O

Bars	O
show	O
mean	O
+/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Chromatin	O
immunoprecipitation	O
assay	O
results	O
show	O
binding	B-Binding
of	O
RUNX1	O
and	O
RUNX3	O
complexes	O
containing	O
CBFbeta	O
to	O
the	O
human	O
FOXP3	O
promoter	O
in	O
naive	O
CD4+	O
T	O
cells	O
that	O
were	O
cultured	O
with	O
IL	O
-	O
2	O
together	O
with	O
anti	O
-	O
CD2/3/28	O
and	O
TGF	O
-	O
beta	O
.	O

There	O
was	O
no	O
change	O
in	O
site	O
occupancy	O
in	O
all	O
immunoprecipitations	O
when	O
IGX1A	O
negative	O
control	O
primers	O
were	O
used	O
.	O

The	O
results	O
are	O
normalized	O
to	O
input	O
and	O
isotype	O
control	O
antibody	O
.	O

Bars	O
show	O
mean	O
+/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
's	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0.05	O

Regulation	O
of	O
FOXP3	O
promoter	O
activity	O
by	O
RUNX1	O
and	O
RUNX3	O
.	O

(	O
A	O
)	O
Human	O
primary	O
CD4+	O
cells	O
were	O
transfected	B-Gene_expression
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
Basic	O
)	O
,	O
a	O
vector	O
containing	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
FOXP3	O
promoter	O
region	O
(	O
FOXP3	O
-	O
511/+176	O
)	O
fused	O
to	O
the	O
luciferase	O
reporter	O
gene	O
together	O
with	O
a	O
GFP	O
,	O
RUNX1	O
,	O
or	O
RUNX3	O
expression	O
vector	O
.	O

Bars	O
show	O
the	O
mean	O
luciferase	O
activity	O
+/	O
-	O
SE	O
measured	O
as	O
arbitrary	O
light	O
units	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Human	O
primary	O
CD4+	O
cells	O
were	O
transfected	B-Gene_expression
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
Basic	O
)	O
,	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	O
promoter	O
region	O
(	O
FOXP3	O
-	O
511/+176	O
)	O
fused	O
to	O
the	O
luciferase	O
reporter	O
gene	O
,	O
or	O
with	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	O
promoter	O
region	O
(	O
FOXP3	O
-	O
511/+176	O
)	O
with	O
single	O
RUNX	O
binding	O
sites	O
mutated	O
(	O
53	O
,	O
287	O
,	O
or	O
333	O
)	O
or	O
with	O
the	O
combination	O
of	O
two	O
or	O
three	O
RUNX	O
binding	O
sites	O
mutated	O
(	O
53	O
,	O
287	O
,	O
or	O
333	O
)	O
fused	O
to	O
the	O
luciferase	O
reporter	O
gene	O
.	O

Bars	O
show	O
the	O
mean	O
luciferase	O
activity	O
+/	O
-	O
SD	O
measured	O
as	O
arbitrary	O
light	O
units	O
of	O
three	O
independent	O
experiments	O
.	O

Diminished	O
capacity	O
of	O
Cbfb	O
-	O
deficient	B-Negative_regulation
CD4	O
-	O
cre	O
mice	O
T	O
cells	O
in	O
the	O
generation	O
of	O
Foxp3+	O
CD4+	O
T	O
cells	O
.	O

(	O
A	O
)	O
FACS	O
-	O
purified	O
naive	O
CD4+	O
CD8	O
-	O
T	O
cells	O
from	O
CbfbF/F	O
CD4	O
-	O
cre	O
and	O
control	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
were	O
activated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3/28	O
mAb	O
,	O
50	O
U/ml	O
IL	O
-	O
2	O
,	O
+/	O
-	O
10	O
nM	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
and	O
increasing	O
concentrations	O
of	O
TGF	O
-	O
beta	O
.	O

After	O
3	O
d	O
in	O
culture	O
,	O
the	O
cells	O
were	O
restimulated	O
with	O
PMA	O
+	O
ionomycin	O
,	O
and	O
then	O
analyzed	O
for	O
intracellular	O
Foxp3	O
and	O
IFN	O
-	O
gamma	O
expression	B-Gene_expression
.	O

One	O
of	O
five	O
experiments	O
is	O
shown	O
.	O

(	O
B	O
)	O
Naive	O
CD4+	O
T	O
cells	O
from	O
Cbfb	O
CD4	O
-	O
cre	O
or	O
control	O
mice	O
(	O
harboring	O
a	O
Foxp3-IRES	O
-	O
GFP	O
allele	O
)	O
were	O
adoptively	O
transferred	O
into	O
Rag	O
-	O
deficient	B-Negative_regulation
mice	O
(	O
5	O
x	O
106	O
cells	O
per	O
transfer	O
)	O
.	O

6	O
wk	O
later	O
,	O
TCRbeta+CD4+	O
cells	O
from	O
the	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
(	O
MLN	O
)	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
(	O
LP	O
)	O
were	O
analyzed	O
for	O
Foxp3	O
-	O
GFP	O
expression	B-Gene_expression
.	O

Results	O
from	O
one	O
of	O
four	O
CbfbF/F	O
CD4	O
-	O
cre	O
and	O
control	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
with	O
same	O
findings	O
are	O
shown	O
.	O

The	O
data	O
from	O
four	O
sets	O
of	O
mice	O
is	O
shown	O
in	O
C	O
.	O

Statistical	O
analysis	O
was	O
performed	O
with	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

*	O
,	O
P	O
<	O
0.05	O
between	O
groups	O
.	O

CbfbF/F	O
CD4	O
-	O
cre	O
mouse	O
cells	O
and	O
iT	O
reg	O
cells	O
generated	O
from	O
human	O
naive	O
CD4+	O
T	O
cells	O
undergoing	O
siRNA	O
-	O
mediated	B-Positive_regulation
RUNX1	O
and	O
RUNX3	O
knock	B-Negative_regulation
down	I-Negative_regulation
show	O
a	O
diminished	O
suppressive	O
activity	O
.	O

Experimental	O
setup	O
(	O
A	O
)	O
and	O
results	O
of	O
the	O
mouse	O
suppression	O
assay	O
(	O
B	O
)	O
,	O
FACS	O
-	O
purified	O
naive	O
CD4+8	O
-	O
T	O
cells	O
from	O
CbfbF/F	O
CD4	O
-	O
cre	O
(	O
left	O
)	O
and	O
control	O
CbfbF/+	O
CD4	O
-	O
cre	O
mice	O
(	O
Cd45.2	O
;	O
right	O
)	O
were	O
activated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3/28	O
mAb	O
,	O
50	O
U/ml	O
IL	O
-	O
2	O
,	O
and	O
2.5	O
ng/ml	O
TGF	O
-	O
beta	O
.	O

After	O
3	O
d	O
,	O
Foxp3	O
-	O
GFP+	O
cells	O
were	O
FACS	O
-	O
sorted	O
and	O
mixed	O
with	O
CFSE	O
-	O
loaded	O
naive	O
CD45.1+	O
CD4+	O
cells	O
at	O
the	O
indicated	O
ratios	O
.	O

These	O
were	O
then	O
incubated	O
with	O
inactivated	O
splenocytes	O
and	O
anti	O
-	O
CD3	O
mAb	O
.	O

After	O
a	O
further	O
4	O
d	O
,	O
CD45.1+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
.	O

(	O
C	O
)	O
As	O
a	O
control	O
,	O
CbfbF/+	O
CD4	O
-	O
cre	O
CD4+	O
T	O
cells	O
activated	O
in	O
absence	O
of	O
TGF	O
-	O
beta	O
were	O
mixed	O
with	O
CFSE	O
-	O
loaded	O
naive	O
CD45.1+	O
CD4+	O
cells	O
at	O
the	O
indicated	O
ratios	O
.	O

Four	O
days	O
later	O
CD45.1+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
.	O

The	O
median	O
division	O
number	O
(	O
of	O
the	O
naive	O
CD45.1+	O
CD4+	O
cells	O
in	O
the	O
cultures	O
containing	O
Foxp3	O
-	O
GFP+	O
cells	O
)	O
is	O
indicated	O
in	O
each	O
of	O
the	O
histograms	O
.	O

One	O
of	O
three	O
experiments	O
is	O
shown	O
.	O

(	O
D	O
)	O
Human	O
naive	O
CD4+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	O
and	O
RUNX3	O
siRNA	B-Negative_regulation
and	O
cultured	O
under	O
iT	O
reg	O
differentiating	O
conditions	O
were	O
used	O
in	O
an	O
in	O
vitro	O
suppression	O
assay	O
,	O
cultured	O
together	O
with	O
autologous	O
CFSE	O
-	O
labeled	O
CD4+	O
T	O
cells	O
,	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
.	O

The	O
CFSE	O
dilution	O
of	O
the	O
CD4+	O
T	O
cell	O
responder	O
cells	O
was	O
analyzed	O
after	O
5	O
d	O
by	O
flow	O
cytometry	O
.	O

The	O
T	O
reg/responder	O
CD4+	O
T	O
cell	O
ratios	O
used	O
were	O
1	O
:	O
20	O
,	O
1	O
:	O
10	O
,	O
and	O
1	O
:	O
5	O
.	O

One	O
of	O
two	O
experiments	O
is	O
shown	O
.	O

[	O
Supplemental	O
Material	O
]	O

Involvement	B-Regulation
of	O
adenylate	O
cyclase	O
and	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
activation	B-Positive_regulation
in	O
IL	O
-	O
10	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
in	O
human	O
monocytes	O
by	O
gp41	O
envelope	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	O
gp41	O
(	O
aa565	O
-	O
647	O
)	O
,	O
the	O
extracellular	O
domain	O
of	O
HIV	O
-	O
1	O
transmembrane	O
glycoprotein	O
,	O
stimulates	B-Positive_regulation
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
production	B-Gene_expression
in	O
human	O
monocytes	O
.	O

The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	O
-	O
induced	B-Positive_regulation
IL	O
-	O
10	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
is	O
mediated	B-Positive_regulation
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF	O
-	O
kappaB	O
pathways	O
.	O

gp41	O
induced	O
cAMP	O
accumulation	O
in	O
monocytes	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
and	O
the	O
adenylate	O
cyclase	O
inhibitor	O
SQ	O
22536	O
suppressed	B-Negative_regulation
gp41	O
-	O
induced	B-Positive_regulation
IL	O
-	O
10	O
production	B-Gene_expression
in	O
monocytes	O
.	O

In	O
contrast	O
,	O
gp41	O
failed	O
to	O
stimulate	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
as	O
much	O
as	O
no	O
NF	O
-	O
kappaB	O
bound	B-Binding
to	O
the	O
main	O
NF-kappaB	O
-	O
binding	O
site	O
2	O
of	O
the	O
IL	O
-	O
10	O
promoter	O
after	O
addition	O
of	O
gp41	O
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O

Specific	O
inhibitors	O
of	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
(	O
rapamycin	O
)	O
,	O
and	O
Gi	O
protein	O
(	O
pertussis	O
toxin	O
)	O
,	O
prevented	B-Negative_regulation
induction	B-Positive_regulation
of	O
IL	O
-	O
10	O
production	B-Gene_expression
by	O
gp41	O
in	O
monocytes	O
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
(	O
wortmannin	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	O
.	O

Thus	O
HIV	O
-	O
1	O
gp41	O
-	O
induced	B-Positive_regulation
IL	O
-	O
10	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
in	O
monocytes	O
may	O
not	O
involve	O
NF	O
-	O
kappaB	O
,	O
MAPK	O
,	O
or	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
but	O
rather	O
may	O
operate	B-Positive_regulation
through	O
activation	O
of	O
adenylate	O
cyclase	O
and	O
pertussis-toxin	O
-	O
sensitive	O
Gi/Go	O
protein	O
to	O
effect	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
activation	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
viral	O
protein	O
Tax	O
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

However	O
,	O
the	O
HTLV	O
-	O
I	O
genes	O
including	O
Tax	O
are	O
not	O
expressed	B-Gene_expression
significantly	O
in	O
primary	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
freshly	O
isolated	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV-I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
,	O
display	O
constitutive	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
increased	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
IkappaBalpha	O
(	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
)	O
.	O

Whereas	O
the	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
Tax	O
-	O
expressing	O
T	O
-	O
cell	O
lines	O
consisted	O
mostly	O
of	O
p50/c	O
-	O
Rel	O
,	O
fresh	O
ATL	O
samples	O
contained	O
p50/p50	O
and	O
p50/p65	O
heterodimers	O
.	O

One	O
T	O
-	O
cell	O
line	O
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL	O
-	O
Om1	O
,	O
displayed	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
well	O
as	O
enhanced	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
IkappaBalpha	O
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	O
expression	B-Gene_expression
.	O

Interestingly	O
,	O
the	O
NF	O
-	O
kappaB	O
in	O
TL	O
-	O
Om1	O
consists	O
of	O
p50/p50	O
and	O
p50/p65	O
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
a	O
Tax	O
-	O
independent	O
mechanism	O
in	O
leukemic	O
cells	O
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF	O
-	O
kappaB	O
subunit	O
activation	O
.	O

Apoptosis	O
-	O
resistant	O
T	O
cells	O
have	O
a	O
deficiency	B-Negative_regulation
in	O
NF-kappaB	O
-	O
mediated	O
induction	B-Positive_regulation
of	O
Fas	O
ligand	O
transcription	B-Transcription
.	O

Apoptosis	O
induced	O
through	O
the	O
TCR	O
in	O
CD4+	O
T	O
cells	O
is	O
mostly	O
mediated	O
by	O
the	O
inducible	B-Positive_regulation
expression	B-Gene_expression
of	O
Fas	O
ligand	O
(	O
FasL	O
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	O
Jurkat	O
cells	O
.	O

These	O
cells	O
are	O
deficient	B-Negative_regulation
in	O
FasL	O
expression	B-Gene_expression
and	O
apoptosis	O
induced	B-Positive_regulation
upon	O
TCR	O
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL	O
-	O
2	O
and	O
IFN	O
-	O
gamma	O
)	O
production	B-Gene_expression
is	O
normal	B-Negative_regulation
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL	O
-	O
and	O
a	O
consensus	O
NF-kappaB	O
-	O
reporter	O
construct	O
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	O
reporter	O
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	O
cells	O
to	O
an	O
inefficient	O
NF	O
-	O
kappaB	O
activation	O
,	O
evidencing	O
a	O
relevant	O
role	B-Regulation
for	O
NF	O
-	O
kappaB	O
in	O
the	O
regulation	B-Regulation
of	O
FasL	O
expression	B-Gene_expression
in	O
activated	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	B-Positive_regulation
of	O
FasL	O
versus	O
cytokine	O
gene	O
expression	B-Gene_expression
is	O
differentially	O
sensitive	O
to	O
NF	O
-	O
kappaB	O
deprivation	O
.	O

NF	O
-	O
kappaB	O
regulates	O
Fas/APO-1/CD95	O
-	O
and	O
TCR	O
-	O
mediated	O
apoptosis	O
of	O
T	O
lymphocytes	O
.	O

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	O
We	O
show	O
here	O
that	O
NF	O
-	O
kappaB	O
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas/APO-1/CD95	O
-	O
mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	O
T	O
cell	O
death	O
.	O

Transfection	B-Gene_expression
of	O
Jurkat	O
cells	O
with	O
the	O
NF	O
-	O
kappaB	O
subunits	O
p50	O
and	O
p65	O
confers	O
resistance	O
against	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

Reciprocally	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
IkappaB	O
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	O
cell	O
hybridoma	O
more	O
susceptible	O
to	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

Correspondingly	O
,	O
transfection	B-Positive_regulation
of	O
p50	O
and	O
p65	O
provided	O
considerable	O
protection	O
from	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	O
-	O
mediated	O
death	O
in	O
primary	O
T	O
cells	O
.	O

Concanavalin	O
A	O
-	O
activated	O
cycling	O
T	O
cell	O
blasts	O
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	O
IkappaB	O
molecule	O
have	O
increased	O
sensitivity	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
complexes	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
blocking	O
TNF	O
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF	O
-	O
kappaB	O
,	O
with	O
neutralizing	O
antibodies	O
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti-Fas	O
-	O
mediated	O
apoptosis	O
.	O

In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF	O
-	O
kappaB	O
protects	O
against	O
Fas	O
-	O
mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34+	O
progenitor	O
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	O
hemopoietic	O
progenitors	O
to	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
largely	O
undefined	O
.	O

We	O
have	O
previously	O
shown	O
that	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
(	O
with	O
phorbol	O
ester	O
(	O
PMA	O
)	O
alone	O
)	O
specifically	O
induces	O
differentiation	O
of	O
primary	O
human	O
CD34+	O
hemopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
to	O
mature	O
DC	O
.	O

We	O
now	O
find	O
that	O
cytokine	O
-	O
driven	O
(	O
granulocyte	O
-	O
macrophage	O
CSF	O
and	O
TNF	O
-	O
alpha	O
)	O
CD34+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	O
activation	O
.	O

To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O

The	O
CD34+	O
myelomonocytic	O
cell	O
line	O
KG1	O
differentiates	O
into	O
dendritic	O
-	O
like	O
cells	O
in	O
response	O
to	O
granulocyte	O
-	O
macrophage	O
CSF	O
plus	O
TNF	O
-	O
alpha	O
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF	O
-	O
alpha	O
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

Phenotypic	O
DC	O
characteristics	O
of	O
KG1	O
dendritic	O
-	O
like	O
cells	O
include	O
morphology	O
(	O
loosely	O
adherent	O
cells	O
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	O
I+/MHC	O
IIbright/CD83+/CD86+/CD14	O
-	O
surface	O
Ag	O
expression	B-Gene_expression
,	O
and	O
RelB	O
and	O
DC	O
-	O
CK1	O
gene	O
expression	B-Gene_expression
.	O

Functional	O
DC	O
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC	O
-	O
dextran	O
)	O
and	O
activation	O
of	O
resting	O
T	O
cells	O
.	O

Comparison	O
of	O
KG1	O
to	O
the	O
PMA	O
-	O
unresponsive	O
subline	O
KG1a	O
reveals	O
differences	O
in	O
expression	B-Gene_expression
of	O
TNF	O
receptors	O
1	O
and	O
2	O
;	O
PKC	O
isoforms	O
alpha	O
,	O
beta	O
I	O
,	O
beta	O
II	O
,	O
and	O
mu	O
;	O
and	O
RelB	O
,	O
suggesting	O
that	O
these	O
components/pathways	O
are	O
important	B-Positive_regulation
for	O
DC	O
differentiation	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
cytokine	O
or	O
phorbol	O
ester	O
stimulation	O
of	O
KG1	O
is	O
a	O
model	O
of	O
human	O
CD34+	O
HPC	O
to	O
DC	O
differentiation	O
and	O
suggest	O
that	O
specific	O
intracellular	O
signaling	O
pathways	O
mediate	O
specific	O
events	O
in	O
DC	O
lineage	O
commitment	O
.	O

IL-2	O
-	O
mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF	O
-	O
kappa	O
B	O
or	O
activating	O
protein	O
-	O
1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

The	O
IL	O
-	O
2	O
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

IL	O
-	O
2	O
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag	O
-	O
activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and/or	O
activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	O
factors	O
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL	O
-	O
2	O
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL	O
-	O
2	O
does	O
not	O
induce	B-Positive_regulation
I	O
kappa	O
B	O
alpha	O
degradation	B-Protein_catabolism
or	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
that	O
respond	O
to	O
IL	O
-	O
2	O
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O

Similarly	O
,	O
IL	O
-	O
2	O
neither	O
activates	O
JNK	O
nor	O
increases	O
AP	O
-	O
1	O
binding	O
activity	O
to	O
a	O
consensus	O
o	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
response	O
element	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	O
factor	O
does	O
induce	B-Positive_regulation
the	O
activation	B-Positive_regulation
of	O
STAT3	O
and	O
STAT5	O
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF	O
-	O
kappa	O
B	O
nor	O
AP	O
-	O
1	O
activation	O
is	O
required	O
for	O
IL-2	O
-	O
mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	O
human	O
T	O
cells	O
.	O

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	B-Gene_expression
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
(	O
mut	O
-	O
I	O
kappa	O
B	O
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	O
-	O
CD25+	O
,	O
CD4-CD8	O
-	O
double	O
-	O
negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double	O
-	O
positive	O
and	O
single	O
-	O
positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	B-Regulation
normal	I-Regulation
,	O
as	O
did	O
rearrangement	O
and	O
expression	B-Gene_expression
of	O
the	O
TCR	O
beta	O
-	O
chain	O
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Differential	O
regulation	B-Regulation
of	O
4E	O
-	O
BP1	O
and	O
4E	O
-	O
BP2	O
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
.	O

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
using	O
the	O
HL	O
-	O
60	O
promyelocytic	O
leukemia	O
cell	O
line	O
and	O
the	O
U	O
-	O
937	O
monoblastic	O
cell	O
line	O
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic/macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	B-Regulation
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E	O
-	O
BP1	O
and	O
4E	O
-	O
BP2	O
.	O

Induction	O
of	O
HL	O
-	O
60	O
and	O
U	O
-	O
937	O
cell	O
differentiation	O
into	O
monocytes/macrophages	O
by	O
IFN	O
-	O
gamma	O
or	O
PMA	O
results	B-Positive_regulation
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	B-Positive_regulation
of	O
4E	O
-	O
BP1	O
.	O

Dephosphorylation	O
of	O
4E	O
-	O
BP1	O
was	O
also	O
observed	O
when	O
U	O
-	O
937	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
monocytes/macrophages	O
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
cells	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	B-Negative_regulation
4E	O
-	O
BP1	O
amount	O
without	O
affecting	B-Regulation
its	O
phosphorylation	B-Phosphorylation
and	O
strongly	O
increases	B-Positive_regulation
4E	O
-	O
BP2	O
amount	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic/macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

Stimulation	B-Positive_regulation
of	O
CD40	O
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	O
T	O
lymphocyte	O
-	O
mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	B-Gene_expression
of	O
CD40	O
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	O
surface	O
expression	B-Gene_expression
is	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	I-Negative_regulation
during	O
tumor	O
progression	O
.	O

CD40	O
expression	B-Gene_expression
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	O
negative	B-Gene_expression
.	O

CD40	O
expression	B-Gene_expression
could	O
be	O
enhanced	B-Positive_regulation
in	O
CD40	O
-	O
positive	O
MM	O
by	O
stimulation	O
with	O
IFN	O
-	O
gamma	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
but	O
not	O
by	O
interleukin	O
(	O
IL	O
)	O
-	O
1beta	O
or	O
CD40	O
triggering	O
.	O

CD40	O
ligation	B-Binding
on	O
MM	O
by	O
CD40L	O
-	O
transfected	O
murine	O
L	O
-	O
cells	O
or	O
by	O
a	O
soluble	O
CD40L	O
fusion	O
protein	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
their	O
expression	B-Gene_expression
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
MHC	O
class	O
I	O
and	O
class	O
II	O
molecules	O
and	O
their	O
secretion	B-Localization
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
tumor	O
necrosis	O
factor	O
-	O
a	O
,	O
and	O
granulocyte	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
.	O

Furthermore	O
,	O
CD40	O
ligation	B-Binding
of	O
a	O
HLA	O
-	O
A2+	O
,	O
MelanA/MART1+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA-A2	O
-	O
restricted	O
,	O
MelanA/MART-1	O
-	O
specific	O
CTL	O
clone	O
.	O

Finally	O
,	O
CD40	O
ligation	B-Binding
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

These	O
results	O
indicate	O
that	O
CD40	O
-	O
CD40L	O
interactions	B-Binding
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	O
-	O
positive	O
immunogenic	O
human	O
MMs	O
.	O

Essential	O
role	O
of	O
alveolar	O
macrophages	O
in	O
intrapulmonary	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	O
G	O
immune	O
complexes	O
requires	O
expression	O
of	O
cytokines	O
and	O
chemokines	O
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
.	O

There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	O
macrophages	O
in	O
these	O
activation	O
events	O
.	O

In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	O
macrophages	O
by	O
airway	O
instillation	O
of	O
liposome	O
-	O
encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O

These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	O
macrophages	O
,	O
suppressed	O
activation	O
of	O
lung	O
NF	O
-	O
kappaB	O
in	O
the	O
inflammatory	O
model	O
.	O

In	O
addition	O
,	O
bronchoalveolar	O
lavage	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
the	O
CXC	O
chemokine	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
were	O
substantially	O
reduced	B-Negative_regulation
.	O

In	O
parallel	O
,	O
upregulation	B-Positive_regulation
of	O
the	O
lung	O
vascular	O
adhesion	O
molecule	O
,	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
,	O
was	O
greatly	O
reduced	B-Negative_regulation
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate	O
-	O
containing	O
liposomes	O
.	O

Neutrophil	O
accumulation	O
and	O
development	O
of	O
lung	O
injury	O
were	O
also	O
substantially	O
diminished	O
.	O

Lung	O
instillation	O
of	O
TNF	O
-	O
alpha	O
in	O
alveolar	O
macrophage	O
-	O
depleted	O
rats	O
restored	O
the	O
NF	O
-	O
kappaB	O
activation	O
response	O
in	O
whole	O
lung	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
in	O
alveolar	O
macrophages	O
and	O
the	O
ensuing	O
production	B-Gene_expression
of	O
TNF	O
-	O
alpha	O
may	O
propagate	O
NF	O
-	O
kappaB	O
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O

Role	O
of	O
cellular	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	O
.	O

The	O
STP	O
oncoproteins	O
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	B-Binding
with	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
1	O
,	O
2	O
,	O
or	O
3	O
.	O

Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT/S	O
in	O
STP	O
-	O
A11	O
as	O
critical	O
for	O
TRAF	O
association	B-Binding
.	O

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP	O
-	O
C488	O
is	O
critical	O
for	O
TRAF	O
association	B-Binding
.	O

Mutational	O
analysis	O
also	O
revealed	O
that	O
STP	O
-	O
C488	O
induced	O
NF	O
-	O
kappaB	O
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	B-Binding
with	O
TRAFs	O
.	O

The	O
HVS	O
STP	O
-	O
C488	O
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T	O
-	O
lymphocyte	O
transformation	O
to	O
interleukin-2	O
-	O
independent	O
growth	O
but	O
showed	O
wild	O
-	O
type	O
phenotype	O
for	O
marmoset	O
T	O
-	O
lymphocyte	O
transformation	B-Positive_regulation
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
STP	O
-	O
C488	O
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
also	O
defective	O
in	O
Rat	O
-	O
1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	O
dominant	O
-	O
negative	O
mutant	O
.	O

These	O
data	O
implicate	O
TRAFs	O
in	O
STP-C488	O
-	O
mediated	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	O
marmoset	O
T	O
lymphocytes	O
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Regulation	B-Regulation
of	O
Fas	O
ligand	O
expression	B-Gene_expression
and	O
cell	O
death	O
by	O
apoptosis	O
-	O
linked	O
gene	O
4	O
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas/Fas	O
ligand	O
(	O
FasL	O
)	O
interaction	B-Binding
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell	O
-	O
receptor	O
engagement	O
,	O
we	O
identified	O
ALG	O
-	O
4F	O
,	O
a	O
truncated	O
transcript	O
that	O
prevents	B-Negative_regulation
T	O
cell-receptor	O
-	O
induced	B-Positive_regulation
FasL	O
upregulation	B-Positive_regulation
and	O
cell	O
death	O
.	O

Overexpression	B-Positive_regulation
of	O
full	O
-	O
length	O
ALG	O
-	O
4	O
induced	B-Positive_regulation
transcription	B-Transcription
of	O
FasL	O
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O

These	O
results	O
indicate	O
that	O
ALG	O
-	O
4	O
is	O
necessary	B-Positive_regulation
and	I-Positive_regulation
sufficient	I-Positive_regulation
for	O
FasL	O
expression	B-Gene_expression
.	O

Fas/FasL	O
interaction	B-Binding
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	B-Regulation
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	O
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF-kappaB	O
-	O
regulated	O
promoter	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	O
T	O
-	O
cell	O
mitogens	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	O
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
correlated	O
with	O
the	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
B7.1	O
molecules	O
.	O

It	O
was	O
postulated	O
that	O
this	O
NF-kappaB	O
-	O
regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase	O
-	O
1	O
and	O
-	O
3	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	O
genes	O
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	O
cells	O
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
with	O
cell	O
-	O
permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	O
-	O
kappa	O
B1	O
dimers	O
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	O
normal	O
human	O
PBL	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	O
inhibitor	O
Z-VAD	O
-	O
fmk	O
and	O
partially	O
blocked	O
by	O
Ac-DEVD	O
-	O
fmk	O
,	O
suggesting	O
that	O
SN50	O
-	O
mediated	O
apoptosis	O
is	O
caspase	O
-	O
dependent	O
.	O

Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF	O
-	O
kappa	O
B	O
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'	O
-	O
tetrakis	O
[	O
2	O
-	O
pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	O
Fas	O
ligand	O
(	O
CD95	O
)	O
,	O
was	O
observed	O
in	O
the	O
absence	O
of	O
active	O
death	O
effector	O
proteases	O
caspase-1	O
-	O
like	O
(	O
IL	O
-	O
1	O
converting	O
enzyme	O
)	O
,	O
caspase-3	O
-	O
like	O
(	O
CPP32/Yama/apopain	O
)	O
,	O
and	O
caspase-6	O
-	O
like	O
and	O
without	O
cleavage	O
of	O
caspase	O
-	O
3	O
substrates	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
and	O
DNA	O
fragmentation	O
factor	O
-	O
45	O
.	O

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	B-Positive_regulation
is	O
required	O
or	O
that	O
different	O
caspases	O
are	O
involved	O
.	O

Preactivation	O
of	O
T	O
cells	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50	O
-	O
induced	O
apoptosis	O
.	O

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
survival	O
of	O
naive	O
PBL	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	O
-	O
activated	B-Positive_regulation
toll	O
-	O
like	O
receptor	O
2	O
.	O

Human	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
is	O
a	O
signaling	O
receptor	O
that	O
responds	B-Regulation
to	O
LPS	O
and	O
activates	O
NF	O
-	O
kappaB	O
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	O
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	O
associates	B-Binding
with	O
the	O
high	O
-	O
affinity	O
LPS	O
binding	O
protein	O
membrane	O
CD14	O
to	O
serve	O
as	O
an	O
LPS	O
receptor	O
complex	O
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	O
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
is	O
recruited	O
to	O
the	O
TLR2	O
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	O
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	B-Binding
IRAK	O
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	B-Binding
complexes	I-Binding
with	O
wild	O
-	O
type	O
TLR2	O
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	O
-	O
mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	O
differentiation	O
protein	O
,	O
IRAK	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
6	O
,	O
and	O
NF-kappaB	O
-	O
inducing	O
kinase	O
,	O
when	O
coexpressed	B-Gene_expression
with	O
TLR2	O
,	O
abrogate	O
TLR2	O
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	O
and	O
IL	O
-	O
1Rs	O
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	B-Negative_regulation
of	O
TLR2	O
by	O
DN	O
variants	O
.	O

Activation	O
of	O
the	O
Janus	O
kinase	O
3	O
-	O
STAT5a	O
pathway	O
after	O
CD40	O
triggering	O
of	O
human	O
monocytes	O
but	O
not	O
of	O
resting	O
B	O
cells	O
.	O

CD40/CD40	O
ligand	O
interactions	B-Binding
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross	O
-	O
linking	O
of	O
the	O
CD40	O
receptor	O
have	O
been	O
widely	O
studied	O
in	O
B	O
cell	O
lines	O
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	O
stimulation	O
of	O
monocytes	O
and	O
resting	O
tonsillar	O
B	O
cells	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	O
pathway	O
in	O
highly	O
purified	O
human	O
monocytes	O
and	O
resting	O
B	O
cells	O
.	O

After	O
CD40	O
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
(	O
but	O
not	O
of	O
the	O
AP	O
-	O
1	O
)	O
transcription	O
factor	O
complex	O
occurred	O
in	O
both	O
cell	O
preparations	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
complexes	O
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	O
is	O
part	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
induced	B-Positive_regulation
by	O
CD40	O
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	O
was	O
only	O
induced	B-Positive_regulation
in	O
B	O
cells	O
.	O

In	O
contrast	O
,	O
although	O
the	O
Janus	O
kinase	O
3	O
tyrosine	O
kinase	O
was	O
associated	B-Binding
with	O
CD40	O
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	O
kinase	O
3	O
phosphorylation	B-Phosphorylation
induction	B-Positive_regulation
was	O
observed	O
only	O
in	O
CD40	O
-	O
activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	B-Positive_regulation
of	O
STAT5a	O
DNA	O
binding	B-Binding
activity	O
in	O
the	O
nucleus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	O
B	O
cells	O
and	O
monocytes	O
differ	O
following	O
CD40	O
stimulation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	O
-	O
induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	O
ligand+	O
hyper	O
IgM	O
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	O
-	O
induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O

Suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
normal	O
T	O
cells	O
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

T	O
lymphocytes	O
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	O
-	O
kappaB	O
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC	O
-	O
S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
normal	O
T	O
cells	O
that	O
is	O
observed	O
in	O
patient	O
T	O
cells	O
.	O

The	O
pattern	O
of	O
kappaB	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	O
cells	O
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	O
activation	B-Positive_regulation
of	O
RelA/NFkappaB1	O
-	O
binding	B-Binding
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	O
-	O
binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O

IkappaBalpha	O
was	O
degraded	B-Protein_catabolism
normally	O
following	B-Positive_regulation
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	O
cells	O
from	O
RCC	O
patients	O
.	O

RCC	O
-	O
S	O
did	O
not	O
alter	B-Regulation
the	O
cytoplasmic	O
levels	O
of	O
RelA	O
and	O
NF	O
-	O
kappaB1	O
but	O
did	O
suppress	B-Negative_regulation
their	O
nuclear	O
localization	B-Localization
and	O
inhibited	O
the	O
activation	O
of	O
RelA/NF	O
-	O
kappaB1	O
binding	O
complexes	O
.	O

These	O
results	O
show	O
that	O
RCC	O
-	O
S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF	O
-	O
kappaB	O
suppression	O
by	O
RCC	O
-	O
S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

Monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O

OBJECTIVE	O
:	O
To	O
create	O
monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
(	O
mAECA	O
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	O
was	O
generated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein	O
-	O
Barr	O
virus	O
transformation	O
.	O

Activity	O
against	O
macrovascular	O
EC	O
(	O
HUVEC	O
)	O
and	O
microvascular	O
EC	O
(	O
human	O
bone	O
marrow	O
EC	O
immortalized	O
by	O
SV40	O
)	O
antigens	O
was	O
detected	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	O
antibodies	O
(	O
mAECA	O
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	O
IgG	O
-	O
AECA	O
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O

The	O
binding	O
of	O
the	O
mAECA	O
to	O
human	O
aortic	O
EC	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O

The	O
secretion	B-Localization
levels	O
of	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

The	O
activated	O
EC	O
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	O
cell	O
line	O
(	O
U937	O
)	O
,	O
as	O
well	O
as	O
for	O
expression	B-Gene_expression
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
,	O
intercellular	O
adhesion	O
molecule	O
1	O
,	O
and	O
E	O
-	O
selectin	O
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA	O
-	O
treated	O
EC	O
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
using	O
a	O
specific	O
NF	O
-	O
kappaB	O
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Six	O
mAECA	O
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	O
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	O
.	O

All	O
mAECA	O
possessed	O
high	O
activity	O
against	O
macrovascular	O
EC	O
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O

The	O
mAECA	O
,	O
but	O
not	O
normal	O
human	O
IgG	O
,	O
had	O
anti	O
-	O
human	O
aortic	O
EC	O
activity	O
.	O

Four	O
of	O
the	O
6	O
mAECA	O
activated	O
EC	O
,	O
manifested	O
by	O
increased	B-Positive_regulation
IL	O
-	O
6	O
and	O
vWF	O
secretion	B-Localization
.	O

The	O
4	O
mAECA	O
induced	O
EC	O
expression	O
of	O
adhesion	O
molecules	O
and	O
increased	O
adhesion	O
of	O
U937	O
monocytic	O
cells	O
to	O
EC	O
.	O

In	O
addition	O
,	O
these	O
mAECA	O
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	O
may	O
directly	O
stimulate	O
EC	O
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	O
molecule	O
expression	O
associated	O
with	O
NF	O
-	O
kappaB	O
activation	O
and	O
adhesion	O
of	O
monocytes	O
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	O
membrane	O
protein	O
1	O
engages	B-Binding
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
proteins	O
TRADD	O
and	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

A	O
site	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	O
that	O
constitutively	O
associates	B-Binding
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
1	O
(	O
TNFR1	O
)	O
-	O
associated	O
death	O
domain	O
protein	O
TRADD	O
to	O
mediate	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
activation	O
is	O
critical	O
for	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	O
signaling	O
through	O
TRADD	O
differs	O
from	O
TNFR1	O
signaling	O
through	O
TRADD	O
.	O

LMP1	O
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF	O
-	O
kappaB	O
or	O
synergize	O
with	O
TRADD	O
in	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	O
requires	O
approximately	O
70	O
residues	O
.	O

Further	O
,	O
LMP1	O
does	O
not	O
require	O
TRADD	O
residues	O
294	O
to	O
312	O
for	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	O
requires	O
TRADD	O
residues	O
296	O
to	O
302	O
.	O

LMP1	O
is	O
partially	O
blocked	O
for	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
TRADD	O
mutant	O
consisting	O
of	O
residues	O
122	O
to	O
293	O
.	O

Unlike	O
TNFR1	O
,	O
LMP1	O
can	O
interact	B-Binding
directly	O
with	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
and	O
stably	O
associates	B-Binding
with	O
RIP	O
in	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
LMP1	O
does	O
not	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

Despite	O
constitutive	O
association	B-Binding
with	O
TRADD	O
or	O
RIP	O
,	O
LMP1	O
does	O
not	O
induce	O
apoptosis	O
in	O
EBV	O
-	O
negative	O
Burkitt	O
lymphoma	O
or	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	O
,	O
TRADD	O
,	O
and	O
RIP	O
participate	O
in	O
B	O
-	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Regulatory	O
effects	O
of	O
interleukin	O
-	O
11	O
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O

The	O
role	O
of	O
interleukin	O
-	O
11	O
(	O
IL	O
-	O
11	O
)	O
was	O
evaluated	O
in	O
the	O
IgG	O
immune	O
complex	O
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

IL	O
-	O
11	O
mRNA	O
and	O
protein	O
were	O
both	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

Exogenously	O
administered	O
IL	O
-	O
11	O
substantially	O
reduced	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	O
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	O
.	O

These	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
IL	O
-	O
11	O
were	O
associated	O
with	O
reduced	O
NF	O
-	O
kappaB	O
activation	O
in	O
lung	O
,	O
reduced	B-Negative_regulation
levels	I-Negative_regulation
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	B-Negative_regulation
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
lung	O
vascular	O
ICAM	O
-	O
1	O
.	O

It	O
is	O
interesting	O
that	O
IL	O
-	O
11	O
did	O
not	O
affect	B-Regulation
BAL	O
fluid	O
content	O
of	O
the	O
CXC	O
chemokines	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
(	O
MIP	O
-	O
2	O
)	O
and	O
cytokine	O
-	O
inducible	O
neutrophil	O
chemoattractant	O
(	O
CINC	O
)	O
;	O
the	O
presence	O
of	O
IL	O
-	O
11	O
did	O
not	O
affect	B-Regulation
these	O
chemokines	O
.	O

However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL	O
-	O
11	O
.	O

These	O
data	O
indicate	O
that	O
IL	O
-	O
11	O
is	O
a	O
regulatory	O
cytokine	O
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti	O
-	O
inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
diminished	B-Negative_regulation
production	B-Gene_expression
of	O
TNF	O
-	O
alpha	O
,	O
and	O
reduced	B-Negative_regulation
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
lung	O
vascular	O
ICAM	O
-	O
1	O
.	O

ETS	O
transcription	O
factors	O
regulate	B-Regulation
an	O
enhancer	O
activity	O
in	O
the	O
third	O
intron	O
of	O
TNF	O
-	O
alpha	O
.	O

We	O
describe	O
an	O
enhancer	O
site	O
in	O
the	O
third	O
intron	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

A	O
reporter	O
construct	O
containing	O
the	O
5'	O
-	O
flanking	O
region	O
of	O
the	O
mouse	O
TNF	O
-	O
alpha	O
gene	O
displayed	O
weak	O
activity	B-Gene_expression
when	B-Positive_regulation
transfected	O
into	O
RAW264.7	O
macrophage	O
-	O
like	O
cells	O
.	O

The	O
addition	O
of	O
the	O
third	O
intron	O
of	O
TNF	O
-	O
alpha	O
to	O
this	O
construct	O
resulted	B-Positive_regulation
in	I-Positive_regulation
an	I-Positive_regulation
enhancement	I-Positive_regulation
of	O
CAT	O
protein	O
.	O

This	O
enhancement	O
was	O
eliminated	B-Negative_regulation
if	O
a	O
conserved	O
20	O
-	O
bp	O
sequence	O
was	O
removed	O
from	O
the	O
intron	O
or	O
if	O
a	O
dominant	O
-	O
negative	O
ets	O
-	O
binding	O
factor	O
was	O
co	O
-	O
transfected	O
with	O
the	O
reporter	O
gene	O
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	O
transcription	O
factor	O
binding	O
sites	O
had	O
reduced	O
transcriptional	O
activity	O
.	O

The	O
major	O
transcription	O
factor	O
that	O
bound	B-Binding
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	O
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

In	O
RAW264.7	O
cells	O
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon	O
-	O
gamma	O
inducible	B-Positive_regulation
.	O

This	O
may	O
imply	O
a	O
role	B-Regulation
for	O
ets	O
transcription	O
factors	O
in	O
the	O
production	B-Gene_expression
of	O
TNF	O
-	O
alpha	O
.	O

Abnormal	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65	O
-	O
RelA	O
protein	O
expression	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	O
receptor	O
-	O
initiated	O
signaling	O
events	O
and	O
lymphokine	O
production	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	O
genes	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
protein	O
complex	O
in	O
lupus	O
T	O
cells	O
.	O

Freshly	O
isolated	O
T	O
cells	O
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
Abs	O
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane	O
-	O
mediated	O
signaling	O
events	O
.	O

We	O
measured	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

When	O
compared	O
with	O
normal	O
cells	O
,	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

Also	O
,	O
NF	O
-	O
kappa	O
B	O
activity	O
remained	O
absent	O
in	O
follow	O
-	O
up	O
studies	O
.	O

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	O
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF	O
-	O
kappa	O
B	O
activity	O
,	O
p65	O
complexes	O
were	O
not	O
formed	O
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	B-Negative_regulation
or	I-Negative_regulation
absent	I-Negative_regulation
p65	O
protein	O
levels	O
.	O

As	O
p65	O
complexes	O
are	O
transcriptionally	B-Positive_regulation
active	I-Positive_regulation
in	O
comparison	O
to	O
the	O
p50	O
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	O
cytokine	O
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

We	O
have	O
studied	O
the	O
effects	B-Regulation
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	B-Gene_expression
of	O
cytokines	O
(	O
IL	O
-	O
2	O
,	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
10	O
)	O
by	O
peripheral	O
T	O
lymphocytes	O
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF	O
-	O
kB	O
DNA	O
binding	O
activity	O
by	O
activated	O
Jurkat	O
cell	O
line	O
.	O

The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	O
production	O
by	O
T	O
lymphocytes	O
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kB	O
in	O
Jurkat	O
cells	O
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	O
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF	O
-	O
kB	O
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue	O
-	O
specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	O
factor	O
.	O

The	O
p53	O
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O

Recent	O
evidence	O
suggests	O
that	O
the	O
p53	O
molecule	O
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	O
p53	O
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	O
type	O
p53	O
that	O
inhibits	O
tumor	O
progression	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
can	O
activate	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
wild	O
type	O
p53	O
in	O
concert	O
with	O
the	O
nuclear	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

Both	O
TNF	O
-	O
alpha	O
and	O
NF	O
-	O
kappa	O
B	O
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	O
cells	O
.	O

In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF	O
-	O
alpha	O
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF	O
-	O
alpha	O
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	B-Regulation
of	O
wild	O
type	O
p53	O
.	O

Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	B-Positive_regulation
TNF	O
-	O
alpha	O
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O

Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	O
necrosis	O
factor	O
on	O
monocytic	O
IkappaB	O
kinase	O
signalsome	O
activation	O
and	O
IkappaB	O
proteolysis	O
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
.	O

This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
signalsome	O
activation	O
and	O
IkappaB	O
phosphorylation/proteolysis	O
in	O
human	O
monocytic	O
cells	O
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	O
proteins	O
IKK	O
-	O
alpha	O
,	O
IKK	O
-	O
beta	O
,	O
NF-kappaB	O
-	O
inducing	O
kinase	O
(	O
NIK	O
)	O
,	O
IKK	O
-	O
gamma	O
(	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
)	O
,	O
and	O
IKK	O
complex	O
-	O
associated	O
protein	O
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	O
elicited	O
a	O
rapid	O
but	O
short	O
-	O
lived	O
induction	O
of	O
IKK	O
activity	O
with	O
a	O
3	O
-	O
fold	O
greater	O
effect	B-Regulation
on	O
IKK	O
-	O
alpha	O
than	O
on	O
IKK	O
-	O
beta	O
,	O
peaking	O
at	O
5	O
min	O
.	O

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	B-Positive_regulation
IKK	O
-	O
beta	O
activity	O
,	O
which	O
slowly	O
increased	B-Positive_regulation
,	O
peaking	O
at	O
30	O
min	O
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	B-Positive_regulation
,	O
which	O
consisted	O
of	O
both	O
IKK	O
-	O
alpha	O
and	O
-	O
beta	O
activity	O
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	B-Binding
of	O
the	O
IKK	O
-	O
alpha/beta	O
heterodimer	O
with	O
NIK	O
,	O
IkappaB	O
-	O
alpha	O
and	O
-	O
epsilon	O
in	O
unstimulated	O
cells	O
.	O

Exposure	O
to	O
LPS	O
or	O
TNF	O
led	B-Positive_regulation
to	O
differential	O
patterns	O
of	O
IkappaB	O
-	O
alpha	O
and	O
IkappaB	O
-	O
epsilon	O
disappearance	B-Binding
from	O
and	O
reassembly	B-Binding
with	O
the	O
signalsome	O
,	O
whereas	O
IKK	O
-	O
alpha	O
,	O
IKK	O
-	O
beta	O
,	O
and	O
NIK	O
remained	B-Regulation
complex	O
-	O
associated	B-Binding
.	O

NIK	O
can	O
not	O
phosphorylate	B-Phosphorylation
IkappaB	O
-	O
alpha	O
directly	O
,	O
but	O
it	O
appears	O
to	O
be	O
a	O
functionally	O
important	O
subunit	O
,	O
because	O
mutated	O
NIK	O
inhibited	O
stimulus	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK	O
-	O
alpha	O
or	O
-	O
beta	O
.	O

Overexpression	O
of	O
IKK	O
complex	O
-	O
associated	O
protein	O
inhibited	O
stimulus	O
-	O
mediated	O
transcription	O
,	O
whereas	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
enhanced	O
it	O
.	O

The	O
understanding	O
of	O
LPS	O
-	O
and	O
TNF	O
-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis	O
-	O
associated	O
disease	O
.	O

Activation	O
of	O
protein	O
kinase	O
C	O
and	O
elevation	O
of	O
cAMP	O
interact	B-Positive_regulation
synergistically	I-Positive_regulation
to	I-Positive_regulation
raise	I-Positive_regulation
c	O
-	O
Fos	O
and	O
AP	O
-	O
1	O
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	O
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	B-Regulation
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
)	O
which	O
stimulates	B-Positive_regulation
PKC	O
and	O
a	O
combination	O
of	O
the	O
adenosine	O
receptor	O
agonist	O
NECA	O
(	O
5'	O
-	O
(	O
N	O
-	O
ethyl	O
)	O
-	O
carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	B-Positive_regulation
of	O
c	O
-	O
Fos	O
and	O
Jun	O
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
increase	B-Positive_regulation
in	O
both	O
c	O
-	O
Fos	O
and	O
Jun	O
immunoreactivity	B-Regulation
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	B-Positive_regulation
only	I-Positive_regulation
a	I-Positive_regulation
slight	I-Positive_regulation
effect	I-Positive_regulation
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	B-Positive_regulation
(	O
c	O
-	O
Fos	O
)	O
or	O
decrease	B-Negative_regulation
(	O
Jun	O
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP	O
-	O
1	O
binding	O
,	O
as	O
judged	O
by	O
gel	O
-	O
shift	O
assay	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

Furthermore	O
there	O
was	O
a	O
clear	O
-	O
cut	O
synergy	O
between	O
the	O
PKC	O
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	B-Positive_regulation
of	O
PKC	O
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP	O
-	O
1	O
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
leukemia	O
cell	O
line	O
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Functional	O
interaction	O
between	O
the	O
two	O
zinc	O
finger	O
domains	O
of	O
the	O
v	O
-	O
erb	O
A	O
oncoprotein	O
.	O

The	O
v	O
-	O
erb	O
A	O
oncogene	O
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	O
cell	O
gene	O
encoding	O
a	O
thyroid	O
hormone	O
receptor	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v	O
-	O
erb	O
A	O
oncogene	O
binds	O
to	O
DNA	O
and	O
acts	B-Negative_regulation
as	I-Negative_regulation
a	I-Negative_regulation
dominant	I-Negative_regulation
negative	I-Negative_regulation
inhibitor	I-Negative_regulation
of	O
both	O
the	O
thyroid	O
hormone	O
receptor	O
and	O
the	O
closely	O
related	O
retinoic	O
acid	O
receptor	O
.	O

The	O
v	O
-	O
erb	O
A	O
protein	O
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA	O
-	O
binding	O
domain	O
relative	O
to	O
that	O
of	O
c	O
-	O
erb	O
A	O
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	B-Regulation
for	O
v	O
-	O
erb	O
A	O
function	O
in	O
the	O
neoplastic	O
cell	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	B-Regulation
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c	O
-	O
erb	O
A	O
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	B-Positive_regulation
function	I-Positive_regulation
to	O
a	O
v	O
-	O
erb	O
A	O
protein	O
rendered	B-Negative_regulation
defective	I-Negative_regulation
due	O
to	O
a	O
mutation	O
at	O
position	O
61	O
.	O

Threonine	O
78	O
lies	O
within	O
the	O
D	O
-	O
box	O
of	O
the	O
v	O
-	O
erb	O
A	O
protein	O
,	O
a	O
region	O
thought	O
to	O
mediate	O
receptor	O
-	O
receptor	O
dimerizations	O
,	O
and	O
is	O
not	O
in	O
physical	O
proximity	O
to	O
the	O
serine	O
at	O
position	O
61	O
.	O

It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	B-Positive_regulation
for	O
v	O
-	O
erb	O
A	O
function	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel/NF	O
-	O
kappa	O
B	O
family	O
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	O
factor	O
,	O
which	O
binds	B-Binding
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	O
class	O
I	O
gene	O
H	O
-	O
2Kb	O
,	O
is	O
indistinguishable	O
from	O
the	O
p50	O
DNA	O
binding	O
subunit	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1/p50	O
factor	O
binds	B-Binding
as	I-Binding
a	I-Binding
homodimer	I-Binding
but	O
can	O
also	O
form	B-Binding
heterodimers	I-Binding
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c	O
-	O
rel	O
and	O
v	O
-	O
rel	O
(	O
proto	O
)	O
oncogenes	O
.	O

The	O
dimerization	O
domain	O
of	O
KBF1/p50	O
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O

A	O
mutant	O
of	O
KBF1/p50	O
(	O
delta	O
SP	O
)	O
,	O
unable	O
to	O
bind	B-Binding
to	O
DNA	O
but	O
able	O
to	O
form	B-Binding
homo	I-Binding
-	I-Binding
or	O
heterodimers	B-Binding
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	B-Negative_regulation
or	I-Negative_regulation
abolishes	I-Negative_regulation
in	O
vitro	O
the	O
DNA	O
binding	B-Binding
activity	O
of	O
wild	O
-	O
type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1/p50	O
,	O
c	O
-	O
and	O
v	O
-	O
rel	O
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	O
-	O
acting	O
dominant	O
negative	O
regulator	O
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-	O
transfected	O
into	O
CD4+	O
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	O
or	O
IL1	O
-	O
induced	O
activity	O
of	O
the	O
MHC	O
class	O
I	O
H	O
-	O
2Kb	O
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel/NF	O
-	O
kappa	O
B	O
family	O
.	O

NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
cells	O
stably	O
expressing	B-Gene_expression
the	O
Tax	O
protein	O
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	O
expression	B-Gene_expression
on	O
the	O
interaction	O
of	O
NF	O
-	O
kappa	O
B	O
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	O
expression	O
vector	O
.	O

Tax	O
expressing	B-Gene_expression
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross	O
-	O
linking	O
using	O
a	O
palindromic	O
NF	O
-	O
kappa	O
B	O
probe	O
homologous	O
to	O
the	O
interferon	O
beta	O
PRDII	O
site	O
.	O

In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	O
binding	O
proteins	O
of	O
85	O
,	O
75	O
,	O
and	O
54	O
kDa	O
,	O
whereas	O
in	O
Tax	O
expressing	B-Gene_expression
cells	O
the	O
85	O
-	O
kDa	O
protein	O
and	O
a	O
92	O
-	O
kDa	O
DNA	O
binding	O
protein	O
were	O
constitutively	O
induced	O
.	O

Expression	B-Gene_expression
of	O
Tax	O
protein	O
in	O
19D	O
and	O
9J	O
resulted	B-Positive_regulation
in	O
transcription	B-Transcription
of	O
the	O
endogenous	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	B-Positive_regulation
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
gene	O
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

Tax	O
expression	B-Gene_expression
in	O
Jurkat	O
T	O
cells	O
may	O
alter	O
the	O
stoichiometry	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
and	O
thus	O
change	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O

Anti	O
-	O
CD2	O
receptor	O
antibodies	O
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	O
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV	O
-	O
infected	O
PBMC	O
with	O
anti	O
-	O
CD2	O
mAb	O
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti	O
-	O
CD2	O
antibodies	O
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti	O
-	O
CD2	O
antibodies	O
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	O
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat	O
-	O
CAT	O
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

These	O
studies	O
suggest	O
that	O
interaction	B-Binding
of	O
CD2	O
with	O
its	O
natural	O
ligand	O
,	O
LFA	O
-	O
3	O
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

v	O
-	O
erbA	O
overexpression	B-Gene_expression
is	O
required	O
to	O
extinguish	B-Negative_regulation
c	O
-	O
erbA	O
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	B-Regulation
of	O
the	O
erbA	O
target	O
gene	O
CAII	O
.	O

The	O
v	O
-	O
erbA	O
oncoprotein	O
represents	O
a	O
retrovirus	O
-	O
transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	O
hormone	O
(	O
T3/T4	O
)	O
receptor	O
c	O
-	O
erbA	O
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus	O
-	O
induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte	O
-	O
specific	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
v	O
-	O
erbA	O
and	O
c	O
-	O
erbA	O
bind	B-Binding
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte	O
-	O
specific	O
carbonic	O
anhydrase	O
II	O
(	O
CAII	O
)	O
,	O
a	O
gene	O
whose	O
transcription	B-Transcription
is	O
efficiently	O
suppressed	B-Negative_regulation
by	O
v	O
-	O
erbA	O
.	O

This	O
erbA	O
-	O
binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	B-Regulation
for	O
efficient	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
CAII	O
transcription	B-Transcription
by	O
the	O
v	O
-	O
erbA	O
oncoprotein	O
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	B-Gene_expression
the	O
v	O
-	O
erbA	O
oncoprotein	O
and	O
the	O
c	O
-	O
erbA/T3	O
receptor	O
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c	O
-	O
erbA	O
activity	O
is	O
dominant	O
over	O
v	O
-	O
erbA	O
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v-erbA	O
-	O
mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	B-Positive_regulation
CAII	O
transcription	B-Transcription
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3	O
-	O
responsive	O
reporter	O
gene	O
containing	O
the	O
CAII	O
-	O
specific	O
erbA	O
-	O
binding	O
site	O
.	O

The	O
c-erbA	O
-	O
dependent	O
activation	O
of	O
this	O
CAII	O
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v	O
-	O
erbA	O
.	O

Our	O
results	O
suggest	O
that	O
overexpression	B-Positive_regulation
of	O
v	O
-	O
erbA	O
is	O
required	B-Positive_regulation
for	O
its	O
function	O
as	O
an	O
oncoprotein	O
.	O

NF	O
-	O
X2	O
that	O
binds	O
to	O
the	O
DRA	O
X2	O
-	O
box	O
is	O
activator	O
protein	O
1	O
.	O

Expression	O
cloning	O
of	O
c	O
-	O
Jun	O
.	O

Human	O
class	O
II	O
MHC	O
Ag	O
are	O
a	O
family	O
of	O
cell	O
surface	O
glycoproteins	O
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN	O
-	O
gamma	O
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue	O
-	O
specific	O
expression	O
of	O
class	O
II	O
genes	O
.	O

In	O
the	O
DRA	O
promoter	O
,	O
one	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
motifs	O
is	O
the	O
X2	O
-	O
box	O
to	O
which	O
nuclear	O
factor	O
X2	O
(	O
NF	O
-	O
X2	O
)	O
binds	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
encoding	O
NF	O
-	O
X2	O
.	O

This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	O
c	O
-	O
Jun	O
protein	O
,	O
which	O
together	O
with	O
c	O
-	O
Fos	O
forms	O
the	O
heterodimeric	O
activator	O
protein	O
-	O
1	O
transcription	O
complex	B-Binding
.	O

Whereas	O
c-Fos/c	O
-	O
Jun	O
heterodimers	O
do	O
not	O
exist	B-Gene_expression
in	O
B	O
cells	O
,	O
they	O
form	B-Binding
and	O
bind	B-Binding
to	O
the	O
X2	O
-	O
box	O
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O

Thus	O
,	O
c-Fos/c	O
-	O
Jun	O
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	B-Negative_regulation
of	O
DRA	O
gene	O
expression	B-Gene_expression
.	O

Regulation	B-Regulation
of	O
jun	O
and	O
fos	O
gene	B-Gene_expression
expression	I-Gene_expression
in	O
human	O
monocytes	O
by	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O

The	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	B-Regulation
of	O
M	O
-	O
CSF	O
on	O
potential	O
signaling	O
pathways	O
involving	B-Regulation
expression	B-Gene_expression
of	O
the	O
jun	O
and	O
fos	O
early	O
response	O
genes	O
.	O

Low	O
levels	O
of	O
c	O
-	O
jun	O
transcripts	B-Transcription
were	O
detectable	B-Positive_regulation
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units/ml	O
human	O
recombinant	O
M	O
-	O
CSF	O
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	B-Positive_regulation
in	O
c	O
-	O
jun	O
mRNA	O
levels	B-Transcription
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M	O
-	O
CSF	O
regulates	B-Regulation
c	O
-	O
jun	O
expression	B-Gene_expression
by	O
both	O
an	O
increase	B-Positive_regulation
in	O
transcription	B-Transcription
rate	O
and	O
a	O
prolongation	B-Positive_regulation
in	I-Positive_regulation
the	I-Positive_regulation
half	I-Positive_regulation
-	I-Positive_regulation
life	I-Positive_regulation
of	O
c	O
-	O
jun	O
transcripts	O
.	O

M	O
-	O
CSF	O
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	B-Positive_regulation
of	O
the	O
jun	O
-	O
B	O
gene	O
,	O
although	O
expression	B-Gene_expression
of	O
this	O
gene	O
was	O
prolonged	B-Positive_regulation
compared	O
to	O
that	O
of	O
c	O
-	O
jun	O
.	O

We	O
further	O
demonstrate	O
that	O
M	O
-	O
CSF	O
increases	B-Positive_regulation
c	O
-	O
fos	O
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	B-Positive_regulation
of	O
the	O
c	O
-	O
fos	O
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos	O
-	O
B	O
gene	O
.	O

Moreover	O
,	O
M-CSF	O
-	O
induced	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
fos	O
-	O
related	O
gene	O
,	O
fra	O
-	O
1	O
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c	O
-	O
fos	O
and	O
fos	O
-	O
B	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M	O
-	O
CSF	O
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun/fos	O
family	O
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O

cAMP	O
-	O
dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	O
and	O
JunB	O
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP	O
-	O
1	O
proteins	O
.	O

We	O
demonstrate	O
that	O
JunD	O
,	O
a	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
complex	O
,	O
activates	O
transcription	O
of	O
the	O
human	O
proenkephalin	O
gene	O
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
protein	O
kinase	O
A	O
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	O
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP	O
-	O
,	O
phorbol	O
ester	O
-	O
,	O
and	O
Ca	O
(	O
2+	O
)	O
-	O
inducible	O
enhancer	O
,	O
and	O
JunD	O
is	O
shown	O
to	O
bind	B-Binding
the	O
enhancer	O
as	O
a	O
homodimer	O
.	O

Another	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
complex	O
,	O
JunB	O
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	O
.	O

As	O
a	O
homodimer	O
JunB	O
is	O
unable	O
to	O
bind	B-Binding
the	O
enhancer	O
;	O
however	O
in	B-Positive_regulation
the	I-Positive_regulation
presence	I-Positive_regulation
of	I-Positive_regulation
c	O
-	O
Fos	O
,	O
high	O
-	O
affinity	O
binding	B-Binding
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	O
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	O
kinase	O
A	O
-	O
dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1	O
-	O
related	O
protein	O
is	O
regulated	O
by	O
the	O
cAMP	O
-	O
dependent	O
second	O
-	O
messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	O
and	O
other	O
AP-1	O
-	O
related	O
proteins	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP	O
-	O
dependent	O
intracellular	O
signaling	O
pathways	O
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB	O
-	O
985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	O
on	O
the	O
cell	O
surface	O
,	O
PLB	O
-	O
985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV	O
-	O
1	O
strain	O
IIIB	O
.	O

PLB	O
-	O
IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	B-Positive_regulation
expression	O
of	O
the	O
myeloid	O
-	O
specific	O
surface	O
markers	O
,	O
and	O
transcription	B-Transcription
of	O
the	O
c	O
-	O
fms	O
proto	O
-	O
oncogene	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
inducible	O
by	O
tumor	O
necrosis	O
factor	O
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB	O
-	O
985	O
.	O

However	O
,	O
in	O
PLB	O
-	O
IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF	O
-	O
kappa	O
B	O
complex	O
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	B-Binding
specifically	O
with	O
the	O
symmetric	O
NF	O
-	O
kappa	O
B	O
site	O
from	O
the	O
interferon	O
beta	O
(	O
IFN	O
-	O
beta	O
)	O
promoter	O
.	O

Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	O
to	O
compete	O
for	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
proteins	O
.	O

Inducibility	B-Transcription
of	O
endogenous	O
IFN	O
-	O
beta	O
and	O
IFN	O
-	O
alpha	O
RNA	O
was	O
also	O
increased	B-Positive_regulation
in	O
PLB	O
-	O
IIIB	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
HIV	O
-	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
may	O
contribute	O
to	O
differential	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

The	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
,	O
but	O
not	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	O
kinase	O
C	O
in	O
the	O
interleukin	O
2	O
promoter	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation	O
-	O
related	O
genes	O
.	O

We	O
have	O
examined	O
the	O
potential	O
role	B-Regulation
of	O
PKC	O
in	O
induction	B-Gene_expression
of	O
the	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	O
cell	O
receptor/CD3	O
complex	O
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar	O
-	O
5	O
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	O
and	O
beta	O
isozymes	O
of	O
PKC	O
,	O
and	O
abrogates	B-Negative_regulation
induction	B-Transcription
of	O
IL	O
-	O
2	O
mRNA	O
and	O
protein	O
.	O

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	B-Negative_regulation
induction	B-Positive_regulation
of	O
chloramphenicol	O
acetyltransferase	O
activity	O
in	O
Ar	O
-	O
5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL	O
-	O
2	O
promoter	O
linked	O
to	O
this	O
reporter	O
gene	O
.	O

The	O
IL	O
-	O
2	O
promoter	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factors	O
including	O
NFAT	O
-	O
1	O
,	O
Oct	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
AP	O
-	O
1	O
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	O
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	O
and	O
Oct	O
sites	O
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
have	O
no	O
effect	B-Regulation
on	O
inducibility	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP	O
-	O
1	O
site	O
located	O
at	O
-	O
150	O
bp	O
almost	O
completely	O
abrogate	B-Negative_regulation
induction	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
,	O
and	O
appearance	O
of	O
an	O
inducible	O
nuclear	O
factor	O
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	O
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
expression	B-Gene_expression
plasmids	O
markedly	O
enhance	B-Positive_regulation
induction	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	O
responsiveness	O
in	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U	O
-	O
937	O
and	O
HL	O
-	O
60	O
by	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
induced	O
differentiation	O
,	O
with	O
c	O
-	O
jun	O
expression	B-Gene_expression
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP	O
-	O
1	O
complexes	O
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP	O
-	O
1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP	O
-	O
1	O
regulated	O
genes	O
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP	O
-	O
1	O
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c	O
-	O
jun	O
expression	B-Gene_expression
,	O
the	O
generation	O
of	O
AP	O
-	O
1	O
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	O
complex	O
during	O
this	O
process	O
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	O
nuclear	O
factor	O
-	O
1	O
alpha	O
(	O
HNF	O
-	O
1	O
alpha	O
)	O
is	O
a	O
homeodomain	O
-	O
containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	O
cofactor	O
of	O
HNF	O
-	O
1	O
alpha	O
(	O
DCoH	O
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	B-Localization
and	O
did	O
not	O
bind	B-Binding
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	B-Positive_regulation
HNF	O
-	O
1	O
alpha	O
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH-HNF	O
-	O
1	O
alpha	O
complex	B-Binding
,	O
which	O
required	B-Positive_regulation
the	O
dimerization	O
domain	O
of	O
HNF	O
-	O
1	O
alpha	O
,	O
did	O
not	O
change	B-Regulation
the	O
DNA	O
binding	B-Binding
characteristics	O
of	O
HNF	O
-	O
1	O
alpha	O
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	O
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
.	O

These	O
results	O
indicate	O
that	O
DCoH	O
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
activates	B-Positive_regulation
proenkephalin	O
transcription	B-Transcription
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	O
mRNA	O
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	B-Positive_regulation
of	O
the	O
proenkephalin	O
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	B-Negative_regulation
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	B-Binding
(	O
two	O
p50s	O
)	O
of	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
binds	B-Binding
the	O
B2	O
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B-Binding
(	O
two	O
p65s	O
plus	O
two	O
p50s	O
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T-cell	O
-	O
specific	O
activation	B-Positive_regulation
of	O
the	O
proenkephalin	O
promoter	O
is	O
mediated	B-Positive_regulation
by	O
NF	O
-	O
kappa	O
B	O
.	O

However	O
,	O
as	O
NF	O
-	O
kappa	O
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T-cell	O
-	O
specific	O
factor	O
which	O
synergizes	O
with	O
NF	O
-	O
kappa	O
B	O
should	O
be	O
considered	O
.	O

ETS1	O
transactivates	B-Positive_regulation
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
is	O
one	O
such	O
cytokine	O
whose	O
increased	B-Positive_regulation
expression	B-Gene_expression
results	O
partly	O
from	O
increases	B-Positive_regulation
in	O
transcription	B-Transcription
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NF	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
are	O
expressed	B-Gene_expression
in	O
T	O
cells	O
,	O
including	O
ETS1	O
and	O
ELF1	O
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	B-Binding
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-	O
47	O
to	O
-	O
40	O
upstream	O
of	O
the	O
GM	O
-	O
CSF	O
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	O
,	O
but	O
not	O
ELF1	O
,	O
can	O
transactivate	B-Positive_regulation
GM	O
-	O
CSF	O
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA/ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS	O
-	O
like	O
factors	O
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-GGAA	O
-	O
to	O
-GGAT	O
-	O
prevents	O
the	O
binding	B-Binding
of	O
ETS	O
-	O
like	O
factors	O
with	O
the	O
exception	B-Negative_regulation
of	O
ETS1	O
.	O

The	O
GM	O
-	O
CSF	O
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	O
specific	B-Binding
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	B-Positive_regulation
,	O
in	O
addition	O
to	O
ETS1	O
transactivation	B-Positive_regulation
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	O
may	O
be	O
involved	B-Regulation
in	O
mediating	B-Positive_regulation
the	O
increased	B-Positive_regulation
GM	O
-	O
CSF	O
production	B-Gene_expression
associated	O
with	O
T	O
cell	O
activation	O
.	O

Tissue	O
-	O
specific	O
regulation	B-Regulation
of	O
the	O
rabbit	O
15	O
-	O
lipoxygenase	O
gene	O
in	O
erythroid	O
cells	O
by	O
a	O
transcriptional	O
silencer	O
.	O

The	O
15	O
-	O
lipoxygenase	O
(	O
lox	O
)	O
gene	O
is	O
expressed	B-Gene_expression
in	O
a	O
tissue	O
-	O
specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	O
cells	O
but	O
also	O
in	O
airway	O
epithelial	O
cells	O
and	O
eosinophils	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
15	O
-	O
lox	O
gene	O
contains	O
sequences	O
which	O
down	B-Negative_regulation
-	I-Negative_regulation
regulate	I-Negative_regulation
its	O
activity	O
in	O
a	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
lines	O
but	O
not	O
in	O
two	O
erythroid	O
cell	O
lines	O
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	O
'silencer	O
'	O
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O

The	O
main	O
activity	O
of	O
the	O
silencer	O
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	O
factor	O
present	O
in	O
non	O
-	O
erythroid	O
cells	O
but	O
not	O
in	O
erythroid	O
cells	O
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	O
sites	O
confer	O
tissue	O
-	O
specific	O
down	O
-	O
regulation	O
when	O
attached	O
to	O
a	O
minimal	O
lox	O
promoter	O
fragment	O
.	O

The	O
5	O
'	O
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	O
sites	O
for	O
the	O
GATA	O
family	O
of	O
transcription	O
factors	O
.	O

Coexpression	B-Gene_expression
of	O
NF	O
-	O
kappa	O
B/Rel	O
and	O
Sp1	O
transcription	O
factors	O
in	O
human	O
immunodeficiency	O
virus	O
1	O
-	O
induced	O
,	O
dendritic	O
cell-T	O
-	O
cell	O
syncytia	O
.	O

Productive	O
infection	O
of	O
T	O
cells	O
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
typically	O
requires	O
that	O
the	O
T	O
cells	O
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O

This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
synergizes	O
with	O
the	O
constitutive	O
transcription	O
factor	O
Sp1	O
to	O
drive	O
the	O
HIV	O
-	O
1	O
promoter	O
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV	O
-	O
1	O
takes	O
place	O
in	O
nonactivated	O
memory	O
T	O
cells	O
after	O
syncytium	O
formation	O
with	O
dendritic	O
cells	O
(	O
DCs	O
)	O
.	O

These	O
syncytia	O
lack	O
activated	O
cells	O
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki	O
-	O
67	O
cell	O
cycle	O
antigen	O
.	O

The	O
expression	B-Gene_expression
and	O
activity	B-Positive_regulation
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	O
cells	O
and	O
DCs	O
from	O
humans	O
and	O
mice	O
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

T	O
cells	O
lack	O
active	O
NF	O
-	O
kappa	O
B	O
but	O
express	B-Gene_expression
Sp1	O
as	O
expected	O
.	O

DCs	O
express	O
high	O
levels	O
of	O
all	O
known	O
NF	O
-	O
kappa	O
B	O
and	O
Rel	O
proteins	O
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	O
,	O
p50	O
,	O
and	O
p65	O
.	O

However	O
,	O
DCs	O
lack	B-Gene_expression
Sp1	O
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV	O
-	O
1	O
to	O
replicate	O
in	O
purified	O
DCs	O
.	O

Coexpression	B-Gene_expression
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
occurs	O
in	O
the	O
heterologous	O
DC-T	O
-	O
cell	O
syncytia	O
that	O
are	O
induced	O
by	O
HIV	O
-	O
1	O
.	O

Therefore	O
,	O
HIV-1	O
-	O
induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Since	O
DCs	O
and	O
memory	O
T	O
cells	O
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	O
syncytia	O
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV	O
-	O
1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O

Costimulation	O
requirement	O
for	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
activation	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	B-Transcription
activity	I-Transcription
of	O
the	O
IL	O
-	O
2	O
promoter	O
requires	B-Positive_regulation
T	O
-	O
cell	O
costimulation	O
delivered	O
by	O
the	O
TCR	O
and	O
the	O
auxiliary	O
receptor	O
CD28	O
.	O

Several	O
transcription	O
factors	O
participate	B-Regulation
in	O
IL	O
-	O
2	O
promoter	O
activation	B-Positive_regulation
,	O
among	O
which	O
are	O
AP-1	O
-	O
like	O
factors	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP	O
-	O
1	O
protein	O
c	O
-	O
Jun	O
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
from	O
NF	O
-	O
kappa	O
B	O
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T	O
-	O
cell	O
costimulation	O
.	O

Furthermore	O
,	O
in	O
activated	O
T	O
cells	O
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O

Whereas	O
TPCK	O
inhibits	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	O
,	O
the	O
MAP	O
kinase	O
-	O
related	O
kinase	O
that	O
phosphorylates	B-Phosphorylation
the	O
transactivation	O
domain	O
of	O
c	O
-	O
Jun	O
.	O

We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T	O
-	O
cell	O
costimulation	O
.	O

Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	O
and	O
CD28	O
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	B-Positive_regulation
I	O
kappa	O
B	O
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	O
activation	O
and	O
c	O
-	O
Jun	O
phosphorylation	B-Phosphorylation
on	O
the	O
other	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1/NF	O
-	O
kappa	O
B	O
pathway	O
.	O

Cupric	O
ion	O
blocks	O
NF	O
kappa	O
B	O
activation	O
through	O
inhibiting	B-Negative_regulation
the	O
signal	O
-	O
induced	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
.	O

A	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	B-Binding
with	O
an	O
inhibitory	O
protein	O
I	O
kappa	O
B	O
.	O

Various	O
extracellular	O
signals	O
induce	B-Positive_regulation
phosphorylation	B-Phosphorylation
and	O
rapid	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
to	O
release	O
NF	O
kappa	O
B	O
.	O

Cu2+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
induced	O
by	O
TNF	O
-	O
alpha	O
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	O
-	O
alpha	O
in	O
the	O
presence	O
of	O
Cu2+	O
resulted	O
in	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
from	O
I	O
kappa	O
B	O
alpha	O
,	O
indicating	O
that	O
Cu2+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	O
kappa	O
B	O
-	O
I	O
kappa	O
B	O
complex	O
.	O

Neither	O
phosphorylation	B-Phosphorylation
nor	O
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
was	O
observed	O
upon	O
TNF	O
-	O
alpha	O
stimulation	O
in	B-Positive_regulation
the	I-Positive_regulation
presence	I-Positive_regulation
of	I-Positive_regulation
Cu2+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2+	O
inhibits	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
by	O
blockade	B-Negative_regulation
of	O
a	O
signal	O
leading	B-Positive_regulation
to	O
the	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Binding	B-Binding
of	O
plasma	O
Factor	O
VII/VIIa	O
to	O
the	O
tissue	O
factor	O
(	O
TF	O
)	O
receptor	O
initiates	O
the	O
coagulation	O
protease	O
cascades	O
.	O

TF	O
expression	B-Gene_expression
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
human	O
TF	O
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	B-Positive_regulation
by	O
binding	B-Binding
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
to	O
a	O
kappa	O
B	O
site	O
in	O
the	O
TF	O
promoter	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	B-Negative_regulation
LPS	O
induction	B-Positive_regulation
of	O
TF	O
activity	O
and	O
TF	O
gene	O
transcription	B-Transcription
in	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	B-Negative_regulation
the	O
LPS	O
-	O
induced	B-Positive_regulation
proteolytic	B-Protein_catabolism
degradation	I-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
,	O
which	O
prevented	B-Negative_regulation
the	O
nuclear	O
translocation	B-Localization
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	B-Negative_regulation
LPS	O
induction	B-Positive_regulation
of	O
the	O
TF	O
gene	O
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	B-Negative_regulation
LPS	O
induction	B-Positive_regulation
of	O
TF	O
gene	O
transcription	B-Transcription
in	O
monocytic	O
cells	O
by	O
preventing	B-Negative_regulation
nuclear	O
translocation	B-Localization
of	O
c	O
-	O
Rel/p65	O
heterodimers	O
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

CIITA	O
activates	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
.	O

It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	O
class	O
II	O
molecules	O
are	O
expressed	O
in	O
human	O
T	O
cells	O
after	O
activation	O
but	O
not	O
in	O
mouse	O
T	O
cells	O
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O

Recently	O
the	O
MHC	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
regulatory	O
factor	O
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

Here	O
we	O
show	O
that	O
human	O
T	O
cells	O
expressing	O
MHC	O
class	O
II	O
have	B-Transcription
CIITA	O
transcripts	O
while	O
MHC	O
class	O
II	O
-	O
negative	O
human	O
T	O
cells	O
and	O
mouse	O
T	O
cells	O
do	O
not	O
.	O

The	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	B-Gene_expression
with	O
the	O
human	O
CIITA	O
cDNA	O
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	B-Gene_expression
of	O
CIITA	O
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	O
class	O
II	O
in	O
human	O
and	O
mouse	O
T	O
cells	O
respectively	O
.	O

Identification	O
of	O
an	O
I	O
kappa	O
B	O
alpha	O
-	O
associated	O
protein	O
kinase	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
and	O
determination	O
of	O
its	O
phosphorylation	O
sites	O
on	O
I	O
kappa	O
B	O
alpha	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	O
kappa	O
B	O
.	O

Stimulation	O
of	O
cells	O
leads	B-Positive_regulation
to	O
a	O
rapid	O
phosphorylation	B-Phosphorylation
of	O
I	O
kappa	O
B	O
alpha	O
,	O
which	O
is	O
presumed	O
to	O
be	B-Positive_regulation
important	I-Positive_regulation
for	O
the	O
subsequent	O
degradation	B-Protein_catabolism
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
dependent	O
cell	O
-	O
free	O
activation	O
system	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
association	O
with	O
the	O
induction	B-Positive_regulation
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	B-Phosphorylation
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	O
in	O
cell	O
extracts	O
from	O
the	O
LPS	O
-	O
stimulated	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
that	O
specifically	O
binds	B-Binding
and	O
phosphorylates	B-Phosphorylation
I	O
kappa	O
B	O
alpha	O
.	O

LPS	O
stimulation	O
transiently	O
enhanced	B-Positive_regulation
the	O
I	O
kappa	O
B	O
alpha	O
-	O
bound	B-Binding
kinase	O
activity	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Mutational	O
analyses	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	B-Phosphorylation
sites	I-Phosphorylation
by	B-Positive_regulation
the	O
bound	O
kinase	O
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
blocked	B-Negative_regulation
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	B-Phosphorylation
of	O
endogenous	O
I	O
kappa	O
B	O
alpha	O
in	O
a	O
cell	O
-	O
free	O
system	O
using	O
THP	O
-	O
1	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	O
kinase	O
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	B-Positive_regulation
the	O
phosphorylation	B-Phosphorylation
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
subsequent	O
dissociation	O
of	O
the	O
NF	O
-	O
kappa	O
B.I	O
kappa	O
B	O
alpha	O
complex	B-Binding
.	O

Triggering	B-Positive_regulation
of	O
the	O
human	O
interleukin	O
-	O
6	O
gene	O
by	O
interferon	O
-	O
gamma	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
in	O
monocytic	O
cells	O
involves	B-Regulation
cooperation	I-Regulation
between	O
interferon	O
regulatory	O
factor	O
-	O
1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
Sp1	O
transcription	O
factors	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	B-Positive_regulation
by	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
/tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
of	O
human	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
gene	O
in	O
THP	O
-	O
1	O
monocytic	O
cells	O
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	B-Positive_regulation
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Functional	O
studies	O
with	O
IL	O
-	O
6	O
promoter	O
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN	O
-	O
gamma	O
and/or	O
TNF	O
-	O
alpha	O
action	B-Regulation
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O

The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-	O
73	O
and	O
-	O
36	O
,	O
which	O
is	O
the	O
minimal	O
element	O
inducible	O
by	O
LPS	O
or	O
TNF	O
-	O
alpha	O
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-	O
181	O
and	O
-	O
73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	O
element	O
upstream	O
of	O
-	O
224	O
,	O
which	O
was	O
inducible	O
by	O
IFN	O
-	O
gamma	O
alone	O
.	O

LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	O
kappa	O
B	O
activation	B-Positive_regulation
by	O
the	O
p50/p65	O
heterodimers	O
.	O

Synergistic	O
induction	B-Positive_regulation
of	O
the	O
IL	O
-	O
6	O
gene	O
by	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
,	O
in	O
monocytic	O
cells	O
,	O
involved	B-Positive_regulation
cooperation	O
between	O
the	O
IRF	O
-	O
1	O
and	O
NF	O
kappa	O
B	O
p65	O
homodimers	O
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	O
control	O
element	O
present	O
in	O
the	O
IL	O
-	O
6	O
promoter	O
.	O

This	O
removal	O
occurred	O
by	O
activation	B-Positive_regulation
of	O
the	O
constitutive	O
Sp1	O
factor	O
,	O
whose	O
increased	B-Positive_regulation
binding	B-Binding
activity	I-Binding
and	O
phosphorylation	B-Phosphorylation
were	O
mediated	B-Positive_regulation
by	O
IFN	O
-	O
gamma	O
.	O

The	O
lymphotoxin	O
promoter	O
is	O
stimulated	O
by	O
HTLV	O
-	O
I	O
tax	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
T	O
-	O
cell	O
lines	O
.	O

The	O
HTLV	O
-	O
I	O
transcriptional	O
activator	O
tax	O
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	O
(	O
LT	O
;	O
TNF	O
-	O
beta	O
)	O
gene	O
induction	B-Gene_expression
.	O

Tax	O
-	O
expressing	O
cell	O
lines	O
produce	O
LT	O
biologic	O
activity	O
.	O

An	O
LT	O
promoter	O
(	O
LT	O
-	O
293	O
)	O
CAT	O
construct	O
that	O
contained	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
was	O
active	O
in	O
the	O
LT	O
-	O
producing	O
C81-66	O
-	O
45	O
cell	O
line	O
,	O
which	O
contains	O
defective	O
HTLV	O
-	O
I	O
but	O
expresses	B-Gene_expression
tax	O
.	O

The	O
observation	O
that	O
a	O
mutated	O
LT	O
-	O
kappa	O
B	O
construct	O
(	O
M1	O
-	O
CAT	O
)	O
was	O
inactive	B-Positive_regulation
in	O
C81-66	O
-	O
45	O
,	O
confirmed	O
the	O
importance	B-Positive_regulation
of	O
NF	O
-	O
kappa	O
B	O
in	O
LT	O
gene	O
expression	B-Gene_expression
.	O

Tax	O
was	O
transfected	O
into	O
HTLV-I	O
-	O
negative	O
human	O
T	O
-	O
cell	O
lines	O
.	O

Jurkat	O
T	O
cells	O
stably	O
expressing	B-Gene_expression
tax	O
contained	O
elevated	O
levels	O
of	O
NF	O
-	O
kappa	O
B	O
that	O
directly	O
bound	O
to	O
the	O
LT	O
-	O
kappa	O
B	O
site	O
.	O

Tax	O
co	O
-	O
transfected	B-Positive_regulation
with	O
reporter	O
constructs	O
into	O
Jurkat	O
cells	O
maximally	O
activated	O
HTLV-I-LTR	O
-	O
CAT	O
and	O
kappa	O
B-fos	O
-	O
CAT	O
and	O
also	O
activated	O
LT	O
-	O
293	O
to	O
a	O
lesser	O
extent	O
.	O

In	O
JM	O
T	O
cells	O
,	O
tax	O
induced	O
LT	O
-	O
293	O
activity	O
by	O
two	O
-	O
to	O
four	O
-	O
fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1	O
-	O
CAT	O
.	O

The	O
increase	O
in	O
LT	O
-	O
293	O
CAT	O
activity	O
mirrored	O
the	O
increase	O
in	O
LT	O
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	O
promoter	O
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV	O
-	O
I	O
tax	O
causes	O
low	O
-	O
level	O
activation	O
of	O
both	O
endogenous	O
LT	O
and	O
the	O
LT	O
promoter	O
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T	O
-	O
cell	O
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	O
tyrosine	O
phosphatases	O
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T	O
-	O
lymphocytes	O
.	O

The	O
regulatory	O
role	O
of	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	O
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	O
human	O
leukaemic	O
T	O
-	O
cells	O
.	O

Pervanadate	O
induced	O
activation	B-Positive_regulation
of	O
the	O
tyrosine	O
kinases	O
lck	O
and	O
fyn	O
(	O
4	O
-	O
and	O
3	O
-	O
fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	B-Positive_regulation
in	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
cellular	O
proteins	O
,	O
notably	O
phospholipase	O
C	O
gamma	O
1	O
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	B-Gene_expression
of	O
the	O
CD45	O
PTPase	O
and	O
was	O
not	O
observed	O
in	O
CD45	O
-	O
deficient	O
variants	O
of	O
Jurkat	O
cells	O
.	O

In	O
the	O
CD45	O
-	O
negative	O
variant	O
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Pervanadate	O
also	O
stimulated	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
c	O
-	O
fos	O
gene	O
and	O
accumulation	B-Positive_regulation
of	O
its	O
mRNA	O
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T	O
-	O
lymphocyte	O
activation	O
such	O
as	O
surface	O
expression	B-Gene_expression
of	O
the	O
CD69	O
antigen	O
and	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
CD25	O
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T	O
-	O
cell	O
antigen	O
receptor	O
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	O
2	O
production	O
.	O

Pervanadate	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA	O
-	O
binding	O
activity	O
of	O
this	O
transcription	O
factor	O
.	O

We	O
thus	O
conclude	O
that	O
PTPases	O
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T	O
-	O
lymphocyte	O
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

The	O
interleukin	O
-	O
8	O
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
genetic	O
end	O
targets	B-Regulation
of	O
FK506	O
-	O
sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	O
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	B-Negative_regulation
the	O
transcription	B-Transcription
of	O
a	O
chemotactic	O
cytokine	O
,	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
cells	O
,	O
activated	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL	O
-	O
8	O
promoters	O
,	O
the	O
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	B-Negative_regulation
the	O
transcriptions	O
through	B-Positive_regulation
the	O
AP	O
-	O
1	O
or	O
kappa	O
B	O
-	O
like	O
sites	O
induced	B-Positive_regulation
by	O
PMA	O
plus	O
Ca	O
(	O
2+	O
)	O
-	O
mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	B-Positive_regulation
by	O
Ca	O
(	O
2+	O
)	O
-	O
independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP	O
-	O
1	O
site	O
of	O
PMA/ionomycin	O
-	O
induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	B-Binding
with	O
anti	O
-	O
JunD	O
or	O
c	O
-	O
Fos	O
antibody	O
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	O
B	O
-	O
like	O
site	O
binding	O
complexes	O
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	O
against	O
the	O
human	O
Rel	O
family	O
proteins	O
(	O
c	O
-	O
Rel	O
,	O
p65	O
,	O
p50	O
,	O
and	O
p49	O
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA/ionomycin	O
-	O
induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF	O
-	O
kappa	O
B	O
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL	O
-	O
8	O
kappa	O
B	O
-	O
like	O
site	O
and	O
Ig	O
kappa	O
B	O
site	O
are	O
FK506	O
-	O
sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	O
factors	O
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL	O
-	O
2	O
NF	O
-	O
AT	O
and	O
NFIL	O
-	O
2A	O
sites	O
and	O
Ig	O
kappa	O
B	O
site	O
,	O
but	O
also	O
the	O
IL	O
-	O
8	O
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
terminals	B-Regulation
of	O
FK506	O
-	O
sensitive	O
pathway	O
involving	O
Ca2+	O
mobilization	O
.	O

Monocyte	O
tethering	O
by	O
P	O
-	O
selectin	O
regulates	B-Regulation
monocyte	O
chemotactic	O
protein	O
-	O
1	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
secretion	B-Localization
.	O

Signal	O
integration	O
and	O
NF	O
-	O
kappa	O
B	O
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	O
molecules	O
that	O
tether	O
circulating	O
leukocytes	O
to	O
endothelial	O
cells	O
may	O
also	O
transduce	O
or	O
modulate	O
outside	O
-	O
in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	O
monocytes	O
to	O
P	O
-	O
selectin	O
,	O
the	O
most	O
rapidly	O
expressed	B-Gene_expression
endothelial	O
tethering	O
factor	O
,	O
increased	B-Positive_regulation
the	O
secretion	B-Localization
of	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
by	O
the	O
leukocytes	O
when	B-Positive_regulation
they	O
were	O
stimulated	O
with	O
platelet	O
-	O
activating	O
factor	O
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	O
,	O
an	O
anti-P	O
-	O
selectin	O
mAb	O
that	O
prevents	B-Negative_regulation
P	O
-	O
selectin	O
from	O
binding	B-Binding
to	O
its	O
ligand	O
(	O
P	O
-	O
selectin	O
glycoprotein	O
ligand	O
-	O
1	O
)	O
on	O
myeloid	O
cells	O
.	O

Moreover	O
,	O
tethering	O
by	O
P	O
-	O
selectin	O
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
required	B-Positive_regulation
for	O
expression	B-Gene_expression
of	O
MCP	O
-	O
1	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
other	O
immediate	O
-	O
early	O
genes	O
.	O

These	O
results	O
demonstrate	O
that	O
P	O
-	O
selectin	O
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	O
secretion	O
in	O
inflamed	O
tissues	O
.	O

HMG	O
-	O
I	O
binds	B-Binding
to	O
GATA	O
motifs	O
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

We	O
have	O
examined	O
binding	B-Binding
of	O
the	O
nuclear	O
protein	O
HMG	O
-	O
I	O
to	O
the	O
human	O
gamma	O
-	O
globin	O
promoter	O
.	O

We	O
find	O
that	O
HMG	O
-	O
I	O
binds	B-Binding
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	O
motifs	O
in	O
the	O
gamma	O
-	O
globin	O
promoter	O
;	O
this	O
paired	O
motif	O
is	O
bound	B-Binding
by	O
the	O
erythroid	O
factor	O
GATA	O
-	O
1	O
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-	O
175	O
T	O
-	O
C	O
)	O
in	O
the	O
area	O
bound	B-Binding
by	O
HMG	O
-	O
I	O
results	O
in	O
overexpression	O
of	O
gamma	O
-	O
globin	O
in	O
adult	O
red	O
blood	O
cells	O
(	O
HPFH	O
)	O
and	O
up	O
-	O
regulation	O
of	O
the	O
gamma	O
-	O
globin	O
promoter	O
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG	O
-	O
I	O
does	O
not	O
bind	B-Binding
to	O
this	O
mutant	O
sequence	O
.	O

A	O
survey	O
of	O
GATA	O
motifs	O
from	O
other	O
globin	O
cis	O
-	O
elements	O
demonstrates	O
HMG	O
-	O
I	O
binding	B-Binding
to	O
most	O
of	O
them	O
.	O

These	O
findings	O
implicate	O
HMG	O
-	O
I	O
in	O
the	O
HPFH	O
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	O
complexes	O
that	O
regulate	O
globin	O
gene	O
expression	O
.	O

Positive	O
and	O
negative	B-Negative_regulation
regulation	I-Negative_regulation
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
promoter	O
activity	O
by	O
AML1	O
-	O
related	O
transcription	O
factor	O
,	O
PEBP2	O
.	O

The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	O
enhancer	O
binding	O
-	O
protein	O
2	O
(	O
PEBP2	O
)	O
transcription	O
factor	O
,	O
which	O
consists	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	O
A	O
and	O
alpha	O
B	O
,	O
encoding	O
the	O
alpha	O
subunit	O
.	O

alpha	O
B	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
AML1	O
gene	O
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	O
A1	O
(	O
an	O
alpha	O
A	O
-	O
gene	O
product	O
)	O
and	O
alpha	O
B1	O
and	O
alpha	O
B2	O
(	O
two	O
alpha	O
B	O
-	O
encoded	O
isomers	O
)	O
for	O
their	O
effects	B-Regulation
on	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O

PEBP2	O
alpha	O
A1	O
,	O
alpha	O
B1	O
,	O
and	O
alpha	O
B2	O
proteins	O
bound	B-Binding
the	O
PEBP2	O
site	O
within	O
the	O
mouse	O
GM	O
-	O
CSF	O
promoter	O
.	O

PEBP2	O
alpha	O
A1	O
and	O
alpha	O
B1	O
enhanced	O
the	O
expression	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
-	O
driven	O
reporter	O
plasmid	O
in	O
unstimulated	O
and	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate/phytohemagglutinin	O
-	O
stimulated	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	B-Negative_regulation
by	O
alpha	O
B2	O
.	O

Coexpression	B-Gene_expression
of	O
alpha	O
B1	O
and	O
alpha	O
B2	O
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	B-Regulation
by	O
the	O
alpha	O
B1/alpha	O
B2	O
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	O
site	O
-	O
binding	O
protein	O
(	O
s	O
)	O
that	O
cross	O
-	O
reacted	O
with	O
antimouse	O
alpha	O
A1	O
antibodies	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	B-Gene_expression
of	O
human	O
PEBP2	O
alpha	O
A	O
,	O
alpha	O
B	O
(	O
AML1	O
)	O
,	O
and	O
beta	O
genes	O
in	O
Jurkat	O
cells	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	B-Regulation
of	O
PEBP2	O
in	O
the	O
GM	O
-	O
CSF	O
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	B-Regulation
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	O
isoforms	O
in	O
regulating	B-Regulation
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

Differential	O
induction	O
of	O
the	O
NF	O
-	O
AT	O
complex	O
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T	O
-	O
cell	O
anergy	O
.	O

Stimulation	O
of	O
human	O
CD4+	O
T	O
-	O
cell	O
clones	O
through	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long	O
-	O
lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	O
cells	O
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

The	O
amount	O
of	O
TcR	O
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	O
and	O
CD25	O
receptors	O
are	O
increased	O
.	O

When	O
restimulated	O
,	O
however	O
,	O
anergic	O
T	O
cells	O
fail	O
to	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
transcription	B-Transcription
of	O
the	O
IL	O
-	O
2	O
gene	O
and	O
in	B-Positive_regulation
consequence	I-Positive_regulation
do	O
not	O
produce	B-Gene_expression
IL	O
-	O
2	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	O
factors	O
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O

Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	O
cells	O
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O

The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	B-Regulation
T-cell	O
-	O
specific	O
expression	B-Gene_expression
of	O
the	O
IL	O
-	O
2	O
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	O
genes	O
.	O

The	O
measured	O
binding	B-Binding
to	O
a	O
TCF	O
-	O
1	O
site	O
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	O
,	O
activated	O
,	O
and	O
anergized	O
cells	O
.	O

The	O
inducible	O
factors	O
NK	O
-	O
kappa	O
B	O
,	O
beta	O
E2	O
,	O
CD28RC	O
,	O
and	O
AP	O
-	O
1	O
are	O
not	O
expressed	B-Gene_expression
in	O
resting	O
cells	O
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
T	O
cells	O
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF	O
-	O
AT	O
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	O
factors	O
that	O
regulates	B-Regulation
IL	O
-	O
2	O
gene	O
transcription	B-Transcription
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
retinoblastoma	O
gene	O
product	O
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	O
cytomegalovirus	O
IE2	O
protein	O
.	O

The	O
IE2	O
gene	O
product	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	O
regulatory	O
proteins	O
expressed	B-Gene_expression
immediately	O
upon	B-Positive_regulation
infection	O
of	O
the	O
host	O
cell	O
.	O

It	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O

We	O
found	O
that	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
(	O
Rb	O
)	O
dramatically	O
suppressed	O
this	O
IE2	O
transactivation	O
of	O
various	O
promoters	O
.	O

However	O
,	O
unlike	O
another	O
tumor	O
suppressor	O
protein	O
,	O
p53	O
,	O
Rb	O
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	O
specifically	O
interacts	B-Binding
with	O
IE2	O
rather	O
than	O
other	O
cellular	O
factors	O
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein	O
-	O
affinity	O
chromatography	O
that	O
Rb	O
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	B-Binding
to	O
IE2	O
.	O

Our	O
results	O
suggest	O
that	O
Rb	O
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Epstein	O
-	O
Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	O
thymocytes	O
:	O
simultaneous	O
early	O
expression	B-Gene_expression
of	O
BZLF	O
-	O
1	O
and	O
its	O
repressor	O
RAZ	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	O
.	O

Infection	O
of	O
thymocytes	O
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	O
EBV	O
genome	O
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	O
of	O
the	O
EBV	O
genome	O
was	O
not	O
detected	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	O
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	B-Gene_expression
of	O
the	O
BamHI	O
ZLF	O
-	O
1	O
gene	O
product	O
,	O
ZEBRA	O
,	O
by	O
RT	O
-	O
PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	B-Gene_expression
of	O
a	O
novel	O
fusion	O
transcript	O
(	O
RAZ	O
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF	O
-	O
1	O
locus	O
and	O
the	O
adjacent	O
BRLF	O
-	O
1	O
locus	O
,	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

ZEBRA	O
protein	O
was	O
also	O
identified	B-Gene_expression
in	O
infected	O
thymocytes	O
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA	O
-	O
1	O
gene	O
in	O
infected	O
thymocytes	O
was	O
transcribed	B-Transcription
from	B-Positive_regulation
the	O
Fp	O
promoter	O
,	O
rather	B-Positive_regulation
than	I-Positive_regulation
from	O
the	O
Cp/Wp	O
promoter	O
which	O
is	O
used	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

Transcripts	B-Transcription
encoding	O
gp350/220	O
,	O
the	O
major	O
coat	O
protein	O
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	B-Transcription
from	O
the	O
LMP	O
-	O
2A	O
or	O
EBER	O
-	O
1	O
loci	O
in	O
infected	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	O
differs	O
from	O
infection	O
of	O
B	O
cells	O
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	O
genes	O
are	O
transcribed	O
.	O

Induction	B-Positive_regulation
of	O
Sp1	O
phosphorylation	B-Phosphorylation
and	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer	O
-	O
dependent	O
effect	O
of	O
cytokines	O
such	O
as	O
TNF	O
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O

The	O
inducibility	O
of	O
HIV	O
LTR	O
-	O
driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	O
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	O
.	O

In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	B-Positive_regulation
intense	O
phosphorylation	B-Phosphorylation
of	O
the	O
constitutively	O
expressed	O
Sp1	O
protein	O
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	O
,	O
phorbol	O
ester	O
,	O
or	O
PHA	O
and	O
interleukin	O
2	O
.	O

Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	O
B	O
elements	O
to	O
HIV	O
Tat	O
expression	B-Gene_expression
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	O
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	O
phosphorylation	B-Phosphorylation
induced	B-Positive_regulation
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine	O
-	O
threonine	O
phosphatase	O
PP2A	O
,	O
facilitates	B-Positive_regulation
the	O
formation	O
of	O
a	O
transcription	O
complex	B-Binding
involving	O
general	O
transcription	O
factors	O
,	O
HIV	O
Tat	O
,	O
and	O
Sp1	O
proteins	O
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF	O
-	O
kappa	O
B	O
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O

Human	O
MHC	O
class	O
II	O
gene	O
transcription	O
directed	O
by	O
the	O
carboxyl	O
terminus	O
of	O
CIITA	O
,	O
one	O
of	O
the	O
defective	O
genes	O
in	O
type	O
II	O
MHC	O
combined	O
immune	O
deficiency	O
.	O

Type	O
II	O
major	O
histocompatibility	O
complex	O
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	O
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	O
class	O
II	O
expression	O
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
defective	O
gene	O
in	O
group	O
II	O
type	O
II	O
MHC	O
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	O
is	O
an	O
MHC	O
class	O
II	O
gene	O
-	O
specific	O
transcription	O
activator	O
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N	O
-	O
terminal	O
acidic	O
domain	O
(	O
amino	O
acids	O
26	O
-	O
137	O
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	O
viral	O
transcription	O
-	O
activating	O
domain	O
.	O

The	O
specificity	O
of	O
CIITA	O
for	O
three	O
major	O
MHC	O
class	O
II	O
genes	O
,	O
DR	O
,	O
DQ	O
and	O
DP	O
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C	O
-	O
terminal	O
residues	O
(	O
amino	O
acids	O
317	O
-	O
1130	O
)	O
.	O

The	O
transactivation	B-Positive_regulation
of	O
multiple	O
cis	O
elements	O
,	O
especially	O
S	O
and	O
X2	O
,	O
of	O
the	O
DR	O
alpha	O
proximal	O
promoter	O
in	O
group	O
II	O
CID	O
cells	O
is	O
CIITA	O
dependent	B-Regulation
.	O

Since	O
CIITA	O
overexpression	B-Gene_expression
in	O
normal	O
cells	O
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	B-Positive_regulation
of	O
CIITA	O
expression	B-Gene_expression
serves	O
as	O
the	O
on	O
-	O
off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O

Abnormal	B-Regulation
regulation	I-Regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
in	O
lpr	O
CD4-CD8	O
-	O
T	O
lymphocytes	O
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
-	O
binding	O
factor	O
.	O

The	O
inert	O
quality	O
of	O
MRL	O
-	O
Ipr/Ipr	O
(	O
Ipr	O
)	O
peripheral	O
CD4-CD8	O
-	O
(	O
CD4-8	O
-	O
)	O
T	O
cells	O
manifests	O
primarily	O
as	O
an	O
inability	B-Positive_regulation
to	O
proliferate	O
or	O
produce	B-Gene_expression
IL	O
-	O
2	O
in	O
response	O
to	O
TCR	O
or	O
mitogenic	O
stimulation	O
.	O

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	O
-	O
mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O

They	O
also	O
display	O
constitutively	O
high	B-Positive_regulation
levels	I-Positive_regulation
of	O
p59fyn	O
and	O
CD3	O
zeta	O
tyrosine	O
phosphorylation	B-Phosphorylation
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	O
cells	O
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	B-Positive_regulation
in	O
transcriptional	B-Positive_regulation
activation	I-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
gene	O
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	B-Positive_regulation
state	O
of	O
the	O
IL	O
-	O
2	O
gene	O
promoter	O
region	O
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	O
CD4-8	O
-	O
T	O
cells	O
with	O
that	O
of	O
normal	O
T	O
lymphocytes	O
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
-	O
p65	O
heterodimer	O
)	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
factors	O
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	O
CD4-8	O
-	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	O
CD4-8	O
-	O
T	O
cells	O
.	O

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF	O
-	O
AT	O
complex	O
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	O
cells	O
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	O
CD4-8	O
-	O
T	O
cells	O
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF	O
-	O
AT	O
site	O
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	O
T	O
lymphocytes	O
.	O

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF-AT	O
-	O
binding	O
factor	O
is	O
rapidly	O
down	O
-	O
regulated	O
in	O
normal	O
T	O
cells	O
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	O
CD4-8	O
-	O
T	O
cells	O
.	O

These	O
two	O
abnormalities	O
at	O
the	O
NF	O
-	O
AT	O
site	O
provide	O
a	O
potential	O
mechanism	O
to	O
account	B-Positive_regulation
for	O
the	O
defect	B-Negative_regulation
in	O
IL	O
-	O
2	O
production	B-Gene_expression
from	O
Ipr	O
CD4-8	O
-	O
T	O
cells	O
.	O

GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
share	O
common	O
control	O
mechanisms	O
in	B-Regulation
response	I-Regulation
to	I-Regulation
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O

Antigen	O
complexed	O
with	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
molecules	O
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	O
cytokines	O
produced	O
by	O
antigen	O
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
also	O
required	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
requires	B-Positive_regulation
sequences	O
in	O
the	O
promoter	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3kb	O
upstream	O
to	O
respond	B-Regulation
to	O
TCR	O
-	O
like	O
signals	O
.	O

These	O
promoter	O
and	O
enhancer	O
regions	O
are	O
mainly	O
activated	O
by	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

The	O
activation	O
of	O
NFAT	O
by	O
TCR	O
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
and	O
IL	O
-	O
4	O
gene	B-Transcription
transcription	I-Transcription
in	O
T	O
cells	O
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	B-Positive_regulation
of	O
the	O
CD28	O
cell	O
surface	O
molecule	O
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	B-Positive_regulation
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
promoter	O
.	O

This	O
region	O
is	O
termed	O
the	O
CK	O
-	O
1	O
or	O
CD28RE	O
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
factors	O
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	B-Positive_regulation
GM	O
-	O
CSF	O
expression	B-Gene_expression
.	O

We	O
have	O
found	O
that	O
the	O
HTLV	O
-	O
1	O
transactivator	O
protein	O
,	O
tax	O
,	O
acts	B-Positive_regulation
as	I-Positive_regulation
a	I-Positive_regulation
costimulatory	I-Positive_regulation
signal	I-Positive_regulation
for	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
gene	B-Transcription
transcription	I-Transcription
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	O
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	O
activates	B-Positive_regulation
the	O
GM	O
-	O
CSF	O
promoter	O
through	O
the	O
CK	O
-	O
1/CD28RE	O
region	O
and	O
also	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	O
factors	O
or	O
coactivators	O
of	O
NF	O
-	O
kappa	O
B	O
are	O
required	O
for	O
tax	O
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK	O
-	O
1/CD28RE	O
of	O
GM	O
-	O
CSF	O
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL	O
-	O
2	O
CD28RE	O
and	O
the	O
IL	O
-	O
3	O
gene	O
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
respond	B-Regulation
to	O
TCR	O
signals	O
via	O
NFAT	O
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

MIP1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
,	O
a	O
novel	O
transcription	O
factor	O
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	B-Positive_regulation
for	O
transcription	B-Transcription
of	O
the	O
human	O
MIP	O
-	O
1	O
alpha	O
gene	O
.	O

Murine	O
macrophage	O
inflammatory	O
protein	O
1	O
alpha	O
(	O
MIP	O
-	O
1	O
alpha	O
)	O
and	O
its	O
human	O
equivalent	O
(	O
GOS19	O
,	O
LD78	O
,	O
or	O
AT464	O
)	O
are	O
members	O
of	O
the	O
-C	O
-	O
C	O
family	O
of	O
low-molecular	O
-	O
weight	O
chemokines	O
.	O

Secreted	B-Localization
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow	O
-	O
derived	B-Positive_regulation
MIP	O
-	O
1	O
alpha/GOS19	O
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	B-Regulation
the	O
expression	B-Gene_expression
of	O
MIP	O
-	O
1	O
alpha/GOS19	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	O
T	O
cells	O
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	O
factors	O
(	O
the	O
ICK	O
-	O
1	O
family	O
)	O
affect	B-Regulation
the	O
GOS19	O
promoter	O
.	O

One	O
member	O
,	O
ICK	O
-	O
1A	O
,	O
behaves	O
as	O
a	O
strong	O
negative	O
regulator	O
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	B-Positive_regulation
in	O
the	O
macrophage	O
cell	O
line	O
U937	O
is	O
different	O
from	O
that	O
in	O
Jurkat	O
cells	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK	O
-	O
1	O
binding	O
site	O
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	O
cells	O
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP	O
-	O
1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK	O
-	O
1	O
site	O
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	O
cell	O
lines	O
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast	O
-	O
migrating	O
protein	O
-	O
DNA	O
complexes	O
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	O
abrogate	O
ICK	O
-	O
1	O
binding	O
inactivates	O
the	O
GOS19.1	O
promoter	O
in	O
U937	O
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	O
cells	O
.	O

We	O
propose	O
that	O
the	O
MNP	O
protein	O
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	O
factor	O
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

Ligand	O
-	O
dependent	O
repression	B-Negative_regulation
of	O
the	O
erythroid	O
transcription	O
factor	O
GATA	O
-	O
1	O
by	O
the	O
estrogen	O
receptor	O
.	O

High	O
-	O
dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	O
marrow	O
-	O
derived	O
erythroid	O
progenitor	O
cells	O
and	O
delay	O
their	O
maturation	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
many	O
erythroid	O
cell	O
-	O
specific	O
genes	O
,	O
including	O
alpha	O
-	O
and	O
beta	O
-	O
globin	O
,	O
band	O
3	O
,	O
band	O
4.1	O
,	O
and	O
the	O
erythroid	O
cell	O
-	O
specific	O
histone	O
H5	O
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	O
progenitor	O
cells	O
in	O
primary	O
human	O
bone	O
marrow	O
cultures	O
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	B-Regulation
on	O
GATA	O
-	O
1	O
,	O
an	O
erythroid	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	O
cell	O
-	O
specific	O
genes	O
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	O
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA	O
-	O
1	O
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4	O
-	O
hydroxytamoxifen	O
.	O

ER	O
-	O
mediated	O
repression	O
of	O
GATA	O
-	O
1	O
activity	O
occurs	O
on	O
an	O
artificial	O
promoter	O
containing	O
a	O
single	O
GATA	O
-	O
binding	O
site	O
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	O
promoter	O
which	O
is	O
normally	O
regulated	O
by	O
GATA	O
-	O
1	O
.	O

GATA	O
-	O
1	O
and	O
ER	O
bind	B-Binding
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	O
cells	O
,	O
GATA	O
-	O
1	O
and	O
ER	O
associate	B-Binding
in	O
a	O
ligand	O
-	O
dependent	B-Regulation
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA	O
-	O
1	O
and	O
the	O
ER	O
form	O
at	O
least	O
two	O
contacts	B-Binding
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N	O
-	O
terminal	O
activation	O
domain	O
of	O
GATA	O
-	O
1	O
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	B-Regulation
GATA	O
-	O
1	O
activity	O
through	O
protein	O
-	O
protein	O
interaction	B-Binding
with	O
the	O
ER	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	B-Positive_regulation
of	O
pp90rsk	O
and	O
early	O
growth	O
response	O
-	O
1	O
gene	O
expression	B-Gene_expression
by	O
pokeweed	O
mitogen	O
in	O
human	O
B	O
cells	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	B-Regulation
of	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
on	O
the	O
induction	B-Positive_regulation
of	O
early	O
growth	O
response	O
-	O
1	O
gene	O
(	O
EGR	O
-	O
1	O
)	O
in	O
normal	O
human	O
B	O
cells	O
.	O

PWM	O
regulates	B-Regulation
EGR	O
-	O
1	O
gene	O
expression	B-Gene_expression
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR	O
-	O
1	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
demonstrated	O
that	O
PWM	O
induced	B-Positive_regulation
EGR	O
-	O
1	O
transcription	B-Transcription
is	O
conferred	B-Positive_regulation
by	O
the	O
CArG	O
motif	O
(	O
C	O
C	O
[	O
AT	O
]	O
6GG	O
)	O
in	O
the	O
EGR	O
-	O
1	O
promoter	O
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	O
kinase	O
(	O
pp90rsk	O
)	O
,	O
evidenced	O
by	O
phosphorylation	B-Phosphorylation
of	O
S6	O
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	O
treated	O
B	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	O
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR	O
-	O
1	O
induction	B-Positive_regulation
in	O
normal	O
human	O
B	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
controls	B-Regulation
expression	B-Gene_expression
of	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
.	O

Phorbol	O
ester	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
induction	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
associated	O
with	O
both	O
the	O
degradation	B-Protein_catabolism
of	O
performed	O
I	O
kappa	O
B	O
alpha	O
and	O
the	O
activation	B-Positive_regulation
of	O
I	O
kappa	O
B	O
alpha	O
gene	O
expression	B-Gene_expression
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	O
kappa	O
B	O
alpha	O
gene	O
is	O
specifically	O
induced	B-Positive_regulation
by	O
the	O
65	O
-	O
kilodalton	O
transactivating	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Association	B-Binding
of	O
the	O
newly	O
synthesized	O
I	O
kappa	O
B	O
alpha	O
with	O
p65	O
restores	O
intracellular	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	O
-	O
kappa	O
B	O
controls	B-Regulation
the	O
expression	B-Gene_expression
of	O
I	O
kappa	O
B	O
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	O
plus	O
CD28	O
adhesion	O
molecules	O
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Stimulation	O
of	O
highly	O
purified	O
human	O
T	O
-	O
cells	O
via	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

This	O
potent	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
-	O
dependent	O
activation	O
does	O
not	O
require	O
monocytes	O
or	O
accessory	O
cells	O
.	O

Long	O
-	O
lasting	O
IL	O
-	O
2	O
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	B-Gene_expression
of	O
the	O
inducible	O
IL	O
-	O
2	O
receptor	O
alpha	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
gene	O
that	O
is	O
regulated	B-Regulation
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Increase	B-Positive_regulation
of	O
IL	O
-	O
2R	O
alpha	O
gene	O
transcription	B-Transcription
involves	O
the	O
enhanced	B-Positive_regulation
binding	B-Binding
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5'	O
-	O
regulatory	O
region	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	B-Transcription
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
a	O
radiolabeled	O
IL	O
-	O
2R	O
alpha	O
kappa	O
B	O
-	O
specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	O
+	O
CD28	O
activation	B-Positive_regulation
.	O

Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1/p50	O
homodimer	O
.	O

After	O
stimulation	O
,	O
two	O
new	O
kappa	O
B	O
-	O
specific	O
complexes	O
were	O
identified	B-Positive_regulation
as	O
NF	O
-	O
kappa	O
B	O
p50	O
-	O
p65	O
heterodimer	B-Binding
and	O
putative	O
c	O
-	O
Rel	O
homodimer	B-Binding
or	O
c-Rel	O
-	O
p65	O
heterodimer	B-Binding
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O

In	O
parallel	O
,	O
CD2	O
+	O
CD28	O
activation	B-Positive_regulation
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	O
molecules	O
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
-	O
lymphocytes	O
,	O
also	O
inhibited	B-Negative_regulation
IL	O
-	O
2	O
secretion	B-Localization
,	O
IL	O
-	O
2R	O
alpha	O
cell	O
surface	O
expression	B-Gene_expression
,	O
and	O
T	O
-	O
cell	O
proliferation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
long	O
-	O
term	O
activation	O
of	O
human	O
primary	O
T	O
-	O
lymphocytes	O
via	O
CD2	O
+	O
CD28	O
.	O

Synergism	O
between	O
the	O
CD3	O
antigen	O
-	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
.	O

Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3/TCR	O
complex	O
with	O
the	O
CD2	O
antigen	O
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O

The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	B-Gene_expression
of	O
the	O
IL	O
-	O
2	O
gene	O
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O

To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
in	O
highly	O
purified	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
the	O
CD3	O
and/or	O
CD2	O
proteins	O
.	O

The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	O
cells	O
with	O
ionomycin	O
,	O
and/or	O
sn	O
-	O
1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O

The	O
emergence	O
of	O
nuclear	O
binding	O
proteins	O
was	O
investigated	O
using	O
interleukin	O
-	O
2	O
sequence	O
specific	O
oligonucleotide	O
probes	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	O
antigen	O
-	O
derived	O
signals	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT1	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kB	O
sites	O
located	O
in	O
the	O
promoter/enhancer	O
region	O
of	O
the	O
IL	O
-	O
2	O
gene	O
.	O

Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA	O
-	O
binding	O
proteins	O
in	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen	O
-	O
dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	O
cells	O
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Antisense	O
oligonucleotides	O
to	O
the	O
p65	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
block	B-Negative_regulation
CD11b	O
expression	B-Gene_expression
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL	O
-	O
60	O
granulocytes	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O

This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
distinct	O
regions	O
of	O
the	O
promoter	O
elements	O
of	O
numerous	O
genes	O
,	O
including	O
cytokines	O
,	O
growth	O
factor	O
receptors	O
,	O
and	O
adhesion	O
molecules	O
.	O

Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
resting	O
and	O
stimulated	O
granulocytes	O
.	O

A	O
reduction	B-Negative_regulation
in	O
the	O
expression	B-Gene_expression
of	O
p65	O
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O

This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	O
sulfoxide	O
-	O
differentiated	O
HL	O
-	O
60	O
leukemia	O
cells	O
stimulated	O
by	O
12-O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	B-Negative_regulation
in	O
CD11b	O
integrin	O
expression	B-Gene_expression
on	O
the	O
surface	O
of	O
treated	O
cells	O
.	O

Furthermore	O
,	O
the	O
p65	O
antisense	O
oligomer	O
effectively	O
abolished	B-Negative_regulation
an	O
upregulation	B-Positive_regulation
of	O
CD11b	O
that	O
was	O
produced	O
by	O
formyl-met-leu	O
-	O
phe	O
and	O
TPA	O
.	O

However	O
,	O
the	O
p65	O
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	O
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O

Human	O
interferon	O
regulatory	O
factor	O
2	O
gene	O
.	O

Intron	O
-	O
exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5'	O
-	O
flanking	O
region	O
.	O

Interferon	O
regulatory	O
factor	O
2	O
(	O
IRF	O
-	O
2	O
)	O
is	O
a	O
transcriptional	O
regulatory	O
protein	O
that	O
terminates	B-Negative_regulation
interferon	O
beta	O
expression	B-Gene_expression
initiated	B-Positive_regulation
by	O
interferon	O
regulatory	O
factor	O
1	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	O
DNA	O
for	O
human	O
IRF	O
-	O
2	O
gene	O
,	O
determined	O
the	O
intron	O
-	O
exon	O
structure	O
of	O
the	O
human	O
IRF	O
-	O
2	O
gene	O
,	O
mapped	O
the	O
major	O
transcription	O
initiation	O
site	O
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5'	O
-	O
flanking	O
region	O
,	O
and	O
localized	O
the	O
IRF	O
-	O
2	O
gene	O
on	O
human	O
chromosome	O
4	O
.	O

The	O
IRF	O
-	O
2	O
promoter	O
region	O
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	O
boxes	O
,	O
a	O
putative	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
,	O
and	O
a	O
CAAT	O
box	O
,	O
but	O
no	O
TATA	O
box	O
.	O

When	O
the	O
promoter	O
region	O
was	O
linked	O
with	O
a	O
heterologous	O
reporter	O
gene	O
,	O
we	O
found	O
that	O
the	O
promoter	O
region	O
is	O
inducible	B-Positive_regulation
by	O
both	O
interferons	O
(	O
interferon	O
-	O
alpha	O
and	O
-	O
gamma	O
)	O
and	O
interferon	O
regulatory	O
factor	O
1	O
.	O

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	O
nucleotides	O
5	O
'	O
to	O
the	O
major	O
transcriptional	O
initiation	O
site	O
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	O
promoter	O
of	O
IRF	O
-	O
2	O
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	O
enhancers	O
of	O
other	O
genes	O
including	O
interferon	O
regulatory	O
factor	O
1	O
,	O
interferon	O
beta	O
,	O
and	O
interferon	O
-	O
inducible	O
genes	O
.	O

These	O
data	O
suggest	O
that	O
interferon	O
regulatory	O
factor	O
1	O
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	O
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	B-Positive_regulation
the	O
transcription	B-Transcription
of	O
IRF	O
-	O
2	O
.	O

Overproduction	B-Gene_expression
of	O
NFKB2	O
(	O
lyt	O
-	O
10	O
)	O
and	O
c	O
-	O
Rel	O
:	O
a	O
mechanism	O
for	O
HTLV	O
-	O
I	O
Tax	O
-	O
mediated	O
trans	O
-	O
activation	O
via	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV	O
-	O
I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
Tax	O
protein	O
of	O
HTLV	O
-	O
I	O
,	O
a	O
positive	O
transcriptional	O
activator	O
of	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	B-Positive_regulation
transcription	B-Transcription
of	O
cellular	O
genes	O
including	O
GM	O
-	O
CSF	O
,	O
IL	O
-	O
2R	O
alpha	O
and	O
IL	O
-	O
2	O
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans	O
-	O
activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
family	O
of	O
transcription	O
factors	O
,	O
pleiotropic	O
regulators	O
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	O
(	O
lyt	O
-	O
10	O
)	O
and	O
c	O
-	O
Rel	O
are	O
overexpressed	B-Gene_expression
in	O
HTLV	O
-	O
I	O
infected	O
and	O
Tax	O
-	O
expressing	O
cells	O
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	O
-	O
dependent	O
correlation	O
between	O
expression	B-Gene_expression
of	O
NFKB2	O
(	O
p100	O
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	O
(	O
p52	O
)	O
form	O
,	O
induction	B-Positive_regulation
of	O
c	O
-	O
Rel	O
,	O
and	O
trans	O
-	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	O
precursor	O
is	O
physically	O
associated	B-Binding
with	O
c	O
-	O
Rel	O
and	O
with	O
Tax	O
in	O
HTLV	O
-	O
I	O
infected	O
cells	O
.	O

We	O
propose	O
that	O
NFKB2	O
synthesis	B-Gene_expression
and	O
processing	O
allows	B-Positive_regulation
continuous	O
nuclear	O
expression	B-Localization
of	O
an	O
otherwise	O
cytoplasmic	O
protein	O
and	O
,	O
in	O
conjunction	O
with	O
overexpression	B-Gene_expression
of	O
c	O
-	O
Rel	O
,	O
NFKB2	O
alters	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

Autoregulation	B-Regulation
of	O
the	O
NF	O
-	O
kappa	O
B	O
transactivator	O
RelA	O
(	O
p65	O
)	O
by	O
multiple	O
cytoplasmic	O
inhibitors	O
containing	O
ankyrin	O
motifs	O
.	O

RelA	O
(	O
p65	O
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	O
p50	O
-	O
p65	O
NF	O
-	O
kappa	O
B	O
complex	O
and	O
contains	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
for	O
its	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
alpha	O
.	O

After	B-Positive_regulation
cellular	O
activation	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
rapidly	O
degraded	B-Protein_catabolism
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
induced	B-Positive_regulation
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
alpha	O
in	O
human	O
T	O
cells	O
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	B-Phosphorylation
in	O
vivo	O
.	O

However	O
,	O
these	O
effects	O
on	O
I	O
kappa	O
B	O
alpha	O
result	B-Positive_regulation
in	I-Positive_regulation
nuclear	O
mobilization	B-Localization
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	O
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	O
RelA	O
is	O
stably	O
associated	B-Binding
not	O
only	O
with	O
I	O
kappa	O
B	O
alpha	O
but	O
also	O
with	O
other	O
ankyrin	O
motif	O
-	O
rich	O
proteins	O
including	O
the	O
products	O
of	O
the	O
NF	O
-	O
kappa	O
B2	O
(	O
p100	O
)	O
and	O
NF	O
-	O
kappa	O
B1	O
(	O
p105	O
)	O
genes	O
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	O
-	O
I	O
kappa	O
B	O
alpha	O
,	O
RelA	O
-	O
p100	O
cytoplasmic	O
complexes	O
are	O
not	O
dissociated	O
following	O
tumor	O
necrosis	O
factor	O
alpha	O
activation	O
;	O
(	O
iii	O
)	O
p100	O
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	O
-	O
mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	B-Binding
of	O
RelA	O
and	O
p100	O
involves	O
the	O
conserved	O
Rel	O
homology	O
domain	O
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	O
localization	O
signal	O
of	O
RelA	O
,	O
which	O
is	O
required	B-Positive_regulation
for	O
I	O
kappa	O
B	O
alpha	O
binding	B-Binding
;	O
(	O
v	O
)	O
p100	O
inhibition	B-Negative_regulation
of	O
RelA	O
function	O
requires	B-Positive_regulation
the	O
C	O
-	O
terminal	O
ankyrin	O
motif	O
domain	O
,	O
which	O
mediates	B-Positive_regulation
cytoplasmic	O
retention	B-Localization
of	O
RelA	O
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	O
kappa	O
B	O
alpha	O
,	O
nuclear	O
RelA	O
stimulates	B-Positive_regulation
p100	O
mRNA	O
and	O
protein	O
expression	B-Transcription
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

Calcineurin	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	B-Negative_regulation
I	O
kappa	O
B/MAD3	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
responsive	O
elements	O
.	O

The	O
induction	B-Positive_regulation
of	O
promoters	O
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	B-Negative_regulation
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK	O
-	O
506	O
)	O
.	O

Calcineurin	O
,	O
a	O
Ca2+/calmodulin	O
-	O
dependent	O
protein	O
phosphatase	O
,	O
is	O
the	O
FK-506	O
-	O
and	O
CsA	O
-	O
sensitive	O
enzyme	O
required	B-Positive_regulation
for	O
TcR	O
mediated	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
partially	O
substitutes	O
for	O
the	O
Ca2+	O
co	O
-	O
stimulus	O
required	O
to	O
activate	B-Positive_regulation
the	O
IL	O
-	O
2	O
promoter	O
elements	O
IL	O
-	O
2A	O
(	O
which	O
binds	B-Binding
the	O
factors	O
OAP	O
and	O
Oct	O
-	O
1	O
)	O
and	O
IL	O
-	O
2E	O
(	O
which	O
binds	O
NF	O
-	O
AT	O
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2+	O
co	O
-	O
stimulus	O
required	O
to	O
stimulate	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
element	O
.	O

Calcineurin	O
stimulates	O
the	O
NF	O
-	O
kappa	O
B	O
element	O
by	O
enhancing	B-Positive_regulation
inactivation	B-Negative_regulation
of	O
I	O
kappa	O
B/MAD3	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	O
phosphatase	O
can	O
inactivate	O
I	O
kappa	O
B	O
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism	O
-	O
based	O
toxicities	O
associated	O
with	O
FK	O
-	O
506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	O
-	O
dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	O
transcription	O
factor	O
.	O

Activation	B-Positive_regulation
of	O
the	O
interleukin	O
6	O
gene	O
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	B-Positive_regulation
by	O
nuclear	O
factors	O
NF	O
-	O
IL6	O
and	O
NF	O
-	O
kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O

The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O

Cytokines	O
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O

In	O
this	O
regard	O
,	O
the	O
cytokine	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	O
(	O
LAM	O
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	O
phagocytes	O
to	B-Positive_regulation
release	B-Localization
IL	O
-	O
6	O
in	O
a	O
dose	O
-	O
response	O
manner	O
.	O

LAM	O
and	O
LPS	O
were	O
potent	O
inducers	B-Positive_regulation
of	O
IL	O
-	O
6	O
gene	O
expression	B-Gene_expression
in	O
peripheral	O
blood	O
monocytes	O
.	O

Both	O
LAM	O
-	O
and	O
LPS	O
-	O
inducible	B-Positive_regulation
IL	O
-	O
6	O
promoter	O
activity	O
was	O
localized	O
to	O
a	O
DNA	O
fragment	O
,	O
positions	O
-	O
158	O
to	O
-	O
49	O
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	O
acetyltransferase	O
assay	O
.	O

Two	O
nuclear	O
factor	O
NF	O
-	O
IL6	O
(	O
positions	O
-	O
153	O
to	O
-	O
145	O
and	O
-	O
83	O
to	O
-	O
75	O
)	O
and	O
one	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
(	O
positions	O
-	O
72	O
to	O
-	O
63	O
)	O
motifs	O
are	O
present	O
within	O
this	O
fragment	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL	O
-	O
6	O
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O

Deletion	O
of	O
all	O
three	O
elements	O
abolished	B-Negative_regulation
inducibility	B-Positive_regulation
of	O
IL	O
-	O
6	O
promoter	O
activity	O
by	O
both	O
LAM	O
and	O
LPS	O
.	O

We	O
conclude	O
that	O
the	O
NF	O
-	O
IL6	O
and	O
NF	O
-	O
kappa	O
B	O
sites	O
mediate	B-Positive_regulation
IL	O
-	O
6	O
induction	B-Positive_regulation
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	O
,	O
acting	O
as	O
bacterial	O
or	O
mycobacterial	O
response	O
elements	O
.	O

Calcineurin	O
activates	B-Positive_regulation
transcription	B-Transcription
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
in	O
synergy	O
with	O
either	O
protein	O
kinase	O
C	O
or	O
NF	O
-	O
kappa	O
B/AP	O
-	O
1	O
in	O
T	O
cells	O
.	O

Two	O
cis	O
-	O
acting	O
elements	O
GM	O
-	O
kappa	O
B/GC	O
-	O
box	O
and	O
CLE0	O
,	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
are	O
required	B-Regulation
for	O
maximal	O
induction	B-Positive_regulation
in	O
Jurkat	O
T	O
cells	O
by	O
costimulation	O
with	O
phorbol-12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
(	O
A23187	O
)	O
.	O

The	O
GM	O
-	O
kappa	O
B	O
sequence	O
is	O
recognized	O
by	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O

The	O
CLE0	O
sequence	O
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA	O
-	O
induced	O
AP	O
-	O
1	O
and	O
a	O
PMA/A23187	O
-	O
induced	O
NF	O
-	O
AT	O
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	O
cells	O
can	O
activate	B-Positive_regulation
transcription	B-Transcription
of	O
the	O
GM	O
-	O
CSF	O
gene	O
.	O

Cotransfection	B-Gene_expression
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50/p65	O
)	O
-	O
or	O
AP	O
-	O
1	O
(	O
c-Jun/c	O
-	O
Fos	O
)	O
-	O
expression	O
vectors	O
into	O
Jurkat	O
cells	O
with	O
a	O
luciferase	O
reporter	O
containing	O
the	O
GM	O
-	O
CSF	O
promoter	O
did	O
not	O
stimulate	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O

In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
significantly	O
augmented	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
containing	O
the	O
GM	O
-	O
kappa	O
B/GC	O
-	O
box	O
and	O
the	O
CLE0	O
(	O
AP-1/NF	O
-	O
AT	O
)	O
.	O

Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2+/calmodulin	O
-	O
dependent	O
protein	O
phosphatase	O
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF	O
-	O
kappa	O
B/AP	O
-	O
1	O
.	O

Both	O
constitutively	O
active	O
forms	O
of	O
CN	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF	O
-	O
kappa	O
B	O
-	O
,	O
AP-1	O
-	O
and	O
NF-AT	O
-	O
binding	O
sequences	O
is	O
required	B-Positive_regulation
for	O
induction	B-Positive_regulation
of	O
the	O
GM	O
-	O
CSF	O
gene	O
through	O
PKC	O
-	O
and	O
Ca2+	O
-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Cell	O
-	O
specific	O
bifunctional	O
role	O
of	O
Jun	O
oncogene	O
family	O
members	O
on	O
glucocorticoid	O
receptor	O
-	O
dependent	O
transcription	O
.	O

Interaction	O
between	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
-	O
mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	O
activating	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	O
-	O
dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	O
LTR	O
in	O
several	O
T	O
cell	O
lines	O
but	O
was	O
inhibitory	O
in	O
NIH	O
-	O
3T3	O
fibroblasts	O
.	O

TPA	O
-	O
GR	O
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR	O
-	O
responsive	O
element	O
(	O
GRE	O
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	O
mutants	O
or	O
synthetic	O
GRE	O
oligonucleotides	O
driving	O
chloramphenicol	O
acetyl	O
-	O
transferase	O
expression	O
.	O

Synergism	O
required	O
an	O
intact	O
GR	O
DNA	O
-	O
binding	O
domain	O
,	O
whereas	O
amino	O
-	O
or	O
carboxyl	O
-	O
terminal	O
domains	O
were	O
dispensable	O
.	O

The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	O
.	O

Increased	B-Positive_regulation
c	O
-	O
jun	O
,	O
jun	O
-	O
B	O
,	O
and	O
jun	O
-	O
D	O
expression	B-Gene_expression
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP	O
-	O
1/TPA	O
responsive	O
elements	O
fused	O
to	O
chloramphenicol	O
acetyl	O
-	O
transferase	O
vectors	O
were	O
observed	O
in	O
T	O
cells	O
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O

The	O
ability	O
of	O
Jun	O
proteins	O
to	O
cooperate	O
with	O
GR	O
in	O
T	O
cells	O
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c	O
-	O
jun	O
,	O
jun	O
-	O
B	O
,	O
or	O
jun	O
-	O
D	O
expression	O
vectors	O
,	O
which	O
augmented	O
GR	O
-	O
dependent	O
transcription	O
from	O
either	O
MMTV	O
LTR	O
or	O
GRE	O
.	O

Conversely	O
,	O
c	O
-	O
jun	O
and	O
jun	O
-	O
B	O
transfection	O
blunted	O
GR	O
-	O
dependent	O
transcription	O
in	O
HeLa	O
cells	O
.	O

The	O
presence	O
of	O
c	O
-	O
fos	O
had	B-Negative_regulation
a	I-Negative_regulation
negative	I-Negative_regulation
influence	I-Negative_regulation
on	O
GR	O
function	O
and	O
correlated	O
with	O
the	O
cell	O
-	O
specific	O
synergistic	O
or	O
antagonistic	B-Negative_regulation
activity	I-Negative_regulation
of	O
Jun	O
with	O
respect	O
to	O
GR	O
;	O
high	B-Positive_regulation
basal	O
expression	B-Gene_expression
of	O
c	O
-	O
fos	O
as	O
well	O
as	O
AP	O
-	O
1	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

Furthermore	O
overexpression	B-Gene_expression
of	O
exogenous	O
c	O
-	O
fos	O
has	O
an	O
inhibitory	O
effect	O
on	O
GR	O
-	O
dependent	O
transcription	O
from	O
GRE	O
in	O
T	O
cells	O
.	O

We	O
propose	O
that	O
Jun	O
plays	O
a	O
bifunctional	O
role	O
on	O
GR	O
-	O
dependent	O
transcriptional	O
activation	O
of	O
GRE	O
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell	O
-	O
specific	O
microenvironment	O
.	O

In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c	O
-	O
fos	O
appear	O
to	O
be	O
influential	O
.	O

Defective	O
translocation	O
of	O
protein	O
kinase	O
C	O
in	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
human	O
HL	O
-	O
60	O
myeloid	O
leukemia	O
cells	O
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O

This	O
event	O
is	O
associated	O
with	O
induction	B-Positive_regulation
of	O
the	O
c	O
-	O
jun	O
early	O
response	O
gene	O
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine	O
-	O
selected	O
,	O
multidrug	O
resistance	O
on	O
12-O-tetradecanoylphorbol-13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
HL	O
-	O
60	O
cell	O
differentiation	O
.	O

The	O
results	O
demonstrate	O
that	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
,	O
designated	O
HL	O
-	O
60/vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	B-Positive_regulation
in	O
c	O
-	O
jun	O
transcripts	O
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60/vinc	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine/threonine	O
protein	O
phosphatases	O
,	O
induces	B-Positive_regulation
c	O
-	O
jun	O
transcription	B-Transcription
,	O
growth	O
arrest	O
,	O
and	O
expression	B-Gene_expression
of	O
the	O
c	O
-	O
fms	O
gene	O
.	O

Studies	O
were	O
also	O
performed	O
with	O
an	O
HL	O
-	O
60/vinc	O
revertant	O
(	O
HL	O
-	O
60/vinc/R	O
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O

The	O
finding	O
that	O
HL	O
-	O
60/vinc/R	O
cells	O
respond	O
to	O
TPA	O
with	O
induction	B-Positive_regulation
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c	O
-	O
jun	O
expression	B-Gene_expression
,	O
suggests	O
that	O
c	O
-	O
jun	O
induction	B-Positive_regulation
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun	O
-	O
B	O
and	O
fra	O
-	O
1	O
genes	O
are	O
induced	B-Positive_regulation
by	O
TPA	O
in	O
both	O
HL	O
-	O
60/vinc	O
and	O
HL	O
-	O
60/vinc/R	O
cells	O
,	O
whereas	O
c	O
-	O
fos	O
expression	B-Gene_expression
is	O
attenuated	B-Negative_regulation
in	O
the	O
HL	O
-	O
60/vinc	O
line	O
.	O

Since	O
TPA	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	O
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

Although	O
HL	O
-	O
60	O
and	O
HL	O
-	O
60/vinc/R	O
cells	O
demonstrated	O
translocation	O
of	O
PKC	O
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL	O
-	O
60/vinc	O
cells	O
.	O

Activity	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
with	O
associated	O
phosphorylation	O
of	O
c	O
-	O
Jun	O
Y	O
-	O
peptide	O
was	O
markedly	O
diminished	O
in	O
TPA	O
-	O
treated	O
HL	O
-	O
60/vinc	O
cells	O
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA	O
-	O
induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	O
-	O
mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun/fos	O
early	O
response	O
gene	O
expression	O
.	O

Initiation	O
binding	O
repressor	O
,	O
a	O
factor	O
that	O
binds	B-Binding
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	O
growth	O
regulators	O
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

Initiation	O
binding	O
repressor	O
[	O
corrected	O
]	O
(	O
IBR	O
)	O
is	O
a	O
chicken	O
erythrocyte	O
factor	O
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	B-Binding
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
repressing	B-Negative_regulation
its	O
transcription	B-Transcription
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	B-Gene_expression
IBR	O
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	O
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	B-Binding
the	O
same	O
IBR	O
sites	O
.	O

We	O
have	O
cloned	O
the	O
IBR	O
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	O
and	O
IBF	O
.	O

IBR	O
is	O
a	O
503-amino-acid	O
-	O
long	O
acidic	O
protein	O
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	O
NRF-1/alpha	O
-	O
Pal	O
factor	O
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	O
factors	O
P3A2	O
and	O
erected	O
wing	O
gene	O
product	O
(	O
EWG	O
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	O
and	O
IBF	O
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	O
and	O
shown	O
that	O
the	O
factor	O
associates	B-Binding
as	I-Binding
stable	I-Binding
homodimers	I-Binding
and	O
that	O
the	O
dimer	O
is	O
the	O
relevant	O
DNA	O
-	O
binding	B-Binding
species	O
.	O

The	O
evolutionarily	O
conserved	O
N	O
-	O
terminal	O
half	O
of	O
IBR/F	O
harbors	O
the	O
DNA	O
-	O
binding/dimerization	O
domain	O
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	O
kinase	O
II	O
sites	O
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	B-Positive_regulation
for	O
nuclear	O
targeting	B-Localization
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	O
consensus	O
constitutes	O
high	O
-	O
affinity	O
IBR/F	O
binding	O
sites	O
and	O
that	O
the	O
direct	O
-	O
repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth	O
-	O
related	O
metabolism	O
.	O

Inhibition	O
of	O
NF	O
-	O
AT	O
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	O
.	O

An	O
inhibitory	O
,	O
"	O
dominant	O
-	O
negative	O
,	O
"	O
form	O
of	O
the	O
calcineurin	O
catalytic	O
(	O
A	O
)	O
subunit	O
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	O
-	O
binding	O
domain	O
,	O
autoinhibitory	O
domain	O
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	O
-	O
dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
"	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
"	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	O
-	O
AT	O
,	O
the	O
pivotal	O
promoter	B-Regulation
element	I-Regulation
for	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
gene	O
induction	B-Gene_expression
.	O

Immunoprecipitation	O
of	O
epitope	O
-	O
labeled	O
BKO	O
demonstrated	O
for	O
the	O
formation	B-Binding
of	I-Binding
a	I-Binding
tight	I-Binding
complex	I-Binding
with	O
endogenous	O
B	O
subunit	O
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	B-Negative_regulation
mechanism	I-Negative_regulation
that	O
involves	B-Positive_regulation
the	O
sequestration	B-Localization
of	O
the	O
B	O
subunit	O
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	O
-	O
AT	O
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
"	O
rescued	O
"	O
by	O
overexpression	B-Positive_regulation
of	O
transfected	O
B	O
subunit	O
,	O
suggesting	O
that	O
depletion	B-Negative_regulation
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	O
-	O
mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	B-Negative_regulation
formation	B-Binding
of	I-Binding
the	I-Binding
catalytically	I-Binding
active	I-Binding
dimer	I-Binding
of	O
calcineurin	O
A	O
and	O
B	O
subunits	O
.	O

Modulation	O
of	O
endogenous	O
IL	O
-	O
1	O
beta	O
and	O
IL	O
-	O
1	O
receptor	O
antagonist	O
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
proportion	O
of	O
HIV	O
-	O
infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram	O
-	O
negative	O
bacteria	O
.	O

The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS	O
-	O
mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	O
cells	O
,	O
a	O
promonocytic	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
.	O

Stimulation	O
of	O
U1	O
cells	O
by	O
LPS	O
alone	O
induced	O
minimal	O
levels	O
of	O
HIV	O
expression	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
.	O

Costimulation	O
of	O
U1	O
cells	O
with	O
LPS	O
plus	O
GM	O
-	O
CSF	O
resulted	O
in	O
the	O
accumulation	O
of	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
RNA	O
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	O
long	O
terminal	O
repeat	O
-	O
driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
was	O
noted	O
.	O

Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM	O
-	O
CSF	O
induced	B-Positive_regulation
the	O
production	B-Gene_expression
of	O
proinflammatory	O
cytokines	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
1	O
beta	O
and	O
IL	O
-	O
6	O
,	O
but	O
not	O
TNF	O
-	O
alpha	O
.	O

IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
ra	O
)	O
inhibited	O
LPS	O
enhancement	O
of	O
HIV	O
expression	O
in	O
GM-CSF	O
-	O
stimulated	O
cells	O
,	O
suggesting	O
that	O
endogenous	O
IL	O
-	O
1	O
was	O
involved	O
in	O
LPS	O
-	O
mediated	O
viral	O
production	O
.	O

In	O
this	O
regard	O
,	O
anti	O
-	O
inflammatory	O
cytokines	O
inhibited	O
LPS	O
plus	O
GM-CSF	O
-	O
stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	B-Negative_regulation
of	O
IL	O
-	O
1	O
beta	O
release	B-Localization
and	O
,	O
in	O
particular	O
,	O
with	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
endogenous	O
IL	O
-	O
1ra	O
production	B-Gene_expression
.	O

Thus	O
,	O
the	O
balance	B-Negative_regulation
between	O
an	O
endogenously	O
produced	B-Gene_expression
viral	O
inducer	O
(	O
IL	O
-	O
1	O
beta	O
)	O
and	O
an	O
inhibitor	O
(	O
IL	O
-	O
1ra	O
)	O
may	O
represent	O
an	O
important	O
pathway	O
leading	O
to	O
modulation	O
of	O
HIV	O
expression	O
from	O
monocytic	O
cells	O
.	O

Transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
interleukin	O
-	O
2	O
gene	O
in	O
normal	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	O
T	O
cells	O
.	O

To	O
study	O
transcriptional	O
regulation	O
in	O
normal	O
human	O
T	O
cells	O
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O

Interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
promoter	O
-	O
reporter	O
gene	O
behavior	O
closely	O
parallels	O
the	O
endogenous	O
gene	O
in	O
response	O
to	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
signals	O
.	O

As	O
assessed	O
with	O
mutagenized	O
promoters	O
,	O
the	O
most	O
important	O
IL	O
-	O
2	O
cis	O
-	O
regulatory	O
elements	O
in	O
normal	O
T	O
cells	O
are	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
and	O
the	O
NF	O
-	O
kappaB	O
site	O
.	O

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	O
or	O
antibodies	O
to	O
CD3	O
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	O
antibodies	O
or	O
B7	O
-	O
positive	O
(	O
B	O
cells	O
)	O
or	O
B7	O
-	O
negative	O
(	O
endothelial	O
)	O
accessory	O
cells	O
,	O
are	O
mediated	O
through	O
the	O
same	O
cis	O
-	O
elements	O
.	O

Interestingly	O
,	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
sites	O
are	O
much	O
less	O
important	O
in	O
normal	O
T	O
cells	O
than	O
in	O
Jurkat	O
T	O
cells	O
.	O

We	O
conclude	O
that	O
IL	O
-	O
2	O
transcriptional	B-Regulation
regulation	I-Regulation
differs	O
in	O
tumor	O
cell	O
lines	O
compared	O
with	O
normal	O
T	O
cells	O
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis	O
-	O
elements	O
in	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

A	O
hydrophobic	O
domain	O
of	O
Ca2+	O
-	O
modulating	O
cyclophilin	O
ligand	O
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O

Ca2+	O
-	O
modulating	O
cyclophilin	O
ligand	O
(	O
CAML	O
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	O
B	O
-	O
binding	O
protein	O
whose	O
overexpression	B-Positive_regulation
in	O
T	O
cells	O
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	O
factors	O
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

As	O
reported	O
here	O
,	O
structure	O
-	O
function	O
analysis	O
of	O
the	O
CAML	O
gene	O
in	O
Jurkat	O
T	O
cells	O
indicates	O
that	O
two	O
of	O
CAML	O
's	O
putative	O
membrane	O
-	O
spanning	O
domains	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O

We	O
propose	O
that	O
the	O
hydrophobic	O
C	O
-	O
terminal	O
tail	O
of	O
CAML	O
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N	O
-	O
terminal	O
hydrophilic	O
domain	O
in	O
a	O
regulatory	O
role	O
.	O

These	O
findings	O
define	O
a	O
novel	O
protein	O
motif	O
that	O
functions	O
in	O
intracellular	O
calcium	O
signaling	O
.	O

Interactions	B-Binding
of	O
a	O
transcriptional	O
activator	O
in	O
the	O
env	O
gene	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
with	O
activation	O
-	O
dependent	O
,	O
T	O
cell	O
-	O
specific	O
transacting	O
factors	O
.	O

The	O
mouse	O
mammary	O
tumor	O
virus	O
env	O
gene	O
contains	O
a	O
transcriptional	O
activator	O
(	O
META	O
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	O
terminal	O
repeat	O
region	O
.	O

Transcriptional	O
control	O
by	O
META	O
parallels	O
that	O
of	O
several	O
lymphokine	O
genes	O
,	O
being	O
specific	O
to	O
T	O
cells	O
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

DNase	O
I	O
footprinting	O
indicated	O
that	O
nuclear	O
factors	O
from	O
activated	O
T	O
lymphocytes	O
bound	O
a	O
promoter	O
-	O
proximal	O
site	O
,	O
META	O
(	O
P	O
)	O
,	O
and	O
a	O
promoter	O
-	O
distal	O
site	O
,	O
META	O
(	O
D+	O
)	O
,	O
within	O
the	O
400	O
-	O
base	O
pair	O
META	O
region	O
.	O

Nuclear	O
factors	O
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	O
(	O
D	O
-	O
)	O
,	O
adjacent	O
to	O
META	O
(	O
D+	O
)	O
.	O

META	O
(	O
D+	O
)	O
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	O
gene	O
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA	O
-	O
sensitive	O
T	O
cell	O
factors	O
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

Authentic	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
targets	O
did	O
not	O
compete	O
for	O
the	O
META	O
(	O
D+	O
)	O
binding	O
factor	O
(	O
s	O
)	O
.	O

The	O
SV40	O
core	O
sequence	O
competed	O
for	O
META	O
(	O
D+	O
)	O
binding	O
factors	O
,	O
but	O
META	O
(	O
D+	O
)	O
failed	O
to	O
compete	O
for	O
the	O
complexes	O
obtained	O
with	O
the	O
SV40	O
probe	O
.	O

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	O
(	O
D+	O
)	O
is	O
a	O
novel	O
transcriptional	O
enhancer	O
element	O
that	O
is	O
similar	O
in	O
its	O
cell	O
-	O
type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	O
element	O
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	O
antigens	O
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O

Monocytic	O
cell	O
type	O
-	O
specific	O
transcriptional	O
induction	O
of	O
collagenase	O
.	O

Interstitial	O
collagenase	O
(	O
MMP	O
-	O
1	O
)	O
,	O
a	O
metalloproteinase	O
produced	B-Gene_expression
by	O
resident	O
and	O
inflammatory	O
cells	O
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	O
I	O
collagen	O
fibrils	O
.	O

This	O
catalytic	O
event	O
is	O
rate	O
limiting	O
in	O
remodeling	O
of	O
tissues	O
rich	O
in	O
fibrillar	O
collagen	O
such	O
as	O
the	O
skin	O
and	O
lungs	O
.	O

The	O
regulation	O
of	O
collagenase	O
expression	O
is	O
cell	O
-	O
type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	O
expression	O
in	O
macrophages	O
,	O
but	O
do	O
not	O
alter	O
fibroblast	O
collagenase	O
expression	O
.	O

Since	O
promoter	O
elements	O
controlling	O
collagenase	O
transcription	O
in	O
monocytic	O
cells	O
have	O
not	O
been	O
previously	O
defined	O
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
collagenase	O
promoter	O
in	O
transiently	O
transfected	O
human	O
(	O
U937	O
)	O
and	O
murine	O
(	O
J774	O
)	O
monocytic	O
cell	O
lines	O
.	O

Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
collagenase	O
promoter	O
were	O
sufficient	O
for	O
LPS	O
-	O
or	O
zymosan	O
-	O
mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	O
enhancer	O
A	O
-	O
binding	O
protein	O
-	O
3	O
site	O
(	O
-	O
83	O
to	O
-	O
91	O
)	O
and	O
TTCA	O
sequence	O
(	O
-	O
102	O
to	O
-	O
105	O
)	O
in	O
both	O
monocytic	O
cells	O
and	O
fibroblasts	O
.	O

Mutagenesis	O
of	O
the	O
activator	O
protein	O
-	O
1	O
[	O
AP	O
-	O
1	O
]	O
site	O
at	O
-	O
72	O
abolished	O
basal	O
promoter	O
activity	O
and	O
LPS/zymosan	O
inducibility	O
,	O
while	O
mutagenesis	O
of	O
an	O
NF-kappaB	O
-	O
like	O
site	O
at	O
-	O
20	O
to	O
-	O
10	O
had	O
no	O
effect	O
.	O

Nuclear	O
extracts	O
from	O
LPS	O
-	O
and	O
zymosan	O
-	O
treated	O
cells	O
showed	O
strong	O
AP	O
-	O
1	O
activity	O
by	O
gel	O
-	O
shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP	O
-	O
1	O
complexes	O
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	O
and	O
fos	O
gene	O
families	O
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP	O
-	O
1	O
,	O
but	O
not	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	O
transcription	O
in	O
macrophagelike	O
cells	O
.	O

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	O
induction	O
in	O
monocytic	O
cells	O
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	O
promoter	O
sequences	O
.	O

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	B-Negative_regulation
tumor	O
necrosis	O
factor	O
-	O
alpha	O
generation	B-Gene_expression
,	O
on	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

(	O
2E	O
)	O
-3	O
-	O
[	O
5	O
-	O
(	O
2	O
,	O
3-Dimethoxy-6-methyl	O
-	O
1	O
,	O
4	O
-	O
benzoquinoyl	O
)	O
]	O
-2-nonyl-2	O
-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
gene	O
and	O
on	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activation	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF	O
-	O
alpha	O
gene	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	O
peripheral	O
monocytes	O
.	O

To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted	O
-	O
type	O
placental	O
alkaline	O
phosphatase	O
(	O
PLAP	O
)	O
reporter	O
gene	O
whose	O
transcription	B-Transcription
is	O
controlled	B-Regulation
by	O
a	O
1.4	O
-	O
kb	O
human	O
TNF	O
-	O
alpha	O
promoter	O
.	O

A	O
stable	O
transformant	O
of	O
the	O
PLAP	O
reporter	O
gene	O
derived	O
from	O
human	O
monocytic	O
cell	O
line	O
showed	O
very	O
little	O
activity	O
on	O
the	O
promoter	O
before	O
stimulation	O
,	O
whereas	O
LPS	O
stimulation	O
led	O
to	O
a	O
dramatic	O
increase	O
in	O
PLAP	O
activity	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

There	O
are	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
(	O
kappa	O
B	O
-	O
1	O
,	O
kappa	O
B	O
-	O
2	O
,	O
kappa	O
B	O
-	O
3	O
,	O
kappa	O
B	O
-	O
4	O
)	O
in	O
human	O
TNF	O
-	O
alpha	O
promoter	O
.	O

By	O
using	O
mutated	O
promoter	O
-	O
PLAP	O
plasmids	O
,	O
we	O
established	O
that	O
these	O
NF	O
-	O
kappa	O
B	O
sites	O
were	O
necessary	B-Positive_regulation
for	O
induction	B-Positive_regulation
of	O
TNF	O
-	O
alpha	O
transcription	B-Transcription
on	O
stimulation	O
with	O
LPS	O
.	O

A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double	O
-	O
stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF	O
-	O
kappa	O
B	O
consisting	O
of	O
p50/p65	O
heterodimer	O
bound	B-Binding
to	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
DNA	O
probes	O
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
recognition	O
sites	O
play	B-Positive_regulation
an	I-Positive_regulation
important	I-Positive_regulation
role	I-Positive_regulation
in	O
inducible	O
TNF	O
-	O
alpha	O
expression	B-Gene_expression
.	O

E3330	O
decreased	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF	O
-	O
kappa	O
B	O
activation	O
and/or	O
translocation	O
of	O
the	O
nuclei	O
.	O

Western	O
blotting	O
analysis	O
with	O
anti	O
-	O
I	O
kappa	O
B	O
-	O
alpha	O
antibody	O
indicated	O
that	O
E3330	O
inhibited	B-Negative_regulation
degradation	B-Protein_catabolism
of	O
I	O
kappa	O
B	O
-	O
alpha	O
,	O
which	O
is	O
an	O
inhibitory	O
protein	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O

E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
role	B-Regulation
of	O
p16	O
in	O
the	O
E2F	O
-	O
dependent	O
thymidine	O
kinase	O
regulation	B-Regulation
.	O

The	O
role	O
of	O
alterations	B-Regulation
of	O
the	O
MTS1	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
9p21	O
,	O
which	O
encodes	O
p16	O
,	O
the	O
inhibitor	B-Negative_regulation
of	O
cyclin-dependent-kinase	O
-	O
4	O
and	O
6	O
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O

Phosphorylation	B-Phosphorylation
of	O
the	O
retinoblastoma	O
protein	O
by	O
cyclin	O
-	O
dependent	O
kinases	O
4	O
and	O
6	O
prevents	B-Negative_regulation
its	O
interaction	B-Binding
with	O
the	O
transcription	O
factor	O
E2F	O
,	O
which	O
subsequently	O
promotes	B-Positive_regulation
the	O
expression	B-Gene_expression
of	O
S	O
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	O
kinase	O
.	O

Although	O
a	O
role	B-Regulation
of	O
p16	O
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	B-Negative_regulation
of	O
this	O
tumor	O
suppressor	O
gene	O
really	O
affects	O
E2F	O
-	O
mediated	O
regulations	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	O
kinase	O
in	O
phytohemagglutinin	O
-	O
stimulated	O
normal	O
human	O
lymphocytes	O
and	O
in	O
the	O
p16	O
-	O
negative	B-Gene_expression
human	O
acute	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
.	O

Compared	O
to	O
normal	O
lymphocytes	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	B-Positive_regulation
of	O
thymidine	O
kinase	O
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	O
,	O
and	O
higher	O
thymidine	O
kinase	O
mRNA	O
expression	B-Transcription
.	O

Transient	O
expression	B-Gene_expression
of	O
p16	O
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
,	O
although	O
all	O
of	O
them	O
express	B-Gene_expression
functional	O
retinoblastoma	O
protein	O
.	O

Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	O
cell	O
lines	O
transient	O
overexpression	B-Positive_regulation
of	O
p16	O
reestablished	B-Positive_regulation
the	O
normal	O
regulation	B-Regulation
of	O
thymidine	O
kinase	O
,	O
paralleled	O
by	O
an	O
increase	B-Positive_regulation
of	O
the	O
underphosphorylated	B-Negative_regulation
form	I-Negative_regulation
of	O
retinoblastoma	O
protein	O
and	O
decrease	B-Negative_regulation
of	O
free	O
E2F	O
bound	B-Binding
to	O
its	O
motif	O
in	O
the	O
thymidine	O
kinase	O
promoter	O
.	O

We	O
demonstrate	O
that	O
loss	O
of	O
p16	O
causes	B-Positive_regulation
upregulation	I-Positive_regulation
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	O
via	O
activation	O
of	O
E2F	O
by	O
a	O
mechanism	O
involving	O
retinoblastoma	O
protein	O
.	O

Rel	O
-	O
deficient	B-Negative_regulation
T	O
cells	O
exhibit	O
defects	B-Negative_regulation
in	O
production	B-Gene_expression
of	O
interleukin	O
3	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O

The	O
c	O
-	O
rel	O
protooncogene	O
encodes	O
a	O
subunit	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
family	O
of	O
transcription	O
factors	O
.	O

Mice	O
lacking	B-Negative_regulation
Rel	O
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	O
and	O
T	O
lymphocytes	O
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T	O
-	O
cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	B-Negative_regulation
of	O
Rel	O
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	O
surface	O
activation	O
markers	O
and	O
cytokine	O
production	O
in	O
mitogen	O
-	O
stimulated	O
Rel-/	O
-	O
T	O
cells	O
.	O

The	O
expression	B-Gene_expression
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
chain	O
(	O
CD25	O
)	O
,	O
CD69	O
and	O
L	O
-	O
selectin	O
(	O
CD62	O
)	O
is	O
normal	O
in	O
mitogen	O
-	O
activated	O
Rel-/	O
-	O
T	O
cells	O
,	O
but	O
cytokine	O
production	O
is	O
impaired	O
.	O

In	O
Rel-/	O
-	O
splenic	O
T	O
cell	O
cultures	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL	O
-	O
3	O
,	O
IL	O
-	O
5	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
and	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
were	O
only	O
2	O
-	O
to	O
3	O
-	O
fold	O
lower	B-Negative_regulation
compared	O
with	O
normal	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
stimulated	O
Rel-/	O
-	O
T	O
cells	O
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	O
.	O

Exogenous	O
IL	O
-	O
2	O
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti-CD3	O
-	O
and	O
anti-CD28	O
-	O
treated	O
Rel-/	O
-	O
T	O
cells	O
,	O
restores	B-Positive_regulation
production	B-Gene_expression
of	O
IL	O
-	O
5	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
IFN	O
-	O
gamma	O
,	O
but	O
not	O
IL	O
-	O
3	O
and	O
GM	O
-	O
CSF	O
expression	B-Gene_expression
to	O
approximately	O
normal	O
levels	O
.	O

In	O
contrast	O
to	O
mitogen	O
-	O
activated	O
Rel-/	O
-	O
T	O
cells	O
,	O
lipopolysaccharide	O
-	O
stimulated	O
Rel-/	O
-	O
macrophages	O
produce	B-Positive_regulation
higher	I-Positive_regulation
than	O
normal	O
levels	O
of	O
GM	O
-	O
CSF	O
.	O

These	O
findings	O
establish	O
that	O
Rel	O
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	B-Positive_regulation
by	O
T	O
lymphocytes	O
for	O
production	B-Gene_expression
of	O
IL	O
-	O
3	O
and	O
GM	O
-	O
CSF	O
.	O

Human	O
T	O
lymphotropic	O
virus	O
-	O
I	O
infection	O
of	O
human	O
T	O
lymphocytes	O
induces	B-Positive_regulation
expression	B-Gene_expression
of	O
the	O
beta-galactoside	O
-	O
binding	O
lectin	O
,	O
galectin	O
-	O
3	O
.	O

Animal	O
lectins	O
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

Galectin	O
-	O
3	O
is	O
a	O
beta-galactoside	O
-	O
binding	O
lectin	O
previously	O
designated	O
as	O
epsilon	O
BP	O
(	O
IgE	O
-	O
binding	O
protein	O
)	O
,	O
CBP35	O
,	O
Mac	O
-	O
2	O
,	O
L	O
-	O
29	O
,	O
and	O
L	O
-	O
34	O
,	O
and	O
its	O
expression	B-Gene_expression
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O

Galectin	O
-	O
3	O
is	O
widely	O
distributed	B-Gene_expression
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	B-Gene_expression
in	O
many	O
leukocytes	O
,	O
with	O
the	O
notable	O
exception	O
of	O
B	O
and	O
T	O
lymphocytes	O
.	O

We	O
now	O
report	O
that	O
galectin	O
-	O
3	O
is	O
abundantly	O
expressed	B-Gene_expression
in	O
a	O
number	O
of	O
human	O
T	O
lymphotropic	O
virus	O
(	O
HTLV	O
)	O
-I	O
-	O
infected	O
human	O
T	O
cell	O
lines	O
,	O
including	O
F6T	O
,	O
HUT	O
102	O
,	O
K3T	O
,	O
MT	O
-	O
2	O
,	O
and	O
SLB	O
-	O
I	O
,	O
but	O
is	O
not	O
expressed	B-Gene_expression
in	O
non-HTLV-I	O
-	O
infected	O
T	O
cell	O
lines	O
such	O
as	O
Jurkat	O
,	O
CEM	O
,	O
and	O
MOLT	O
-	O
4	O
.	O

In	O
addition	O
,	O
the	O
galectin	O
-	O
3	O
level	O
was	O
markedly	O
increased	B-Positive_regulation
in	O
human	O
thymocytes	O
after	O
infection	O
with	O
HTLV	O
-	O
I	O
as	O
compared	O
with	O
uninfected	O
thymocytes	O
.	O

The	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
galectin	O
-	O
3	O
expression	B-Gene_expression
appeared	O
to	O
correlate	O
well	O
with	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
as	O
undetectable	B-Gene_expression
or	O
very	O
low	B-Gene_expression
levels	I-Gene_expression
of	O
galectin	O
-	O
3	O
were	O
found	O
in	O
the	O
S1T	O
and	O
ATL	O
-	O
1K	O
cell	O
lines	O
,	O
which	O
are	O
nonproductively	O
infected	O
with	O
HTLV	O
-	O
I	O
.	O

In	O
co	O
-	O
transfection	O
experiments	O
,	O
the	O
galectin	O
-	O
3	O
promoter	O
was	O
significantly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
by	O
expression	O
vectors	O
encoding	O
the	O
40	O
-	O
kd	O
Tax	O
protein	O
,	O
a	O
potent	O
transactivator	O
in	O
HTLV	O
-	O
I	O
.	O

Analysis	O
of	O
various	O
Tax	O
mutants	O
suggested	O
that	O
galectin	O
-	O
3	O
promoter	O
induction	B-Positive_regulation
is	O
dependent	B-Positive_regulation
on	O
activation	O
of	O
the	O
cyclic-AMP	O
-	O
responsive	O
element	O
binding	O
protein/activation	O
transcription	O
factor	O
family	O
of	O
transcription	O
factors	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	O
factor	O
-	O
kappa	O
B/Rel	O
induction	O
.	O

Transfection	B-Positive_regulation
of	O
human	O
promonocytic	O
U	O
-	O
937	O
cells	O
with	O
an	O
HTLV	O
-	O
I	O
Tax	O
expression	O
vector	O
induced	B-Positive_regulation
galectin	O
-	O
3	O
expression	B-Gene_expression
in	O
this	O
cell	O
line	O
.	O

Functionally	O
,	O
galectin	O
-	O
3	O
was	O
shown	O
to	O
activate	B-Positive_regulation
interleukin	O
-	O
2	O
production	B-Gene_expression
in	O
Jurkat	O
T	O
cells	O
.	O

Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
HTLV	O
-	O
I	O
Tax	O
production	B-Gene_expression
induces	B-Positive_regulation
the	O
transcription	B-Transcription
and	O
subsequent	O
synthesis	O
and	O
secretion	B-Localization
of	O
galectin	O
-	O
3	O
,	O
which	O
in	O
turn	O
may	O
further	O
activate	O
these	O
T	O
cells	O
and	O
contribute	O
to	O
the	O
altered	O
properties	O
of	O
cell	O
growth	O
found	O
in	O
adult	O
T	O
cell	O
leukemia	O
induced	O
by	O
HTLV	O
-	O
I	O
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	O
response	O
element	O
within	O
the	O
interleukin	O
-	O
2	O
enhancer	O
correlates	O
with	O
interleukin	O
-	O
2	O
production	B-Gene_expression
.	O

Activation	O
of	O
T	O
lymphocytes	O
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
molecules	O
such	O
as	O
CD28	O
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
produce	B-Gene_expression
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O

The	O
IL	O
-	O
2	O
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

The	O
CD28RE	O
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	O
kappaB	O
binding	O
motif	O
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	O
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	O
factor	O
of	O
mitogenic	O
-	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
MATp35	O
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF	O
-	O
kappaB/Rel	O
family	O
members	O
.	O

Induction	O
of	O
NF	O
-	O
MATp35	O
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	O
cells	O
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	O
signaling	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF	O
-	O
MATp35	O
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF	O
-	O
MATp35	O
induction	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL	O
-	O
2	O
production	B-Gene_expression
,	O
cyclosporin	O
A	O
inhibited	B-Negative_regulation
the	O
induction	O
of	O
NF	O
-	O
MATp35	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
MATp35	O
shows	O
excellent	O
correlation	O
with	O
IL	O
-	O
2	O
production	B-Gene_expression
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	B-Regulation
of	O
IL	O
-	O
2	O
gene	O
expression	B-Gene_expression
.	O

Preassociation	O
of	O
STAT1	O
with	O
STAT2	O
and	O
STAT3	O
in	O
separate	B-Regulation
signalling	O
complexes	O
prior	O
to	O
cytokine	O
stimulation	O
.	O

A	O
variety	O
of	O
cytokines	O
and	O
growth	O
factors	O
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	O
transcription	O
factors	O
called	O
STAT	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O

Ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	O
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

We	O
demonstrate	O
here	O
that	O
STAT	O
protein	O
heterocomplexes	O
exist	O
prior	O
to	O
cytokine	O
treatment	O
.	O

When	O
unstimulated	O
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	O
or	O
STAT2	O
from	O
the	O
resulting	O
cytosol	O
yields	B-Binding
coimmunoadsorption	I-Binding
of	O
the	O
other	O
STAT	O
protein	O
.	O

Similarly	O
,	O
STAT1	O
-	O
STAT3	O
heterocomplexes	B-Binding
are	I-Binding
coimmunoadsorbed	I-Binding
from	O
hypotonic	O
cytosol	O
.	O

STAT1	O
and	O
STAT2	O
or	O
STAT1	O
and	O
STAT3	O
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	B-Binding
heterocomplexes	I-Binding
when	B-Positive_regulation
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O

Our	O
data	O
suggest	O
that	O
interferon	O
-	O
alpha	O
/beta	O
-	O
induced	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
increases	B-Positive_regulation
the	I-Positive_regulation
stability	I-Positive_regulation
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	O
-	O
STAT2	O
signaling	O
complex	O
.	O

Newly	O
translated	O
STAT1	O
binds	B-Binding
in	O
equilibrium	O
fashion	O
to	O
STAT2	O
and	O
STAT3	O
,	O
but	O
we	O
show	O
that	O
STAT2	O
and	O
STAT3	O
exist	B-Binding
in	I-Binding
separate	I-Binding
heterocomplexes	I-Binding
with	O
STAT1	O
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	O
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	O
proteins	O
.	O

Inhibition	O
of	O
p105	O
processing	O
by	O
NF	O
-	O
kappaB	O
proteins	O
in	O
transiently	O
transfected	O
cells	O
.	O

Regulation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
involves	O
proteasome	O
-	O
mediated	O
processing	O
of	O
the	O
NF	O
-	O
kappaB1	O
p105	O
precursor	O
protein	O
,	O
which	O
generates	B-Positive_regulation
the	O
p50	O
subunit	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
processing	O
of	O
p105	O
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal	O
-	O
mediated	O
induction	O
of	O
p105	O
processing	O
in	O
human	O
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	O
protein	O
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	O
cells	O
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	O
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	B-Binding
with	O
the	O
processed	O
product	O
p50	O
.	O

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	O
is	O
markedly	O
inhibited	O
in	O
cells	O
co	O
-	O
transfected	O
with	O
p50	O
or	O
other	O
NF	O
-	O
kappaB	O
subunits	O
,	O
including	O
RelA	O
and	O
c	O
-	O
Rel	O
,	O
that	O
physically	O
interact	B-Binding
with	O
p105	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	O
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF	O
-	O
kappaB	O
subunits	O
.	O

We	O
further	O
demonstrate	O
that	O
p105	O
undergoes	B-Positive_regulation
degradation	B-Protein_catabolism
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
.	O

However	O
,	O
the	O
inducible	O
degradation	B-Protein_catabolism
of	O
p105	O
is	O
not	O
coupled	O
with	O
the	O
generation	B-Gene_expression
of	O
p50	O
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	B-Protein_catabolism
of	O
p105	O
are	O
differentially	B-Regulation
regulated	I-Regulation
.	O

Globin	O
gene	O
switching	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
interactions	B-Binding
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
in	O
erythroid	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
program	O
.	O

To	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
important	B-Positive_regulation
for	O
the	O
developmental	O
control	B-Regulation
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	O
cells	O
expressing	B-Positive_regulation
either	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
developmental	O
program	O
.	O

In	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
,	O
in	O
vivo	O
footprints	O
on	O
NF	O
-	O
E2	O
(	O
or	O
AP	O
-	O
1	O
)	O
and	O
GATA	O
-	O
1	O
motifs	O
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
genes	O
are	O
expressed	B-Gene_expression
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	O
(	O
CACCC	O
)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	B-Gene_expression
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O

In	O
promoter	O
regions	O
,	O
the	O
actively	O
transcribed	O
genes	O
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	O
and	O
CCAAT	O
motifs	O
.	O

The	O
adult	O
globin	O
expressing	O
cells	O
displayed	O
more	B-Positive_regulation
extensive	I-Positive_regulation
footprints	B-Binding
than	O
the	O
fetal	O
globin	O
expressing	O
cells	O
in	O
the	O
3	O
'	O
regulatory	O
sequences	O
of	O
both	O
the	O
Agamma	O
-	O
and	O
the	O
beta	O
-	O
globin	O
genes	O
,	O
suggesting	O
a	O
role	B-Regulation
of	O
these	O
3	O
'	O
elements	O
in	O
beta	O
-	O
globin	O
gene	O
expression	B-Gene_expression
.	O

Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein	O
-	O
DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	O
genes	O
takes	O
place	O
in	O
the	O
gamma	O
-	O
and	O
beta	O
-	O
globin	O
gene	O
promoters	O
,	O
and	O
that	O
GT	O
motifs	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
LCR	O
may	O
play	B-Positive_regulation
a	I-Positive_regulation
role	I-Positive_regulation
in	O
the	O
developmental	O
regulation	B-Regulation
of	O
human	O
beta	O
-	O
globin	O
gene	O
expression	B-Gene_expression
,	O
perhaps	O
by	O
increasing	B-Positive_regulation
the	O
probability	O
of	O
interaction	B-Binding
of	O
the	O
LCR	O
holocomplex	O
with	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
.	O

Interleukin	O
10	O
induced	B-Positive_regulation
c	O
-	O
fos	O
expression	B-Gene_expression
in	O
human	O
B	O
cells	O
by	O
activation	O
of	O
divergent	O
protein	O
kinases	O
.	O

IL	O
-	O
10	O
is	O
a	O
potent	O
mediator	O
of	O
human	O
B	O
cell	O
growth	O
and	O
plasma	O
cell	O
formation	O
.	O

However	O
,	O
signal	O
transduction	O
of	O
IL	O
-	O
10	O
in	O
B	O
cells	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
the	O
effect	B-Regulation
of	O
IL	O
-	O
10	O
on	O
the	O
expression	B-Gene_expression
of	O
the	O
protooncogene	O
c	O
-	O
fos	O
was	O
investigated	O
,	O
because	O
Fos	O
plays	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

B	O
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	O
CD20	O
monoclonal	O
antibody	O
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

B	O
cells	O
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O

Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL	O
-	O
10	O
(	O
100	O
ng/ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O

RNA	O
was	O
extracted	O
by	O
phenol/chloroform	O
and	O
c	O
-	O
fos	O
expression	B-Gene_expression
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O

A	O
significant	O
2	O
-	O
4	O
fold	O
increase	B-Positive_regulation
of	O
c	O
-	O
fos	O
expression	B-Gene_expression
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL	O
-	O
10	O
(	O
p	O
<	O
0.01	O
)	O
.	O

After	O
2	O
hrs	O
c	O
-	O
fos	O
expression	B-Gene_expression
declined	B-Negative_regulation
to	O
basal	O
levels	O
.	O

The	O
effect	O
of	O
IL	O
-	O
10	O
was	O
dose	O
-	O
dependent	O
with	O
a	O
maximum	O
stimulation	O
using	O
100	O
ng/ml	O
of	O
IL	O
-	O
10	O
.	O

The	O
IL	O
-	O
10	O
effect	B-Regulation
on	O
c	O
-	O
fos	O
expression	B-Gene_expression
was	O
not	O
blocked	B-Negative_regulation
by	O
polymyxin	O
B	O
.	O

Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(	O
10	O
microM	O
)	O
a	O
complete	O
inhibition	B-Negative_regulation
of	O
IL	O
-	O
10	O
induced	B-Positive_regulation
c	O
-	O
fos	O
expression	B-Gene_expression
was	O
observed	O
.	O

In	O
addition	O
,	O
H	O
-	O
7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine/threonine	O
kinases	O
,	O
significantly	O
blocked	B-Negative_regulation
IL	O
-	O
10	O
mediated	B-Positive_regulation
c	O
-	O
fos	O
expression	B-Gene_expression
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
show	O
that	O
IL	O
-	O
10	O
induces	B-Positive_regulation
c	O
-	O
fos	O
expression	B-Gene_expression
in	O
human	O
B	O
-	O
cells	O
by	O
activation	O
of	O
tyrosine	O
and	O
serine/threonine	O
kinases	O
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL	O
-	O
10	O
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL	O
-	O
10	O
stimulates	O
human	O
B	O
-	O
cells	O
.	O

IL	O
-	O
10	O
inhibits	O
nuclear	O
factor	O
-	O
kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
human	O
peripheral	O
T	O
lymphocytes	O
.	O

IL	O
-	O
10	O
markedly	O
reduces	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B/Rel	O
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti	O
-	O
CD3	O
mAb	O
OKT3	O
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
activation	O
induced	O
by	O
mAb	O
OKT3	O
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA	O
-	O
protein	O
complexes	O
with	O
Abs	O
recognizing	O
specific	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
protein	O
family	O
,	O
the	O
p50/p65	O
(	O
Rel	O
A	O
)	O
heterodimeric	O
form	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
primarily	O
affected	B-Negative_regulation
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL	O
-	O
10	O
concentration	O
of	O
20	O
U/ml	O
.	O

IL	O
-	O
10	O
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
monocytes	O
.	O

Indeed	O
,	O
monocytes	O
pretreated	O
with	O
IL	O
-	O
10	O
are	O
able	O
so	O
inhibit	O
NF	O
-	O
kappa	O
B	O
nuclear	O
activity	O
in	O
purified	O
T	O
lymphocytes	O
stimulated	O
with	O
OKT3	O
.	O

Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
CD80	O
Ag	O
,	O
found	O
on	O
monocytes	O
obtained	O
from	O
PBMC	O
incubated	O
with	O
OKT3	O
,	O
is	O
not	O
detected	B-Positive_regulation
after	O
addition	O
of	O
IL	O
-	O
10	O
,	O
and	O
the	O
anti	O
-	O
CD28	O
mAb	O
CLB	O
-	O
CD28/1	O
restores	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
IL-10	O
-	O
inhibited	O
lymphocytes	O
.	O

Therefore	O
,	O
the	O
NF	O
-	O
kappa	O
B/Rel	O
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	O
lymphocytes	O
,	O
resulting	O
from	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	O
,	O
produced	O
by	O
IL	O
-	O
10	O
on	O
activated	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL	O
-	O
10	O
can	O
inhibit	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	O
B	O
-	O
driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

Vitamin	O
D3	O
-	O
and	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	O
vitamin	O
D3	O
receptor	O
,	O
retinoic	O
acid	O
receptors	O
,	O
and	O
retinoid	O
X	O
receptors	O
in	O
U	O
-	O
937	O
cells	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
alpha	O
-	O
dihydroxycholecalciferol	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O

Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	O
and	O
VitD3	O
receptor	O
network	O
operates	O
in	O
hematopoietic	O
cells	O
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA	O
-	O
and	O
VitD3	O
-	O
signaling	O
pathways	O
during	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	B-Gene_expression
,	O
DNA	O
binding	B-Binding
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	O
RA	O
and	O
VitD3	O
receptors	O
[	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
,	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
and	O
VitD3	O
receptor	O
(	O
VDR	O
)	O
]	O
in	O
the	O
U	O
-	O
937	O
cell	O
line	O
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

VitD3	O
induction	O
resulted	B-Positive_regulation
in	O
the	O
formation	B-Binding
of	O
VDR/RXR	O
DNA	O
-	O
binding	O
complexes	O
on	O
both	O
VitD3	O
response	O
elements	O
and	O
RA	O
response	O
elements	O
(	O
RAREs	O
)	O
.	O

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	O
response	O
element	O
-	O
driven	O
reporter	O
construct	O
.	O

Several	O
DNA	O
-	O
binding	O
complexes	O
were	O
detected	O
on	O
RAREs	O
in	O
undifferentiated	O
cells	O
.	O

Stimulation	O
by	O
RA	O
resulted	B-Positive_regulation
in	I-Positive_regulation
increased	I-Positive_regulation
RAR	O
beta/RXR	O
DNA	O
binding	B-Binding
,	O
activated	O
RARE	O
-	O
dependent	O
transcription	O
,	O
and	O
increased	B-Positive_regulation
expression	B-Gene_expression
of	O
RAR	O
-	O
beta	O
.	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	B-Negative_regulation
the	O
RA	O
-	O
stimulated	B-Positive_regulation
formation	O
of	O
RAR	O
beta/RXR	O
heterodimers	B-Binding
,	O
favoring	B-Positive_regulation
VDR/RXR	O
binding	B-Binding
to	O
the	O
RARE	O
.	O

Also	O
,	O
VitD3	O
inhibited	B-Negative_regulation
the	O
expression	B-Gene_expression
of	O
CD23	O
and	O
CD49f	O
,	O
characteristic	O
markers	O
of	O
retinoid	O
-	O
induced	O
U	O
-	O
937	O
cell	O
differentiation	O
.	O

In	O
contrast	O
,	O
neither	O
the	O
RA	O
-	O
stimulated	O
,	O
RARE	O
-	O
mediated	O
transcription	O
nor	O
the	O
induced	B-Positive_regulation
RAR	O
-	O
beta	O
expression	B-Gene_expression
was	O
suppressed	B-Negative_regulation
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid	O
-	O
induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	O
-	O
mediated	O
signal	O
.	O

These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation	O
-	O
inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O

Calcium	O
-	O
dependent	O
immediate	O
-	O
early	O
gene	O
induction	O
in	O
lymphocytes	O
is	O
negatively	O
regulated	O
by	O
p21Ha	O
-	O
ras	O
.	O

The	O
induction	B-Positive_regulation
of	O
immediate	O
-	O
early	O
(	O
IE	O
)	O
response	O
genes	O
,	O
such	O
as	O
egr	O
-	O
1	O
,	O
c	O
-	O
fos	O
,	O
and	O
c	O
-	O
jun	O
,	O
occurs	B-Positive_regulation
rapidly	O
after	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	O
kinases	O
.	O

p21	O
(	O
ras	O
)	O
,	O
a	O
guanine	O
nucleotide	O
binding	O
factor	O
,	O
mediates	O
T	O
-	O
cell	O
signal	O
transduction	O
through	O
PKC	O
-	O
dependent	O
and	O
PKC	O
-	O
independent	O
pathways	O
.	O

The	O
involvement	O
of	O
p21	O
(	O
ras	O
)	O
in	O
the	O
regulation	O
of	O
calcium	O
-	O
dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF	O
-	O
AT	O
.	O

We	O
have	O
investigated	O
the	O
inductions	O
of	O
the	O
IE	O
genes	O
in	O
response	O
to	O
calcium	O
signals	O
in	O
Jurkat	O
cells	O
(	O
in	O
the	O
presence	O
of	O
activated	B-Positive_regulation
p21	O
(	O
ras	O
)	O
)	O
and	O
their	O
correlated	O
consequences	O
.	O

The	O
expression	B-Positive_regulation
of	I-Positive_regulation
activated	I-Positive_regulation
p21	O
(	O
ras	O
)	O
negatively	O
regulated	O
the	O
induction	O
of	O
IE	O
genes	O
by	O
calcium	O
ionophore	O
.	O

This	O
inhibition	O
of	O
calcium	O
-	O
activated	O
IE	O
gene	O
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	O
in	O
this	O
regulation	O
.	O

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	O
(	O
ras	O
)	O
was	O
down	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
and	O
subsequent	O
coordinate	O
reductions	B-Negative_regulation
in	O
IL	O
-	O
2	O
gene	B-Transcription
expression	I-Transcription
and	O
protein	O
production	O
.	O

These	O
results	O
suggest	O
that	O
p2l	O
(	O
ras	O
)	O
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	O
cells	O
in	O
response	O
to	O
inductive	O
stimulations	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	O
cells	O
:	O
differential	O
activity	O
of	O
Bcl	O
-	O
2	O
and	O
IL-1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
on	O
glucocorticoid	O
-	O
and	O
Fas	O
-	O
mediated	O
cytotoxicity	O
.	O

Fas	O
-	O
mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O

Restimulation	O
of	O
T	O
cell	O
blasts	O
up	B-Positive_regulation
-	I-Positive_regulation
regulates	I-Positive_regulation
Fas	O
and	O
Fas	O
ligand	O
expression	B-Gene_expression
,	O
with	O
subsequent	O
interaction	B-Binding
leading	O
to	O
cell	O
death	O
.	O

Overexpression	B-Positive_regulation
of	O
Bcl	O
-	O
2	O
in	O
tumor	O
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	O
-	O
mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl	O
-	O
2	O
in	O
normal	O
cells	O
,	O
T	O
cell	O
blasts	O
were	O
transiently	O
transfected	B-Positive_regulation
with	O
Bcl	O
-	O
2	O
and	O
related	O
gene	O
products	O
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O

Transient	O
overexpression	B-Gene_expression
of	O
Bcl	O
-	O
2	O
in	O
mouse	O
and	O
human	O
T	O
cell	O
blasts	O
did	O
not	O
block	O
Fas	O
-	O
mediated	O
apoptosis	O
,	O
whereas	O
etoposide	O
-	O
and	O
glucocorticoid	O
-	O
induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	B-Gene_expression
of	O
Bcl	O
-	O
xL	O
and	O
adenovirus	O
E1B	O
19K	O
did	O
not	O
interfere	O
with	O
anti	O
-	O
Fas	O
killing	O
.	O

In	O
contrast	O
,	O
interleukin-1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac-DEVD	O
-	O
CHO	O
and	O
CrmA	O
blocked	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl	O
-	O
2	O
and	O
interleukin-1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Since	O
T	O
cells	O
normally	O
express	B-Gene_expression
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
following	B-Positive_regulation
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	O
-	O
mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self	O
-	O
reactive	O
cells	O
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

Interferons	O
induce	B-Positive_regulation
normal	O
and	O
aberrant	O
retinoic	O
-	O
acid	O
receptors	O
type	O
alpha	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid	O
-	O
dependent	O
differentiation	O
markers	O
.	O

Treatment	O
of	O
the	O
acute	O
promyelocytic	O
(	O
APL	O
)	O
cell	O
line	O
NB4	O
with	O
interferon	O
alpha	O
(	O
IFN	O
(	O
alpha	O
)	O
)	O
,	O
as	O
well	O
as	O
IFN	O
(	O
beta	O
)	O
and	O
gamma	O
,	O
results	B-Positive_regulation
in	I-Positive_regulation
an	I-Positive_regulation
increased	I-Positive_regulation
expression	B-Transcription
of	O
the	O
transcripts	O
coding	O
for	O
retinoic	O
-	O
acid	O
receptor	O
type	O
alpha	O
(	O
RAR	O
(	O
alpha	O
)	O
)	O
and	O
the	O
leukemia	O
-	O
specific	O
retinoic	O
acid	O
receptor	O
PML	O
-	O
RAR	O
.	O

Transcriptional	B-Positive_regulation
induction	I-Positive_regulation
of	O
the	O
RAR	O
(	O
alpha	O
)	O
and	O
PML	O
-	O
RAR	O
mRNAs	O
is	O
rapid	O
and	O
it	O
is	O
parallelled	B-Positive_regulation
by	O
an	O
increase	B-Positive_regulation
in	O
the	O
corresponding	O
proteins	O
.	O

Up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
RAR	O
(	O
alpha	O
)	O
and	O
PML	O
-	O
RAR	O
gene	O
expression	B-Gene_expression
by	O
IFN	O
(	O
alpha	O
)	O
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	B-Positive_regulation
of	O
2	O
retinoid	O
-	O
dependent	B-Positive_regulation
granulocytic	O
markers	O
,	O
i.e.	O
,	O
granulocyte-colony	O
-	O
stimulating	O
factor	O
receptor	O
mRNA	O
and	O
leukocyte	O
alkaline	O
phosphatase	O
.	O

However	O
,	O
IFN	O
(	O
alpha	O
)	O
does	O
not	O
have	O
any	O
effects	B-Regulation
on	O
the	O
retinoid	O
-	O
dependent	O
regulation	B-Regulation
of	O
the	O
myeloid	O
surface	O
markers	O
CD11b	O
and	O
CD33	O
.	O

The	O
IFN	O
-	O
dependent	O
increase	B-Positive_regulation
in	O
RAR	O
(	O
alpha	O
)	O
levels	B-Gene_expression
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	O
on	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML	O
-	O
RAR	O
positive	O
cells	O
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	B-Positive_regulation
in	O
HL	O
-	O
60	O
promyelocytes	O
.	O

Interferons	O
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	O
cells	O
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti	O
-	O
proliferative	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	O
and	O
retinoic	O
acid	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

An	O
IL	O
-	O
2	O
response	O
element	O
in	O
the	O
human	O
IL	O
-	O
2	O
receptor	O
alpha	O
chain	O
promoter	O
is	O
a	O
composite	O
element	O
that	O
binds	B-Binding
Stat5	O
,	O
Elf	O
-	O
1	O
,	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
and	O
a	O
GATA	O
family	O
protein	O
.	O

Expression	B-Gene_expression
of	O
the	O
human	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
receptor	O
alpha	O
chain	O
gene	O
is	O
potently	O
upregulated	B-Positive_regulation
by	O
its	O
own	O
ligand	O
,	O
IL	O
-	O
2	O
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL	O
-	O
2	O
response	O
element	O
that	O
contains	O
both	O
consensus	O
and	O
non	O
-	O
consensus	O
GAS	O
motifs	O
,	O
two	O
putative	O
Ets	O
binding	O
sites	O
(	O
EBS	O
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	O
GAS	O
motif	O
,	O
and	O
a	O
GATA	O
motif	O
,	O
which	O
overlaps	O
the	O
non	O
-	O
consensus	O
GAS	O
motif	O
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL	O
-	O
2	O
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL	O
-	O
2	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O

Multiple	O
factors	O
including	O
Stat5	O
,	O
Elf	O
-	O
1	O
,	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
and	O
GATA	O
family	O
proteins	O
bind	B-Binding
to	O
the	O
IL	O
-	O
2	O
response	O
element	O
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

An	O
unidentified	O
Ets	O
family	O
protein	O
binds	O
to	O
the	O
EBS	O
overlapping	O
the	O
consensus	O
GAS	O
motif	O
and	O
appears	O
to	O
negatively	B-Negative_regulation
regulate	I-Negative_regulation
the	O
human	O
IL	O
-	O
2R	O
alpha	O
promoter	O
.	O

Thus	O
,	O
IL-2	O
-	O
induced	B-Positive_regulation
IL	O
-	O
2R	O
alpha	O
promoter	O
activity	O
requires	B-Positive_regulation
a	O
complex	O
upstream	O
element	O
,	O
which	O
appears	O
to	O
contain	O
binding	O
sites	O
for	O
both	O
positive	O
and	O
negative	O
regulatory	O
factors	O
.	O

Active	B-Positive_regulation
suppression	B-Negative_regulation
of	O
the	O
class	O
II	O
transactivator	O
-	O
encoding	O
AIR	O
-	O
1	O
locus	O
is	O
responsible	O
for	O
the	O
lack	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
expression	O
observed	O
during	O
differentiation	O
from	O
B	O
cells	O
to	O
plasma	O
cells	O
.	O

In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
gene	O
expression	O
during	O
the	O
transition	O
from	O
B	O
cell	O
to	O
plasma	O
cell	O
has	O
been	O
analyzed	O
.	O

Class	O
II	O
molecules	O
are	O
not	O
expressed	O
in	O
plasma	O
cells	O
because	O
of	O
an	O
active	O
suppression	O
resulting	O
in	O
the	O
abrogation	O
of	O
class	O
II	O
gene	O
transcription	O
.	O

We	O
show	O
here	O
that	O
the	O
plasma	O
cell	O
-	O
specific	O
repressor	O
function	O
,	O
designated	O
SIR	O
(	O
suppressor	O
of	O
immune	O
response	O
genes	O
)	O
,	O
does	O
not	O
act	B-Negative_regulation
directly	O
on	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
,	O
but	O
instead	O
on	O
the	O
transcription	B-Transcription
of	O
the	O
AIR	O
-	O
1	O
gene	O
,	O
whose	O
product	O
,	O
the	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

This	O
was	O
unambiguously	O
demonstrated	O
by	O
the	O
fact	O
that	O
plasmacytoma	O
x	O
B	O
cell	O
hybrids	O
carrying	O
an	O
AIR	O
-	O
1	O
locus	O
derived	O
from	O
CIITA	O
-	O
expressing	O
cells	O
do	O
not	O
express	B-Positive_regulation
CIITA	O
-	O
specific	O
transcripts	B-Transcription
.	O

Transfection	B-Gene_expression
of	O
a	O
cDNA	O
containing	O
the	O
human	O
CIITA	O
coding	O
sequence	O
under	B-Regulation
the	I-Regulation
control	I-Regulation
of	O
an	O
heterologous	O
promoter	O
restores	O
expression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	O
MHC	O
class	O
II	O
genes	O
in	O
both	O
the	O
mouse	O
plasmacytoma	O
cell	O
line	O
and	O
the	O
hybrids	O
.	O

These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR	O
-	O
1	O
gene	O
product	O
across	O
species	O
barriers	O
.	O

Interestingly	O
,	O
in	O
CIITA	O
-	O
transfected	B-Positive_regulation
cell	O
hybrids	O
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
heterodimer	O
was	O
not	O
observed	O
.	O

This	O
result	O
was	O
not	O
attributable	B-Regulation
to	O
lack	B-Negative_regulation
of	O
HLA	O
-	O
DQ	O
alpha	O
or	O
-	O
DQ	O
beta	O
transcription	B-Transcription
,	O
because	O
both	O
transcripts	O
were	O
present	B-Gene_expression
in	O
the	O
CIITA	O
-	O
transfected	B-Positive_regulation
hybrids	O
,	O
although	O
at	O
reduced	B-Negative_regulation
levels	I-Negative_regulation
.	O

These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
class	O
II	O
subset	O
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA	O
-	O
independent	O
mechanism	O
.	O

Silencing	B-Negative_regulation
of	O
human	O
fetal	O
globin	O
expression	B-Gene_expression
is	O
impaired	B-Negative_regulation
in	O
the	O
absence	B-Negative_regulation
of	O
the	O
adult	O
beta	O
-	O
globin	O
gene	O
activator	O
protein	O
EKLF	O
.	O

Globin	O
genes	O
are	O
subject	O
to	O
tissue	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
.	O

A	O
switch	B-Negative_regulation
from	O
human	O
fetal	O
(	O
gamma	O
)	O
-	O
to	O
adult	O
(	O
beta	O
)	O
-	O
globin	O
expression	B-Gene_expression
occurs	O
within	O
erythroid	O
precursor	O
cells	O
of	O
the	O
adult	O
lineage	O
.	O

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	O
finger	O
gene	O
,	O
erythroid	O
Kruppel	O
-	O
like	O
factor	O
(	O
EKLF	O
)	O
,	O
is	O
required	B-Positive_regulation
for	O
expression	B-Gene_expression
of	O
the	O
beta	O
-	O
globin	O
gene	O
in	O
mice	O
,	O
presumably	O
through	B-Positive_regulation
interaction	B-Binding
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
.	O

To	O
examine	O
the	O
role	B-Positive_regulation
of	O
EKLF	O
in	O
the	O
developmental	O
regulation	B-Regulation
of	O
the	O
human	O
gamma	O
-	O
globin	O
gene	O
we	O
interbred	O
EKLF	O
heterozygotes	O
(	O
+/	O
-	O
)	O
with	O
mice	O
harboring	O
a	O
human	O
beta	O
-	O
globin	O
yeast	O
artificial	O
chromosome	O
transgene	O
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	O
,	O
while	O
human	O
beta	O
-	O
globin	O
expression	B-Gene_expression
is	O
dramatically	O
reduced	B-Negative_regulation
,	O
gamma	O
-	O
globin	O
transcripts	O
are	O
elevated	B-Positive_regulation
approximately	O
5	O
-	O
fold	O
.	O

Impaired	B-Negative_regulation
silencing	B-Negative_regulation
of	O
gamma	O
-	O
globin	O
expression	B-Gene_expression
identifies	O
EKLF	O
as	O
the	O
first	O
transcription	O
factor	O
participating	B-Positive_regulation
quantitatively	O
in	O
the	O
gamma	O
-	O
globin	O
to	O
beta	O
-	O
globin	O
switch	B-Negative_regulation
.	O

Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	O
mediates	B-Positive_regulation
an	O
adult	O
stage	O
-	O
specific	O
interaction	B-Binding
between	O
the	O
beta	O
-	O
globin	O
gene	O
promoter	O
and	O
the	O
locus	O
control	O
region	O
that	O
excludes	B-Negative_regulation
the	O
gamma	O
-	O
globin	O
gene	O
.	O

Nasal	O
NK	O
-	O
and	O
T	O
-	O
cell	O
lymphomas	O
share	O
the	O
same	O
type	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
as	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
.	O

Nasal	O
T/NK	O
-	O
cell	O
lymphomas	O
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lineage	O
or	O
of	O
T	O
-	O
cell	O
lineage	O
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
gene	O
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O

Both	O
NK	O
-	O
and	O
T	O
-	O
cell	O
subtypes	O
are	O
closely	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
study	O
,	O
EBV	O
gene	O
expression	O
was	O
determined	O
in	O
23	O
cases	O
of	O
nasal	O
lymphoma	O
(	O
NL	O
)	O
by	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
(	O
IH	O
)	O
.	O

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK	O
-	O
cell	O
and	O
4	O
as	O
T	O
-	O
cell	O
tumours	O
.	O

ISH	O
for	O
EBV	O
-	O
encoded	O
small	O
non	O
-	O
polyadenylated	O
RNAs	O
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	O
cells	O
.	O

RT	O
-	O
PCR	O
demonstrated	O
that	O
NL	O
of	O
both	O
subtypes	O
expressed	B-Gene_expression
EBNAI	O
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	O
membrane	O
proteins	O
,	O
LMP1	O
and	O
2	O
and	O
the	O
BamHI	O
A	O
rightward	O
transcripts	O
in	O
the	O
absence	B-Transcription
of	O
EBNA2	O
mRNAs	O
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	O
gene	O
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
consisting	O
of	O
both	O
LMP1+	O
and	O
LMP1	O
-	O
tumour	O
cells	O
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O

Although	O
2	O
early	O
lytic	O
transcripts	O
,	O
BZLF1	O
and	O
BHRF1	O
,	O
were	O
also	O
detected	B-Transcription
in	O
13	O
and	O
10	O
cases	O
,	O
respectively	O
,	O
the	O
lack	B-Transcription
of	O
ZEBRA	O
staining	O
in	O
any	O
case	O
indicates	O
that	O
these	O
lytic	O
transcripts	O
are	O
most	O
likely	O
expressed	B-Transcription
by	O
rare	O
cells	O
in	O
the	O
biopsies	O
entering	O
lytic	O
cycle	O
.	O

The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O

Down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
immunogenic	O
proteins	O
(	O
EBNA2	O
-	O
EBNA6	O
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	O
cells	O
to	O
evade	O
host	O
cytotoxic	O
T	O
-	O
cell	O
surveillance	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte	O
-	O
specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	O
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140	O
-	O
kDa	O
protein	O
designated	O
Sp140	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Sp140	O
was	O
similar	O
to	O
Sp100	O
,	O
a	O
previously	O
identified	O
NB	O
protein	O
.	O

The	O
carboxyl	O
portion	O
of	O
Sp140	O
contained	O
a	O
zinc	O
-	O
finger	O
domain	O
and	O
a	O
bromodomain	O
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	B-Positive_regulation
levels	I-Positive_regulation
of	O
Sp140	O
mRNA	O
were	O
detected	B-Transcription
in	O
human	O
spleen	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

The	O
level	B-Transcription
of	O
SP140	O
mRNA	O
in	O
myeloid	O
precursor	O
cell	O
lines	O
HL60	O
and	O
NB4	O
markedly	O
increased	B-Positive_regulation
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	O
localized	B-Localization
to	O
the	O
NB	O
in	O
differentiated	O
HL60	O
and	O
NB4	O
cells	O
.	O

The	O
location	B-Localization
of	O
Sp140	O
in	O
the	O
NB	O
,	O
and	O
expression	B-Gene_expression
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

Potent	O
gene	O
regulatory	O
and	O
antiproliferative	O
activities	O
of	O
20	O
-	O
methyl	O
analogues	O
of	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
.	O

The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O

This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O

However	O
,	O
hypercalcemia	O
is	O
a	O
side	O
effect	O
,	O
which	O
is	O
caused	O
by	O
VD	O
's	O
classical	O
action	O
,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O

This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O

Studies	O
with	O
20	O
-	O
epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon	O
-	O
20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20	O
-	O
methyl	O
derivatives	O
of	O
VD	O
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20-methyl	O
-	O
and	O
20-methyl-23	O
-	O
eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O

Both	O
compounds	O
show	O
about	O
2	O
-	O
fold	O
lower	B-Binding
affinity	I-Binding
to	O
the	O
VD	O
receptor	O
(	O
VDR	O
)	O
than	O
VD	O
.	O

However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30	O
-	O
fold	O
higher	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
even	O
up	O
to	O
300	O
-	O
fold	O
higher	O
on	O
human	O
breast	O
cancer	O
MCF	O
-	O
7	O
cells	O
.	O

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10	O
-	O
fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium	O
-	O
mobilizing	O
potency	O
as	O
VD	O
.	O

Moreover	O
,	O
ZK161422	O
,	O
but	O
not	O
ZK157202	O
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	O
carrying	O
a	O
VD	O
response	O
element	O
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	O
receptor	O
binding	O
sites	O
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	O
than	O
for	O
activation	O
from	O
a	O
response	O
element	O
formed	O
by	O
a	O
direct	O
repeat	O
spaced	O
by	O
3	O
nucleotides	O
(	O
DR3	O
)	O
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

Second	O
messenger	O
up	O
-	O
regulation	O
of	O
androgen	O
receptor	O
gene	O
transcription	O
is	O
absent	O
in	O
androgen	O
insensitive	O
human	O
prostatic	O
carcinoma	O
cell	O
lines	O
,	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
.	O

A	O
theoretical	O
pathway	O
of	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
is	O
via	B-Positive_regulation
a	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
present	O
in	O
its	O
promoter	O
region	O
(	O
-	O
508	O
to	O
-	O
501	O
)	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8-bromo	O
-	O
cAMP	O
,	O
AR	O
mRNA	O
was	O
upregulated	B-Positive_regulation
in	O
LNCaP	O
but	O
not	O
in	O
either	O
PC	O
-	O
3	O
or	O
DU	O
-	O
145	O
cell	O
lines	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	O
binding	O
protein	O
(	O
CREB	O
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR	O
-	O
CRE	O
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	B-Binding
with	O
CREB	O
.	O

The	O
ability	O
to	O
regulate	B-Regulation
AR	O
gene	O
transcription	B-Transcription
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	B-Negative_regulation
in	O
the	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
cell	O
lines	O
.	O

This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O

Activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
by	O
hypochlorous	O
acid	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
in	O
human	O
cells	O
.	O

During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	O
polymorphonuclear	O
leukocytes	O
.	O

Treatment	O
of	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	B-Positive_regulation
the	O
appearance	B-Localization
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
(	O
the	O
heterodimer	O
p50/p65	O
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
.	O

Western	O
blot	O
analysis	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
subunits	O
(	O
IkappaB	O
)	O
demonstrated	O
that	O
both	O
IkappaB	O
-	O
alpha	O
proteolysis	B-Protein_catabolism
and	O
p105	O
processing	O
were	O
induced	B-Positive_regulation
by	O
the	O
treatment	O
.	O

NF	O
-	O
kappaB	O
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O

Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p-bromophenacyl	O
-	O
bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF	O
-	O
kappaB	O
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O

Moreover	O
,	O
ACH	O
-	O
2	O
cells	O
treated	B-Positive_regulation
with	I-Positive_regulation
HOCl	O
or	O
H2O2	O
released	B-Localization
tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
in	O
the	O
supernatants	O
.	O

The	O
importance	O
of	O
TNF	O
-	O
alpha	O
release	B-Localization
in	O
NF	O
-	O
kappaB	O
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappaB	O
was	O
promoted	O
in	O
untreated	O
cells	O
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF	O
-	O
alpha	O
and	O
HOCl	O
was	O
detected	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF	O
-	O
kappaB	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long	O
-	O
distance	O
effect	O
through	O
subsequent	B-Positive_regulation
TNF	O
-	O
alpha	O
release	B-Localization
.	O

Thymocytes	O
control	B-Regulation
the	O
CD4	O
gene	O
differently	O
from	O
mature	O
T	O
lymphocytes	O
.	O

We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	O
,	O
the	O
promoter	O
and	O
the	O
silencer	O
of	O
the	O
human	O
CD4	O
gene	O
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O

Immunofluorescence	O
studies	O
on	O
thymic	O
populations	O
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	O
DNA	O
elements	O
revealed	O
that	O
thymocytes	O
control	B-Regulation
the	O
CD4	O
gene	O
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O

The	O
5'	O
-	O
positive	O
regulatory	O
unit	O
,	O
consisting	O
of	O
the	O
promoter	O
and	O
the	O
5	O
'	O
enhancer	O
,	O
is	O
already	O
active	O
at	O
the	O
CD4-CD8-double	O
-	I-Negative_regulation
negative	I-Negative_regulation
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O

However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double	B-Positive_regulation
-	I-Positive_regulation
positive	I-Positive_regulation
and	O
a	O
fraction	O
of	O
the	O
CD4+	O
CD8int/	O
-	O
cell	O
population	O
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	O
or	O
the	O
third	O
intron	O
of	O
the	O
CD4	O
gene	O
,	O
is	O
required	B-Positive_regulation
for	O
CD4	O
gene	O
expression	B-Gene_expression
in	O
this	O
population	O
.	O

The	O
other	O
studied	O
regulatory	O
element	O
is	O
the	O
minimal	O
CD4	O
silencer	O
which	O
inhibits	B-Negative_regulation
CD4	O
gene	O
expression	B-Gene_expression
in	O
peripheral	O
CD8	O
T	O
lymphocytes	O
.	O

This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	O
DN	O
thymocytes	O
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down	B-Negative_regulation
-	I-Negative_regulation
regulate	I-Negative_regulation
CD4	O
gene	O
expression	B-Gene_expression
.	O

Unexpectedly	O
,	O
the	O
CD4	O
silencer	O
is	O
also	O
active	O
in	O
CD4+	O
CD8int/	O
-	O
cells	O
of	O
the	O
thymus	O
,	O
implying	O
that	O
an	O
anti	O
-	O
silencer	O
may	O
be	O
required	B-Positive_regulation
to	O
resume	B-Negative_regulation
CD4	O
expression	B-Gene_expression
in	O
this	O
cell	O
population	O
.	O

Altogether	O
,	O
the	O
CD4	O
gene	O
is	O
regulated	B-Positive_regulation
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O

Triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
differentially	O
modulates	B-Regulation
tumor	O
necrosis	O
factor	O
alpha	O
release	B-Localization
by	O
B	O
cells	O
at	O
distinct	O
stage	O
of	O
maturation	O
.	O

Triggering	O
of	O
HLA	O
class	O
II	O
antigens	O
by	O
the	O
anti-HLA	O
-	O
DR	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
L243	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
and	O
differentially	O
enhanced	B-Positive_regulation
the	O
release	B-Localization
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
by	O
the	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
cells	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
and	O
Sc	O
-	O
I	O
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	O
lymphoma	O
cell	O
Raji	O
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	B-Positive_regulation
TNF	O
-	O
alpha	O
release	B-Localization
by	O
the	O
pre	O
-	O
B	O
leukemia	O
cells	O
Nalm	O
-	O
6	O
and	O
BV173	O
.	O

TNF	O
-	O
alpha	O
release	B-Localization
peaked	B-Positive_regulation
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	B-Positive_regulation
by	O
an	O
increase	B-Positive_regulation
of	O
TNF	O
-	O
alpha	O
mRNA	O
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	O
L243	O
.	O

Secreted	B-Localization
TNF	O
-	O
alpha	O
mediated	O
the	O
enhancement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
in	O
the	O
presence	O
of	O
antihuman	O
TNF-alpha	O
-	O
neutralizing	O
antibodies	O
did	O
not	O
upregulate	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O

In	O
contrast	O
,	O
released	B-Localization
TNF	O
-	O
alpha	O
was	O
not	O
responsible	O
for	O
the	O
homotypic	O
aggregation	O
of	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
Sc	O
-	O
I	O
,	O
and	O
Raji	O
cells	O
induced	O
by	O
mAb	O
L243	O
,	O
and	O
it	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
B	O
cells	O
investigated	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	B-Localization
TNF	O
-	O
alpha	O
after	B-Positive_regulation
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	B-Localization
of	I-Localization
released	I-Localization
TNF	O
-	O
alpha	O
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B	O
-	O
cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	O
surface	O
HLA	O
-	O
DR	O
antigens	O
;	O
(	O
c	O
)	O
secreted	B-Localization
TNF	O
-	O
alpha	O
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	B-Positive_regulation
TNF	O
-	O
alpha	O
release	B-Localization
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

Cytomegalovirus	O
immediate	O
early	O
genes	O
upregulate	B-Positive_regulation
interleukin	O
-	O
6	O
gene	O
expression	B-Gene_expression
.	O

BACKGROUND	O
:	O
The	O
immediate	O
early	O
genes	O
(	O
IE	O
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	O
cells	O
and	O
are	O
known	O
to	O
regulate	O
viral	O
and	O
cellular	O
genes	O
.	O

Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

Interleukin	O
-	O
6	O
levels	O
are	O
increased	B-Positive_regulation
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O

The	O
regulation	B-Regulation
of	O
IL	O
-	O
6	O
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	O
.	O

These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	B-Regulation
IL	O
-	O
6	O
production	B-Gene_expression
.	O

METHODS	O
:	O
THP	O
-	O
1	O
cells	O
,	O
a	O
monocytic	O
cell	O
line	O
,	O
were	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
.	O

Interleukin	O
-	O
6	O
protein	O
and	O
IL	O
-	O
6	O
mRNA	O
were	O
measured	O
in	O
control	O
and	O
CMV	O
immediate	O
early	O
transfected	O
cells	O
.	O

Cotransfection	O
of	O
CMV	O
IE	O
genes	O
and	O
IL	O
-	O
6	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
or	O
IL	O
-	O
6	O
luciferase	O
constructs	O
were	O
used	O
to	O
study	O
IL	O
-	O
6	O
promoter	O
activity	O
.	O

RESULTS	O
:	O
Interleukin	O
-	O
6	O
protein	O
and	O
mRNA	O
production	B-Transcription
were	O
significantly	O
increased	B-Positive_regulation
in	O
cells	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS	O
-	O
stimulated	O
control	O
cells	O
.	O

Cytomegalovirus	O
IE	O
gene	O
products	O
significantly	O
enhanced	B-Positive_regulation
LPS	O
stimulation	B-Positive_regulation
of	O
IL	O
-	O
6	O
promoter	O
activity	O
in	O
both	O
IL	O
-	O
6	O
CAT	O
and	O
IL	O
-	O
6	O
luciferase	O
assays	O
.	O

A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF	O
-	O
kappa	O
B	O
site	O
but	O
is	O
missing	O
the	O
multiple	O
response	O
region	O
demonstrated	O
a	O
continued	O
increase	O
in	O
IL	O
-	O
6	O
luciferase	O
activity	O
in	O
LPS	O
-	O
stimulated	O
CMV	O
transfected	O
cells	O
.	O

CONCLUSION	O
:	O
Cytomegalovirus	O
immediate	O
early	O
gene	O
products	O
significantly	O
enhanced	B-Positive_regulation
expression	B-Gene_expression
of	O
IL	O
-	O
6	O
in	O
LPS	O
-	O
stimulated	O
cells	O
.	O

The	O
increase	O
in	O
IL	O
-	O
6	O
luciferase	O
activity	O
occurs	O
in	O
the	O
absence	O
of	O
the	O
multiple	O
response	O
region	O
,	O
the	O
area	O
of	O
the	O
IL	O
-	O
6	O
promoter	O
responsive	B-Regulation
to	O
IL	O
-	O
1	O
,	O
TNF	O
alpha	O
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

The	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
enhance	B-Positive_regulation
IL	O
-	O
6	O
production	B-Gene_expression
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O

Homodimerization	B-Binding
of	O
the	O
human	O
interleukin	O
4	O
receptor	O
alpha	O
chain	O
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	O
of	O
the	O
interleukin	O
2	O
receptor	O
gamma	O
chain	O
.	O

The	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
-	O
4	O
and	O
IL	O
-	O
13	O
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
human	O
B	O
cells	O
.	O

The	O
IL	O
-	O
4	O
receptor	O
(	O
IL	O
-	O
4R	O
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL-4	O
-	O
binding	B-Binding
IL	O
-	O
4Ralpha	O
chain	O
,	O
which	O
is	O
shared	O
with	O
the	O
IL	O
-	O
13R	O
,	O
and	O
the	O
IL	O
-	O
2Rgamma	O
(	O
gammac	O
)	O
chain	O
,	O
which	O
is	O
shared	O
with	O
IL	O
-	O
7R	O
,	O
IL	O
-	O
9R	O
,	O
and	O
IL	O
-	O
15R	O
.	O

IL	O
-	O
4	O
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	O
chain	O
deficiency	B-Negative_regulation
.	O

Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL	O
-	O
4	O
in	O
B	O
cells	O
that	O
lack	B-Gene_expression
the	O
gammac	O
chain	O
may	O
involve	O
signaling	O
via	O
the	O
IL	O
-	O
13R	O
.	O

Alternatively	O
,	O
the	O
IL	O
-	O
4Ralpha	O
chain	O
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O

We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	O
surface	O
receptors	O
consisting	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
of	O
the	O
erythropoietin	O
receptor	O
and	O
of	O
the	O
intracellular	O
domain	O
of	O
IL	O
-	O
4Ralpha	O
induces	B-Positive_regulation
Janus	O
kinase	O
1	O
(	O
Jak1	O
)	O
activation	B-Positive_regulation
,	O
STAT6	O
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O

Disruption	O
of	O
the	O
Jak1	O
-	O
binding	O
proline	O
-	O
rich	O
Box1	O
region	O
of	O
IL	O
-	O
4Ralpha	O
abolished	O
signaling	O
by	O
this	O
chimeric	O
receptor	O
.	O

Furthermore	O
,	O
B	O
cells	O
transfected	B-Positive_regulation
with	O
a	O
chimeric	O
CD8alpha/IL	O
-	O
4Ralpha	O
receptor	O
,	O
which	O
is	O
expressed	B-Gene_expression
on	O
the	O
cell	O
surface	O
as	B-Binding
a	I-Binding
homodimer	I-Binding
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	B-Binding
of	O
the	O
IL	O
-	O
4Ralpha	O
chain	O
is	O
sufficient	O
to	O
transduce	O
Jak1	O
-	O
dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	O
isotype	O
switching	O
.	O

Characterization	O
of	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
transduced	B-Gene_expression
with	O
HTLV	O
-	O
I	O
Tax	O
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
.	O

Tax1	O
,	O
a	O
transcriptional	O
trans	O
-	O
activator	O
of	O
the	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	B-Binding
with	O
at	O
least	O
three	O
distinct	O
cellular	O
transcription	O
factors	O
;	O
CREB/ATF	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
SRF	O
.	O

This	O
Tax1	O
-	O
induced	O
activation	O
of	O
cellular	O
genes	O
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T	O
-	O
cell	O
transformation	O
by	O
HTLV	O
-	O
I	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	O
-	O
inducible	O
transcriptional	O
pathway	O
in	O
T	O
-	O
cell	O
transformation	O
,	O
we	O
introduced	B-Gene_expression
Tax1	O
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
into	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
by	O
retroviral	O
vectors	O
.	O

Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL	O
-	O
2	O
.	O

However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4+	O
T	O
-	O
cells	O
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV	O
-	O
I	O
infection	O
,	O
activation	O
of	O
the	O
CREB/ATF	O
and	O
SRF	O
pathways	O
is	O
also	O
required	O
.	O

Involvement	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
human	O
mineralocorticoid	O
receptor	O
hormone	O
-	O
binding	O
domain	O
in	O
agonist	O
and	O
antagonist	O
binding	B-Binding
as	O
revealed	O
by	O
a	O
new	O
monoclonal	O
antibody	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	B-Binding
to	O
the	O
human	O
mineralocorticoid	O
receptor	O
(	O
hMR	O
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
raised	O
against	O
the	O
hormone	O
-	O
binding	O
domain	O
(	O
HBD	O
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	O
protein	O
including	O
the	O
sequence	O
Thr729	O
-	O
Lys984	O
of	O
hMR	O
.	O

After	O
ELISA	O
screening	O
,	O
mAb	O
18C7	O
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	O
.	O

This	O
antibody	O
recognized	B-Binding
both	O
the	O
denatured	O
and	O
native	O
MR	O
forms	O
,	O
as	O
well	O
as	O
the	O
hetero	O
-	O
oligomeric	O
MR	O
form	O
and	O
the	O
transformed	O
MR	O
state	O
.	O

By	O
using	O
several	O
HBD	O
subfragments	O
,	O
the	O
mAb	O
18C7	O
epitope	O
was	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
HBD	O
from	O
Thr729	O
to	O
Leu765	O
.	O

We	O
then	O
studied	O
the	O
effect	B-Regulation
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	B-Binding
to	O
the	O
hMR	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
liganded	B-Binding
MR	O
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
MR	O
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	B-Negative_regulation
75	O
-	O
80	O
%	O
of	O
the	O
binding	B-Binding
.	O

The	O
effect	B-Regulation
of	O
18C7	O
on	O
the	O
binding	B-Binding
was	O
similar	O
with	O
both	O
hormones	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid	O
-	O
MR	O
complex	B-Binding
and	O
the	O
antibody	O
-	O
MR	O
complex	B-Binding
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat	O
-	O
shock	O
protein	O
hsp90	O
,	O
had	O
been	O
cross	B-Binding
-	I-Binding
linked	I-Binding
with	O
the	O
hMR	O
by	O
dimethylpimelimidate	O
,	O
18C7	O
was	O
still	B-Negative_regulation
able	I-Negative_regulation
to	I-Negative_regulation
react	B-Regulation
with	O
the	O
receptor	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	O
recognized	O
by	O
18C7	O
was	O
directly	O
implicated	O
in	O
hormone	O
binding	B-Binding
.	O

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	O
mutants	O
with	O
the	O
Thr729	O
-	O
Leu765	O
sequence	O
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J.Steroid	O
Biochem.Mol.Biol.57	O
,	O
43	O
-	O
50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N	O
-	O
terminal	O
Thr729	O
-	O
Leu765	O
region	O
of	O
the	O
HBD	O
is	O
similarly	O
involved	O
in	O
the	O
binding	B-Binding
of	O
both	O
hormones	O
.	O

Abnormal	O
T	O
lymphocyte	O
development	O
induced	O
by	O
targeted	O
overexpression	B-Positive_regulation
of	O
IkappaB	O
alpha	O
.	O

A	O
role	O
in	O
thymic	O
maturation	O
for	O
factors	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
has	O
long	O
been	O
suspected	O
,	O
but	O
not	O
yet	O
proven	O
.	O

Transgenic	O
mice	O
with	O
a	O
lymphocyte	O
-	O
specific	O
defect	O
in	O
NF	O
-	O
kappaB	O
activation	O
were	O
produced	O
by	O
targeted	O
expression	B-Gene_expression
of	O
human	O
IkappaB	O
alpha	O
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	O
thymocytes	O
of	O
the	O
alphabeta	O
lineage	O
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	O
population	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double	O
-	O
positive	O
cells	O
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose	O
-	O
dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O

These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB/Rel	O
family	O
proteins	O
in	O
late	O
stages	O
of	O
T	O
lymphocyte	O
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor	O
-	O
bearing	O
mice	O
.	O

The	O
TCR	O
alpha	O
beta	O
or	O
-	O
gamma	O
delta	O
chains	O
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	O
deltaepsilongamma	O
and	O
TCR	O
zeta	O
subunits	O
couple	O
the	O
TCR	O
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	O
cells	O
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	O
zeta	O
chain	O
,	O
NF	O
kappaB	O
family	O
proteins	O
,	O
and	O
tyrosine	O
kinase	O
p56	O
(	O
lck	O
)	O
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	O
kappaB	O
family	O
proteins	O
,	O
specifically	O
the	O
failure	B-Negative_regulation
of	O
p65	O
translocation	B-Localization
to	O
the	O
nucleus	O
,	O
occur	B-Positive_regulation
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	B-Negative_regulation
in	O
zeta	O
-	O
chain	O
.	O

These	O
defects	O
are	O
paralleled	B-Positive_regulation
by	O
an	O
impaired	B-Negative_regulation
ability	I-Negative_regulation
to	O
produce	B-Gene_expression
Th1	O
cytokines	O
(	O
IL	O
-	O
2	O
and	O
IFN	O
-	O
gamma	O
)	O
.	O

These	O
initial	O
changes	O
are	O
followed	B-Positive_regulation
by	O
the	O
eventual	O
loss	B-Negative_regulation
of	O
TCR	O
zeta	O
chain	O
and	O
p56	O
(	O
lck	O
)	O
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta	O
-	O
chain	O
.	O

An	O
isotype	O
-	O
specific	O
activator	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
that	O
is	O
independent	O
of	O
class	O
II	O
transactivator	O
.	O

Patients	O
with	O
one	O
type	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	O
class	O
II	O
genes	O
,	O
HLA	O
-	O
DR	O
,	O
-	O
DQ	O
,	O
and	O
-	O
DP	O
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B	O
-	O
lymphoblastoid	O
cell	O
line	O
,	O
clone	O
13	O
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DP	O
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	O
13	O
CIITA	O
alleles	O
bore	O
a	O
mutation	O
that	O
allowed	O
HLA	O
-	O
DQ	O
,	O
but	O
not	O
HLA	O
-	O
DR	O
or	O
-	O
DP	O
transcription	O
.	O

Alternatively	O
,	O
another	O
factor	O
,	O
distinct	O
from	O
CIITA	O
,	O
might	O
control	O
HLA	O
-	O
DQ	O
expression	O
.	O

We	O
report	O
here	O
that	O
ectopic	O
expression	B-Gene_expression
of	O
CIITA	O
cDNAs	O
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	O
13	O
do	O
not	O
restore	O
expression	O
of	O
HLA	O
-	O
DQ	O
in	O
another	O
CIITA	O
-	O
deficient	O
cell	O
line	O
,	O
RJ2.2.5	O
.	O

In	O
addition	O
,	O
no	O
CIITA	O
protein	O
is	O
detectable	B-Gene_expression
in	O
clone	O
13	O
nuclear	O
extracts	O
.	O

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	O
13	O
and	O
RJ2.2.5	O
restored	O
expression	O
of	O
the	O
HLA	O
-	O
DQ	O
haplotype	O
encoded	O
by	O
the	O
RJ2.2.5	O
DQB	O
gene	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
existence	O
of	O
an	O
HLA	O
-	O
DQ	O
isotype	O
-	O
specific	O
trans	O
-	O
acting	O
factor	O
,	O
which	O
functions	O
independently	O
of	O
CIITA	O
.	O

Induction	O
of	O
cytokine	O
expression	O
in	O
leukocytes	O
by	O
binding	O
of	O
thrombin	O
-	O
stimulated	O
platelets	O
.	O

BACKGROUND	O
:	O
Activated	O
platelets	O
tether	O
and	O
activate	O
myeloid	O
leukocytes	O
.	O

To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	O
induction	O
by	O
leukocyte	O
-	O
platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte	O
-	O
platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
CD41	O
immunofluorescence	O
of	O
leukocytes	O
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte	O
-	O
platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+/	O
-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+/	O
-	O
16	O
versus	O
35	O
+/	O
-	O
9	O
;	O
P	O
=	O
.003	O
)	O
.	O

In	O
vitro	O
,	O
thrombin	O
-	O
stimulated	O
fixed	O
platelets	O
bound	O
to	O
neutrophils	O
and	O
monocytes	O
.	O

Within	O
2	O
hours	O
,	O
this	O
resulted	B-Positive_regulation
in	I-Positive_regulation
increased	I-Positive_regulation
mRNA	O
for	O
interleukin	O
(	O
IL	O
)	O
,	O
1	O
beta	O
,	O
IL	O
-	O
8	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
(	O
MCP	O
)	O
-	O
1	O
in	O
unfractionated	O
leukocytes	O
.	O

After	O
4	O
hours	O
,	O
IL	O
-	O
1	O
beta	O
and	O
IL	O
-	O
8	O
concentration	O
of	O
the	O
cell	O
-	O
free	O
supernatant	O
had	O
increased	B-Positive_regulation
by	O
268	O
+/	O
-	O
36	O
%	O
and	O
210	O
+/	O
-	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP	O
-	O
1	O
content	O
had	O
increased	B-Positive_regulation
by	O
170	O
+/	O
-	O
8	O
%	O
.	O

Addition	O
of	O
activated	O
platelets	O
to	O
adherent	O
monocytes	O
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
.	O

Inhibition	O
of	O
binding	O
by	O
anti	O
-	O
P	O
selectin	O
antibodies	O
reduced	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
cytokine	O
production	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte	O
-	O
platelet	O
adhesion	O
is	O
increased	O
.	O

Binding	O
of	O
activated	O
platelets	O
induces	B-Positive_regulation
IL	O
-	O
1	O
beta	O
,	O
IL	O
-	O
8	O
,	O
and	O
MCP	O
-	O
1	O
in	O
leukocytes	O
.	O

Our	O
findings	O
suggest	O
that	O
leukocyte	O
-	O
platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O

The	O
class	O
II	O
trans	O
-	O
activator	O
CIITA	O
interacts	B-Binding
with	O
the	O
TBP	O
-	O
associated	O
factor	O
TAFII32	O
.	O

The	O
class	O
II	O
trans	O
-	O
activator	O
(	O
CIITA	O
)	O
is	O
the	O
main	O
transcriptional	O
co	O
-	O
activator	O
for	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
proteins	O
.	O

Its	O
N	O
-	O
terminal	O
125	O
amino	O
acids	O
function	O
as	O
an	O
independent	O
transcriptional	O
activation	O
domain	O
.	O

Analyses	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
the	O
activation	O
domain	O
predict	O
the	O
presence	O
of	O
three	O
alpha	O
-	O
helices	O
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha	O
-	O
helices	O
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	O
.	O

Moreover	O
,	O
a	O
CIITA	O
protein	O
in	O
which	O
both	O
functional	O
alpha	O
-	O
helices	O
have	O
been	O
deleted	O
displays	B-Negative_regulation
a	I-Negative_regulation
dominant	I-Negative_regulation
negative	I-Negative_regulation
phenotype	I-Negative_regulation
.	O

This	O
activation	O
domain	O
of	O
CIITA	O
interacts	B-Binding
with	O
the	O
32	O
kDa	O
subunit	O
of	O
the	O
general	O
transcription	O
complex	O
TFIID	O
,	O
TAFII32	O
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N	O
-	O
terminal	O
deletions	O
of	O
CIITA	O
is	O
correlated	O
directly	O
with	O
their	O
reduced	B-Negative_regulation
binding	B-Binding
to	O
TAFII32	O
.	O

We	O
conclude	O
that	O
interactions	B-Binding
between	O
TAFII32	O
and	O
CIITA	O
are	O
responsible	O
for	O
activation	O
of	O
class	O
II	O
genes	O
.	O

Lipopolysaccharide	O
induction	B-Positive_regulation
of	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
in	O
human	O
monocytic	O
cells	O
.	O

Regulation	B-Regulation
by	O
Egr	O
-	O
1	O
,	O
c	O
-	O
Jun	O
,	O
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
.	O

Biosynthesis	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

This	O
study	O
examined	O
the	O
role	B-Regulation
of	O
various	O
cis	O
-	O
acting	O
regulatory	O
elements	O
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	B-Positive_regulation
of	O
the	O
human	O
TNF	O
-	O
alpha	O
promoter	O
in	O
cells	O
of	O
monocytic	O
lineage	O
.	O

Functional	O
analysis	O
of	O
monocytic	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
plasmids	O
containing	O
various	O
lengths	O
of	O
TNF	O
-	O
alpha	O
promoter	O
localized	O
enhancer	O
elements	O
in	O
a	O
region	O
(	O
-	O
182	O
to	O
-	O
37	O
base	O
pairs	O
(	O
bp	O
)	O
)	O
that	O
were	O
required	B-Positive_regulation
for	O
optimal	O
transcription	B-Transcription
of	O
the	O
TNF	O
-	O
alpha	O
gene	O
in	B-Positive_regulation
response	I-Positive_regulation
to	I-Positive_regulation
LPS	O
.	O

Two	O
regions	O
were	O
identified	O
:	O
region	O
I	O
(	O
-	O
182	O
to	O
-	O
162	O
bp	O
)	O
contained	O
an	O
overlapping	O
Sp1/Egr	O
-	O
1	O
site	O
,	O
and	O
region	O
II	O
(	O
-	O
119	O
to	O
-	O
88	O
)	O
contained	O
CRE	O
and	O
NF	O
-	O
kappaB	O
(	O
designated	O
kappaB3	O
)	O
sites	O
.	O

In	O
unstimulated	O
THP	O
-	O
1	O
,	O
CRE	O
-	O
binding	O
protein	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c	O
-	O
Jun	O
complexes	O
were	O
found	O
to	O
bind	B-Binding
to	O
the	O
CRE	O
site	O
.	O

LPS	O
stimulation	O
increased	B-Positive_regulation
the	O
binding	B-Binding
of	O
c-Jun	O
-	O
containing	O
complexes	O
.	O

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	B-Binding
of	O
cognate	O
nuclear	O
factors	O
to	O
the	O
Egr	O
-	O
1	O
and	O
kappaB3	O
sites	O
,	O
which	O
were	O
identified	O
as	O
Egr	O
-	O
1	O
and	O
p50/p65	O
,	O
respectively	O
.	O

The	O
CRE	O
and	O
kappaB3	O
sites	O
in	O
region	O
II	O
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	O
and	O
the	O
kappaB3	O
sites	O
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c	O
-	O
Jun	O
complexes	O
and	O
p50/p65	O
.	O

These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	B-Positive_regulation
of	O
the	O
TNF	O
-	O
alpha	O
promoter	O
is	O
mediated	B-Regulation
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
.	O

Involvement	O
of	O
Rel	O
,	O
Fos	O
,	O
and	O
Jun	O
proteins	O
in	O
binding	O
activity	O
to	O
the	O
IL	O
-	O
2	O
promoter	O
CD28	O
response	O
element/AP	O
-	O
1	O
sequence	O
in	O
human	O
T	O
cells	O
.	O

CD28	O
is	O
an	O
important	O
costimulatory	O
molecule	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
.	O

Costimulation	O
of	O
T	O
cells	O
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	O
leads	B-Positive_regulation
to	O
high	B-Positive_regulation
level	I-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	O
stimulation	O
contributes	B-Positive_regulation
to	O
the	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
promoter	O
by	O
up	O
-	O
regulating	O
the	O
activity	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
AP	O
-	O
1	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
/Rel	O
family	O
members	O
as	O
well	O
as	O
an	O
uncharacterized	O
transcription	O
factor	O
called	O
CD28	O
response	O
complex	O
.	O

While	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
NF	O
-	O
kappaB/Rel	O
family	O
members	O
make	O
up	O
the	O
CD28	O
response	O
complex	O
transcription	O
factor	O
,	O
other	O
work	O
has	O
not	O
supported	O
this	O
conclusion	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	O
promoter	O
proximal	O
AP-1	O
-	O
binding	O
site	O
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O

Also	O
in	O
the	O
current	O
study	O
,	O
binding	B-Binding
activity	I-Binding
to	O
the	O
CD28RE/AP	O
-	O
1	O
sequence	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
is	O
evaluated	O
.	O

Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	B-Binding
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	O
and	O
the	O
adjacent	O
AP	O
-	O
1	O
site	O
.	O

Of	O
the	O
NF	O
-	O
kappaB/Rel	O
family	O
members	O
tested	O
,	O
this	O
CD28RE/AP-1	O
-	O
specific	O
complex	O
contains	O
predominantly	O
c	O
-	O
Rel	O
,	O
despite	O
the	O
fact	O
that	O
both	O
p50	O
and	O
RelA	O
can	O
efficiently	O
bind	B-Binding
to	O
the	O
CD28RE	O
.	O

c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
are	O
also	O
found	O
in	O
this	O
CD28RE/AP-1	O
-	O
specific	O
complex	O
.	O

These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	O
and	O
the	O
AP-1	O
-	O
binding	O
sites	O
influence	B-Regulation
IL	O
-	O
2	O
promoter	O
activity	O
in	O
CD28	O
-	O
costimulated	O
T	O
cells	O
.	O

c	O
-	O
Myb	O
and	O
Ets	O
proteins	O
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	O
.	O

The	O
Zfh	O
family	O
of	O
zinc	O
finger/homeodomain	O
proteins	O
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	O
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh	O
-	O
1	O
,	O
binds	B-Binding
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	O
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O

Two	O
families	O
of	O
transcription	O
factors	O
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c	O
-	O
Myb	O
and	O
Ets	O
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O

ZEB	O
blocks	B-Negative_regulation
the	O
activity	O
of	O
c	O
-	O
Myb	O
and	O
Ets	O
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	B-Negative_regulation
to	I-Negative_regulation
resist	I-Negative_regulation
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c	O
-	O
Myb	O
and	O
Ets	O
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	O
and	O
transcriptional	O
activation	O
by	O
c	O
-	O
Myb/Ets	O
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive/negative	B-Regulation
regulation	I-Regulation
in	O
vivo	O
is	O
the	O
alpha4	O
integrin	O
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O

GABP	O
factors	O
bind	B-Binding
to	O
a	O
distal	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
enhancer	O
and	O
contribute	B-Regulation
to	O
c-Raf	O
-	O
mediated	O
increase	B-Positive_regulation
in	O
IL	O
-	O
2	O
induction	B-Positive_regulation
.	O

Triggering	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
-	O
CD3	O
complex	O
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	O
lymphocytes	O
,	O
(	O
i	O
)	O
Ca2+	O
-	O
dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	O
kinase	O
cascades	O
.	O

Both	O
signal	O
cascades	O
contribute	B-Regulation
to	O
the	O
induction	B-Positive_regulation
of	O
the	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Prominent	O
protein	O
kinase	O
cascades	O
are	O
those	O
that	O
activate	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
.	O

We	O
show	O
here	O
that	O
c	O
-	O
Raf	O
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP	O
-	O
Erk	O
cascade	O
,	O
contributes	O
to	O
IL	O
-	O
2	O
induction	B-Positive_regulation
through	O
a	O
distal	O
enhancer	O
element	O
spanning	O
the	O
nucleotides	O
from	O
positions	O
-	O
502	O
to	O
-	O
413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL	O
-	O
2	O
gene	O
.	O

Induction	O
of	O
this	O
distal	O
IL	O
-	O
2	O
enhancer	O
differs	O
from	O
induction	B-Positive_regulation
of	O
the	O
proximal	O
IL	O
-	O
2	O
promoter	O
-	O
enhancer	O
,	O
since	O
it	O
is	O
induced	B-Positive_regulation
by	O
phorbol	O
esters	O
alone	O
and	O
independent	B-Positive_regulation
from	O
Ca2+	O
signals	O
.	O

In	O
DNA	O
-	O
protein	O
binding	O
studies	O
,	O
we	O
detected	O
the	O
binding	B-Binding
of	O
transcription	O
factors	O
GABP	O
alpha	O
and	O
-	O
beta	O
to	O
a	O
dyad	O
symmetry	O
element	O
(	O
DSE	O
)	O
of	O
the	O
distal	O
enhancer	O
,	O
which	O
is	O
formed	O
by	O
palindromic	O
binding	O
sites	O
of	O
Ets	O
-	O
like	O
factors	O
.	O

Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	O
interfered	B-Negative_regulation
with	O
the	O
induction	B-Positive_regulation
of	O
the	O
distal	O
enhancer	O
and	O
the	O
entire	O
IL	O
-	O
2	O
promoter	O
-	O
enhancer	O
,	O
while	O
overexpression	B-Positive_regulation
of	O
both	O
GABP	O
factors	O
enhanced	B-Positive_regulation
the	O
IL	O
-	O
2	O
promoter	O
-	O
enhancer	O
induction	B-Positive_regulation
.	O

Overexpression	B-Gene_expression
of	O
BXB	O
,	O
a	O
constitutive	O
active	O
version	O
of	O
c	O
-	O
Raf	O
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras-Raf	O
-	O
Erk	O
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	O
-	O
mediated	O
promoter	O
-	O
enhancer	O
induction	O
.	O

In	O
conjunction	O
with	O
previously	O
published	O
data	O
on	O
c-Raf	O
-	O
induced	O
phosphorylation	O
of	O
GABP	O
factors	O
(	O
E.Flory	O
,	O
A	O
.	O

Hoffmeyer	O
,	O
U.Smola	O
,	O
U.R.Rapp	O
,	O
and	O
J.T.Bruder	O
,	O
J.Virol.70	O
:	O
2260	O
-	O
2268	O
,	O
1996	O
)	O
,	O
these	O
results	O
indicate	O
a	O
contribution	B-Regulation
of	O
GABP	O
factors	O
to	O
the	O
Raf	O
-	O
mediated	O
enhancement	B-Positive_regulation
of	O
IL	O
-	O
2	O
induction	B-Positive_regulation
during	O
T	O
-	O
cell	O
activation	O
.	O

Genomic	B-Regulation
organization	I-Regulation
,	O
sequence	O
,	O
and	O
transcriptional	B-Regulation
regulation	I-Regulation
of	O
the	O
human	O
eotaxin	O
gene	O
.	O

Eotaxin	O
is	O
an	O
eosinophil	O
specific	O
beta	O
-	O
chemokine	O
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O

Its	O
expression	B-Gene_expression
is	O
stimulus	O
-	O
and	O
cell	O
-	O
specific	O
.	O

We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	O
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	O
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	O
'	O
upstream	O
region	O
of	O
the	O
human	O
eotaxin	O
gene	O
.	O

Among	O
the	O
regulatory	O
promoter	O
elements	O
potentially	O
regulating	B-Regulation
eotaxin	O
gene	O
expression	B-Gene_expression
and/or	O
mediating	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
drugs	O
we	O
identified	O
consensus	O
sequences	O
known	O
to	O
interact	B-Binding
with	O
nuclear	O
factors	O
like	O
NF	O
-	O
IL6	O
,	O
AP	O
-	O
1	O
,	O
a	O
NF-kappa	O
-	O
B	O
like	O
consensus	O
sequence	O
and	O
gamma-interferon	O
-	O
as	O
well	O
as	O
glucocorticoid	O
response	O
elements	O
.	O

Dysregulation	O
of	O
monocytic	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/Rel	O
transcription	O
factors	O
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
atherosclerotic	O
lesions	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	O
LDL	O
(	O
oxLDL	O
)	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
in	O
human	O
THP	O
-	O
1	O
monocytic	O
cells	O
as	O
well	O
as	O
adherent	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
short	O
-	O
term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	O
activated	O
p50/p65	O
containing	O
NF	O
-	O
kappa	O
B	O
dimers	O
and	O
induced	O
the	O
expression	O
of	O
the	O
target	O
gene	O
IL	O
-	O
8	O
.	O

This	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
PSI	O
.	O

The	O
oxLDL	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	B-Negative_regulation
of	O
I	O
kappa	O
B	O
-	O
alpha	O
followed	O
by	O
a	O
slight	O
transient	O
increase	B-Positive_regulation
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O

In	O
contrast	O
,	O
long	O
-	O
term	O
treatment	O
with	O
oxLDL	O
prevented	B-Negative_regulation
the	O
lipopolysaccharide	O
-	O
induced	O
depletion	B-Negative_regulation
of	O
I	O
kappa	O
B	O
-	O
alpha	O
,	O
accompanied	O
by	O
an	O
inhibition	B-Negative_regulation
of	O
both	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
the	O
expression	B-Gene_expression
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
1	O
beta	O
genes	O
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	O
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF	O
-	O
kappa	O
B/Rel	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O

Suppression	O
of	O
MHC	O
class	O
II	O
expression	O
by	O
human	O
class	O
II	O
trans	O
-	O
activator	O
constructs	O
lacking	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

The	O
class	O
II	O
trans	O
-	O
activator	O
(	O
CIITA	O
)	O
is	O
a	O
bi	O
-	O
or	O
multi	O
-	O
functional	O
domain	O
protein	O
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
report	O
that	O
removal	O
of	O
the	O
N	O
-	O
terminal	O
151	O
amino	O
acids	O
,	O
encompassing	O
all	O
of	O
the	O
acidic	O
domain	O
but	O
leaving	O
intact	O
the	O
proline/serine/threonine	O
-	O
rich	O
domain	O
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	O
class	O
II	O
expression	O
.	O

HeLa	O
cells	O
stably	O
or	O
transiently	O
transfected	B-Positive_regulation
with	O
mutant	O
CIITA	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	O
class	O
II	O
antigen	O
induction	O
by	O
IFN	O
-	O
gamma	O
and	O
marked	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
expression	O
.	O

Transient	O
transfection	B-Gene_expression
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	O
class	O
II	O
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
synthesis	O
.	O

CD30	O
-	O
dependent	B-Regulation
degradation	B-Protein_catabolism
of	O
TRAF2	O
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	O
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O

CD30	O
is	O
a	O
cell	O
-	O
surface	O
receptor	O
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

CD30	O
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	O
.	O

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	O
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	O
1	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR1	O
)	O
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF	O
-	O
binding	O
sites	O
within	O
the	O
CD30	O
cytoplasmic	O
domain	O
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	B-Binding
to	O
these	O
sites	O
is	O
TRAF2	O
,	O
a	O
signal	O
transduction	O
molecule	O
that	O
is	O
also	O
utilized	O
by	O
TNFR1	O
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	O
and	O
transcription	O
factors	O
.	O

During	O
CD30	O
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	B-Binding
of	O
TRAF2	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD30	O
results	B-Positive_regulation
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	O
and	O
the	O
associated	O
protein	O
TRAF1	O
by	O
proteolysis	B-Protein_catabolism
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	O
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal	O
-	O
coupled	O
depletion	O
of	O
TRAF2	O
.	O

Depletion	O
of	O
intracellular	O
TRAF2	O
and	O
its	O
coassociated	O
proteins	O
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	B-Positive_regulation
of	O
death	O
-	O
inducing	O
receptors	O
such	O
as	O
TNFR1	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
TRAF2	O
was	O
found	O
to	O
potentiate	O
TNFR1	O
-	O
mediated	O
death	O
.	O

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	O
,	O
as	O
well	O
as	O
other	O
TRAF	O
-	O
binding	O
members	O
of	O
the	O
TNFR	O
superfamily	O
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O

TNFalpha	O
cooperates	O
with	O
the	O
protein	O
kinase	O
A	O
pathway	O
to	O
synergistically	O
increase	O
HIV	O
-	O
1	O
LTR	O
transcription	O
via	O
downstream	O
TRE	O
-	O
like	O
cAMP	O
response	O
elements	O
.	O

Activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
TPA	O
responsive	O
elements	O
(	O
TRE	O
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
the	O
U5	O
region	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

These	O
downstream	O
sequence	O
elements	O
,	O
termed	O
DSE	O
,	O
can	O
bind	O
both	O
AP	O
-	O
1	O
and	O
CREB/ATF	O
transcription	O
factors	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	O
are	O
also	O
cAMP	O
-	O
responsive	O
elements	O
(	O
CRE	O
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	O
toxin	O
(	O
Ctx	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signal	O
transduction	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV	O
-	O
1	O
DSE	O
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	O
and	O
TNFalpha	O
.	O

Ctx	O
combined	O
with	O
TNFalpha	O
or	O
IL	O
-	O
1beta	O
to	B-Positive_regulation
produce	I-Positive_regulation
a	I-Positive_regulation
synergistic	I-Positive_regulation
increase	I-Positive_regulation
in	O
p24	O
antigen	O
production	B-Gene_expression
in	O
U1	O
promonocytic	O
cells	O
.	O

Transfection	O
studies	O
of	O
LTR	O
reporter	O
constructs	O
indicated	O
that	O
mutation	O
of	O
the	O
DSE	O
sites	O
abrogated	O
the	O
LTR	O
-	O
mediated	O
synergy	O
induced	O
by	O
Ctx	O
and	O
TNFalpha	O
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	O
and	O
IL	O
-	O
1beta	O
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	O
and	O
IL	O
-	O
1beta	O
cooperate	O
differently	O
with	O
the	O
cAMP/PKA	O
activation	O
pathway	O
to	O
induce	O
HIV	O
-	O
1	O
expression	O
in	O
U1	O
cells	O
.	O

Because	O
the	O
DSE	O
are	O
also	O
TRE	O
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP-1	O
-	O
dependent	O
transcription	O
.	O

TNFalpha	O
as	O
well	O
as	O
IL	O
-	O
1beta	O
cooperated	O
with	O
Ctx	O
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP-1	O
-	O
mediated	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE	O
-	O
like	O
cAMP	O
-	O
responsive	O
DSE	O
sites	O
within	O
the	O
5'	O
-	O
untranslated	O
leader	O
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	O
and	O
the	O
cAMP/PKA	O
pathway	O
.	O

Since	O
the	O
DSE	O
and	O
TRE	O
sites	O
can	O
not	O
bind	O
CREB/ATF	O
homodimers	O
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV	O
-	O
1	O
DSE	O
bind	O
heterodimers	O
composed	O
of	O
both	O
AP	O
-	O
1	O
and	O
CREB/ATF	O
proteins	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
product	O
latent	O
membrane	O
protein	O
1	O
engages	B-Binding
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF	O
-	O
kappaB	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	O
lymphocytes	O
into	O
lymphoblastoid	O
cell	O
lines	O
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	O
is	O
a	O
constitutively	O
activated	B-Positive_regulation
receptor	O
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
tail	O
.	O

One	O
transformation	O
effector	O
site	O
(	O
TES1	O
)	O
,	O
located	O
within	O
the	O
membrane	O
proximal	O
45	O
residues	O
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
.	O

Signals	O
from	O
TES1	O
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	O
,	O
but	O
most	O
lymphoblastoid	O
cells	O
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	O
residues	O
beyond	O
TES1	O
fail	O
to	O
grow	O
as	O
long	O
-	O
term	O
cell	O
lines	O
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	O
end	O
of	O
the	O
cytoplasmic	O
tail	O
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	O
effector	O
site	O
,	O
TES2	O
.	O

A	O
yeast	O
two	O
-	O
hybrid	O
screen	O
identified	O
TES2	O
interacting	B-Binding
proteins	O
,	O
including	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
death	O
domain	O
protein	O
(	O
TRADD	O
)	O
.	O

TRADD	O
was	O
the	O
only	O
protein	O
that	O
interacted	B-Binding
with	O
wild	O
-	O
type	O
TES2	O
and	O
not	O
with	O
isoleucine	O
-	O
mutated	O
TES2	O
.	O

TRADD	O
associated	B-Binding
with	O
wild	O
-	O
type	O
LMP1	O
but	O
not	O
with	O
isoleucine	O
-	O
mutated	O
LMP1	O
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	O
constitutively	O
associated	B-Binding
with	O
LMP1	O
in	O
EBV	O
-	O
transformed	O
cells	O
.	O

In	O
transfection	O
assays	O
,	O
TRADD	O
and	O
TES2	O
synergistically	O
mediated	O
high	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	O
appropriates	O
TRADD	O
to	O
enable	O
efficient	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

High	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long	O
-	O
term	O
outgrowth	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
regulates	B-Regulation
inducible	B-Positive_regulation
Oct	O
-	O
2	O
gene	B-Gene_expression
expression	I-Gene_expression
in	O
precursor	O
B	O
lymphocytes	O
.	O

The	O
POU	O
transcription	O
factors	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
regulate	O
the	O
activity	O
of	O
octamer	O
-	O
dependent	O
promoters	O
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	O
genes	O
.	O

Unlike	O
Oct	O
-	O
1	O
,	O
which	O
is	O
constitutively	O
expressed	B-Gene_expression
in	O
many	O
cell	O
types	O
,	O
Oct	O
-	O
2	O
expression	B-Gene_expression
is	O
restricted	B-Positive_regulation
primarily	O
to	O
B	O
lymphocytes	O
and	O
can	O
be	O
induced	B-Positive_regulation
in	O
precursor	O
B	O
cells	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	B-Positive_regulation
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct	O
-	O
2	O
expression	B-Gene_expression
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
an	O
LPS	O
-	O
responsive	O
member	O
of	O
the	O
Rel	O
transcription	O
factor	O
family	O
.	O

Despite	B-Negative_regulation
stimulation	O
with	O
LPS	O
,	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
in	O
precursor	O
B	O
cells	O
led	O
to	O
the	O
loss	B-Negative_regulation
of	O
inducible	B-Positive_regulation
Oct	O
-	O
2	O
DNA	O
binding	B-Binding
activity	O
in	O
vitro	O
and	O
the	O
suppression	O
of	O
Oct-2	O
-	O
directed	O
transcription	O
in	O
vivo	O
.	O

This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	B-Negative_regulation
to	O
Oct	O
-	O
2	O
gene	O
expression	B-Transcription
at	I-Transcription
the	I-Transcription
level	I-Transcription
of	I-Transcription
transcription	I-Transcription
,	O
whereas	O
the	O
expression	B-Gene_expression
of	O
Oct	O
-	O
1	O
was	O
unaffected	B-Negative_regulation
.	O

The	O
finding	O
that	O
Oct	O
-	O
2	O
is	O
under	O
NF	O
-	O
kappaB	O
control	B-Regulation
highlights	O
an	O
important	O
cross	O
-	O
talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	O
factor	O
families	O
that	O
regulate	O
B	O
lymphocyte	O
function	O
.	O

Paternal	B-Gene_expression
expression	I-Gene_expression
of	O
WT1	O
in	O
human	O
fibroblasts	O
and	O
lymphocytes	O
.	O

The	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	O
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	B-Gene_expression
expression	I-Gene_expression
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O

We	O
examined	O
the	O
allele	B-Gene_expression
-	I-Gene_expression
specific	I-Gene_expression
expression	I-Gene_expression
of	O
WT1	O
in	O
cultured	O
human	O
fibroblasts	O
from	O
15	O
individuals	O
.	O

Seven	O
of	O
15	O
fibroblast	O
lines	O
were	O
heterozygous	O
for	O
polymorphic	O
alleles	O
,	O
and	O
the	O
expression	B-Gene_expression
patterns	O
were	O
variable	O
,	O
i.e.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

Exclusive	O
paternal	B-Gene_expression
expression	I-Gene_expression
of	O
WT1	O
was	O
also	O
shown	O
in	O
non	O
-	O
cultured	O
peripheral	O
lymphocytes	O
from	O
the	O
latter	O
two	O
individuals	O
.	O

The	O
allele	B-Gene_expression
-	I-Gene_expression
specific	I-Gene_expression
expression	I-Gene_expression
profiles	O
of	O
other	O
imprinted	O
genes	O
,	O
IGF2	O
and	O
H19	O
,	O
on	O
human	O
chromosome	O
11	O
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	B-Gene_expression
expression	I-Gene_expression
of	O
WT1	O
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	B-Gene_expression
expression	I-Gene_expression
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele	B-Regulation
-	I-Regulation
specific	I-Regulation
regulatory	I-Regulation
system	O
of	O
WT1	O
is	O
unique	O
and	O
may	O
be	O
controlled	B-Regulation
by	O
a	O
putative	O
tissue	O
-	O
and	O
individual	O
-	O
specific	O
modifier	O
.	O

Extinction	O
of	O
immunoglobulin	O
gene	O
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	O
transcription	O
factors	O
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

When	O
immunoglobulin	O
(	O
Ig	O
)	O
expressing	O
B	O
cells	O
are	O
fused	O
with	O
non	O
-	O
B	O
cells	O
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	O
cells	O
with	O
either	O
diploid	O
or	O
tetraploid	O
B	O
cells	O
(	O
Daudi	O
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	O
cell	O
-	O
encoded	O
genes	O
that	O
are	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
B	O
cell	O
-	O
expressed	O
genes	O
that	O
are	O
not	O
dependent	O
on	O
cell	O
-	O
specific	O
controls	O
is	O
unaffected	O
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	O
gene	O
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	O
factors	O
that	O
are	O
essential	O
for	O
Ig	O
gene	O
transcription	O
.	O

These	O
transcription	O
factors	O
are	O
either	O
not	O
produced	O
due	O
to	O
block	B-Negative_regulation
of	O
transcription	B-Transcription
of	O
their	O
respective	O
genes	O
(	O
Oct	O
-	O
2	O
,	O
OBF	O
-	O
1	O
,	O
PU.1	O
)	O
,	O
or	O
are	O
rendered	O
inactive	B-Negative_regulation
posttranslationally	O
(	O
NF	O
-	O
kappa	O
B	O
,	O
E47	O
)	O
.	O

By	O
isolating	O
Daudi	O
x	O
HeLa	O
heterokaryons	O
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
involved	O
in	O
Ig	O
gene	O
transcription	O
,	O
Oct	O
-	O
2	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
,	O
the	O
nuclear	O
contents	O
of	O
B	O
cell	O
-	O
expressed	O
transcription	O
factors	O
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	O
gene	O
extinction	O
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

We	O
suggest	O
that	O
extinction	O
of	O
Ig	O
genes	O
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	O
phenotype	O
.	O

Regulation	B-Regulation
of	O
Id3	O
cell	O
cycle	O
function	O
by	O
Cdk-2	O
-	O
dependent	B-Positive_regulation
phosphorylation	B-Phosphorylation
.	O

The	O
functions	O
of	O
basic	O
helix-loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
in	O
activating	O
differentiation	O
-	O
linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
Id	O
family	O
of	O
HLH	O
proteins	O
.	O

These	O
bHLH	O
antagonists	O
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	O
targets	O
in	O
inactive	O
heterodimers	O
that	O
are	O
unable	O
to	O
bind	O
to	O
specific	O
gene	O
regulatory	O
(	O
E	O
box	O
)	O
sequences	O
.	O

Recently	O
,	O
cyclin	O
E-Cdk2	O
-	O
and	O
cyclin	O
A-Cdk2	O
-	O
dependent	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	O
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1-to	O
-	O
S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	O
in	O
abrogating	O
E-box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E.Hara	O
,	O
M.Hall	O
,	O
and	O
G.Peters	O
,	O
EMBO	O
J.16	O
:	O
332	O
-	O
342	O
,	O
1997	O
)	O
.	O

We	O
now	O
show	O
that	O
an	O
analogous	O
cell-cycle	O
-	O
regulated	B-Regulation
phosphorylation	B-Phosphorylation
of	O
Id3	O
alters	O
the	O
specificity	O
of	O
Id3	O
for	O
abrogating	O
both	O
E-box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
and	O
E-box	O
-	O
dependent	O
reporter	O
gene	O
function	O
in	O
vivo	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild	O
-	O
type	O
Id3	O
,	O
an	O
Id3	O
Asp5	O
mutant	O
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	O
fibroblasts	O
,	O
whereas	O
an	O
Id3	O
Ala5	O
mutant	O
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild	O
-	O
type	O
Id3	O
protein	O
.	O

Cdk2	O
-	O
dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1-to	O
-	O
S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	O
and	O
modulates	O
its	O
target	O
bHLH	O
specificity	O
.	O

These	O
data	O
also	O
demonstrate	O
that	O
the	O
ability	O
of	O
Id3	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
is	O
not	O
simply	O
a	O
function	O
of	O
its	O
ability	O
to	O
modulate	O
bHLH	O
heterodimer	O
-	O
dependent	O
gene	O
expression	O
and	O
establish	O
a	O
biologically	O
important	O
mechanism	O
through	O
which	O
Cdk2	O
and	O
Id	O
-	O
bHLH	O
functions	O
are	O
integrated	O
in	O
the	O
coordination	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Cytokine	O
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	O
cells	O
is	O
mediated	O
through	O
inhibition	B-Negative_regulation
of	O
IkappaBalpha	O
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	O
Th	O
cell	O
lines	O
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	O
,	O
namely	O
,	O
by	O
IL	O
-	O
2	O
in	O
Th1	O
cells	O
and	O
by	O
IL	O
-	O
4	O
in	O
Th2	O
cells	O
.	O

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	O
in	O
Th	O
cells	O
correlates	O
with	O
the	O
level	B-Gene_expression
of	O
IkappaBalpha	O
that	O
is	O
regulated	B-Regulation
by	O
DEX	O
and	O
cytokines	O
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	B-Transcription
of	O
IkappaBalpha	O
mRNA	O
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

Interestingly	O
,	O
the	O
DEX	O
-	O
mediated	O
IkappaBalpha	O
induction	B-Positive_regulation
was	O
completely	O
inhibited	B-Negative_regulation
by	O
IL	O
-	O
2	O
,	O
but	O
not	O
IL	O
-	O
4	O
,	O
in	O
Th1	O
cells	O
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	O
cells	O
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	O
that	O
inhibits	B-Negative_regulation
the	O
induction	B-Positive_regulation
of	O
IkappaBalpha	O
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX	O
-	O
induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O

Our	O
results	O
imply	O
that	O
T	O
cells	O
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up	O
-	O
or	O
down	O
-	O
regulation	O
of	O
nuclear	O
NF	O
kappaB	O
through	O
modulation	B-Regulation
of	O
IkappaBalpha	O
expression	B-Gene_expression
by	O
cytokines	O
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O

Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	O
natural	O
antibodies	O
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O

Porcine	O
aortic	O
endothelial	O
cells	O
(	O
PAEC	O
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	O
leukocytes	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	O
dynes/cm2	O
)	O
.	O

Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O

Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
as	O
compared	O
with	O
porcine	O
serum	O
.	O

A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U/ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	O
cell	O
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O

In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	O
cell	O
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	O
molecules	O
and	O
chemoattractants	O
.	O

By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	B-Gene_expression
staining	I-Gene_expression
for	O
NF	O
-	O
kappa	O
B	O
(	O
p65	O
subunit	O
)	O
in	O
the	O
nuclei	O
of	O
PAEC	O
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
this	O
setting	O
.	O

At	O
variance	O
,	O
in	O
PAEC	O
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF	O
-	O
kappa	O
B	O
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O

Treatment	O
of	O
PAEC	O
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl	O
-	O
phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	O
treated	O
with	O
human	O
serum	O
alone	O
.	O

Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte	O
-	O
endothelium	O
interaction	O
possibly	O
through	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O

IL-2	O
-	O
induced	O
growth	O
of	O
CD8+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
cells	O
mediated	O
by	O
NF	O
-	O
kappaB	O
induction	O
and	O
IL	O
-	O
2	O
receptor	O
alpha	O
expression	B-Gene_expression
.	O

The	O
binding	B-Binding
of	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	O
cells	O
induces	B-Positive_regulation
nuclear	O
expression	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
activation	B-Positive_regulation
of	O
the	O
IL	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
alpha	O
chain	O
gene	O
,	O
and	O
cell	O
proliferation	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
IL	O
-	O
2R	O
signaling	O
in	O
the	O
growth	O
of	O
CD8+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
(	O
T	O
-	O
PLL	O
)	O
cells	O
has	O
been	O
investigated	O
.	O

Flow	O
cytometry	O
revealed	O
that	O
primary	O
leukemia	O
cells	O
from	O
a	O
patient	O
with	O
CD8+	O
T	O
-	O
PLL	O
expressed	B-Gene_expression
IL	O
-	O
2Ralpha	O
and	O
beta	O
chains	O
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	B-Positive_regulation
in	O
IL	O
-	O
2Ralpha	O
expression	B-Gene_expression
on	O
culture	O
with	O
exogeneous	O
IL	O
-	O
2	O
.	O

Northern	O
blot	O
analysis	O
failed	O
to	O
detect	B-Transcription
IL	O
-	O
2	O
mRNA	O
,	O
suggesting	O
that	O
IL	O
-	O
2	O
may	O
act	O
in	O
a	O
paracrine	O
manner	O
in	O
vivo	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
revealed	O
that	O
recombinant	O
IL	O
-	O
2	O
increased	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	O
cells	O
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL	O
-	O
2	O
increased	B-Positive_regulation
the	O
abundance	B-Transcription
of	I-Transcription
mRNAs	I-Transcription
encoding	O
the	O
NF	O
-	O
kappaB	O
components	O
c	O
-	O
Rel	O
and	O
KBF1	O
in	O
these	O
cells	O
.	O

IL	O
-	O
2	O
binding	B-Binding
analysis	O
demonstrated	O
that	O
IL	O
-	O
2	O
markedly	O
increased	O
the	O
number	O
of	O
low	O
affinity	O
IL	O
-	O
2Rs	O
on	O
the	O
leukemia	O
cells	O
,	O
without	O
an	O
effect	O
on	O
the	O
number	O
of	O
high	O
-	O
affinity	O
IL	O
-	O
2Rs	O
.	O

These	O
results	O
show	O
that	O
IL	O
-	O
2	O
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
CD8+	O
T	O
-	O
PLL	O
cells	O
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
induced	O
apoptosis	O
in	O
lymphoblastoid	O
T-cell-line	O
-	O
expressing	B-Gene_expression
wild	O
-	O
type	O
and	O
mutated	O
CD4	O
receptors	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	O
cytoplasmic	O
tail	O
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
induced	O
apoptosis	O
(	O
J.Corbeil	O
,	O
M.Tremblay	O
,	O
and	O
D.D.Richman	O
,	O
J.Exp.Med.183	O
:	O
39	O
-	O
48	O
,	O
1996	O
)	O
.	O

We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	O
transduction	O
pathway	O
in	O
HIV	O
-	O
induced	O
apoptosis	O
.	O

To	O
do	O
this	O
,	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	O
cytoplasmic	O
tail	O
were	O
stably	O
expressed	B-Gene_expression
in	O
the	O
lymphoblastoid	O
T	O
-	O
cell	O
line	O
A2.01	O
.	O

Apoptosis	O
was	O
prevented	O
when	O
CD4	O
truncated	O
at	O
residue	O
402	O
was	O
expressed	B-Gene_expression
;	O
however	O
,	O
cells	O
expressing	B-Gene_expression
mutated	O
receptors	O
that	O
do	O
not	O
associate	B-Binding
with	O
p56	O
(	O
lck	O
)	O
(	O
mutated	O
at	O
the	O
dicysteine	O
motif	O
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	O
tail	O
underwent	O
apoptosis	O
like	O
wild	O
-	O
type	O
CD4	O
.	O

The	O
differences	O
between	O
wild	O
-	O
type	O
and	O
mutated	O
receptors	O
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	O
(	O
lck	O
)	O
or	O
NF	O
-	O
kappaB	O
activation	O
.	O

Initial	O
signaling	O
through	O
the	O
CD4	O
receptor	O
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV	O
-	O
infected	O
T	O
cells	O
to	O
undergo	O
apoptosis	O
.	O

Incubation	O
of	O
HIV	O
-	O
infected	O
cells	O
with	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
13B8	O
-	O
2	O
,	O
which	O
binds	B-Binding
to	O
CD4	O
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O

Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	O
-	O
Fas	O
ligand	O
interaction	B-Binding
;	O
however	O
,	O
an	O
antagonistic	O
anti	O
-	O
Fas	O
MAb	O
(	O
ZB	O
-	O
4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV	O
-	O
infected	O
cells	O
without	O
inducing	O
apoptosis	O
in	O
uninfected	O
cells	O
.	O

These	O
observations	O
demonstrate	O
that	O
CD4	O
signaling	O
mediates	O
HIV	O
-	O
induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	O
-	O
Fas	O
ligand	O
interaction	B-Binding
,	O
does	O
not	O
require	O
p56	O
(	O
lck	O
)	O
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	O
dimerization	B-Binding
.	O

NF	O
-	O
kappaB	O
only	O
partially	O
mediates	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
1	O
activation	O
of	O
B	O
cells	O
.	O

The	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
immortalization	O
of	O
human	O
B	O
cells	O
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	O
lines	O
.	O

LMP1	O
expression	B-Gene_expression
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up	O
-	O
regulation	O
of	O
cell	O
surface	O
activation	O
markers	O
.	O

LMP1	O
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
one	O
through	O
interactions	O
with	O
TRAF	O
proteins	O
and	O
the	O
other	O
with	O
the	O
TRADD	O
protein	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	B-Regulation
of	O
NF	O
-	O
kappaB	O
induction	O
in	O
the	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM	O
-	O
1	O
and	O
CD71	O
by	O
LMP1	O
.	O

This	O
study	O
shows	O
that	O
expression	B-Gene_expression
of	O
LMP1	O
activates	O
transcription	O
from	O
p50/p65	O
-	O
and	O
c-Rel	O
-	O
responsive	O
promoters	O
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	O
IkappaB	O
mutant	O
.	O

ICAM	O
-	O
1	O
and	O
CD71	O
are	O
nevertheless	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
by	O
LMP1	O
in	O
primary	O
B	O
cells	O
and	O
cell	O
lines	O
expressing	O
the	O
dominant	O
IkappaB	O
.	O

Furthermore	O
,	O
LMP1	O
-	O
induced	O
cell	O
size	O
increase	O
of	O
primary	O
B	O
cells	O
was	O
unaffected	O
by	O
IkappaB	O
expression	O
.	O

It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	O
is	O
unable	O
to	O
activate	O
NF	O
-	O
kappaB	O
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	O
B	O
cells	O
,	O
strongly	O
suggesting	O
that	O
LMP1	O
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF	O
-	O
kappaB	O
.	O

Relationship	O
between	O
IkappaBalpha	O
constitutive	O
expression	B-Gene_expression
,	O
TNFalpha	O
synthesis	B-Gene_expression
,	O
and	O
apoptosis	O
in	O
EBV	O
-	O
infected	O
lymphoblastoid	O
cells	O
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	B-Gene_expression
transfected	I-Gene_expression
IkappaBalpha	O
into	O
lymphoblastoid	O
cells	O
.	O

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF	O
-	O
kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	B-Gene_expression
expression	I-Gene_expression
of	O
the	O
transgenic	O
IkappaBalpha	O
.	O

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O

Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	O
cell	O
cycle	O
analysis	O
after	O
BrdU	O
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O

Percentage	O
of	O
apoptotic	O
cells	O
was	O
determined	O
by	O
in	O
-	O
situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O

No	O
significative	O
changes	O
in	O
EBV	O
latency	O
nor	O
in	O
cell	O
surface	O
marker	O
expression	O
was	O
found	O
.	O

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	O
levels	O
were	O
strongly	O
reduced	B-Negative_regulation
in	O
transfected	O
clones	O
.	O

Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	O
transfected	B-Gene_expression
cells	O
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	O
treatment	O
.	O

This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	O
treatment	O
.	O

No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	O
cells	O
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	O
gene	O
could	O
be	O
one	O
of	O
the	O
targets	B-Regulation
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
protects	O
EBV	O
-	O
infected	O
cells	O
from	O
apoptosis	O
induced	O
by	O
TNFalpha	O
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	O
.	O

Uncoupling	O
activation	O
-	O
dependent	B-Positive_regulation
HS1	O
phosphorylation	B-Phosphorylation
from	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcriptional	O
activation	O
in	O
Jurkat	O
T	O
cells	O
:	O
differential	O
signaling	O
through	O
CD3	O
and	O
the	O
costimulatory	O
receptors	O
CD2	O
and	O
CD28	O
.	O

CD3	O
,	O
CD2	O
,	O
and	O
CD28	O
are	O
functionally	O
distinct	O
receptors	O
on	O
T	O
lymphocytes	O
.	O

Engagement	B-Binding
of	O
any	O
of	O
these	O
receptors	O
induces	B-Positive_regulation
the	O
rapid	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
a	O
shared	O
group	O
of	O
intracellular	O
signaling	O
proteins	O
,	O
including	O
Vav	O
,	O
Cbl	O
,	O
p85	O
phosphoinositide	O
3	O
-	O
kinase	O
,	O
and	O
the	O
Src	O
family	O
kinases	O
Lck	O
and	O
Fyn	O
.	O

Ligation	O
of	O
CD3	O
also	O
induces	B-Positive_regulation
the	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
HS1	O
,	O
a	O
75	O
-	O
kDa	O
hematopoietic	O
cell	O
-	O
specific	O
intracellular	O
signaling	O
protein	O
of	O
unknown	O
function	O
.	O

We	O
have	O
examined	O
changes	B-Regulation
in	O
HS1	O
phosphorylation	B-Phosphorylation
after	O
differential	O
stimulation	B-Positive_regulation
of	O
CD3	O
,	O
CD2	O
,	O
and	O
CD28	O
to	O
elucidate	O
its	O
role	O
in	O
T	O
cells	O
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O

Unlike	O
ligation	O
of	O
CD3	O
,	O
stimulation	O
with	O
anti	O
-	O
CD28	O
mAb	O
or	O
CHO	O
cells	O
expressing	B-Gene_expression
the	O
CD28	O
ligands	B-Binding
CD80	O
or	O
CD86	O
did	O
not	O
lead	B-Positive_regulation
to	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
HS1	O
in	O
Jurkat	O
T	O
cells	O
.	O

Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
HS1	O
was	O
induced	B-Positive_regulation
by	O
mitogenic	O
pairs	O
of	O
anti	O
-	O
CD2	O
mAbs	O
capable	O
of	O
activating	O
the	O
transcription	O
factor	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
.	O

Costimulation	O
through	O
CD28	O
and/or	O
CD2	O
did	O
not	O
modulate	B-Regulation
the	O
CD3	O
-	O
dependent	B-Positive_regulation
phosphorylation	B-Phosphorylation
of	O
HS1	O
.	O

In	O
vivo	O
studies	O
indicated	O
that	O
CD3	O
-	O
induced	B-Positive_regulation
HSI	O
phosphorylation	B-Phosphorylation
was	O
dependent	B-Positive_regulation
upon	O
both	O
the	O
Src	O
family	O
tyrosine	O
kinase	O
Lck	O
and	O
the	O
tyrosine	O
phosphatase	O
CD45	O
,	O
did	O
not	O
require	B-Positive_regulation
MEK1	O
kinase	O
activity	O
,	O
and	O
was	O
regulated	B-Regulation
by	O
protein	O
kinase	O
C	O
activation	O
.	O

Thus	O
,	O
although	O
CD3	O
,	O
CD28	O
,	O
and	O
CD2	O
activate	O
many	O
of	O
the	O
same	O
signaling	O
molecules	O
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	B-Positive_regulation
the	O
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
HSI	O
.	O

Furthermore	O
,	O
activation	O
-	O
dependent	B-Positive_regulation
tyrosine	O
phosphorylation	B-Phosphorylation
of	O
HS1	O
was	O
not	O
required	O
for	O
NFAT	O
transcriptional	O
activation	O
.	O

IL	O
-	O
7	O
reconstitutes	B-Positive_regulation
multiple	O
aspects	O
of	O
v-Abl	O
-	O
mediated	O
signaling	B-Positive_regulation
.	O

The	O
mechanism	O
by	O
which	O
early	O
lymphoid	O
cells	O
are	O
selectively	O
transformed	O
by	O
v	O
-	O
Abl	O
is	O
currently	O
unknown	O
.	O

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
7	O
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	B-Positive_regulation
of	O
Janus	O
protein	O
kinase	O
(	O
JAK	O
)	O
1	O
,	O
JAK3	O
,	O
STAT5	O
,	O
and	O
STAT6	O
,	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
v	O
-	O
Abl	O
.	O

To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v	O
-	O
Abl	O
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
7	O
on	O
pre	O
-	O
B	O
cells	O
transformed	O
with	O
a	O
temperature	O
-	O
sensitive	O
v	O
-	O
Abl	O
mutant	O
were	O
examined	O
.	O

Whereas	O
IL	O
-	O
4	O
had	O
little	O
or	O
no	O
effect	O
,	O
IL	O
-	O
7	O
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v	O
-	O
Abl	O
kinase	O
inactivation	O
.	O

IL	O
-	O
7	O
also	O
delayed	B-Negative_regulation
the	O
decreases	B-Negative_regulation
in	O
the	O
levels	O
of	O
c	O
-	O
Myc	O
,	O
Bcl	O
-	O
2	O
,	O
and	O
Bcl	O
-	O
xL	O
that	O
occur	O
upon	O
loss	O
of	O
v	O
-	O
Abl	O
kinase	O
activity	O
.	O

IL	O
-	O
7	O
did	O
not	O
maintain	O
v-Abl	O
-	O
mediated	O
differentiation	O
arrest	O
of	O
the	O
pre	O
-	O
B	O
cells	O
,	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
RAG	O
gene	O
transcription	O
was	O
unaffected	O
by	O
IL	O
-	O
7	O
.	O

These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL	O
-	O
7	O
signaling	O
pathways	O
in	O
transformation	O
by	O
v	O
-	O
Abl	O
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
7	O
signaling	O
can	O
not	O
substitute	O
for	O
an	O
active	O
v	O
-	O
Abl	O
kinase	O
in	O
transformed	O
pre	O
-	O
B	O
cells	O
.	O

p21ras	O
initiates	O
Rac	O
-	O
1	O
but	O
not	O
phosphatidyl	O
inositol	O
3	O
kinase/PKB	O
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

p21ras	O
is	O
activated	B-Positive_regulation
by	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
then	O
co	O
-	O
ordinates	O
important	O
signaling	O
pathways	O
for	O
T	O
lymphocyte	O
activation	O
.	O

Effector	B-Regulation
pathways	I-Regulation
for	O
this	O
guanine	O
nucleotide	O
binding	O
protein	O
in	O
T	O
cells	O
are	O
mediated	B-Positive_regulation
by	O
the	O
serine/threonine	O
kinase	O
Raf	O
-	O
1	O
and	O
the	O
Ras	O
-	O
related	O
GTPase	O
Rac	O
-	O
1	O
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PtdIns	O
3	O
-	O
kinase	O
)	O
.	O

Activation	O
of	O
this	O
lipid	O
kinase	O
is	O
able	O
to	O
induce	O
critical	O
Rac	O
-	O
1	O
signaling	O
pathways	O
and	O
can	O
couple	B-Positive_regulation
p21ras	O
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine/threonine	O
kinase	O
Akt/PKB	O
.	O

The	O
role	O
of	O
PtdIns	O
3	O
-	O
kinase	O
in	O
Ras	O
signaling	O
in	O
T	O
cells	O
has	O
not	O
been	O
explored	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	O
3	O
-	O
kinase	O
to	O
initiate	O
the	O
Rac	O
-	O
1	O
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt/PKB	O
is	O
regulated	B-Regulation
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	O
can	O
initiate	O
a	O
Rac	O
-	O
1	O
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP	O
-	O
1	O
complexes	O
.	O

PtdIns	O
3	O
-	O
kinase	O
signals	O
can	O
not	O
mimic	O
p21ras	O
and	O
induce	O
the	O
Rac	O
mediated	O
responses	O
of	O
AP	O
-	O
1	O
transcriptional	O
activation	O
.	O

Moreover	O
,	O
neither	O
TCR	O
or	O
Ras	O
activation	O
of	O
AP	O
-	O
1	O
is	O
dependent	O
on	O
PtdIns	O
3	O
-	O
kinase	O
.	O

PKB	O
is	O
activated	B-Positive_regulation
in	O
response	O
to	O
triggering	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
;	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
is	O
both	O
required	B-Positive_regulation
and	I-Positive_regulation
sufficient	I-Positive_regulation
for	O
this	O
TCR	O
response	O
.	O

In	O
contrast	O
,	O
p21ras	O
signals	O
are	O
unable	O
to	O
induce	B-Positive_regulation
Akt/PKB	O
activity	O
in	O
T	O
cell	O
nor	O
is	O
Ras	O
function	O
required	B-Positive_regulation
for	O
Akt/PKB	O
activation	B-Positive_regulation
in	O
response	O
to	O
the	O
TCR	O
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	O
3	O
-	O
kinase	O
and	O
Akt/PKB	O
are	O
not	O
universal	O
Ras	O
effector	O
molecules	O
.	O

Ras	O
can	O
initiate	O
Rac	O
-	O
1	O
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	O
cell	O
antigen	O
receptor	O
function	O
independently	O
of	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
.	O

Signal	O
transduction	O
abnormalities	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	O
therapy	O
.	O

Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3/T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	O
lymphocytes	O
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O

Diminished	B-Negative_regulation
expression	B-Gene_expression
of	O
TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
that	O
are	O
associated	B-Binding
with	O
the	O
TCR	O
and	O
reduced	B-Negative_regulation
nuclear	O
localization	B-Localization
of	O
RelA	O
containing	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
complexes	O
have	O
been	O
noted	O
.	O

These	O
defects	B-Negative_regulation
have	O
been	O
described	O
in	O
T	O
cells	O
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O

Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O

To	O
further	O
characterize	O
altered	B-Negative_regulation
expression	B-Gene_expression
of	O
TCRzeta	O
,	O
p56	O
(	O
lck	O
)	O
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	O
,	O
T	O
lymphocytes	O
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	O
therapy	O
[	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
,	O
IFN	O
alpha	O
-	O
containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O

In	O
29	O
of	O
these	O
patients	O
,	O
levels	B-Gene_expression
of	O
TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
were	O
determined	O
by	O
Western	O
blots	O
of	O
T	O
-	O
cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O

In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	O
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	O
cells	O
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
.	O

Changes	B-Positive_regulation
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	O
treatment	O
were	O
also	O
investigated	O
.	O

TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
were	O
detected	B-Gene_expression
in	O
the	O
peripheral	O
blood	O
T	O
cells	O
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	B-Negative_regulation
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	B-Negative_regulation
of	O
TCRzeta	O
(	O
P	O
=	O
0.029	O
)	O
and	O
p56	O
(	O
lck	O
)	O
(	O
P	O
=	O
0.029	O
)	O
but	O
not	O
CD3epsilon	O
(	O
P	O
=	O
0.131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

In	O
patients	O
treated	O
with	O
IL	O
-	O
2/IFN	O
alpha	O
-	O
based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	O
increased	B-Positive_regulation
significantly	O
(	O
P	O
=	O
0.002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O

Correlations	O
of	O
TCRzeta	O
or	O
p56	O
(	O
lck	O
)	O
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	B-Negative_regulation
TCRzeta	O
levels	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O

Abnormal	O
NFkappaB	O
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
and/or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O

Activation	O
of	O
NFkappaB	O
in	O
peripheral	O
blood	O
T	O
cells	O
was	O
inducible	O
during	O
cytokine	O
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	O
activity	O
prior	O
to	O
therapy	O
.	O

Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	O
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	B-Negative_regulation
of	O
TCRzeta	O
expression	B-Gene_expression
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	O
levels	O
were	O
present	O
although	O
kappaB	O
binding	O
was	O
not	O
inducible	O
.	O

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	O
blood	O
T	O
cells	O
express	B-Gene_expression
TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	B-Negative_regulation
levels	I-Negative_regulation
of	O
these	O
TCRzeta	O
associated	O
molecules	O
are	O
seen	O
that	O
may	O
increase	B-Positive_regulation
during	O
cytokine	O
-	O
based	O
therapy	O
.	O

Abnormal	O
activation	O
of	O
NFkappaB	O
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL	O
-	O
2/IFN	O
alpha	O
-	O
based	O
treatment	O
.	O

This	O
alteration	O
in	O
NFkappaB	O
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta	O
-	O
associated	O
signaling	O
elements	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O

Transcriptional	B-Regulation
regulation	I-Regulation
of	O
lysosomal	O
acid	O
lipase	O
in	O
differentiating	O
monocytes	O
is	O
mediated	B-Regulation
by	O
transcription	O
factors	O
Sp1	O
and	O
AP	O
-	O
2	O
.	O

Human	O
lysosomal	O
acid	O
lipase	O
(	O
LAL	O
)	O
is	O
a	O
hydrolase	O
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O

It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	B-Transcription
of	O
LAL	O
-	O
mRNA	O
is	O
induced	B-Positive_regulation
.	O

This	O
induction	O
is	O
dependent	B-Positive_regulation
on	O
protein	O
kinase	O
C	O
activity	O
and	O
protein	O
synthesis	O
.	O

The	O
cell	O
type	O
-	O
specific	O
increase	B-Positive_regulation
in	O
LAL	O
expression	B-Gene_expression
is	O
further	O
investigated	O
in	O
the	O
THP	O
-	O
1	O
cell	O
line	O
with	O
respect	O
to	O
transcriptional	B-Regulation
regulation	I-Regulation
.	O

The	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiates	O
into	O
macrophage	O
-	O
like	O
cells	O
when	O
treated	O
with	O
phorbol	O
esters	O
.	O

In	O
order	O
to	O
determine	O
the	O
cis	O
-	O
acting	O
elements	O
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12-myristate	O
-	O
13	O
acetate	O
(	O
PMA	O
)	O
-	O
enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	O
gene	O
assays	O
.	O

A	O
PMA	O
responsive	O
element	O
has	O
been	O
identified	O
between	O
-	O
182	O
bp	O
and	O
-	O
107	O
bp	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	B-Binding
of	O
Sp1	O
and	O
AP	O
-	O
2	O
to	O
the	O
LAL	O
promoter	O
is	O
increased	B-Positive_regulation
by	O
PMA	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Co	O
-	O
transfections	O
with	O
expression	O
plasmids	O
for	O
Sp1	O
and	O
AP	O
-	O
2	O
further	O
emphasized	O
the	O
important	B-Regulation
role	I-Regulation
of	O
these	O
transcription	O
factors	O
in	O
both	O
basal	O
and	O
PMA	O
-	O
enhanced	B-Positive_regulation
LAL	O
expression	B-Gene_expression
.	O

Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	B-Regulation
increase	B-Positive_regulation
of	O
lysosomal	O
acid	O
lipase	O
(	O
LAL	O
)	O
expression	B-Gene_expression
in	O
THP	O
-	O
1	O
cells	O
is	O
mediated	B-Regulation
by	O
a	O
concerted	O
action	O
of	O
Sp1	O
and	O
AP	O
-	O
2	O
.	O

A	O
nongenomic	O
mechanism	O
for	O
progesterone	O
-	O
mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K+	O
channels	O
,	O
Ca2+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O

Using	O
human	O
T	O
lymphocytes	O
and	O
T	O
cell	O
lines	O
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage	O
-	O
gated	O
and	O
calcium	O
-	O
activated	O
K+	O
channels	O
(	O
KV	O
and	O
KCa	O
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O

As	O
a	O
result	O
,	O
Ca2+	O
signaling	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
-	O
driven	O
gene	O
expression	O
are	O
inhibited	O
.	O

Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2+	O
signals	O
,	O
but	O
not	O
the	O
Ca2+	O
transient	O
after	O
TCR	O
stimulation	O
.	O

K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	O
and	O
KCa	O
channels	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	O
channels	O
,	O
reducing	B-Negative_regulation
both	O
Kv1.3	O
and	O
charybdotoxin	O
-	O
resistant	O
components	O
of	O
KV	O
current	O
and	O
KCa	O
current	O
in	O
T	O
cells	O
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	O
KV	O
channels	O
expressed	O
in	O
cell	O
lines	O
.	O

Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	O
voltage	O
-	O
gated	O
Na+	O
channel	O
,	O
an	O
inward	O
rectifier	O
K+	O
channel	O
,	O
or	O
on	O
lymphocyte	O
Ca2+	O
and	O
Cl	O
-	O
channels	O
.	O

We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K+	O
channels	O
in	O
T	O
cells	O
by	O
progesterone	O
contributes	O
to	O
progesterone	O
-	O
induced	O
immunosuppression	O
.	O

Role	O
of	O
IKK1	O
and	O
IKK2	O
in	O
lipopolysaccharide	O
signaling	O
in	O
human	O
monocytic	O
cells	O
.	O

Mononuclear	O
phagocytes	O
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	O
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF	O
-	O
kappaB/Rel	O
transcription	O
factor	O
family	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	O
1	O
signaling	O
pathways	O
activate	B-Positive_regulation
two	O
kinases	O
,	O
IKK1	O
and	O
IKK2	O
.	O

Phosphorylation	B-Phosphorylation
of	O
the	O
IkappaB	O
cytoplasmic	O
inhibitors	O
,	O
IkappaBalpha	O
,	O
IkappaBbeta	O
,	O
and	O
IkappaBepsilon	O
,	O
by	B-Positive_regulation
these	O
kinases	O
triggers	B-Positive_regulation
proteolytic	B-Protein_catabolism
degradation	I-Protein_catabolism
and	O
the	O
release	O
of	O
NF	O
-	O
kappaB/Rel	O
proteins	O
into	O
the	O
nucleus	O
.	O

At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	O
activity	O
in	O
human	O
monocytes	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
.	O

The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	O
cells	O
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	O
and	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
transfection	O
experiments	O
,	O
overexpression	B-Positive_regulation
of	O
wild	O
type	O
IKK1	O
,	O
a	O
dominant	O
negative	O
mutant	O
IKK1	O
(	O
K44M	O
)	O
,	O
or	O
wild	O
type	O
IKK2	O
did	O
not	O
affect	O
LPS	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
monocytic	O
cells	O
.	O

In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	O
inhibited	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	B-Positive_regulation
of	O
IKK2	O
.	O

Effects	B-Regulation
of	O
overexpression	O
of	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
on	O
NFkappaB	O
activation	O
,	O
IL	O
-	O
2	O
production	B-Gene_expression
and	O
stress	O
-	O
activated	O
protein	O
kinases	O
in	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
.	O

The	O
association	O
and	O
activation	O
of	O
the	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
protein	O
kinase	O
(	O
IRAK	O
)	O
to	O
the	O
IL	O
-	O
1	O
receptor	O
complex	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL	O
-	O
1	O
signal	O
transduction	O
.	O

We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
6.1	O
overexpressing	O
human	O
(	O
h	O
)	O
IRAK	O
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL	O
-	O
1	O
signaling	O
.	O

Overexpression	O
of	O
hIRAK	O
enhanced	O
IL-1	O
-	O
stimulated	O
activation	O
of	O
the	O
transcription	O
factor	O
NFkappaB	O
,	O
whereas	O
a	O
truncated	O
form	O
(	O
N	O
-	O
IRAK	O
)	O
specifically	O
inhibited	O
IL-1	O
-	O
dependent	O
NFkappaB	O
activity	O
.	O

In	O
clones	O
stably	O
overexpressing	O
hIRAK	O
a	O
weak	O
constitutive	O
activation	O
of	O
NFkappaB	O
correlated	O
with	O
a	O
low	O
basal	O
IL	O
-	O
2	O
production	B-Gene_expression
which	O
was	O
enhanced	B-Positive_regulation
in	O
an	O
IL-1	O
-	O
dependent	O
manner	O
.	O

Compared	O
to	O
the	O
parental	O
cell	O
line	O
the	O
dose	O
-	O
response	O
curve	O
of	O
IL-1	O
-	O
induced	B-Positive_regulation
IL	O
-	O
2	O
production	B-Gene_expression
was	O
shifted	O
in	O
both	O
potency	O
and	O
efficacy	O
.	O

These	O
results	O
demonstrate	O
that	O
IRAK	O
directly	O
triggers	O
NFkappaB	O
-	O
mediated	O
gene	O
expression	O
in	O
EL4	O
cells	O
.	O

Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL-1	O
-	O
induced	O
activation	O
of	O
stress	O
-	O
activated	O
protein	O
(	O
SAP	O
)	O
kinases	O
:	O
permanent	O
overexpression	O
of	O
IRAK	O
did	O
not	O
affect	O
the	O
dose	O
dependence	O
but	O
prolonged	O
the	O
kinetics	O
of	O
IL-1	O
-	O
induced	O
activation	O
of	O
SAP	O
kinases	O
,	O
suggesting	O
that	O
this	O
signaling	O
branch	O
may	O
be	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O

Decreased	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
.	O

IL	O
-	O
12	O
is	O
a	O
75	O
-	O
kDa	O
heterodimeric	O
cytokine	O
composed	O
of	O
two	O
covalently	O
linked	O
p35	O
and	O
p40	O
chains	O
.	O

This	O
pro	O
-	O
inflammatory	O
cytokine	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O

Thus	O
,	O
IL	O
-	O
12	O
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti	O
-	O
inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
.	O

ASA	O
was	O
found	O
to	O
inhibit	B-Negative_regulation
secretion	B-Localization
of	O
the	O
IL	O
-	O
12	O
heterodimer	O
as	O
well	O
as	O
p40	O
monomer	O
by	O
human	O
monocytic	O
cells	O
.	O

This	O
was	O
associated	O
with	O
the	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	I-Negative_regulation
of	O
IL	O
-	O
12p40	O
mRNA	B-Transcription
expression	I-Transcription
.	O

Analysis	O
of	O
the	O
regulation	B-Regulation
of	O
the	O
p40	O
gene	O
promoter	O
revealed	O
that	O
ASA	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
and	O
binding	O
to	O
the	O
p40	O
-	O
kappaB	O
site	O
in	O
the	O
p40	O
promoter	O
,	O
leading	B-Positive_regulation
to	I-Positive_regulation
transcriptional	I-Positive_regulation
repression	I-Positive_regulation
of	O
the	O
p40	O
gene	O
.	O

Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti	O
-	O
inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
ASA	O
leads	O
to	O
down	O
-	O
regulation	O
of	O
IL	O
-	O
12	O
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O

Membrane	O
-	O
associated	O
lymphotoxin	O
on	O
natural	O
killer	O
cells	O
activates	O
endothelial	O
cells	O
via	O
an	O
NF-kappaB	O
-	O
dependent	O
pathway	O
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
monocytes	O
associated	O
with	O
endothelial	O
cell	O
(	O
EC	O
)	O
activation	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
human	O
NK	O
cells	O
activate	O
porcine	O
EC	O
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	O
molecule	O
expression	O
and	O
cytokine	O
secretion	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	O
cell	O
line	O
NK92	O
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell	O
-	O
mediated	O
EC	O
activation	O
.	O

METHODS	O
:	O
EC	O
were	O
transfected	O
with	O
either	O
reporter	O
constructs	O
containing	O
the	O
luciferase	O
gene	O
driven	O
either	O
by	O
E	O
-	O
selectin	O
or	O
interleukin	O
(	O
IL	O
)	O
-	O
8	O
promoters	O
or	O
a	O
synthetic	O
NF-kappaB	O
-	O
dependent	O
promoter	O
.	O

In	O
addition	O
,	O
a	O
dominant	O
-	O
negative	O
mutant	O
tumor	O
necrosis	O
factor	O
receptor	O
I	O
(	O
TNFRI	O
)	O
expression	O
vector	O
was	O
co	B-Gene_expression
-	I-Gene_expression
transfected	I-Gene_expression
in	O
inhibition	O
studies	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
EC	O
were	O
stimulated	O
with	O
NK	O
cells	O
or	O
NK	O
cell	O
membrane	O
extracts	O
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	O
assay	O
.	O

RESULTS	O
:	O
Co	O
-	O
culture	O
of	O
NK	O
cells	O
with	O
transfected	O
EC	O
enhanced	O
E	O
-	O
selectin	O
,	O
IL	O
-	O
8	O
,	O
and	O
NF-kappaB	O
-	O
dependent	O
promoter	O
activity	O
.	O

NK	O
cell	O
membrane	O
extracts	O
retained	O
the	O
capacity	O
to	O
activate	O
EC	O
and	O
induced	B-Positive_regulation
nuclear	O
translocation	B-Localization
of	O
NF	O
-	O
kappaB	O
(	O
p50	O
and	O
p65	O
)	O
.	O

Western	O
blotting	O
of	O
NK	O
cell	O
and	O
membrane	O
extracts	O
detected	O
the	O
presence	B-Gene_expression
of	O
Lymphotoxin	O
-	O
alpha	O
(	O
LTalpha	O
)	O
but	O
not	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
.	O

Furthermore	O
,	O
LTalpha	O
was	O
secreted	B-Localization
in	O
NK	O
:	O
EC	O
co	O
-	O
cultures	O
.	O

Co	B-Positive_regulation
-	I-Positive_regulation
transfection	I-Positive_regulation
with	O
dominant	O
-	O
negative	O
mutant	O
TNFRI	O
inhibited	O
EC	O
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	O
cells	O
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O

The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti	O
-	O
human	O
LT	O
sera	O
.	O

CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane	O
-	O
bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	O
,	O
leading	B-Positive_regulation
to	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
transcription	B-Transcription
of	O
E	O
-	O
selectin	O
and	O
IL	O
-	O
8	O
,	O
which	O
results	O
in	O
EC	O
activation	O
.	O

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	O
cells	O
with	O
mutant	O
TNFRI	O
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	O
cells	O
to	O
activate	O
EC	O
.	O

The	O
involvement	O
of	O
multiple	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
-	O
associated	O
factors	O
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
member	O
of	O
the	O
TNFR	O
superfamily	O
.	O

Receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
(	O
RANK	O
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
and	O
is	O
expressed	B-Gene_expression
on	O
activated	O
T	O
cells	O
and	O
dendritic	O
cells	O
.	O

Its	O
cognate	O
ligand	O
(	O
RANKL	O
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O

We	O
demonstrate	O
here	O
the	O
interaction	B-Binding
of	O
RANK	O
with	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
(	O
TRAFs	O
)	O
1	O
,	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
6	O
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF/RANK	O
interaction	B-Binding
revealed	O
multiple	O
TRAF	O
binding	O
sites	O
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	O
cytoplasmic	O
tail	O
.	O

These	O
TRAF	O
binding	O
domains	O
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK	O
-	O
dependent	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
activities	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	O
binding	O
sites	O
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	O
proteins	O
.	O

In	O
particular	O
,	O
TRAF6	O
interacted	B-Binding
with	O
membrane	O
-	O
proximal	O
determinants	O
distinct	O
from	O
those	O
binding	B-Binding
TRAFs	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
5	O
.	O

When	O
this	O
membrane	O
-	O
proximal	O
TRAF6	O
interaction	O
domain	O
was	O
deleted	O
,	O
RANK	O
-	O
mediated	O
NF	O
-	O
kappaB	O
signaling	O
was	O
completely	O
inhibited	O
while	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
activation	O
was	O
partially	O
inhibited	O
.	O

An	O
NH2	O
-	O
terminal	O
truncation	O
mutant	O
of	O
TRAF6	O
inhibited	O
RANKL	O
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
,	O
but	O
failed	O
to	O
affect	O
constitutive	O
signaling	O
induced	O
by	O
receptor	O
overexpression	O
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	O
in	O
ligand	O
-	O
induced	O
activation	O
events	O
.	O

Regulation	B-Regulation
of	O
interleukin	O
-	O
1beta	O
transcription	B-Transcription
by	O
Epstein	O
-	O
Barr	O
virus	O
involves	B-Regulation
a	O
number	O
of	O
latent	O
proteins	O
via	O
their	O
interaction	O
with	O
RBP	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	O
cells	O
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin	O
-	O
1beta	O
(	O
IL	O
-	O
1beta	O
)	O
is	O
expressed	B-Gene_expression
in	O
LCLs	O
and	O
investigate	O
the	O
influence	B-Regulation
of	O
the	O
individual	O
latent	O
proteins	O
on	O
the	O
expression	B-Gene_expression
of	O
IL	O
-	O
1beta	O
.	O

Using	O
RT	O
-	O
PCR	O
,	O
IL	O
-	O
1beta	O
was	O
shown	O
to	O
be	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	I-Positive_regulation
in	O
EBV	O
-	O
transformed	O
LCLs	O
as	O
well	O
as	O
in	O
group	O
III	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
compared	O
with	O
group	O
I	O
BL	O
cell	O
lines	O
.	O

The	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	I-Positive_regulation
of	O
IL	O
-	O
1beta	O
message	O
could	O
be	O
mediated	B-Positive_regulation
by	O
the	O
latent	O
membrane	O
protein	O
-	O
1	O
,	O
EBV	O
nuclear	O
proteins	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
6	O
genes	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-	O
300	O
region	O
of	O
the	O
IL	O
-	O
1beta	O
promoter	O
,	O
which	O
contains	O
a	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
site	O
,	O
contained	O
a	O
functional	O
RBP	O
binding	O
site	O
.	O

Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	O
nuclear	O
proteins	O
3	O
and	O
6	O
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	O
from	O
its	O
recognition	O
sequence	O
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O

In	O
group	O
I	O
BL	O
cells	O
,	O
containing	O
low	O
levels	O
of	O
NF	O
-	O
kappaB	O
,	O
only	O
RBP	O
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF	O
-	O
kappaB	O
binding	O
could	O
be	O
demonstrated	O
in	O
EBV	O
-	O
transformed	O
B	O
cell	O
lines	O
containing	O
high	O
levels	O
of	O
activated	O
NF	O
-	O
kappaB	O
.	O

In	O
addition	O
,	O
the	O
expression	B-Gene_expression
of	O
latent	O
membrane	O
protein	O
-	O
1	O
led	B-Positive_regulation
to	O
activation	B-Positive_regulation
of	O
NF	O
-	O
kappaB	O
that	O
was	O
capable	O
of	O
binding	B-Binding
the	O
IL	O
-	O
1beta	O
promoter	O
.	O

The	O
study	O
demonstrates	O
that	O
EBV	O
can	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	I-Positive_regulation
IL	O
-	O
1beta	O
expression	B-Gene_expression
,	O
possibly	O
by	O
using	O
RBP	O
,	O
NF	O
-	O
kappaB	O
,	O
or	O
both	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Characterization	O
of	O
the	O
human	O
elk	O
-	O
1	O
promoter	O
.	O

Potential	O
role	B-Regulation
of	O
a	O
downstream	O
intronic	O
sequence	O
for	O
elk	O
-	O
1	O
gene	B-Gene_expression
expression	I-Gene_expression
in	O
monocytes	O
.	O

To	O
characterize	O
the	O
human	O
elk	O
-	O
1	O
promoter	O
,	O
we	O
mapped	O
the	O
transcriptional	O
start	O
site	O
and	O
isolated	O
elk-1	O
-	O
specific	O
genomic	O
phage	O
clones	O
that	O
contained	O
extensive	O
upstream	O
and	O
downstream	O
sequences	O
.	O

A	O
TATA	O
-	O
like	O
motif	O
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

Functional	O
analyses	O
of	O
DNA	O
fragments	O
containing	O
the	O
TATA	O
element	O
and	O
the	O
identification	O
of	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
chromatin	O
site	O
(	O
HS	O
1	O
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	O
box	O
suggest	O
that	O
the	O
identified	O
TATA	O
motif	O
is	O
important	B-Regulation
for	O
elk	O
-	O
1	O
transcription	B-Transcription
in	O
vivo	O
.	O

Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	O
box	O
were	O
found	O
to	O
contribute	B-Positive_regulation
to	O
elk	O
-	O
1	O
promoter	O
activity	O
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre	O
-	O
monocytic	O
cells	O
,	O
which	O
express	B-Gene_expression
Elk	O
-	O
1	O
only	O
when	O
differentiating	O
to	O
monocytes	O
.	O

In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk	O
-	O
1	O
expression	B-Gene_expression
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	B-Positive_regulation
of	O
elk	O
-	O
1	O
expression	B-Gene_expression
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O

Egr	O
-	O
1	O
and	O
the	O
serum	O
response	O
factor	O
were	O
found	O
to	O
interact	B-Binding
specifically	O
with	O
the	O
intronic	O
sequence	O
at	O
+265	O
and	O
+448	O
,	O
respectively	O
.	O

Because	O
Egr	O
-	O
1	O
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	B-Positive_regulation
significantly	O
before	O
induction	B-Positive_regulation
of	O
elk	O
-	O
1	O
expression	B-Gene_expression
,	O
we	O
propose	O
that	O
Egr	O
-	O
1	O
is	O
important	O
for	O
the	O
regulation	O
of	O
elk	O
-	O
1	O
transcription	B-Transcription
in	O
differentiating	O
monocytes	O
.	O

Functional	O
association	O
of	O
Nmi	O
with	O
Stat5	O
and	O
Stat1	O
in	O
IL-2	O
-	O
and	O
IFNgamma	O
-	O
mediated	O
signaling	O
.	O

Using	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
Stat5b	O
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	B-Binding
of	O
Nmi	O
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N	O
-	O
Myc	O
interactor	O
.	O

We	O
further	O
show	O
that	O
Nmi	O
interacts	B-Binding
with	O
all	O
STATs	O
except	O
Stat2	O
.	O

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL	O
-	O
2	O
and	O
IFNgamma	O
,	O
and	O
demonstrate	O
that	O
Nmi	O
augments	O
STAT	O
-	O
mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	O
.	O

Interestingly	O
,	O
Nmi	O
lacks	O
an	O
intrinsic	O
transcriptional	O
activation	O
domain	O
;	O
instead	O
,	O
Nmi	O
enhances	B-Positive_regulation
the	O
association	B-Binding
of	O
CBP/p300	O
coactivator	O
proteins	O
with	O
Stat1	O
and	O
Stat5	O
,	O
and	O
together	O
with	O
CBP/p300	O
can	O
augment	O
IL-2	O
-	O
and	O
IFNgamma	O
-	O
dependent	O
transcription	O
.	O

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	O
can	O
potentiate	O
STAT	O
-	O
dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence	O
-	O
specific	O
transcription	O
factors	O
.	O

